An investigation into the structure and function of VanS proteins involved in the two-component VanS/VanR regulatory system controlling antibiotic resistance by Edwards, Richard James
  
 
University of Warwick institutional repository: http://go.warwick.ac.uk/wrap  
 
A Thesis Submitted for the Degree of PhD at the University of Warwick 
 
http://go.warwick.ac.uk/wrap/67112  
 
This thesis is made available online and is protected by original copyright.  
Please scroll down to view the document itself.  
Please refer to the repository record for this item for information to help you to 
cite it. Our policy information is available from the repository home page.  
 
 
 
 
 
 
 
 
 
An Investigation into the Structure and 
Function of VanS proteins involved in the 
Two-Component VanS/VanR Regulatory 
System controlling Antibiotic Resistance 
 
 
Richard James Edwards, MChem (Distinction) 
 
A thesis submitted in partial fulfilment  
of the requirements for the degree of  
Doctor of Philosophy in Chemistry and Biological Sciences 
 
University of Warwick 
Department of Chemistry and School of Life Sciences 
 
September 2014 
  
[ii] 
 
TABLE OF CONTENTS 
 
LIST OF TABLES ................................................................................................................ ix 
LIST OF FIGURES ............................................................................................................... x 
ACKNOWLEDGEMENTS ............................................................................................... xix 
DECLARATION.................................................................................................................. xx 
ABSTRACT ......................................................................................................................... xxi 
ABBREVIATIONS ............................................................................................................ xxii 
CHAPTER 1:      INTRODUCTION .................................................................................... 1 
1.1 Antimicrobials and Bacterial Antibiotic Resistance ........................................... 1 
1.1.1 Historical Background and Current Context .................................................... 1 
1.1.2 The Impact of Antibacterial Resistance on Healthcare .................................... 4 
1.1.3 Mechanisms of Action of Antimicrobial Agents ............................................. 5 
1.1.4 Emergence of Antibiotic Resistance ................................................................ 7 
1.1.5 Development of Bacterial Resistance ............................................................ 10 
1.1.6 Bacterial Resistance Mechanisms to Antibiotics ........................................... 11 
1.2 Peptidoglycan as an Antimicrobial Target ........................................................ 13 
1.2.1 The Cell Wall ................................................................................................. 13 
1.2.2 The Molecular Structure of Peptidoglycan .................................................... 14 
1.2.3 Synthesis of Nucleotide precursors to Peptidoglycan .................................... 15 
1.2.4 Synthesis of lipid-linked intermediates to Peptidoglycan .............................. 16 
1.2.5 Polymerisation Reactions to form Peptidoglycan .......................................... 16 
1.3 Glycopeptide Antibiotics and Resistance Mechanisms ..................................... 18 
1.3.1 Structure and Function ................................................................................... 18 
1.3.2 Vancomycin: A History ................................................................................. 19 
1.3.3 Mode of Action and Development of Resistance to Vancomycin ................. 19 
1.3.4 Vancomycin resistance transfer across species .............................................. 22 
1.3.5 Vancomycin resistance in actinomycetes....................................................... 22 
1.3.6 The van resistance genes ................................................................................ 23 
[iii] 
 
1.4 Inducers of the VanS/VanR system .................................................................... 26 
1.4.1 VanA-type resistance ..................................................................................... 26 
1.4.2 VanB-type resistance ..................................................................................... 29 
1.4.3 Summary of Antibiotic Inducers .................................................................... 32 
1.5 Two Component Regulatory Systems ................................................................ 34 
1.5.1 Diversity of Bacterial Two-Component Systems .......................................... 34 
1.5.2 Domain Architecture and Function ................................................................ 35 
1.5.3 Histidine Kinase ............................................................................................. 37 
1.5.4 Response Regulator (RR) ............................................................................... 42 
1.5.5 Insights into Signal Transduction Mechanisms ............................................. 44 
1.5.6 A Full-Length Histidine Kinase ..................................................................... 50 
1.5.7 Cross-Talk within Two Component Systems ................................................ 51 
1.6 Strategies for the Discovery and Development of Novel Antimicrobials ........ 52 
1.6.1 Platforms for Antibiotic Discovery ................................................................ 52 
1.6.2 Underexplored antibiotic targets .................................................................... 54 
1.7 Aims and Outline of Thesis ................................................................................. 56 
1.7.1 Aims ............................................................................................................... 56 
1.7.2 Outline ............................................................................................................ 59 
 
CHAPTER 2:      MATERIALS AND METHODS........................................................... 60 
2.1 Suppliers of Chemicals and Reagents ................................................................ 60 
2.2 Escherichia coli Strains ....................................................................................... 60 
2.2.1 Bacterial Growth Media ................................................................................. 60 
2.2.2 Bacterial Strains ............................................................................................. 61 
2.2.3 Preparation of Chemically Competent Bacterial Cells for Transformations . 62 
2.3 DNA Transformation of E. coli ........................................................................... 62 
2.3.1 Preparation of Glycerol Stocks ...................................................................... 63 
  
[iv] 
 
2.4  DNA Manipulation and Cloning Techniques ................................................... 63 
2.4.1 Polymerase Chain Reaction (PCR) ................................................................ 65 
2.4.2 Site-directed Mutagenic PCR (‘Round-the-Horn’) ........................................ 66 
2.4.3 Restriction Enzyme Digestion of DNA .......................................................... 67 
2.4.4 Preparation of Plasmid DNA ......................................................................... 67 
2.4.5 Purification of DNA from PCR and Restriction Digests ............................... 68 
2.4.6 Agarose Gel Electrophoresis .......................................................................... 68 
2.4.7 Ligation of DNA Fragments with Complementary Ends .............................. 68 
2.4.8 DNA Sequencing of Plasmid Constructs ....................................................... 69 
2.5 Membrane Protein Expression and Purification .............................................. 71 
2.5.1 Protein Over-Expression ................................................................................ 71 
2.5.2 Preparation of Membrane Protein Lysates ..................................................... 73 
2.5.3 Large-Scale Membrane Protein Preparations ................................................. 73 
2.5.4 Protein Solubilisation using Membrane Mimetics ......................................... 74 
2.6  Protein Analysis and Detection .......................................................................... 75 
2.6.1 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis ................... 75 
2.6.2 Blue Native PAGE ......................................................................................... 76 
2.6.3 Western Blotting for Histidine-tagged proteins ............................................. 77 
2.6.4 Western blotting for MBP-tagged proteins .................................................... 79 
2.6.5 Detergent Screening by Western Blotting...................................................... 80 
2.6.6 Immobilised Metal Affinity Chromatography ............................................... 81 
2.6.7 Analytical Gel Filtration Chromatography .................................................... 83 
2.6.8 Protein Sample Desalting, Concentrating and Dialysing ............................... 83 
2.6.9 Staining of SDS-PAGE Gels .......................................................................... 85 
2.6.10 Determination of Protein Concentration ........................................................ 85 
  
[v] 
 
2.7  ToxCAT assays .................................................................................................... 86 
2.7.1 Cloning VanS transmembrane domains into the ToxCAT plasmid ............... 87 
2.7.2 Maltose malE Complementation assay .......................................................... 90 
2.7.3 Expression check............................................................................................ 90 
2.7.4 Proteolysis of Spheroplasts ............................................................................ 91 
2.7.5 Disk Diffusion Assay ..................................................................................... 92 
2.7.6 Quantitative CAT Assay ................................................................................ 93 
2.8  Mass Spectrometry ............................................................................................. 94 
2.8.1 Full-length protein identification by Mass Spectroscopy .............................. 94 
2.8.2 Protein Identification by Tryptic Digest and nanoLC-ESI-MS/MS............... 94 
2.9  Protein Activity Determination using Coupled Enzymatic Assays ................ 95 
2.9.1 Continuous ADP Release Assay .................................................................... 95 
2.9.2 Continuous Inorganic Phosphate Release Assay ........................................... 96 
2.9.3 Identification of Assay products by Anion Exchange Chromatography ........ 98 
2.10 Circular Dichroism .............................................................................................. 99 
2.11 Fluorescence Spectroscopy ................................................................................ 101 
2.12 Site-specific Enzymatic Tag-Cleavage ............................................................. 103 
2.12.1 Enzymatic digestion with in-house synthesised TEV protease .................... 103 
2.12.2 3C Protease Expression and Purification ..................................................... 104 
2.12.3 Enzymatic Digestion with 3C Protease ........................................................ 105 
2.13 Protein Crystallisation ....................................................................................... 106 
2.13.1 Vapour Diffusion Crystallisation ................................................................. 108 
2.13.2 Sparse Matrix Screening .............................................................................. 108 
2.13.3 Data Collection ............................................................................................ 109 
2.14 Solution State Nuclear Magnetic Resonance Spectroscopy ........................... 110 
2.14.1 2D 
1
H-
15
N HSQC NMR Spectra of VanS proteins in detergent micelles .... 112 
2.14.2 Ligand-based Titrations by 2D 
1
H-
15
N HSQC spectroscopy ....................... 113 
2.14.3 Analysis of NMR-based ligand titration data ............................................... 114 
[vi] 
 
CHAPTER 3:      CLONING, EXPRESSION, PURIFICATION AND FUNCTIONAL 
CHARACTERISATION OF VANS PROTEINS FROM ENTEROCOCCI AND 
STREPTOMYCES ............................................................................................................ 115 
3.1 Introduction ........................................................................................................ 115 
3.2 Aims ..................................................................................................................... 121 
3.3 Cloning vanS genes into Expression Vectors ................................................... 122 
3.4 Expression of VanS constructs.......................................................................... 124 
3.5 Western Blotting for His-tagged VanS proteins .............................................. 129 
3.6 Purification of VanS Membrane Proteins by IMAC ...................................... 131 
3.7 Purification of VanS proteins by Gel Filtration Chromatography ............... 140 
3.8 Histidine Tag Cleavage for Crystallisation Trials ........................................... 143 
3.9 Identification of Full-length VanS Proteins by Mass Spectrometry .............. 145 
3.10 Secondary structure of VanS proteins by Circular Dichroism ...................... 146 
3.11 Determination of VanS Protein Activity by Coupled Enzymatic Assays ...... 149 
3.11.1 ADP Release Assay ..................................................................................... 152 
3.11.2 Phosphate Release Assay ............................................................................. 156 
3.11.3 Assessing the Autophosphorylation of VanS ............................................... 157 
3.11.4 Identifying Nucleotide products using Anion Exchange Chromatography . 160 
3.12 Crystallisation Screens ...................................................................................... 167 
3.13 Discussion............................................................................................................ 170 
3.13.1 Approaches to express and purify VanS proteins for crystal studies ........... 171 
3.13.2 Screening crystallisation of VanS proteins from multiple species ............... 172 
3.13.3 Activity of VanS and its crystallisation is affected by detergent micelles ... 173 
3.13.4 Possibility of secondary reactions during VanS autophosphorylation ......... 174 
  
[vii] 
 
CHAPTER 4:      STRUCTURAL STUDIES OF THE VANS SENSOR DOMAIN BY 
SOLUTION-STATE NMR SPECTROSCOPY .............................................................. 177 
4.1 Introduction ........................................................................................................ 177 
4.2 Aims ..................................................................................................................... 180 
4.3 Gene Modification of vanS sequences to create NMR-relevant constructs .. 181 
4.4 M9 Minimal Media Expression of vanS genes ................................................. 192 
4.5 M9 Minimal Media Expression of mutant vanS genes for Enzymatic Cleavage 
and Purification of the isolated VanS sensor domain ................................................. 198 
4.6 2D Solution State NMR studies of the VanS sensor domain and Optimisation 
of Solution Conditions by Temperature, Detergent and Buffer Screening .............. 204 
4.6.1 Effect of magnetic field strength and temperature ....................................... 204 
4.6.2 Effect of detergent ........................................................................................ 207 
4.6.3 Effect of pH .................................................................................................. 214 
4.6.4 Analysis of protein fold in NMR samples .................................................... 217 
4.7 Discussion............................................................................................................ 219 
4.7.1 Optimal routes to obtain and selectively purify the VanS sensor domain ... 220 
4.7.2 Optimised protocols for the expression of  
15
N-labelled VanS proteins ...... 222 
4.7.3 Obtaining high resolution 2D NMR spectra of the VanS sensor domain .... 224 
 
CHAPTER 5:      ANALYSIS OF RECEPTOR-LIGAND BINDING AND 
EXAMINATION OF THE ROLE OF OLIGOMERISATION IN SIGNALLING .... 227 
5.1 Introduction ........................................................................................................ 227 
5.2 Aims ..................................................................................................................... 232 
5.3 Analysis of Ligand Binding by Fluorescence Spectroscopy ........................... 233 
5.4 Analysis of Ligand Binding by Solution State NMR Spectroscopy ............... 239 
5.4.1 Chemical Shift Perturbation NMR Analysis ................................................ 240 
5.4.2 Analysis of Full-length VanS proteins by NMR Spectroscopy ................... 257 
5.4.3 NMR Titration of the Lipid II cell wall precursor ....................................... 262 
5.4.4 NMR Titration of other glycopeptide antibiotics ......................................... 264 
[viii] 
 
5.5 The Role of VanS Oligomerisation in Ligand Binding and Signalling.......... 266 
5.5.1 Analysis of VanS Oligomerisation by Blue Native PAGE .......................... 267 
5.5.2 Analysis of VanS Homo-Oligomerisation using ToxCAT Assays .............. 270 
5.6 Discussion............................................................................................................ 280 
5.6.1 New evidence for a direct interaction between vancomycin and VanS ....... 281 
5.6.2 The role of transmembrane domains upon signal transduction .................... 283 
5.6.3 The role of vancomycin dimerization in ligand binding .............................. 286 
 
CHAPTER 6:      SUMMARY AND CONCLUSIONS ................................................... 290 
6.1 Background and Objectives .............................................................................. 290 
6.2 Efforts towards Crystallisation or an NMR Structure of a VanS protein .... 290 
6.3 Characterising the Mechanism of VanS autophosphorylation ...................... 292 
6.4 Assessing the Binding of Potential Antibiotic Ligands to VanS proteins...... 293 
6.5 Assessing the role of TM domain association in Signal transduction ............ 294 
6.6 Recommendations for Future Work ................................................................ 296 
 
BILIOGRAPHY ................................................................................................................. 301 
 
APPENDIX ......................................................................................................................... 328 
 
  
[ix] 
 
List of Tables 
 
Chapter 1 : Introduction 
 
Table 1.1.1.1:  Antibiotic classes, their deployment year and observed clinical resistance…..3  
Table 1.1.3.1:  Major classes of antibiotics; their targets and mechanism of action………….5 
Table 1.3.3.1:  VRE Phenotypes, adapted from Sujatha & Praharaj (2012)………………...21 
Table 1.4.3.1:  Induced vancomycin resistance in the E. faecium VanA phenotype by  
            various antibiotics, according to reporter or assay based systems…………..32 
Table 1.4.3.2:  Induced vancomycin resistance in the E. faecalis VanB phenotype by    
           various antibiotics, according to reporter or assay based systems………......33 
Table 1.4.3.3:  Induced vancomycin resistance in the S. coelicolor VanB-like phenotype  
           by various antibiotics, according to reporter or assay based systems……….33 
Table 1.5.1.1:  Examples of bacterial two-component signalling systems……………….....35  
 
Chapter 2 : Materials and Methods 
 
Table 2.2.2.1: E. coli strains used in this project………………………………………….61 
Table 2.4.1: Synthesised oligonucleotide sequences used in this project…………….....63   
Table 2.4.8.1: Initial gene constructs and constructs created……………………………..70 
Table 2.13.1: Factors affecting crystallisation……………………………………….….107  
 
Chapter 3 : Cloning, Expression, Purification and Functional Characterisation 
of VanS proteins from Enterococci and Streptomyces  
 
Table 3.11.3.1:  ADP and phosphate release per assay for VanSA in DDM or DPC and 
             VanSSC in DPC, recorded at 25, 60 or 120 minutes……………………....159  
Table 3.11.4.1A:Relative peak integrals of nucleotide products observed over time by anion   
 exchange chromatography upon addition of ATP to VanSA…………......163  
Table 3.11.4.1B:Relative peak integrals of nucleotide products observed over time by anion  
 exchange chromatography upon addition of ADP to VanSA………….....165  
Table 3.12.1:      Concentrations of detergent-purified, tag-cleaved VanSA proteins  
 used in crystallisation screens…………………………............................169 
 
  
[x] 
 
List of Figures 
 
Chapter 1 : Introduction 
 
Figure 1.1.6.1: A schematic illustration of the five families of drug efflux pumps  
            involved in antibiotic resistance…………………………………………….13 
Figure 1.2.1.1: Structures of Gram-positive (a) and Gram-negative (b) bacterial cell  
            walls, reproduced from Soloman et al., (1999)……………………………..14 
Figure 1.2.5.1: Steps and enzymes involved in the biosynthesis of peptidoglycan………....17 
Figure 1.3.1.1: Structures of vancomycin and teicoplanin.………………………………….18 
Figure 1.3.3.1: (left) Vancomycin binding to the D-Ala-D-Ala N-terminus of Lipid II PG  
            precursor and (right) a resistant D-Ala-D-Lac form………………………..20  
Figure 1.3.6.1: A comparison of van gene clusters from Enterococcal VanA and VanB  
            strains and actinomycetes. ………………………………………………….24 
Figure 1.3.6.2: (left) A model of the VanRS two-component system controlling antibiotic  
            resistance (right) the function of enzymes encoded by van resistance genes26 
Figure 1.4.1.1: A petri plate assay for vancomycin resistance induction, reproduced from 
            Lai & Kirsch (1996)………………………………………………………...28 
Figure 1.4.2.1: Schematic diagram of a direct binding between VPP and VanSSC protein…31 
Figure 1.5.2.1: Domain architecture and signalling in two-component systems…………....36  
Figure 1.5.3.1: The dimerisation and phosphotransfer domain of EnvZ HK ……………….38  
Figure 1.5.3.2: Ribbon diagram of the ATP binding domain of DesK HK from B. subtilis  
                         with bound ATP (PDB: 3EHG)……………………………………………..39  
Figure 1.5.3.3: X-ray crystal structures of monomeric sensor domains of histidine kinases..40  
Figure 1.5.4.1: Structures of the E. coli receiver domain of the PhoB response regulator….43  
Figure 1.5.4.2: Structure of the dimeric effector domain of NarL RR binding to DNA…….44  
Figure 1.5.5.1: Schematic of histidine kinase modular architecture.……………………......45  
Figure 1.5.5.2: Ribbon diagram of the dimeric cytoplasmic portion of HK853…………….47  
Figure 1.5.5.3: Ribbon representation of the crystal structure of HK853-RR468 complex…48  
Figure 1.5.5.4: Signal transduction model, adapted from Casino et al., (2009)…………….49  
Figure 1.5.6.1: Ribbon diagram of the X-ray crystal structure of the dark-adapted sensor  
                         kinase YF1 (PDB: 4GCZ)…………………………………………………..51 
Figure 1.6.1.1: Structures of Platensimycin and Bedaquiline……………………………….54  
Figure 1.6.2.1: A synthetic amidine vancomycin aglycone which binds to D-Ala-D-Lac….55  
Figure 1.7.1.1: Schematic diagram showing the predicted topology of VanS, which is  
            activated by vancomycin antibiotics, to transduce a signal to VanR……….58 
[xi] 
 
Chapter 2 : Materials and Methods 
 
Figure 2.4.2.1: 3C site insertion by “Round-the-Horn” mutagenic PCR……………………67  
Figure 2.6.6.1: Model of the interaction between Ni NTA and a His-tag…………………...81  
Figure 2.7.1.1: Expression of chimeric fusion proteins using the pccKan plasmid.…….…..87  
Figure 2.7.1.2: Example of annealed oligonucleotide sequences of the VanSA TM1 domain  
            for inserting into pccKan plasmids………………………………………….88  
Figure 2.7.1.3: A 0.8% agarose gel stained with ethidium bromide, showing undigested  
            pccKan plasmid, and double-digested pccKan plasmid…………………….89  
Figure 2.9.1.1: Reaction pathway involved in ADP production by ATP hydrolysis, as  
            described by Wampler and Westhead (1968)……………………………....95  
Figure 2.9.2.1: Reaction pathway involved in inorganic phosphate release by ATP  
                         hydrolysis, as described by Webb (1992)…………………………………..97  
Figure 2.11.1:  BODIPY-Vancomycin structure, drawn in IsisDraw……………………...101  
Figure 2.13.1:  Two-dimensional Phase diagram for Crystal growth……………………...106  
Figure 2.13.1.1: The Vapour diffusion method…………………………………………….108  
Figure 2.14.1:  Representation of nuclear spin relative to an axis of rotation, upon  
            irradiation with a 90
o 
pulse at the Larmor frequency (rf)………………….110 
Figure 2.14.2:  An example 2D COSY pulse program…………………………………….111 
 
Chapter 3 : Cloning, Expression, Purification and Functional Characterisation 
of VanS proteins from Enterococci and Streptomyces  
 
Figure 3.1.1:    Model of phosphotransfer relay in the VanS-VanR two-component 
            system……………………………………………………………………...116 
Figure 3.1.2:    Schematic representation of the VanS protein and predicted topology……118  
Figure 3.1.3:    CLUSTALW2 sequence alignment of the VanSA, VanSB and VanSSC protein  
                         sequences…………………………………………………………………..119   
Figure 3.3.1:    Restriction map of the pProEx HTa plasmid between bases 251 and 450...122  
Figure 3.3.2:    A 0.8% agarose gel (inverted image) showing the PCR amplification  
            of (a) vanSA and (b) vanSSC genes…………………………………………123  
Figure 3.3.3:    A 0.8% agarose gel (inverted image) showing correctly-sized gene  
            sequences after NcoI/HindIII double-digestion…………………………...124 
Figure 3.4.1:    A 12% SDS-PAGE gel showing proteins overexpressed in C41 or  
            C43 (DE3) pRIL cell lines after Water Lysis preparations………………..125  
  
[xii] 
 
Figure 3.4.2:    (a) An SDS-PAGE gel showing overexpressed proteins from pttQ18::vanSA  
            in C41pRIL cells at varying [IPTG] and (b) corresponding growth curves.126  
Figure 3.4.3:    12% SDS-PAGE gel showing overexpression from pProEx::vanSA  
            or pProEx::vanSSC constructs in C41pRIL cells, after Water Lysis…….....127  
Figure 3.4.4:    A 12% SDS-PAGE gel showing expression from pProEx::vanSA at 25
o
C  
            overnight prepared by Water Lysis………………………………………..128 
Figure 3.5.1:    (left) 12% SDS-PAGE gel of Water Lysis preparations, and (right) equivalent  
            Western blot developed using Roche non-specific anti-His antibodies…...129  
Figure 3.5.2:    (left) 12% SDS-PAGE gel of Water Lysis preparations, and (right) equivalent  
Western blot developed using Sigma N-term preferential anti-His    
antibodies………………………………………………………………….130  
Figure 3.6.1:    A 12% SDS-PAGE gel showing N-His6-VanSA purification by affinity  
            chromatography……………………………………………………………132  
Figure 3.6.2:    A 12% SDS-PAGE gel of N-His6-VanSA extraction into DDM micelles…133  
Figure 3.6.3:    (a) Western blots showing detergent solubilisation of VanSSC (left) or VanSA  
(right) membrane pellets, and (b) corresponding bar charts of the relative   
percentages of soluble and insoluble protein.……………………………..134   
Figure 3.6.4:    Molecular structures of DPC and DDM detergents, drawn in ISISDraw…135  
Figure 3.6.5:    Crystallisation conditions for C-His6-VanSA at 18
o
C, identified by Dr Marek  
            Brzozowski and Justyna Korczynska at York University…………………137  
Figure 3.6.6:    A 12% SDS-PAGE gel showing the purification of N-His6-VanSA by affinity  
            chromatography……………………………………………………………138  
Figure 3.6.7:    Western blot showing attempted purification of N-His6-VanSSC proteins  
            expressed at 37
o
C………………………………………………………….139  
Figure 3.6.8:    Western blot showing attempted purification of N-His6-VanSSC proteins  
            expressed at 16
o
C………………………………………………………….139  
Figure 3.6.9:    A 12% SDS-PAGE gel showing purification of N-His6-VanSSC proteins by  
            affinity chromatography…………………………………………………...140  
Figure 3.7.1:    Gel Filtration Chromatograms for protein samples of VanSA (black) and  
            VanSSC (red) applied to a Superose 12 column……………………………141  
Figure 3.7.2:    A calibration curve of gel filtration standards, plotted by the log of their  
            weights against their elution times (Ve), relative to a void volume (Vo)…141  
Figure 3.7.3:    A 12% SDS-PAGE gels showing aliquots of 0.3 mL gel filtration elutions  
            collected under the main peak (~10 -12 mL)……………………………...142  
Figure 3.8.1:    A 12% SDS-PAGE gel to test conditions for VanSA tag-cleavage………..143 
Figure 3.8.2:    A 12% SDS-PAGE gel showing tag-cleavage of VanSA with TEV……….144  
  
[xiii] 
 
Figure 3.9.1:    Mass averaged, deconvoluted ESI-TOF mass spectra of tag-cleaved wild-type  
            VanSA (a) and VanSSC (b) proteins………………………………………..145  
Figure 3.10.1:  CD spectra of 5 μM N-His6-VanSA and N-His6-VanSSC in HEPES or  
                          phosphate buffer pH 7.5, containing 2 mM DPC………………………....147   
Figure 3.10.2:  CD spectra of 5 μM N-His-tagged and tag-cleaved VanSA in phosphate buffer   
pH 7.5 or TFE, containing 2 mM DPC…………………………………...148   
Figure 3.11.1:    14% acrylamide SDS-PAGE gel phosphoimage of VanSAΔ110  
              autophosphorylation with time, reproduced from Quigley (2010)………150  
Figure 3.11.2:    ADP release profile of C-His6-VanSA full-length (green), VanSAΔ110  
             (blue) and VanSAΔ155 (red), extracted from Quigley (2010)……………151  
Figure 3.11.1.1: Reaction pathways involved in (a) ADP production by ATP hydrolysis  
              and (b) inorganic phosphate release by ATP hydrolysis………………....153 
Figure 3.11.1.2: ADP release profile for full-length VanSA protein in 6 mM DDM  
 (0.03 %, red) or 2 mM DPC (0.07%, green), and VanSSC protein in 2 mM    
 DPC (0.07%, blue)……………………………………………………….154  
Figure 3.11.1.3: ADP release profile for full-length VanSA protein in 6 mM DDM 
 (0.03 %) produced upon initiation by either enzyme (green) or substrate    
 (red)………………………………………………………………………156  
Figure 3.11.2.1: Phosphate release profile for full-length VanSA in 6 mM DDM  
 (0.03%, red) or 2 mM DPC (0.07%, green), and full-length VanSSC in 2 mM  
 DPC (0.07%, blue)……………………………………………………….157 
Figure 3.11.4.1: MS-MS spectra of ATP phosphorylation reaction of VanSA100 630 m/z, 
              reproduced from Quigley (2010)………………………………………...161  
Figure 3.11.4.2: Anion-exchange chromatography profiles for nucleotide standards (200 μM)  
 applied to a pre-equilibrated MonoQ 5/50 GL column………………….162  
Figure 3.11.4.3: Overlayed anion exchange chromatograms collected at timepoints during  
reaction of VanSA with ATP, showing the relative amounts of nucleotide       
products…………………………………………………………………..163  
Figure 3.11.4.4.: Overlayed anion exchange chromatograms collected at timepoints during  
reaction of VanSA with ADP, showing the relative amounts of nucleotide          
products………………………………………………………………….165 
Figure 3.12.1:    AMP-PNP structure………………………………………………………168  
Figure 3.12.2:    A selection of promising crystallisation conditions for VanSA proteins  
              solubilised in 0.07% DPC on MemGold 96-well screens………………..169  
 
  
[xiv] 
 
Chapter 4 : Structural Studies of the VanS sensor domain by solution-stated 
NMR spectroscopy 
 
Figure 4.1.1:     NMR backbone structures of TM domains of two classes of histidine   
kinase……………………………………………………………………...178  
Figure 4.3.1:     Purified PCR products from amplification of vanSA, encoding the N-terminal  
His6 tag, TEV site and the first 110, 120 or 130 amino acids of the protein     
sequence…………………………………………………………………..182  
Figure 4.3.2:     Western blots showing levels of overexpression of VanSA110, 120 or 130  
after Water Lysis preparation……………………………………………..183  
Figure 4.3.3:     Disorder prediction plots for VanSA (a) and VanSSC (b) using  
                          RONN software…………………………………………………………...184 
Figure 4.3.4: Western blot showing overexpression of SA120 at 16 or 25
o
C, at  
             varying IPTG concentrations……………………………………………..185 
Figure 4.3.5:     Schematic representation of a VanS protein and the proposed position for  
             insertion of an enzymatic cleavage site…………………………………...187 
Figure 4.3.6:     (left) A 15% SDS-PAGE gel containing digested samples of N-His6-VanSA  
             collected over timepoints, (right) the corresponding Western blot……….188  
Figure 4.3.7:     Map of peptide fragments identified by MS/MS analysis of excised gel bands  
         from digestion of VanSA or VanSSC………………………………………189  
Figure 4.3.8:     Secondary structure prediction for VanSA (a) and VanSSC (b) proteins  
between residues 80-160, generated using PSIPred software…………….190  
Figure 4.3.9:     Sequencing data showing a section of the VanSA DNA sequence containing  
an inserted TEV site (GAG AAC CTG TAC TTC CAG AGT) encoding for 
ENLYFQS………………………………………………………………...191 
Figure 4.4.1:  A diagram of the optimised high-cell-density method used for production of  
        uniformly 
15
N-labelled VanS proteins……………………………………195 
Figure 4.4.2:  (left) A 12% SDS-PAGE gel of VanSA and VanSSC overexpression in M9  
minimal media, at different IPTG concentrations, and (right) corresponding 
Western blot………………………………………………………………196  
Figure 4.4.3:  A bar chart showing relative band intensities for full-length VanSA proteins  
          overexpressed under different conditions in 
15
N M9 minimal media…….197  
Figure 4.5.1:  (left) A 12% SDS-PAGE gel showing overexpression of VanSA and VanSSC  
mutants in 
15
N-labelled M9 minimal media, and (right) the corresponding 
Western blot………………………………………………………………198  
  
[xv] 
 
Figure 4.5.2:  (left) A 15%  SDS-PAGE gel showing initial products from digestion of  
                      VanSA-3C after 4 hours, (right) corresponding western blot……………..199  
Figure 4.5.3:  (left) A 15% SDS-PAGE gel showing initial products from TEV digestion  
of VanSA-TEV after 4 hours, (right) corresponding western blot………...199  
Figure 4.5.4:  A 12% SDS-PAGE gel showing selective purification of the VanSA  
N-terminal ‘sensor’ domain away from the C-terminal domain and 3C 
enzyme……………………………………………………………………201  
Figure 4.5.5:  Gel filtration chromatograms of protein samples containing the N-terminal  
sensor domain of 
15
N-labelled VanSA (black line) or VanSSC (red line) in 
DPC micelles, applied to a Superose 12 10/300 GL column……………..202  
Figure 4.5.6:  A 15% SDS-PAGE gel showing digestion and subsequent purification of the  
         N-terminal ‘sensor’ domain of VanSA……………………………………202   
Figure 4.6.1.1:  2D 
1
H-
15
N HSQC spectrum of 140 μM VanSA sensor domain collected at 
  (a) 298K on a 500 MHz spectrometer, or (b) 310K on a 700 MHz  
           spectrometer………………………………………………………………205  
Figure 4.6.1.2:  2D 
1
H-
15N HSQC spectrum of 200 μM VanSSC sensor domain in 50 mM  
            DPC, collected at 310K on a 700 MHz spectrometer…………………….206 
Figure 4.6.2.1:  Molecular structures of LPPG and DPPG detergents, drawn in ISISDraw208  
Figure 4.6.2.2:  Bar charts showing the relative percentages of soluble (red) and insoluble  
                          (blue) protein for (a) VanSA or (b) VanSSC in different detergents……….209  
Figure 4.6.2.3:  Overlayed 2D 
1
H-
15
N HSQC spectra of VanSA sensor domain solubilised in  
             50 mM DPC at 140 μM (red) or in 50 mM LPPG at 200 μM (green)……211  
Figure 4.6.2.4:  Overlayed 2D 
1
H-
15N HSQC spectra of (a) 200 μM VanSA sensor domain 
(b) 150 μM VanSSC sensor domain, at selected temperatures between 288K 
and 318 K…………………………………………………………………213  
Figure 4.6.3.1:  Overlayed 2D 
1
H-
15N HSQC spectra of (a) 200 μM VanSA N-terminal 
sensor domain, or (b) 150 μM VanSSC N-terminal sensor domain, obtained 
at  selected pHs between pH 4.6 and 6.3 in 50 mM LPPG……………….215 
Figure 4.6.3.2:  Overlayed 2D 
1
H-
15N HSQC spectra of 140 μM VanSA N-terminal sensor  
             domain obtained at selected pHs between 4.6 and 6.3 in 50 mM DPC…..217  
Figure 4.6.4.1:  Overlayed CD spectra for VanSA and VanSSC sensor domains purified in  
             different detergents………………………………………………………..218 
Figure 4.7.1.1:  An illustration of the purification route used to express, cleave and purify  
the N-terminal sensor domain of VanS…………………………………...221     
Figure 4.7.3.1: Optimal 2D 
1
H-
15
N HSQC spectra of the N-terminal sensor domains of  
VanSA and VanSSC proteins purified in various detergents and collected on a     
700 MHz spectrometer at 310K…………………………………………...226  
[xvi] 
 
Chapter 5 : Analysis of Receptor-Ligand Binding and Examination of the Role 
of Oligomerisation State in Receptor Signalling 
 
Figure 5.3.1:  Overlayed emission spectra upon excitation of BODIPY-vancomycin dye in  
         HEPES buffer and/or DPC………………………………………………..234  
Figure 5.3.2:  Overlayed emission spectra upon excitation of BODIPY-vancomycin dye in  
HEPES buffer containing DPC, and increasing concentrations of detergent-
solubilised Lipid II………………………………………………………..235  
Figure 5.3.3:  Overlayed emission spectra upon excitation of BODIPY-vancomycin dye in  
HEPES buffer containing DPC, and increasing concentrations of detergent-
solubilised VanSA…………………………………………………………236  
Figure 5.3.4:  Overlayed emission spectra upon excitation of BODIPY-vancomycin dye in  
HEPES buffer containing DPC, and increasing concentrations of detergent-
solubilised VanSSC………………………………………………………..237  
Figure 5.4.1.1:  Overlayed 2D 
1
H-
15N HSQC spectra of 120 μM VanSA N-terminal domain  
solubilised in 50 mM DPC, before and after addition of detergent-solubilised  
vancomycin……………………………………………………………….242 
Figure 5.4.1.2:  The appearance of 2D NMR peak shape under different rates of 
exchange…………………………………………………………………..243  
Figure 5.4.1.3:  Overlayed 2D 
1
H-
15N HSQC spectra of (a) 600 μM VanSA N-terminal  
domain solubilised in 50 mM DPC, 20 mM HEPES pH 6.85, or (b) 700 μM 
VanSA N-terminal domain solubilised in 50 mM LMPG, 50 mM sodium 
acetate pH 5.5, during titration of detergent-solubilised vancomycin……245  
Figure 5.4.1.4:  Overlayed 2D 
1
H-
15N HSQC spectra of 200 μM VanSSC N-terminal domain  
solubilised in 50 mM LPPG, 50 mM phosphate pH 6.1, during titration of 
detergent-solubilised vancomycin………………………………………...247  
Figure 5.4.1.5:  Chemical shift changes observed for individual peaks in the 
1
H-
15
N HSQC  
spectrum of VanSA protein in LMPG (Fig. 5.4.1.3B) upon addition of 
vancomycin, represented by a bar chart of peak number (in ascending 
1
H
N
) 
against chemical shift change (Δδ)…………………………………….....250 
Figure 5.4.1.6:  Overlayed 2D 
1
H-
15N HSQC spectra of 700 μM VanSA N-terminal domain 
in 50 mM LMPG during titration of vancomycin, zoomed in to the region of 
7.5-8.4 ppm in 
1
H and 127-110 ppm in 
15
N, in Figure 5.4.1.3B………….251  
Figure 5.4.1.7:  Overlayed 2D 
1
H-
15N HSQC spectra of 600 μM VanSA N-terminal domain 
in 50 mM DPC during titration of vancomycin, zoomed in to the region of 
7.5-8.2 ppm in 
1
H and 125-110 ppm in 
15
N, in Figure 5.4.1.3A………….252  
[xvii] 
 
Figure 5.4.1.8:  Overlayed 2D 
1
H-
15N HSQC spectra of 200 μM VanSSC N-terminal domain  
in 50 mM LPPG during titration of vancomycin, zoomed in to the region of 
7.4-8.2 ppm in 
1
H and 123-108 ppm in 
15
N, in Figure 5.4.1.4……………253  
Figure 5.4.1.9:  Overlayed 2D 
1
H-
15
N HSQC NMR spectra for VanS proteins during titration  
             of vancomycin, showing individual peak shifts with high calculated CSP256  
Figure 5.4.1.10: Predicted domain positions in the VanSSC protein sequence, showing  
 residues 17 to 85………………………………………………………….257 
Figure 5.4.2.1:  (a) Overlayed 2D 
1
H-
15N HSQC spectra of 700 μM VanSA N-terminal  
domain (red) or 600 μM full-length protein (green), (b) Overlayed 2D 1H-
15
N HSQC spectra of the VanSA full-length protein during titration of 
detergent-solubilised vancomycin………………………………………...259 
Figure 5.4.2.2:  Vancomycin (left) and Desleucyl vancomycin (right) structures, drawn in  
             ISISDraw………………………………………………………………….261  
Figure 5.4.3.1:  Overlayed 2D 
1
H-
15N HSQC spectra of (a) 600 μM VanSA N-terminal 
sensor domain solubilised in 50 mM DPC, or (b) 500 μM VanSSC full-length 
protein solubilised in 50mM DPC, during titration of detergent-solubilised 
vancomycin and Lipid II-Lys……………………………………………..263   
Figure 5.4.4.1:  Overlayed 2D 
1
H-
15N HSQC spectra of 600 μM VanSA N-terminal domain 
in 50 mM LMPG, 50 mM phosphate buffer pH 6.0, during titration of 
detergent-solubilised teicoplanin…………………………………………265 
Figure 5.5.1.1:  (left) BN-PAGE 4-16% gradient gel loaded with purified His-tagged full- 
length VanSA samples in DPC at 0.1% w/v (~2x CMC), or in DDM at 
0.05% w/v (~3x CMC) (right) corresponding Western blot……………...268 
Figure 5.5.1.2:  BN-PAGE 4-16% gradient gel loaded with purified His-tagged full-length  
VanSA (left) or VanSSC (right)  samples in DPC detergent at 0.1% w/v (~2x 
CMC).……………………………………………………………………..269 
Figure 5.5.2.1:  A schematic diagram of the basis for the ToxCAT assay………………...272  
Figure 5.5.2.2:  The malE complementation assay………………………………………...273  
Figure 5.5.2.3:  Anti-MBP Western blots showing (a) the expression of chimeric fusion  
proteins in NT326 cells (normalised by OD600) or (b) a spheroplast assay for 
one fusion protein…………………………………………………………274  
Figure 5.5.2.4:  The disk diffusion assay…………………………………………………..275  
Figure 5.5.2.5:  Fluorescence emission spectra collected upon excitation of samples  
            containing chimeric fusion proteins at 495 nm…………………………...276 
  
[xviii] 
 
Figure 5.5.2.6:  Normalised ToxCAT activity for each chimeric fusion protein………….277  
Figure 5.5.2.7:  A comparison of the predicted TM sequences for VanSA and VanSSC  
             proteins, highlighting helix-helix packing motifs………………………...279  
Figure 5.6.2.1:  (a) Overlayed backbone structures of CitA ligand-free monomers (magenta)  
and ligand-bound dimers (green), reproduced from Wang (2012) and (b) the 
hypothetical model of TM signalling in CitA…………………………….285 
Figure 5.6.3.1:  A back-to-back dimer of the vancomycin aglycone induced by an acetate  
             ligand, represented by sticks and a cartoon ribbon……………………….287  
Figure 5.6.3.2:  Stereo view of the “face-to-face” dimer present for vancomycins 4 and 6 in a  
six-vancomycin-asymmetric unit (PDB: 1FVM), with hydrogen bonding to 
DALAA ligands…………………………………………………………..288  
 
Chapter 6 : Summary and Conclusions 
 
Figure 6.6.1:     Conceptual representation of the protein-tethered lipid bilayer, reproduced  
             from Giess et al., (2004)………………………………………………….299 
  
[xix] 
 
Acknowledgements 
 
First and foremost I would like to thank my supervisors Dr Ann Dixon and Dr David Roper 
for providing me with the opportunity to do a PhD at Warwick University, and for their 
continued support and guidance throughout the last four years. I would also like to thank 
everyone in the Roper and Dixon research groups for providing a great environment to work 
in, and for helping motivate me to keep going in my research studies and finish my thesis.  
 
I would particularly like to thank the following: Dr Gemma Warren for support with cloning, 
Dr Karen Ruane for assistance in purifications and crystallisations, Michael Chow for help 
with screening detergents for NMR, Dr Adrian Lloyd and Dr David Roper for guidance with 
expression and activity assays, and Dr Ann Dixon for help analysing the reams of NMR data.    
 
I would also like to thank my collaborators: Dr Andrew Quigley and Dr Liz Carpenter at the 
Integral Membrane Protein Department (SGC, Oxford) for their expertise in purifying active 
proteins, and for the use of their mass spectrometry and crystallisation facilities, and within 
Warwick: Dr Susan Slade at the Warwick/Waters Centre for help analysing protein gel 
bands, and Anita Catherwood at the Bacwan Facility for providing Lipid II samples. 
 
Thanks also to my sponsor, the Medical Research Council for providing me with the 
financial backing for this PhD and the opportunity to attend and present my studies at 
national and international conferences. And special thanks to Dr John Blood, Conor Proud 
and Dr Dean Rea, for the numerous chats and the occasional beer to help me face the 
challenge of membrane protein research!    
 
Lastly, I would like dedicate this thesis to my parents; Alison Edwards and Martin Edwards, 
and my girlfriend; Amy O’Reilly, for all their love and support during this challenging time.     
  
[xx] 
 
Declaration 
 
This thesis is submitted to the University of Warwick in support of my application for the 
degree of Doctor of Philosophy. It has been composed by myself and has not been submitted 
in any previous application for any degree or at any other university.  
 
I hereby declare that the research submitted in this thesis was conducted by myself, under the 
supervision of Dr David Roper at the School of Life Sciences and Dr Ann Dixon at the 
Department of Chemistry (University of Warwick), or was conducted by myself during 
collaborative research at the Structural Genomics Consortium (University of Oxford), which 
is fully acknowledged. 
 
All sources of information, including the work of others, are acknowledged in the form of 
references, and can be found in the bibliography.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Richard Edwards 
September 2014  
[xxi] 
 
Abstract 
 
VanS is a sensor histidine kinase which forms part of a Two-Component System, with the 
response regulator, VanR. This system regulates inducible transcription of genes responsible 
for glycopeptide resistance in enterococci and actinomycetes. In the presence of an antibiotic 
inducer, VanS autophosphorylates at a conserved histidine residue, and transfers this 
phosphate to VanR. This phosphorylated form of VanR activates transcription of vanHAX 
genes, which confer resistance to glycopeptide antibiotics.  
 
This research investigates the structure and function of VanS proteins derived from E. 
faecium and S. coelicolor, which exhibit different antibiotic resistance phenotypes. The focus 
is on improving understanding of how glycopeptide antibiotics can either, directly or 
indirectly, induce VanS activity in each species, and if direct, to identify any ligand binding 
sites. To date, only one study has shown a direct binding between VanS (derived from S. 
coelicolor) and a vancomycin glycopeptide (Koteva et al., 2010), so this protein (termed 
VanSSC) was chosen as a control in ligand binding assays, alongside VanS proteins derived 
from E. faecium (termed VanSA).  
 
Full-length VanS proteins were purified in a functionally-active state and analysed for their 
structure and ligand binding properties by NMR spectroscopy. High resolution 2D NMR 
spectra of the isolated VanS sensor domains in each protein have been collected for the first 
time, and provided a platform for conducting NMR-based ligand titrations. Chemical Shift 
Perturbation Analysis of the resulting NMR titration data indicates several residues in VanS 
involved in binding to vancomycin. In conjunction with fluorescence assays, this data newly 
suggests that both VanSA and VanSSC can interact directly with vancomycin. This challenges 
consensus belief in the literature that VanSA should only be activated indirectly. NMR-based 
assays outlined here now pave the way for further in-depth studies of the ligand binding 
mechanism and putative identification of other ligands in this Two-Component System.  
[xxii] 
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1 Introduction 
 
1.1 Antimicrobials and Bacterial Antibiotic Resistance 
1.1.1 Historical Background and Current Context 
 
Dame Sally Davies, the UK chief medical officer, has said the threat from infections that are 
resistant to frontline antibiotics is so serious the issue should be added to the government’s 
national risk register of civil emergencies. She went on to say: “There are few public health 
issues of potentially greater importance for society than antibiotic resistance. It means we 
are at increasing risk of developing infections that cannot be treated.” (Sample, 2013) 
 
Despite advances in medical science and technology over the centuries, the threat to the 
human population from bacterial and viral diseases is as great as ever. As human population 
density has increased, so has the emergence of infectious disease, which has evolved to such 
a degree that many microbial strains challenge all current drug treatment options. A poignant 
example is the outbreak of Ebola Virus Disease in Africa this year, for which there is no 
proven treatment, and which has caused many countries to close their borders, and set up 
quarantine camps (WHO, 2014a). It is clear that greater research and development of new 
antimicrobials is required to provide options for treating evolving disease pathogens.  
 
The discovery and development of successful antimicrobial drugs has been accomplished 
historically by two main routes. Firstly, medicinal chemistry was used to design synthetic 
compounds for specific targets (Walsh, 2003), which led to the discovery of the first class of 
antimicrobials, the arsenicals. These include Paul Ehrlich’s ‘magic bullet’, Salvarsan, which 
was used in the treatment of syphilis (Schwartz, 2004). This was followed by the discovery 
of the sulphonamide antibiotic, Protonsil in 1935 by Gerhard Domagk, which was heavily 
prescribed during the Second World War to treat infections from streptococci (Iyer, 2008). 
[2] 
 
Secondly, chemists used the antibacterial activity of natural products, and developed assays 
to purify these agents (Walsh, 2003). This approach is highlighted by the work of Sir 
Alexander Fleming, Sir Howard Florey and Ernst Chain, who were jointly awarded the 
Nobel Prize in 1945 for their novel work relating to “the discovery of penicillin and its 
curative effects in various infectious diseases” (Fleming, 1980). Fleming discovered 
penicillin quite fortuitously whilst working with Staphylococcus spp. variants. After 
mistakenly leaving open the lid from a petri dish containing Staphylococcus culture, he 
noticed a mould growing, around which a halo had formed, where growth of the culture was 
inhibited. This mould contained Penicillium notatum, which exuded a substance with 
antibacterial properties, repressing growth and lysing the bacteria (Fleming, 1980). Further 
development of penicillin as a medicine was then pioneered by Florey and Chain, who 
isolated and purified penicillin for clinical use (as Penicillin G) (Chain et al., 1993).  
 
In 1944, Selman Waksman and his colleagues initiated a screening program to discover new 
antibiotics, by isolating chemical substances from soil bacteria (actinomycetes), recognising 
the activity of actinomycetes against other microorganisms (Rubin, 2007). This led to the 
discovery of streptomycin (Schatz et al., 2005), the first aminoglycoside, which was highly 
effective against tuberculosis (Feldman and Hinshaw, 1948). Waksman was the first to use 
the term ‘antibiotic’ to describe its actions, envisioning the drug as ‘a substance produced by 
one microorganism that antagonized the effect of another’ (Rubin, 2007).  
 
After identification of antibiotics in academic labs, pharmaceutical companies such as Glaxo, 
Beecham, Eli Lilly and Merck conducted intensive screening programs to identify further 
antibiotic classes. They were responsible for compound scale-up, formulation and clinical 
development, allowing antibacterial drug research to gain prominence as a viable area for 
investment, and led to the ‘golden era’ of antibiotic discovery between 1950 and 1960 (see 
Table 1.1.1.1).  
 
[3] 
 
Table 1.1.1.1: Antibiotic classes, their deployment year and observed clinical resistance 
Adapted from Palumbi et al., 2001; Walsh & Wencewicz, 2014. Note: The table shows when 
clinical resistance was observed, but the first report of resistance may be earlier.  
 
Antibiotic Year Deployed Clinical Resistance Observed 
Sulfonamides 1930s 1940s 
Penicillin G 1943 1946 
Streptomycin 1943 1959 
Chloramphenicol 1947 1959 
Tetracycline 1948 1953 
Erythromycin 1952 1988 
Vancomycin 1956 1988 
Methicillin 1960 1961 
Ampicillin 1961 1973 
Cephalosporins 1960s Late 1960s 
Nalidixic acid 1962 1962 
Fluoroquinolones 1980s 1980s 
Linezolid 1999 1999 
Daptomycin 2003 2003 
Retapamulin 2007 2007 
Fidaxomicin 2011 2011 
Bedaquiline 2013 ? 
 
Resistance has developed to every class of antibiotic, natural and synthetic, over time 
courses from a year to around a decade (Table 1.1.1.1), with the exception of erythromycin 
and vancomycin for which resistance was not reported for 30 years. It therefore appears not a 
matter of if but when resistance will occur. The first reported case was that of sulphonamide-
resistant Streptococcus pyogenes, which emerged in military hospitals in the 1940s 
(Damrosch, 1946).  Later that decade, even before FDA approval of penicillin to treat 
Staphylococcal infections, an enzyme was identified (a β-lactamase), which enabled 
penicillin resistance in Staphylococcus aureus (Abraham & Chain, 1988).  
 
As bacterial resistance was identified for each antibiotic, the pharmaceutical industry 
responded by treating patients with multiple antibiotics, in some cases up to seven drugs. 
Although initially successful, multiple drug resistant (MDR) strains were observed from the 
1950s to 1960s. Resistance to multiple drugs was first detected among enteric bacteria e.g. 
Escherichia coli, Shigella and Salmonella in the late 1950s to early 1960s (Levy, 2001), 
posing severe clinical problems and claiming lives, particularly in developing countries. 
[4] 
 
Furthermore in the 1970s, H. influenzae and Neisseria gonorrhoeae organisms (Levy & 
Marshall, 2004) emerged with resistance to ampicillin. By the 1980s, M. tuberculosis had re-
appeared often with multi-drug resistance, along with widespread methicillin-resistant S. 
aureus (MRSA). This brought multi-drug resistant bacteria to the forefront of international 
news, leading to the acknowledgment of a new age of antibiotic resistance. 
   
1.1.2 The Impact of Antibacterial Resistance on Healthcare 
 
Infection by a resistant organism increases the chance of hospitalisation, and makes 
prognosis more difficult for doctors and nurses. This often results in multiple drug therapy 
with increased patient side-effects. Individuals may succumb to MDR infections because all 
available drugs have failed (Levy & Marshall, 2004). Global examples of MDR strains 
include the ‘ESKAPE’ organisms (Enterococcus spp., S. aureus, K. pneumoniae, A. 
baumannii, P. aeruginosa and Enterobacter spp.) (Boucher et al., 2009), as well as strains of 
M. tuberculosis and Neisseria gonorrhoea (WHO, 2014b). A report by the Centre for 
Disease Control (CDC, 2013) has for the first time, prioritized concern over bacterial 
infections into three categories: urgent, serious, and concerning. Within the ‘urgent’ category 
are MDR Neisseria gonorrhoea, C. difficile and carbapenem-resistant Gram-negative 
bacteria, showing antibiotic resistance is not a problem confined to developing countries.  
 
The cost of antibiotic resistance puts a significant burden on government budgets, and one 
estimate for the annual societal cost-of-illness for antimicrobial resistance is $55 billion for 
the US alone (Smith & Coast, 2013). Within the UK National Health Service, the best 
estimate suggests that healthcare-associated infections in hospitals costs at least £1 billion 
per year (House of Commons, 2009), with at least 300,000 patients affected per year (House 
of Commons, 2009). Of those affected around 9000 were reported as having died from 
antibiotic resistant, hospital acquired MRSA and C. difficile infections. This clearly 
demonstrates a need to develop novel antimicrobials to treat these types of infection. 
[5] 
 
1.1.3 Mechanisms of Action of Antimicrobial Agents 
 
Antimicrobials act selectively on a target present in bacteria but not in humans, to affect vital 
microbial functions with minimal effects to the host. The drugs can be broadly described as 
bacteriostatic (inhibiting bacterial growth) or bactericidal (killing bacteria). A summary of 
current antimicrobial drugs, their mechanisms and targets is given in Table 1.1.3.1.  
 
Table 1.1.3.1: Major classes of antibiotics; their targets and mechanism of action. Adapted 
from Walsh, 2003; Mulvey & Simor, 2009; Kohanski et al., 2010; Lewis, 2013. *F1F0 
ATPase catalyses cellular ATP synthesis from ADP, coupled with H
+
 flux. 
 
Target Antibiotic Class; examples Mechanism of Action 
Cell Wall 
Biosynthesis 
β-lactams; penicillins, 
cephalosporins, carbapenems 
Mimics D-Ala-D-Ala peptidoglycan 
chain and inhibits cross-linking. 
Glycopeptides; vancomycin, 
teicoplanin 
Binds to the D-Ala-D-Ala peptide 
chain of peptidoglycan precursors 
Protein 
Synthesis 
Aminoglycosides; streptomycin Bind to 30S ribosomal subunit and 
blocks translation Tetracyclines; chlortetracycline 
Macrolides; erythromycin Binds to 50S ribosomal subunit of 
ribosome and blocks translation. Streptogramins; quinupristin 
Phenicols: chloramphenicol 
Oxazolidinones; linezolid 
DNA synthesis Fluoroquinolones; cefotaxime, 
nalidixic acid 
Binds to DNA gyrase, blocking 
DNA replication 
RNA synthesis Rifamycins; rifampicin Binds to RNA polymerase and 
prevents attachment to DNA 
Fidaxomicins; fidaxomicin Binds to RNA polymerase and 
specifically targets C. difficile 
Folic acid 
synthesis  
Sulphonamides; 
sulphamethoxazole 
Blocks folate metabolism which is 
essential in DNA replication 
Cell membrane 
integrity and 
permeabilization 
Lipopeptides; daptomycin Binds to and depolarises the cell 
membrane  
Polymyxins; colistin Permeabilises the cell membrane, 
allowing components to diffuse out 
Inhibition of 
ATP synthetase 
Diarylquinolines; bedaquiline Inhibits the F1FO-ATPase* and 
specifically targets M. tuberculosis 
 
The table lists a number of classes of antibiotics developed to inhibit different targets, of 
which classically, there were three: cell wall synthesis, protein synthesis, DNA replication.  
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(i) Inhibitors of Protein Synthesis 
 
Drugs that target protein synthesis inhibit either the 50S or 30S subunit of bacterial 
ribosomes (Kohanski et al., 2010).  Proteins are synthesised from mRNA over three phases 
(initiation, elongation and termination) involving the ribosome and cytoplasmic factors. The 
ribosome contains ribosomal RNA (rRNA) and consists of two subunits: 30S which binds 
and reads messenger RNA (mRNA) (initiation), and 50S which binds transfer RNA (tRNA) 
and links amino acids to form a polypeptide chain (elongation) (Vannuffel & Cocito, 1996).  
 
The 50S is the larger subunit containing 23S rRNA; to which inhibitors e.g. macrolides and 
oxazolidinones bind. These either physically block access to the ribosome tunnel to prevent 
initiation, or sterically hinder translocation of the polypeptide chain, inhibiting peptide bond 
formation and elongation. The 30S is the smaller subunit containing 16S rRNA, to which 
inhibitors e.g. aminoglycosides and tetracyclines bind. Aminoglycosides are the best studied, 
and cause inappropriate amino acids to be added into the elongating polypeptide (Kohanski 
et al., 2010), leading to mistranslation and protein misfolding. Misfolded membrane proteins 
also increase membrane permeability allowing greater antibiotic uptake (Davis et al., 1986a).  
 
(ii) Inhibitors of DNA synthesis 
 
To enable the chromosome to be contained with a bacterium, DNA must be supercoiled. 
However, supercoiling presents a problem as it prevents access to the genome, which is 
required by DNA polymerases during replication and repair (Champoux, 2001). Supercoiling 
is modulated by DNA topoisomerases, which are able to insert temporary breaks in the DNA 
helix, which can later be re-joined (Kohanski et al., 2010). These reactions are exploited by 
the fluoroquinolones, which target the DNA-topoisomerase complexes. This includes 
topoisomerase IV and DNA gyrase, which are essential in relieving strain during uncoiling, 
and are critical to DNA replication and bacterial viability (Kohanski et al., 2010).  The 
quinolones interfere with maintenance of chromosomal topology by trapping these enzymes 
at the DNA cleavage stage and preventing strand re-joining (Drlica & Zhao, 1997).  
[7] 
 
(iii) Inhibitors of cell wall biosynthesis 
 
The bacterial cell is encased by layers of peptidoglycan, a covalently cross-linked polymer 
matrix. Maintenance of the peptidoglycan cell wall is accomplished by the activity of 
transglycosylases and penicillin-binding proteins. Antibiotics that interfere with steps in cell 
wall synthesis include β-lactams and glycopeptides (Kahne et al., 2005), for example β-
lactams block crosslinking of peptidoglycan by inhibiting the peptide bond formation 
reaction, as catalysed by penicillin-binding proteins (PBPs) (Tipper & Strominger, 1965). 
The action of glycopeptides, including vancomycin, on cell wall biosynthesis is discussed in 
more detail in section 1.3.  
 
1.1.4 Emergence of Antibiotic Resistance 
 
(i) Antibiotic Prescription in Humans 
 
The main factor to the resistance problem is the use and overuse, of massive quantities of 
antimicrobials in the treatment of people, animals and agriculture globally (Levy & 
Marshall, 2004), which kills susceptible strains and selects resistant ones. This is particularly 
common in intensive care units (ICUs), where patients are immunocompromised and require 
strong antibiotic treatment. Furthermore, the close proximity of wards causes the spread of 
resistant organisms (Harbarth & Samore, 2005).     
 
The wide-spread prescription of antibiotics in the community results in antibiotic misuse, 
and misunderstanding, with patients failing to complete treatment courses, resulting in a sub-
inhibitory concentrations and increasing selection and evolution of resistant bacteria 
(Palumbi, 2001).  Failing to complete an antibiotic course has been associated with increased 
emergence of drug-resistant TB and HIV (Wong et al., 1997; Martin & Lazarus, 2000).  
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(ii) Antibiotic use in Livestock and Agriculture 
 
The use of antimicrobials in agriculture, combined with high numbers of livestock in 
confined environments (factory farming) has promoted the spread of infectious disease 
(Wegener, 2003). Antibiotics have often been prescribed as growth promoters for livestock, 
and used to circumvent disease development and cut the cost of a full treatment. In doing so 
this provides a source for the acquisition of resistance genes. The use of antibiotics in 
feedstocks has contributed to the development of clinically relevant resistance in bacteria 
such as Salmonella, Campylobacter, and E. coli (Levy & Marshall, 2004). Therefore the 
transfer of resistance from animals to humans may occur through the food chain, by direct 
interaction or when spreading antibiotic-laden manure on crops (Levy & Marshall, 2004).  
 
Recommendations from the ‘Swann Report’ in the 1970s caused changes in EU regulation 
on growth promoters in feedstocks, and several antibiotics such as penicillin and tetracycline 
were banned from agricultural use, and reserved only for use in human medicine (National 
Academy of Sciences, 1980). However, these regulations did not withdraw approvals of 
antimicrobial growth promoters (AGPs) that were members of the same class used by 
humans. Therefore initially when glycopeptide antibiotics that were used for growth 
promotion (e.g. avoparcin) became important therapeutic drugs (i.e. vancomycin) for drug-
resistant strains in hospital infections, AGPs still remained in use (Wegener, 2003). 
 
It was not until 1994 (Bates et al., 1994; Klare et al., 1995) that the first wake up call came, 
showing that glycopeptide-resistant enterococci (GRE) were present in isolates from food-
animals, and that these animals may harbour the GRE infections that were rapidly spreading 
across hospitals. Studies of animal isolates in different continents confirmed the association 
of avoparcin, with the occurrence of GRE in chickens and pigs (Bager et al., 1997; 
Aarestrup, 2000). This led to a ban on avoparcin and all AGPs in the EU (but not in the US), 
and has greatly reduced levels of resistance in animals (Klare et al., 1999).  
[9] 
 
(iii) Development of New Antibiotics   
 
The development of antibiotics also contributes to the emergence of resistance. Historically, 
a dominant strategy has been to utilise the antibacterial activity of natural products e.g. 
aminoglycosides or glycopeptides, to create semi-synthetic derivatives based on their 
structural scaffolds. These scaffolds have distinct architectures and many functional groups, 
for recognition and specific interaction with targets in pathogenic bacteria (Walsh, 2003). 
Therefore they act as platforms for re-modelling to create generations of semi-synthetic 
variants, e.g. erythromycin to clarithromycin to telithromycin (Fischbach & Walsh, 2009). 
 
Although mining natural product scaffolds has been a successful strategy up until the 1960s, 
it has resulted in an ‘innovation gap’ of 40 years between the last synthetic antibiotic class, 
the fluoroquinolones (based upon nalidixic acid in 1962), and the introduction of a novel 
synthetic antibacterial, the oxazolidinones (based on linezolid in 1999) (Walsh, 2003). 
During this gap, pharmaceutical companies de-emphasised their screening programs, and 
began research into more profitable areas such as cardiovascular and neurodegenerative 
disorders (CNS) (Bush, 2004; Walsh, 2003), which require long-term treatments.  
 
The last clinically useful antibiotic in a new class was daptomycin (in 1986); a lipopeptide 
based on vancomycin and teicoplanin structures, but this was not approved until 2003 
(Lewis, 2013). And until 2012, when bedaquiline was approved (a new drug for TB), the last 
class of narrow-spectrum antibiotics (acting against a specific target) to be discovered was 
the streptogramins (in 1964), of which streptogramin B was not introduced into the clinic 
until 30 years later (Lewis, 2013). The lack of novel classes has resulted in the spread of 
antibiotic resistance outpacing the rate of antibiotic drug discovery, and although new 
antibiotics are being released, the majority of these target Gram-positive infections and the 
current pipeline prospects for those drugs that target Gram-negative bacteria is less 
promising (Arias & Murray, 2009).   
[10] 
 
1.1.5 Development of Bacterial Resistance 
 
(i) Inherent resistance 
 
Intrinsic resistance applies to a member of a bacterial species that is resistant to an 
antimicrobial without additional gene modification. For example, mycoplasma bacteria (e.g. 
M. tuberculosis) are always resistant to β-lactam antibiotics since they lack peptidoglycan 
(the drug target) in their cell wall (Normark & Normark, 2002; Alekshun & Levy, 2007).  
 
(i) Mutations 
 
The selective pressure of the antibiotic can result in acquired resistance by spontaneous 
mutations, which may be point mutations, deletions or insertions within the bacterial genome 
(Normark & Normark, 2002). Virtually all resistance to fluoroquinolones can be attributed to 
mutations within the drug’s targets; DNA gyrase and topoisomerase IV (see section 1.1.3). 
These complexes involve the genes: gyrA and gyrB for DNA gyrase, and parC and parE for 
topoisomerase IV (Alekshun & Levy, 2007), which are required for DNA replication. 
Mutations giving rise to quinolone resistance occur for specific amino acids in the DNA 
binding domain, resulting in sequential mutations, so as to ‘train’ resistance in the bacterium.  
 
(ii) Horizontal resistance gene transfer 
 
Drug resistance is mobile, and resistance genes borne on bacteriophages, plasmids, naked 
DNA and transposons, and can be transferred among bacteria (Levy & Marshall, 2004). This 
can occur through transduction, conjugation or transformation (Alekshun & Levy, 2007). 
Conjugation is the direct transfer of DNA between two bacterial cells in a mating process. 
Transduction requires a DNA carrier (bacteriophage) to transfer genetic material into another 
bacterium, and transformation involves the uptake of DNA from the environment. 
Transposons have been known to carry resistance genes to β-lactams (Tn1 and Tn3), 
streptomycin (Tn5 and Tn7) and glycopeptides (Tn1546/1547) (Alekshun & Levy, 2007).  
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1.1.6 Bacterial Resistance Mechanisms to Antibiotics 
 
Antibiotic resistance can occur through three main mechanisms: (1) modification of the 
antibiotic, (2) prevention of interaction with the antibiotic target or (3) active efflux of the 
antibiotic from the cell and reduced antibiotic uptake. 
 
(i) Modification of the Antibiotic 
 
Modifying enzymes are involved in antibiotic inactivation by several routes, including 
hydrolysis, group transfer and redox mechanisms (Wright, 2005). Many antibiotics have 
hydrolytically susceptible chemical bonds (e.g. esters and amides), whose integrity is 
essential to biological activity. For instance amidase enzymes have evolved to cleave the β-
lactam ring of penicillins and cephalosporins, and β-lactamases hydrolytically cleave the β-
lactam ring using either an active site serine nucleophile or a nucleophilic water molecule 
(activated via a Zn
2+
 centre). Metallo-β-lactamases utilise the latter mechanism to confer 
resistance to the last line of β-lactam antibiotics, the carbepenems (Wright, 2011).  
 
(ii) Modification of the Antibiotic Target 
 
Modification of target sites confers resistance by preventing the antibiotic from recognising 
or associating with the target, leading to diminished activity. Peptidoglycan in the bacterial 
cell wall is a great example of this as it is essential for growth and survival of most bacteria 
and has a vastly different chemical structure to any mammalian macromolecule (Lambert, 
2005). Therefore enzymes involved in its synthesis and assembly are great targets for 
selective inhibition. The most important of which are the transpeptidases; targets of the β-
lactams, and transglycosylases; substrates of which are the targets for the glycopeptides.  
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For example, β-lactam resistance can occur through modification of the penicillin-binding 
proteins (PBPs), which are a group of enzymes involved in assembly of peptidoglycan (by 
transpeptidation and transglycosylation) (Lambert, 2005). Interaction of a β-lactam with a 
PBP usually involves a rapid formation of a non-covalent complex, which blocks the 
function of PBP. However many PBPs have emerged with decreased antibiotic affinities. 
One example is the altered transpeptidase in S. aureus, PBP2a, which causes resistance to 
methicillin as its rate constant for transpeptidation is reduced 1000-fold (Lambert, 2005).  
 
Target modifications are also involved in resistance to glycopeptide antibiotics, whereby the 
terminating D-Ala-D-Ala group of peptidoglycan precursors is altered to inhibit binding. 
This is discussed in section 1.3.3, and directly relates to studies carried out in this thesis.  
 
(iii) Active Efflux and Reduced Antibiotic Uptake 
 
Efflux pumps are found in all bacteria, but most cannot respond to an antibiotic without 
specific mutations (Normark & Normark, 2002). The combination of reduced uptake and 
efflux is most prominent in the action of the outer membrane permeability barrier and active 
efflux, within Gram negative bacteria (Kumar & Schweizer, 2005). The permeability barrier 
in Gram-negative species is the outer membrane, containing phospholipids and 
lipopolysaccharides (LPS). In order to enter the cell, drug molecules must penetrate the 
membrane by diffusing through porins (water-filled channels) (Kumar & Schweizer, 2005). 
In P. aeruginosa, absorption through these porin channels has been found to be 10-100 times 
less efficient than those of E. coli (Hancock & Speert, 2000). These barriers only slow down 
the rate of absorption of the antibiotic though, so are often coupled with efflux pumps.  
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There are five families of membrane-spanning efflux pumps, which are able to expel a broad 
range of compounds (see Figure 1.1.6.1) (Kumar & Schweizer, 2005). Three single-
component pumps couple drug efflux with a counterflow of protons or sodium ions, while 
one pump uses hydrolysis of ATP to provide energy for the active transport of the antibiotic. 
The multi-component pumps (e.g. RND) function in association with an outer membrane 
protein pore (OMP), and efflux occurs across the entire cell envelope.  
 
 
Figure 1.1.6.1: A schematic illustration of the five families of drug efflux pumps involved 
in antibiotic resistance. Adapted from Kumar & Schweizer, 2005. Efflux pumps are 
represented by cylinders and for the RND class, accessory proteins are also shown.   
 
1.2 Peptidoglycan as an Antimicrobial Target  
1.2.1 The Cell Wall 
 
Bacteria are classified by their reaction to a Gram stain (Gram, 1884). The stain involves the 
use of a crystal violet dye, and differentiates between Gram-negative and Gram-positive 
bacteria due to the chemical and physical properties of their cell walls, by detecting 
peptidoglycan. Gram-positive bacteria have a thick peptidoglycan layer and retain the violet 
dye, whereas Gram-negative bacteria have a much thinner peptidoglycan layer (~1/10
th
 the 
size), and do not retain the dye (once a decolouriser e.g. alcohol has been added) (Figure 
1.2.1.1). The colouration of stained cells is then produced by addition of a counterstain. 
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Figure 1.2.1.1: Structures of Gram-positive (a) and Gram-negative (b) bacterial cell walls, 
reproduced from Soloman et al., (1999). 
 
1.2.2 The Molecular Structure of Peptidoglycan 
 
Peptidoglycan is an essential part of the bacterial cell wall, and consists of polymerised 
linear glycan chains cross-linked by peptide bonds, which provides high mechanical strength 
to resist the internal osmotic pressure. The glycan strands consist of alternating N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) residues, linked by β-
1,4-glycosidic bonds. Each MurNAc residue is appended to a pentapeptide chain, of the form 
L-Ala-D-Glu-X-D-Ala-D-Ala, where X is either L-Lysine in Gram-positive bacteria or 
meso-diaminopimelic acid (meso-DAP) in Gram-negative bacteria. During cross-linking, the 
terminal D-Ala is removed when direct covalent bond forms between the third amino acid 
(X) and the fourth D-Ala residue of a neighbouring strand (Vollmer et al., 2008).  
 
Peptidoglycan biosynthesis can be considered to occur via three stages: 
i) On the cytoplasmic side; synthesis of nucleotide precursors 
ii) In the cell membrane; synthesis of lipid-linked intermediates 
iii) On the periplasmic side; polymerisation reactions 
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1.2.3 Synthesis of Nucleotide precursors to Peptidoglycan 
 
The biosynthesis of peptidoglycan involves around 20 different reactions in the cytoplasm 
alone, and is represented in Figure 1.2.5.1. The cytoplasmic steps in peptidoglycan assembly 
are outlined below. Initially, uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) is 
produced from fructose-6-phosphate, which can then be used to form uridine diphosphate N-
acetyl muramic acid (UDP-MurNAc), to begin peptidoglycan synthesis. The enzymes 
responsible for conversion of UDP-GlcNAc to UDP-MurNAc-pentapeptide during 
cytoplasmic steps in peptidoglycan assembly are the ‘Mur’ proteins (Barreteau et al., 2008). 
 
The first committed step towards the synthesis of peptidoglycan is the conversion of UDP-
GlcNAc to UDP-MurNAc by MurA enzymes. MurA catalyses transfer of enolpyruvate from 
phosphoenolpyruvate (PEP) to the 3-hydroxyl group of UDP-GlcNAc, releasing inorganic 
phosphate and forming UDP-GlcNAc-enol-pyruvate. This is reduced by the MurB enzyme 
using one equivalent of NADPH to form UDP-MurNAc (Barreteau et al., 2008). The peptide 
stem of peptidoglycan is then assembled by the Mur ligases (Mur C, D, E, F), which 
sequentially add the amino acids to UDP-MurNAc to produce the UDP-MurNAc-
pentapeptide, otherwise known as Park’s nucleotide (Park, 1952) (see Figure 1.2.5.1).  
 
Mur ligases catalyse the formation of an amide or peptide bond driven by ATP, and in the 
presence of a divalent cation. Mur C ligase adds the first residue usually L-alanine, to form 
UDP-MurNAc-L-Ala (Schleifer & Kandler, 1972). MurD then adds D-glutamic acid and 
MurE adds an L-lysine (in Gram-positive bacteria), or a meso-DAP (in Gram-negative 
bacteria). Finally, MurF adds the dipeptide D-Ala-D-Ala to the terminus of the growing 
chain, to produce UDP-MurNAc-L-Ala-D-Glu-L-Lys-D-Ala-D-Ala (in Gram-positive 
bacteria). The D-Ala-D-Ala dipeptide is normally formed by a DdlA (D-Ala-D-Ala) ligase, 
but D-Ala-D-Lac and D-Ala-D-Ser are observed in vancomycin-resistant strains (Healy et 
al., 2000), and are discussed later in this thesis (see section 1.3.6)   
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1.2.4 Synthesis of lipid-linked intermediates to Peptidoglycan 
 
 
The Park’s nucleophile is next attached to a membrane-bound lipid carrier. The transferase 
MraY catalyses transfer of the phospho-MurNAc-pentapeptide moiety of Park’s nucleophile 
(UDP-MurNAc-pentapeptide) to the membrane acceptor undecaprenyl phosphate (C55-P), 
with the loss of UMP. This produces a membrane bound intermediate; undecaprenyl-
pyrophosphoryl-MurNAc-pentapeptide (known as Lipid I) (Bouhss et al., 2008).  A second 
transferase, MurG, catalyses transfer of the GlcNAc moiety from UDP-GlcNAc to Lipid I 
yielding undecaprenyl-pyrophosphoryl-GlcNAc-MurNAc-pentapeptide (known as Lipid II).  
Lipid II is then flipped through the membrane, and used in polymerisation reactions.  
 
The translocation of Lipid II across the membrane must be assisted by a flippase protein, 
which shields the disaccharide-pentapeptide as it crosses the hydrophobic core of the 
membrane (Butler et al., 2013). Two candidates appear to be capable of this role; FtsW 
(Mohammadi et al., 2011), an essential protein in division, and MurJ (Butler et al., 2013), an 
essential enzyme in PG synthesis and a member of the MATE drug exporter class (Kuroda & 
Tsuchiya, 2009). Despite a recent paper in which MurJ was stated to be the flippase (Sham et 
al., 2014), there is still heated debate over this and further studies are ongoing.  
 
1.2.5 Polymerisation Reactions to form Peptidoglycan 
 
The final steps of peptidoglycan assembly involve polymerisation of the glycan strand 
(transglycosylation), then cross-linking between glycan strands (transpeptidation), catalysed 
by the penicillin-binding proteins (Sauvage et al., 2008) (see Figure 1.2.5.1). PBPs have 
been historically numbered according to their molecular weight by SDS-PAGE, however, it 
is more informative to categorise them into classes according to their actions. High 
molecular weight PBPs are subdivided into either class A (glycosyltransferase and 
transpeptidase enzymes) or class B (transpeptidase only) (Sauvage et al., 2008).  
[17] 
 
 
 
Figure 1.2.5.1: Steps and enzymes involved in the biosynthesis of peptidoglycan. Adapted 
from Lazar & Walker, 2002; Kahne et al., 2005. The D-Ala-D-Ala binding site for 
glycopeptide antibiotics including vancomycin is highlighted with a red box. 
 
Transglycosylation involves elongation of the glycan chain by successive attacks of the 
growing chain (donor) on Lipid II (acceptor), catalysed by formation of a glycosidic bond 
between the disaccharide pentapeptide chain and the 4-hydroxyl group of the GlcNAc strand. 
This is followed by transpeptidation, which is catalysed by a three-step mechanism: the rapid 
formation of a noncovalent complex, followed by attack of an active serine in the PBP on the 
carbonyl atom of the D-Ala-D-Ala terminus of the strand, leading to formation of an acyl-
enzyme intermediate, and finally loss of the terminal D-Ala (Sauvage et al., 2008). This de-
acylation step forms the cross-link between the fourth position D-Ala and the third position 
residue in a second stem pentapeptide. The joint transpeptidation and transglycosylation 
activities, lead to maturation of the peptidoglycan and provide its strength and stability. 
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1.3 Glycopeptide Antibiotics and Resistance Mechanisms 
1.3.1 Structure and Function 
 
Glycopeptide antibiotics act upon the N-terminal D-Ala-D-Ala in the peptidoglycan cell 
wall, and are crucial in the treatment of serious (e.g. β-lactam resistant) infections caused by 
Gram-positive bacteria. These antibiotics were developed from natural products in the 1950s 
such as vancomycin and teicoplanin (Kahne et al., 2005). Only a few glycopeptide 
antibiotics have been approved for clinical use, including vancomycin, teicoplanin, 
telavancin (Corey et al., 2009), and oritavancin (FDA, 2014). Vancomycin is approved for 
human use in many countries, whereas teicoplanin is widely prescribed in Europe but was 
never FDA approved in the US (Kahne et al., 2005).  
 
 
Figure 1.3.1.1: Structures of vancomycin and teicoplanin. Adapted from Kahne et al., 
(2005). The C10 acyl chain (red) and extra aromatic groups (blue) in teicoplanin are circled.  
 
Vancomycin and teicoplanin have closely related structures, containing a heptapeptide core 
with five (vancomycin) or seven (teicoplanin) aromatic residues (Figure 1.3.1.1) (Kahne et 
al., 2005). The peptide framework is glycosylated too, by a disaccharide chain on residue 4 
in vancomycin or by three monosaccharides at residues 4, 6 and 7 in teicoplanin. It should be 
noted that teicoplanin, but not vancomycin, is a lipoglycopeptide, as it has a C10 fatty acyl 
chain linked to its glucosamine sugar moiety, which is believed to anchor the antibiotic in 
the membrane, whilst interacting with the D-Ala-D-Ala terminus (Kahne et al., 2005).  
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1.3.2 Vancomycin: A History 
 
Vancomycin is a natural product, first isolated from soil samples containing Streptomyces 
orientalis obtained from South East Asia in 1952, by Eli Lilly and Company (Moellering, 
2006).The drug was isolated, purified and approved by the FDA for clinical use in 1958. 
Vancomycin was effective against most gram-positive infections e.g. penicillin resistant 
Staphylococcus. However, methicillin was also approved in this period, and due to the 
perceived toxicity of vancomycin it was reserved for cases of serious β-lactam resistance 
(Levine, 2006). The toxicity of vancomycin has been reduced through improved purification, 
but treatment is still associated with nephrotoxicity (Levine, 2006) and ‘red man syndrome’; 
an infusion-related reaction causing a red burning rash across the body (Davis et al., 1986b).  
 
In 1961, methicillin-resistant S. aureus (MRSA) was first reported, and by the 1970s and 
1980s, the worldwide emergence of MRSA as well as C. difficile infections, rekindled 
interest in vancomycin (Moellering, 2006). This led to a dramatic increase in vancomycin 
use to treat these infections, with a 100-fold increase occurring between 1980 and 2000 
(Kirst et al., 1998). The exponential increase in vancomycin usage during this period, 
inevitably led to the emergence of vancomycin-resistant strains, including vancomycin-
resistant enterococci (VRE) in the 1980s (Gerding, 1997; Levine, 2006).   
 
1.3.3 Mode of Action and Development of Resistance to Vancomycin 
 
The first studies of the mechanism of action of vancomycin were reported by Perkins & 
Chatterjee, (1966) who analysed stepwise degradation of the UDP-MurNAc-pentapeptide, 
and found that vancomycin bound to peptidoglycan precursors at the D-Ala-D-Ala terminus. 
Structural features of vancomycin were then determined by X-ray diffraction analysis in 
1982 by the Harris and Williams labs (Williamson & Williams, 1981; Harris & Harris; 
1982). One year later, the Williams lab demonstrated the binding interaction between 
vancomycin and the D-Ala-D-Ala dipeptide by solution state NMR (Williams et al., 1983). 
[20] 
 
Intermolecular distances within the complex showed that binding occurred via five hydrogen 
bonds between the D-Ala-D-Ala dipeptide and amide groups in the vancomycin heptapeptide 
core (Figure 1.3.3.1). The bound glycopeptide sterically impedes Lipid II chains from 
interacting, thereby inhibiting peptidoglycan cross-linking and causing cell wall instability 
and eventual cell lysis. 
 
 
 
Figure 1.3.3.1: (left) Vancomycin binding to the D-Ala-D-Ala N-terminus of Lipid II PG 
precursor and (right) a resistant D-Ala-D-Lac form.  The hydrogen bond disrupted in VRE 
is highlighted in red. Adapted from Bugg et al., 1991. 
 
 
The mechanism of action of glycopeptide antibiotics, unlike the β-lactams, did not appear to 
be susceptible to modifications that would inactive them and it was widely believed that 
microorganisms could not easily alter the drug target, as that would involve multiple 
enzymes in the pathway to alter peptidoglycan synthesis (Kahne et al., 2005). However, in 
1986, vancomycin resistance in enterococci (VRE) was reported in Europe and the US 
(Murray, 2000), with the first recorded hospital case in the UK in 1988 (Uttley et al., 1989). 
Since then resistance has been reported in streptococci, staphylococci and actinomycetes.  
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Vancomycin-resistant enterococci display inducible resistance to glycopeptides such as 
vancomycin and teicoplanin, and have been observed across the world, with 6 recognised 
resistance phenotypes – designated ‘VanA’ through ‘VanE’ (Levine, 2006). In all of these 
resistance phenotypes, the basic mechanism of resistance is the alteration of the terminal D-
Ala-D-Ala of the peptidoglycan chain to either a D-Ala-D-Lac form (VanA, B, D) (see 
Figure 1.3.3.1), or a D-Ala-D-Ser form (Van C, E, G). This results in decreased binding of 
vancomycin and decreased inhibition of cell wall synthesis. In the case of the D-Ala-D-Lac 
precursor, binding affinity is reduced 1000-fold (Bugg et al., 1991), due to the loss of just 
one hydrogen bond, as a result of the ester linkage in D-Ala-D-Lac (Figure 1.3.3.1). In 
contrast, the D-Ala-D-Ser substitution shows only a 6-fold reduction in binding affinity, 
since the hydroxymethyl group of serine is bulkier than the methyl group of alanine 
(Reynolds & Courvalin, 2005). The van resistance phenotypes, their MICs and resistance 
levels are shown in Table 1.3.3.1. 
 
Table 1.3.3.1: VRE Phenotypes, adapted from Sujatha & Praharaj (2012). MIC criteria for 
resistance are from the CLSI (sensitive: ≤ 4, intermediate: 8-16, and resistant  ≥ 32 μg/ml)  
 
 
Phenotype 
 
Type of resistance 
MIC (μg/ml) 
Vancomycin resistance Teicoplanin resistance 
VanA Inducible 64-1000 (High) 16-512 (High) 
VanB Inducible 4-512 (High) 0.5 (Sensitive) 
VanC Constitutive 2-32 (Low) 0.5 (Sensitive) 
VanD Inducible 64-256 (Moderate-High) 4-32 (Low) 
VanE Inducible 16 (Low) 0.5 (Sensitive) 
VanG Inducible 16 (Low) 0.5 (Sensitive) 
 
VanA and VanB phenotypes are of most clinical relevance and are associated with 
pathogenic strains of E. faecium and E. faecalis respectively, which are one focus of this 
PhD. VanA-type strains are inducibly resistant to high levels of vancomycin and teicoplanin, 
whereas VanB-type strains are inducibly resistant to vancomycin, but only sensitive to 
teicoplanin. The van genes responsible for glycopeptide resistance are located on a 
transposon, which allows a route for gene transfer across species.  
[22] 
 
1.3.4 Vancomycin resistance transfer across species 
 
Vancomycin resistance was observed in S. aureus in Japan in 1996 (Hiramatsu, 2001) and 
later in the US, with an MIC of 8 μg/ml, and so it was classed as vancomycin-intermediate S. 
aureus (VISA). By 2002, vancomycin-resistant S. aureus (VRSA) emerged, with several 
cases in Michigan in the USA (Chang et al., 2003), and 12 further cases observed over the 
next decade (Sujatha & Praharaj, 2012). In almost all cases, in addition to VRSA, a VRE 
isolate was recovered from the patient, and it appears that high-level vancomycin resistance 
in Staphylococcus is the result of acquisition of the VanA phenotype, transferred by mobile 
genetic elements (Perichon & Courvalin, 2009). Because vancomycin is still a front-line 
therapy for treating problematic MRSA infections, the spread of vancomycin resistance to 
other bacterial species such as S. aureus (VRSA) is a major concern to public health. 
    
1.3.5 Vancomycin resistance in actinomycetes 
 
Vancomycin resistance has also been found in soil-dwelling actinomycetes, which produce 
most of the natural glycopeptide antibiotics. This includes Streptomyces orientalis (producer 
of vancomycin), Actinoplanes teichomyceticus (producer of teicoplanin) Streptomyces 
toyocaensis (producer of A47934), and Streptomyces coelicolor (non-producer) (Hong et al., 
2008). Glycopeptide resistance in these strains is often essential to survival, as activation of 
the resistance genes by the antibiotics produced prevents auto-toxicity (Hong et al., 2008).  
 
S. coelicolor is the model species of a Gram-positive, fungal soil bacterium, responsible for 
producing two thirds of the commercially important antibiotics (Hong et al., 2008). S. 
coelicolor is non-pathogenic like most other actinomycetes, and lives in the soil, where it is 
likely that it encounters glycopeptide producers and the vancomycin resistance (van) gene 
cluster confers selective advantage. It is also widely believed that all glycopeptide genes are 
ultimately derived from actinomycete glycopeptide producers. 
[23] 
 
Over 80% of all antibiotics in clinical use originate from soil bacteria (D’Costa et al., 2007) 
and extensive studies of the soil resistome by D’Costa et al., (2006) showed that strains of 
soil organisms were on average resistant to seven to eight antibiotics. It has been suggested 
that horizontal gene transfer among bacteria may account for the presence of van resistance 
genes in actinomycetes, enterococci and other species. Indeed there is high primary sequence 
homology between the vanHAX resistance strains in pathogenic and soil actinomycetes, with 
~60% similarity between resistance genes in the VanA phenotype and those of S. 
toyocaensis and A. orientalis (Marshall et al., 1998). 
 
Resistance between species varies, for instance S. toyocaensis is resistant to A47934 but is 
sensitive to both vancomycin and teicoplanin, whereas S. coelicolor exhibits high-level 
resistance to vancomycin, but is sensitive to teicoplanin (Hong et al., 2008), and could 
therefore be said to have ‘VanB-type’ resistance. Interestingly, A. teichomyceticus exhibits 
‘pan resistance’ to all glycopeptides tested, which is believed to arise from constitutive 
expression of van resistance genes, even in the absence of antibiotic (Hong et al., 2008). 
 
1.3.6 The van resistance genes  
 
Vancomycin resistance is conferred by a set of genes contained upon a transposon (a mobile 
genetic element). The number of genes present in each van cluster varies (Figure 1.3.6.1) but 
the ‘core’ consists of five genes – vanS/vanR, plus a vanHAX operon, which encode the three 
enzymes required for altering cell wall precursors to a D-Ala-D-Lac (or D-Ala-D-Ser) form 
(Walsh et al., 1996; Healy et al., 2000). VanH is a reductase which converts pyruvate into D-
lactate, VanA is a D-Ala-D-Lac ligase, and VanX is a D-Ala-D-Ala dipeptidase that cleaves 
any residual D-Ala-D-Ala (Gao et al., 2002). The result is that peptidoglycan precursors 
accumulate which terminate uniformly in D-Ala-D-Lac.  
[24] 
 
 
 
Figure 1.3.6.1: A comparison of van gene clusters from Enterococcal VanA and VanB 
strains and actinomycetes. Adapted from Hong et al., 2008. 
 
The VanA and VanB phenotypes are found on transposons Tn1546 and Tn1547 respectively 
(Quintiliani & Courvalin, 1996). The VanA transposon encodes two accessory proteins, 
VanY and VanZ, which are not required for resistance, but can contribute to high-level 
resistance to vancomycin and teicoplanin. VanZ confers low-level resistance to teicoplanin 
in the absence of other resistance proteins (Arthur et al., 1995), by an as yet unknown 
mechanism. VanY is a carboxypeptidase that can cleave the terminal D-Ala of peptidoglycan 
precursors, but cannot cleave the D-Ala-D-Ala dipeptide, unlike VanX (Wright et al., 1992). 
 
The S.coelicolor van gene cluster also adds two additional genes to the conserved 
vanRSHAX genes, which are vanJ and vanK. vanK is an interesting gene as it is essential to 
vancomycin resistance in S. coelicolor, but has no orthologues in the van gene cassette of 
pathogenic enterococci (Hong et al., 2004). VanK is a member of the Fem family of 
enzymes, and is responsible for adding ‘branch’ amino acid(s) to the pentapeptide PG 
precursors. In S. coelicolor this branch is a glycine residue which, under normal growth 
conditions, is added by an enzyme called FemX. However, FemX can only recognise 
precursors terminating in D-Ala-D-Ala in S. coelicolor, and therefore VanK is required for 
vancomycin resistance as it alone can add the branch glycine to precursors terminating in D-
Ala-D-Lac (Hong et al., 2005); precursors lacking this bridge would be lethal to the cell.  
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[25] 
 
VanJ is a membrane protein with its C-terminal active site exposed in the periplasm, and was  
recently shown to be the sole mediator of teicoplanin resistance in S. coelicolor (Novotna et 
al., 2012). Although S. coelicolor carries a complete set of glycopeptide resistance genes, it 
is sensitive to teicoplanin, because teicoplanin fails to induce expression of the van gene 
cluster (Hong et al., 2008). Novotna et al. (2012) showed that exposing a plate containing S. 
coelicolor spores to paper discs containing vancomycin and teicoplanin side-by-side led to a 
D-shaped (rather than O-shaped) inhibition zone around the teicoplanin disc. This indicates 
that wild-type cells growing in the presence of vancomycin (as a result of the induction of 
van gene expression) were also able to grow in the presence of teicoplanin. Furthermore in a 
vanJ null mutant strain, the O-shaped zone of inhibition was observed around the teicoplanin 
disc, which could be restored by supplying a copy of vanJ in trans. Therefore VanJ alone 
causes resistance to teicoplanin in S. coelicolor.   
 
The main point about the vancomycin resistance genes is that they are only expressed in the 
presence of an extracellular antibiotic and that signal transduction is effected by a two-
component system (TCS, see section 1.5) consisting of a membrane-bound sensor kinase 
(VanS) and its cytosolic response regulator (VanR) (Healy et al., 2000; Bugg et al., 1991), 
which regulate the transcription of vanHAX (and other genes in the cassette) (see Figure 
1.3.6.2). These two-component signal transduction systems are observed for a wide variety 
of bacteria, in response to stress, for osmoregulation, in quorum sensing, and in many other 
stimulus and response mechanisms. The focus for this PhD is the two-component VanS-
VanR system regulating resistance to glycopeptide antibiotics. The mechanism of two-
component systems, their architecture and the proteins involved, including the VanS/R 
system, is detailed in section 1.5. 
[26] 
 
 
Figure 1.3.6.2: (left) A model of the VanRS two-component system controlling antibiotic 
resistance, (right) the function of enzymes encoded by van resistance genes. Adapted from 
Hong et al., 2008 and Gao et al., 2002. 
  
1.4 Inducers of the VanS/VanR system 
1.4.1 VanA-type resistance 
 
A number of biochemical assays have been conducted in the literature to determine antibiotic 
inducers of VanS proteins from different bacterial strains, which are summarised in Table 
1.4.3.1 for the VanA phenotype (VanSA). The first assays were growth-based (Handwerger 
& Kolokathis, 1990; Allen & Hobbs, 1995), and involved treatment of cell cultures 
containing vancomycin-resistant VanA-type E. faecium strains with potential inducers. 
Handwerger & Kolokathis (1990) showed that growth of cell wall precursors occurred in the 
presence of vancomycin or moenomycin A, and Allen & Hobbs (1995) demonstrated the 
build-up of Lac-containing precursors in the presence of vancomycin, moenomycin A, and 
antibiotics affecting polymerisation steps in cell wall synthesis e.g. penicillin. However, 
growth-based assays cannot be used reliably to identify antibiotics that induce the resistance-
related enzymes as cells often fail to survive induction (Ulijasz et al., 1996).  
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[27] 
 
A better way to test for inducers is by using gene reporter assays, which do not depend on 
cell survival to monitor activity. These include a lacZ:vanH fusion in B. subtilis (Ulijasz et 
al., 1996; De Pascale et al., 2007) and E. faecium (Mani et al., 1998), a lucA:vanH fusion in 
E. faecium (Grissom-Arnold et al., 1997) and a chloramphenicol acetyltransferase (CAT) 
based assay system in E. faecium (Lai & Kirsch, 1996).  
 
In the lacZ:vanH fusions, the E. faecium vanRS operon regulates expression of LacZ from 
the coupled E. faecium vanH promoter. β-galactosidase activity (from LacZ expression) was 
measured in these assays, however, there are significant differences between the observed 
inducers in the B. subtilis system (Ulijasz et al., 1996; De Pascale et al., 2007) and those in 
E. faecium (Mani et al., 1998). For instance, induced LacZ activity in the B. subtilis strain 
was observed upon addition of inhibitors of cytoplasmic (D-cycloserine and fosfomycin), 
membrane-bound (bacitracin) and periplasmic steps (glycopeptides, penicillin) in cell wall 
assembly, (Ulijasz et al., 1996; De Pascale et al., 2007), whereas LacZ activity in E. faecium 
strains was only induced by vancomycin and to a lesser degree by moenomycin A (Mani et 
al., 1998). The authors propose that species differences between B. subtilis and E. faecium 
may have contributed to the differences in observed inducers. By far the strongest inducers 
of activity in the lacZ:vanH fusion are the glycopeptides, and possibly moenomycin A, both 
of which are involved in inhibiting PBP transglycosylation activity (through different 
mechanisms). The lucA:vanH assay by Grissom-Arnold et al., (1997), which measures 
luciferase A expression under control of the vanH promoter, also supports this theory. 
 
In a CAT-based radioisotopic assay (Shaw, 1975) conducted by Lai and Kirsch (1996), a 
total of 6800 compounds were screened for inducers of an E. faecium strain, containing a cat 
gene placed into an operon with the vanHAX genes. Eight active compounds were found to 
show significant CAT activity, including structurally-related glycopeptides (ristocetin, 
avoparcin, vancomycin) and cell-wall acting agents (moenomycin, bacitracin, methicillin).  
[28] 
 
Close examination of the relative CAT activities compared to untreated cells, showed that 
vancomycin was increased at least 6-fold (or 38-fold according to Arthur et al., 1992), 18-
fold for avoparcin and 8-fold for ristocetin. In contrast, the activities were only around 3-fold 
for bacitracin and moenomycin A, and therefore much weaker than glycopeptide antibiotics 
(Lai & Kirsch, 1996). In fact, the authors also used a second assay; a petri plate induction 
assay, which measured CAT activity as a function of colour change, resulting from bacterial 
growth in the presence of chloramphenicol and esculin. The culture was applied to plates, 
and an inducer-soaked disc placed on top (Figure 1.4.1.1). The figure clearly shows that 
although growth in the presence of chloramphenicol (by CAT expression) is observed for 
discs containing glycopeptide antibiotics (and robenidine; an agent against Protozoa), there 
is no growth or colour change for moenomycin, or other non-glycopeptide antibiotics.  
 
 
Figure 1.4.1.1: A petri plate assay for vancomycin resistance induction, reproduced from 
Lai & Kirsch (1996).  A – avoparcin, B – bacitracin, M – moenomycin A, Ri – ristocetin, Ro 
– robenidine, T – tetracycline, V – vancomycin.  
 
Inducers of the VanRS system therefore appear to be the glycopeptide antibiotics, but assays 
are not wholly consistent as an inducer in one assay is not necessarily an inducer in another. 
It should be noted that these methods are limited to their reliance on the induction of reporter 
genes rather than direct measurement of expressed proteins involved in vancomycin 
resistance. For this reason, further assays were developed by Baptista et al., (1996) and 
Arthur et al., (1999) which measured activity of the resistance gene, vanX, directly.   
[29] 
 
VanX enzymatic activity in cell extracts was monitored upon addition of potential antibiotic 
inducers, and is theoretically more reliable than cell reporter systems, as they require the 
antibiotic tested not to target any other mechanism to survive. It was shown that 
accumulation of cytoplasmic PG precursors cannot be the signal that triggers induction, since 
D-cycloserine, ramoplanin, bacitracin and penicillin all failed to act as inducers, whereas 
moenomycin A, vancomycin and teicoplanin were inducers of VanX activity (Baptista et al., 
1996; Arthur et al., 1999). Since moenomycin A inhibits transglycosylase, both 
glycopeptides and moenomycin A are likely to lead to an accumulation of Lipid II (the lipid-
anchored cell wall precursor) on the periplasmic side of the membrane, which could be the 
direct effector ligand of VanS (Baptista et al., 1999; Hong et al., 2008). Interestingly though, 
Arthur et al., (1999) showed that although VanX activity was induced by moenomycin in the 
E. faecium VanRS system, activity was minimal (18 +/- 4 nmol min
-1
 mg
-1
) compared to 
vancomycin (190 +/- 31) or teicoplanin (280 +/- 55), and similar to uninduced cells (5 +/- 1).  
 
It is therefore difficult to conclude from biochemical data alone, whether VanSA is induced 
by a direct interaction with glycopeptide antibiotics, or whether it is activated by an indirect 
signal (e.g. by sensing accumulation of a cell wall intermediate such as Lipid II from 
inhibition of TG activity, or perhaps by interaction with Lipid II in complex with the 
antibiotic) (Hong et al., 2008). Biophysical data is clearly required in order to ascertain 
whether a direct interaction is occurring at the VanS sensor domain (which is exposed to 
antibiotics) to induce gene expression, or if there is an indirect route for activation.  
 
1.4.2 VanB-type resistance 
 
The VanB resistance phenotype shows higher specificity for inducers of glycopeptide 
resistance (see Table 1.4.3.2 and Table 1.4.3.3). Both reporter assays and direct 
measurements of expressed proteins have shown that only vancomycin antibiotics induce 
resistance gene production in the E. faecalis VanB phenotype.  
[30] 
 
CAT radioactivity assays (Evers & Courvalin, 1996) initially showed than VanSB expression 
was induced by vancomycin, but was only sensitive to teicoplanin. This was confirmed by 
VanX activity measurements by Baptista et al. (1996), who showed that all non-
glycopeptides tested, including moenomycin A, failed to induce VanSB. Since all identified 
inducers of VanSB are structurally related glycopeptides, it seems likely that it should be 
induced directly by vancomycin itself. Baptista et al. (1999) also showed by fluorescence 
measurements using a gfpmut1 gene (encoding GFP) fused to the vanB resistance gene 
promoter, that VanSB was also only induced by vancomycin. However, six different point 
mutations in the gene resulted in either a vancomycin- and teicoplanin-resistant VanB strain 
(VanSBA167S), constitutively active VanB strains (VanSBT237M) or intermediate resistance, 
and it is unclear how VanSB could be directly inducible by both antibiotics, especially when 
the point mutations occur in the cytoplasmic region (which cannot be accessed by 
glycopeptide antibiotics), so an indirect mechanism of induction is also conceivable. 
 
For the VanB-like phenotype in S. coelicolor, inducers were identified from a reporter assay 
which involved the expression of a neo gene, conferring resistance to neomycin and 
kanamycin, under control of a vanJ resistance gene promoter (vanJP) (Hong et al., 2004). 
vanJP-neo-containing plasmids were spread onto plates containing a lethal dose of 
kanamycin and potential inducers were applied on paper disks. The assay found that several 
glycopeptides induced vancomycin expression, whereas penicillin and teicoplanin did not. In 
a further optimised assay, a direct measurement of VanK resistance gene expression was 
made, by spreading strains containing a femX null mutant onto plates and applying potential 
inducers on paper disks (Hutchings et al., 2006).  In the absence of vancomycin, FemX 
enzymes add the single Gly amino acid branch to the pentapeptide cell wall precursor, to 
allow transpeptidation reactions. However, in the femX null mutants, the vanK gene must be 
expressed in order to add this branch amino acid. Inducers of this system were also only 
glycopeptide antibiotics, and not antibiotics targeting earlier or later steps in PG synthesis. 
Therefore VanSSC should be activated by a direct interaction with glycopeptide antibiotics.  
[31] 
 
In fact, recently, fluorescent labelling strategies were applied to study the VanSSC proteins in 
the presence of a glycopeptide ligand (Koteva et al., 2010) and it was demonstrated for the 
first time that a direct binding occurs between S. coelicolor VanS and a fluorescent 
vancomycin analogue (a vancomycin photoaffinity probe, VPP) (Figure 1.4.2.1). This VPP 
ligand contained a biotin tether for purification and visualisation on anti-biotin blots, and a 
benzophenone ((C6H5)2CO) probe for covalent labelling of protein-probe complexes (VanS-
benzophenone). By incubating the ligand with membranes isolated from E. coli (containing 
overexpressed His6-VanSSC proteins) and irradiating with UV light, the fluorescent 
biotinylated VPP was observed to covalently bind to the VanS protein (Koteva et al., 2010). 
Using a gene reporter assay it was shown that VPP was a bioactive ligand of VanS, able to 
induce vanH resistance gene expression in vancomycin-resistant S. coelicolor in vivo. The 
synthetic VPP ligand is, however, structurally different from naturally expressed 
vancomycin, so there is a possibility that vancomycin molecules will not interact via the 
same mechanism. One of the goals of this PhD is therefore to determine by biophysical 
studies whether VanS proteins can bind directly to natural glycopeptide antibiotics, or 
whether a signalling molecule or cell wall intermediate is involved in the activation of VanS. 
 
 
Figure 1.4.2.1: Schematic diagram of the direct binding between VPP and VanSSC protein. 
VPP binding activates the protein causing auto-phosphorylation and phosphotransfer to 
VanR, resulting in resistance gene expression. Adapted from Koteva et al., 2010. Biotin 
tether – green, Benzophenone probe – Purple. 
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1.4.3 Summary of Antibiotic Inducers 
 
Table 1.4.3.1: Induced vancomycin resistance in the E. faecium VanA phenotype by various antibiotics, according to reporter or assay based systems.  
Note: Moenomycin A and glycopeptide antibiotics are highlighted in red throughout (as they are potentially both inducers of the VanSA protein). 
 
Antibiotic Targets in Cell Wall Assembly Nucleotide 
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Lac-containing precursors (Allen & Hobbs, 1995) X X   -   - - -     - 
LacZ reporter in B. subilis (Ulijasz et al., 1996)       -     -   -   - 
LacZ reporter in E. faecium (Mani et al., 1998) X X X -     - -   - - 
LucA reporter (Grissom-Arnold et al., 1997) - -  low  low     - -  low X X 
CAT radioactivity assay (Lai & Kirsch, 1996)  - -  low -   -      low - X 
CAT-induced petri plate assay (Lai & Kirsch, 1996)  - - X -   -     X - - 
VanX activity (Baptista et al., 1996) X - X X     - -   X - 
VanX activity (Arthur et al., 1999) - - - -     - - X   
low/none 
- - 
 
[33] 
 
Table 1.4.3.2: Induced vancomycin resistance in the E. faecalis VanB phenotype by various antibiotics, according to reporter or assay based systems. 
 
Antibiotic Targets in Cell Wall Assembly Nucleotide 
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Intermediates 
Lipid II PBPs (TG/TP) 
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CAT radioisotope assay (Evers & Courvalin, 1996)  - - - -   X - - - - - 
VanX activity (Baptista et al., 1996) X - X X   X - - X X - 
VanX activity (Arthur et al., 1999)  - - - -   X - - X - - 
Gfpmut1 fused to vanB operon (Baptista et al., 1999) - - - -   X - - - - - 
 
Table 1.4.3.3: Induced vancomycin resistance in the S. coelicolor VanB-like phenotype by various antibiotics, according to reporter or assay based systems 
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VanK activity (Hutchings et al., 2006)  X - X X   X       X - X 
vanJp-neo fusion assay (Hong et al., 2004) - - - -   X       - X - 
[34] 
 
1.5 Two Component Regulatory Systems 
 
Bacteria, yeast, fungi, archae and some plants (e.g. Arabadopsis thaliana) use two-
component signal transduction systems (TCSs) to regulate physiological and molecular 
processes, by sensing and responding to a specific signal (Gao & Stock, 2009). The 
prototypical TCS is composed of a membrane-bound sensor kinase, which is 
autophosphorylated on a conserved histidine residue upon induction by a specific stimulus, 
and is therefore named a histidine kinase (HK). The second component is a response 
regulator protein (RR), which accepts the phosphate from the kinase, onto a conserved 
aspartate residue (Walsh et al., 1996). The response regulator proteins are transcription 
factors, which control expression of target genes. Upon phosphorylation the response 
regulator changes its conformation, activating an effector domain, to elicit a response.  
 
1.5.1 Diversity of Bacterial Two-Component Systems 
   
Two-component signalling is implicated in many vital cellular processes e.g. in response to 
changes in osmolarity (e.g. EnvZ/OmpR), chemical gradients (CheA/CheY), cell density and 
a vast number of other responses (see Table 1.5.1.1). Bacterial adaptation to environmental 
changes occurs on the level of (a) individual genes and proteins, (b) global regulons, (c) 
whole-cell level (e.g. motility or sporulation), or (d) multicellular level (e.g. quorum sensing 
or biofilm formation) (Perry et al., 2011).  There are more than 200 structures of two-
component proteins identified (Gao & Stock, 2009), and the number of TCSs differs greatly 
between species, which seems to correlate with the variety of environmental signals bacteria 
are exposed to. For instance, Mycoplasma genitalium has 0 TCSs, whereas Escherichia coli 
has 30/32 (HKs/RRs), and Myxococcus xanthus has 132/119 (HKs/RRs) (Jung et al., 2012). 
Because as many as one hundred TCSs can co-exist in a cell, a key characteristic of TCSs is 
their exquisite specificity for their cognate response regulator, in order to elicit the correct 
response amongst such a diverse range of systems (Casino et al., 2010). 
[35] 
 
Table 1.5.1.1: Examples of bacterial two-component signalling systems. Adapted from 
Pirrung, 1999; Perry et al., 2011. 
 
Histidine Kinase Control Function Response Regulator Organism 
NarX  
Anaerobic respiration 
NarQ E. coli 
TorS TorR E.coli 
CitA Citrate fermentation CitB K. pneumoniae 
LuxQ Quorum sensing (Cell density) LuxR Many species 
VanS Antibiotic Sensing VanR Many species 
CheA Chemotaxis (flagella motility) CheY E. coli 
EnvZ  
Osmosensing 
OmpR E. coli 
KinA Spo0F E.coli 
PhoR Phosphate metabolism PhoB E. coli 
BvgS Virulence BvgS (internal) B. pertussis 
 
1.5.2 Domain Architecture and Function 
 
The core of the TCS pathway is the phosphotransfer reaction(s) between a homodimeric 
histidine kinase and a response regulator. Typically the HK is the input component, designed 
to sense stimuli and regulate the signalling pathway, and the RR is typically the output of the 
system, regulated by the HK and effecting cellular response (Gao & Stock, 2009). The HK 
has kinase and phosphotransferase activities, and also functions as a phosphatase. The HK 
can autophosphorylate or dephosphorylate (as a ‘phosphatase’) the RR, to control the level 
of phosphorylation and hence the output response. Additional proteins can also regulate the 
activities of the HK or RR, to augment this basic scheme. Furthermore, besides systems with 
a single phosphotransfer step, the phosphotransfer pathway can be expanded to include 
phosphorelay pathways (with two or more steps) between multiple His- and Asp- residues 
(Figure 1.5.2.1).  Examples of the prototypical class I HKs include EnvZ, HK853 (from 
Thermotoga maritima) and VanS. Class I hybrid HKs include TorS and ArcB, and class II 
HKs are essentially represented by the CheA chemotaxis system (Gao & Stock, 2009). 
 
[36] 
 
 
Figure 1.5.2.1: Domain architecture and signalling in two-component systems. Adapted 
from Jung et al., 2012; Gao & Stock, 2009. In class I HKs, the kinase core has two domains; 
a DHp domain, connected via a linker to the CA domain. In class II HKs, the His residue (H) 
is in a histidine phospho-transfer (HPt) domain, separated from the CA domain by an input 
domain and a dimerisation (Dim) domain.  
 
 
In prototypical HKs, the cytoplasmic kinase core consists of two domains: a well-conserved 
C-terminal catalytic ATP-binding domain (CA), and a less-conserved dimerisation and 
histidine phosphotransfer (DHp) domain, as shown in Figure 1.5.2.1. The DHp domain 
contains the His residue for phosphorylation, and the CA domain exhibits the catalytic 
activity to transfer a phosphoryl group from ATP to the His residue. In around 5% of HKs in 
the SMART database (Letunic et al., 2004), a different organisation of the kinase core exists 
in which the phosphorylation site is located on a histidine phosphotransfer (HPt) domain, 
distant from the CA domain, and is transferred to the RR. The class I hybrid HKs, represent 
around 25% of all HKs and incorporate a receiver domain (REC) of RRs to form hybrid 
kinases. These are believed to function with linked or individual HPt domains to use a more 
elaborate phosphorelay system.   
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1.5.3 Histidine Kinase 
 
Several characteristic sequence motifs are conserved across kinase domains of HKs, termed 
the H, N, G1, F and G2 boxes, based on their amino acid sequences (Stock et al., 2000). The 
H box containing the primary phosphorylation site is in the DHp domain, and the rest are 
located in the CA domain. The CA domain contains the N box, G1, F and G2 boxes (Dutta et 
al., 1999) and alone exists as a monomer in solution, capable of binding ATP and 
transferring phosphoryl groups to the dimeric DHp domain. Common to all classes of HK 
are the dimerisation domain, catalytic ATP binding domain, and the sensor domain. 
 
Atomic structures have been reported for the isolated DHp, CA, or sensor domains of a 
number of HK sensors (Tomomori et al., 1999, Bilwes et al., 1999, Marina et al., 2005) and 
more recently a handful of structures of histidine kinases with bound response regulators 
(Casino et al., 2009, Yamada et al., 2009). Furthermore in 2013, the first full-length structure 
of a histidine kinase was published (Diensthuber et al., 2013). Taken together these 
structures have improved understanding of two-component signal transduction systems and 
enable greater knowledge of ways to inhibit these systems in bacteria. The structures and 
mechanistic insights into the function of the domains are discussed below. 
 
(i) Dimerisation and Histidine Phosphotransfer Domain (DHp) 
 
Histidine kinases are active in the form of a dimer, which is controlled by the interaction of 
the dimerisation domains of each monomer HK subunit. One of the first high resolution 
structures of the dimerisation domain produced was that of EnvZ, a class I HK (hybrid) outer 
membrane protein (OMP) from E. coli (Tomomori et al., 1999), which is involved in 
osmoregulation (see Figure 1.5.3.1). Dimerisation of the transmembrane protein is essential 
for its autophosphorylation and phosphorelay signal transduction to its response regulator 
OmpR, to control expression of porin proteins OmpC and OmpF, which form an efflux 
pump in Gram-negative bacteria (Hall & Silhavy, 1981; Nikaido, 2003).  
[38] 
 
 
Figure 1.5.3.1: The dimerisation and phosphotransfer domain of EnvZ HK.  The His 
residue is shown in stick representation on helix α1 of each subunit (cyan or green) of the 
dimeric EnvZ DHp domain (residues 223-289, PDB: 1JOY), produced in PyMol.  
 
The homodimeric DHp structure of EnvZ includes a solvent-exposed His-243 site of 
autophosphorylation and comprises two antiparallel coiled-coils (or ‘helical hairpins’) (Helix 
I and II), which form a four-helix bundle. The two active His sites are located near the 
middle of Helix I (nearest N-terminus) within the dimeric kinase, which appears more 
mobile than Helix II, which could be important in signalling. Similar structures are also 
observed for Spo0B, a histidine phosphotransferase (without kinase activity), involved in 
phosphorelay with its response regulator, Spo0F in B. subtilis (Zapf et al., 2000). 
 
(ii) Catalytic and ATP binding domain (CA) 
 
The C-terminal catalytic domain proceeds after the dimerisation domain and contains the 
ATP binding site. A number of structures of the CA domain have been solved including 
EnvZ (Tanaka et al., 1998) and PhoQ (Marina et al., 2001) from E. coli, HK853 (Marina et 
al., 2005) and CheA (Bilwes et al., 1999) from Thermotoga maritima, and DesK 
(Trajtenberg et al., 2010) from B. subtilis. All CA domains have a characteristic α/β 
sandwich fold, consisting of three alpha-helices covered with a five-stranded β-sheet (see 
Figure 1.5.3.2), which are distinct from any known Ser/Thr kinases (Dutta & Inouye, 2000).  
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Figure 1.5.3.2: Ribbon diagram of the ATP binding domain of DesK HK from B. subtilis 
with bound ATP (PDB: 3EHG). Each domain is coloured in a rainbow spectrum with blue 
for the N-terminus and red for the C-terminus, adapted from Wang, (2012).  
 
 
 
The highly conserved ATP binding cavity is defined by the conserved residues in the N, G1, 
F and G2 boxes (Gao & Stock, 2009). Between the F and G2 boxes is a flexible region 
named the ATP lid, which can adopt different conformations upon nucleotide binding. This 
domain binds ATP, and donates a γ-phosphate group to the His residue on the DHp domain. 
 
The CA domain for DesK from B. subtilis has the shortest known sequence and represents 
the minimal core structure for this domain. Upon binding ATP and a divalent cation (e.g. 
Mg
2+
) structural changes occur at the ‘ATP lid’ (a highly mobile loop) (Yamada & Shiro, 
2008), giving it an ‘open’ or ‘closed’ (ATP bound) state. In the absence of ATP, this loop is 
partially disordered in crystal structures. Even in the presence of ATP, the lid shows 
flexibility, allowing ATP to bind and interact with the DHp domain for phosphotransfer. The 
ATP-lid also allows the CA domain to adopt multiple positions relative to the DHp domain, 
to function as a kinase, phosphotransferase or phosphatase in response to external stimuli.   
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(iii) Sensor Domain 
 
Histidine kinases detect environmental input at their sensor domain and must adapt to 
changes in their environment by modifying gene expression levels, using the two-component 
system. Despite the great diversity of sequences found within sensor domains, to detect a 
specific ligand, there are patterns of domain organisation which be sorted into discrete 
structural classes. The prototypical HK is a homodimeric membrane protein in which the 
sensor domain is positioned between two transmembrane helices, as a periplasmic loop, and 
the DHp domain follows the last transmembrane helix and is located in the cytoplasm 
(Cheung & Hendrickson, 2010). However, some histidine kinases deviate from the model, 
and have sensor domains either within the membrane or in the cytoplasm.  
 
Periplasmic sensory HKs include VanS (the subject of this thesis), NarX and TorS (Cheung 
& Hendrickson, (2009)), which have an all α-helical fold, and PhoQ, DcuS and CitA 
(Cheung & Hendrickson, 2010) which are the first three members of the PDC mixed α/β-fold 
(see Figure 1.5.3.3).  
 
 
Figure 1.5.3.3: X-ray crystal structures of monomeric sensor domains of histidine kinases. 
Cartoon representation of the PDC sensor domains of PhoQ (PDB: 3BQ8) and CitA (2J80) 
and all-helical NarX (3EZH) and TorS (3I9Y) were prepared in PyMol.  
PhoQ CitA NarX TorS
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Cytoplasmic sensory HKs can have a PAS-type fold (present in PER, ARNT and SIM 
proteins) (Hefti et al., 2004) e.g. FixL (Ayers & Moffat, 2008), which senses oxygen through 
heme. The other cytoplasmic sensor structure is a GAF-type fold (present in cGMP 
phosphodiesterases, Adenyl cyclases and FhlA) e.g. DosS and DosT (Podust et al., 2008), 
which detect changes in the redox state of a bound iron or in bound oxygen. The PAS 
domain structure has the same mixed α/β-fold as the PDC domain, but also has other 
distinctive features. The GAF domain structure consists of a six-stranded anti-parallel β-
sheet core (Cheung & Hendrickson, 2010). The majority of kinase sensors have a PAS 
domain (~33%), which can sense changes in light, oxygen and redox potential in the cell. 
The GAF domain is present in ~9% of HKs, and can also sense a variety of ligands. Both 
PAS and GAF domains have high structural plasticity and sequence variability, which is 
important for stimuli recognition and signal transduction (Cheung & Hendrickson, 2010). 
HAMP domains are also present in ~31% of HKs, which are implicated in signalling and 
follow the last TM helix of the sensor domain, and are discussed in section 1.5.5.     
 
In contrast, there is little information on membrane-embedded sensor domains, as no crystal 
structure exists for a transmembrane sensor domain (Cheung & Hendrickson, 2010). 
Structural data on these systems does however suggest that most transmembrane sensors 
exhibit an all-helical fold. For example, sensory rhodopsin II (SrII) (Gordeliy et al., 2002), 
which is involved in chemotaxis, forms a dimeric four-helix bundle (within the membrane), 
to transduce signals downstream. 
 
  
[42] 
 
1.5.4 Response Regulator (RR) 
 
Response regulators are simpler in structure than histidine kinases. The RR superfamily is 
composed of two main domains; a receiver domain (REC) and an effector domain. A 
prototypical RR (e.g. VanR) has an N-terminal receiver domain that participates in catalysis 
of phosphotransfer by accepting a phosphoryl group from its cognate HK onto a conserved 
aspartate residue. Phosphorylation of the receiver domain changes its conformation, and 
causes activation of its C-terminal effector domain in a phosphorylation-dependent manner 
(Wang, 2012). The effector domain is variable in sequence and elicits the output of the 
signalling event, allowing for a diverse array of output functions. The majority of RRs 
(~63%) are transcription regulators with their effector domains acting as DNA-binding 
regions (Gao & Stock, 2009), or have enzymatic effector domains (~13%).  
 
(i) Receiver domain (REC) 
 
The REC domain acts as a phosphorylation-induced switch. Phosphorylation in the REC 
domain occurs at a conserved Asp residue, generating a high-energy acyl-phosphate. It is 
thought that this acyl phosphate provides the energy to drive a conformational change in the 
REC domain (Gao & Stock, 2009). The REC domain has enzymatic activity, catalysing 
phosphotransfer and dephosphorylation. Phosphotransfer from HK to RR involves a complex 
of the two, where both proteins contribute to the active site. The catalytic activity of the RR 
is exemplified by its ability to autophosphorylate at the Asp residue using small-molecule 
phosphodonors such as acetyl phosphate too. However the rate of phosphotransfer is much 
slower (~100 times) than that of the cognate HK (Lukat et al., 1992).  
 
The REC domain has a α/β-fold, with alternating β-strands and α-helices folding into a 
central five-stranded parallel β-sheet, surrounded by α-helices 1 and 5 on one side and α-
helices 2, 3 and 4 on the other (Wang, 2012) (Figure 1.5.4.1).  
[43] 
 
 
 
Figure 1.5.4.1: Structures of the E. coli receiver domain of the PhoB response regulator. 
Adapted from Wang, (2012) and coloured in a rainbow spectrum (PDB: 1B00). 
Phosphorylation site and switch residues are shown as sticks.  
 
 
The β-sheet consists of mostly hydrophobic side chains, which form a hydrophobic core, as 
shown in the figure.  Most of the conserved binding residues are at the C-terminal ends of β-
strands 1, 3, 5. Helix α1 is involved in binding to the DHp domain of HK (Casino et al., 
2009) and is likely to play an important role in the specificity of HK-RR pairs.  In addition to 
the Asp site of phosphorylation on the β3 strand (Figure 1.5.4.1), the active site contains two 
Asp/Glu residues on the β1 strand, that coordinate a Mg2+ ion (Gao & Stock, 2009).  
 
(ii) Effector Domain 
 
The effector domains are diverse in structure, in order to provide a variety of output 
responses. However they are dominated by a small number of structural families, named 
after highly characterised members. These include the OmpR/PhoB ‘winged-helix’ domain 
(30% of RRs) and the four-helix NarL/FixJ ‘helix-turn-helix’ domain (17%) (Figure 1.5.4.2).  
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Figure 1.5.4.2: Structure of the dimeric effector domain of NarL RR binding to DNA. 
NarL (PDB: 1JE8) is drawn in ribbon form, adapted from Wang, (2012). 
 
The C-terminal DNA-binding domain of the NarL/FixJ sub-family is a compact bundle of 4 
α-helices (Maris et al., 2005). In the inactive form, the REC and effector domains interact, 
masking the DNA-recognition helix (Maris et al., 2002). However in the active 
phosphorylated state, the RRs dimerise and the DNA recognition helix (α9) from both 
monomers inserts into the major groove of DNA, leading to transcription.  
 
1.5.5 Insights into Signal Transduction Mechanisms 
 
(i) Sensor Domain to Catalytic Domain 
 
For a sensor HK to conduct its catalytic functions, a mechanism must exist by which the 
periplasmic loop and transmembrane domains can sense and transduce a signal to the 
catalytic core. Conformational changes must occur from the sensor loop to the kinase core, 
to transduce the signal. As stated in section 1.5.3 a number of sensory domains e.g. PAS and 
GAF domains are involved in sensing signals, which are believed to allow signal 
transduction through their structural plasticity and flexibility. An additional domain involved 
in signal transmission is a HAMP domain (present in Histidine kinases, Adenyl cyclases, 
Methyl-accepting chemotaxis proteins and Phosphatases) (Szurmant et al., 2007).  
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HAMP domains connect the last transmembrane helix of the sensor domain to the catalytic 
domain. They consist of two helices which form a parallel four-helical coiled coil in the 
homodimeric active state, and are proposed to control signal transmission to the catalytic 
core (Hulko et al., 2006; Ferris et al., 2012) (see Figure 1.5.5.1).  
 
 
 
 
Figure 1.5.5.1: Schematic of histidine kinase modular architecture. Adapted from 
Szurmant et al., (2007).  
 
 
Two possible models exist for the function of the HAMP domains: a cog-like rotation of 
each helix relative to one another (‘gearbox model’) (Hulko et al., 2006) or a combination of 
vertical movement and helical rotation (‘screw-like motion’) (Airola et al., 2010). The 
gearbox model was proposed from studies of the first HAMP structure, of Af1503, a receptor 
from the archaeon Archaeoglobus fulgidus. Crystal structures of this receptor indicate that an 
axial rotation of the four-helix bundle by 26
o
 occurs in the active state to transmit a signal to 
the kinase domain (Hulko et al., 2006). This rotation converts the domain packing from a 
‘complementary x-da’ packing to a ‘knobs-into-holes’ geometry.  
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The screw-like signalling mechanism is based on the crystal structure of the receptor Aer2 
from P. aeruginosa, which has three connected HAMP domains, each containing a parallel 
four-helix bundle. However, in middle of HAMP2, there is an offset in the helical register 
between the first and second helix, which leads to a combination of vertical and helical 
rotation to transduce signals, i.e. a screw-like motion (Airola et al., 2010). Therefore it is 
likely that structural changes in the sensor region upon ligand binding could trigger rotations 
of the TM helices and HAMP domain, or structural changes in PAS/GAF or other domains, 
to transduce signals to the kinase domain (Cheung & Hendrickson, (2010), Zhang & 
Hendrickson, (2010).  
 
(ii) Catalytic Domain to Dimerisation Domain  
 
Downstream structural changes in the dimerisation domain induced by signalling elements 
such as the HAMP domains are likely to alter the regulation of interactions between the DHp 
and CA domains. The changes triggered by different HAMP conformations do not appear to 
perturb the active-site histidine or the lower half of the DHp domain (Wang, 2012), but the 
CA domain must rotate to transfer a phosphate to the active His site in the DHp domain. As 
stated in section 1.5.3, numerous atomic structures exist for the isolated cytoplasmic domains 
of different HKs including EnvZ (Tomomori et al., 1999), PhoQ (Marina et al., 2001) and 
HK853 (Marina et al., 2005). The crystal structure of HK853 from T. maritima is 
particularly useful for discussion since a recent co-crystal structure of the kinase and its 
cognate response regulator RR468 has been published (Casino et al., 2009). The crystal 
structure of the entire cytoplasmic portion of HK853 is shown in Figure 1.5.5.2, which 
represents a dimeric conformational state ready for phosphotransfer (Marina et al., 2005). 
[47] 
 
 
Figure 1.5.5.2: Ribbon diagram of the dimeric cytoplasmic portion of HK853. Adapted 
from Casino et al., 2009. Each subunit is coloured in pale blue or light brown, with the H260 
site and bound phosphate mimic (SO4
2-
) shown as spheres, drawn in PyMol (PDB: 2C2A). 
 
 
The CA domain characteristically hosts one ATP molecule between its ATP lid and a central 
helix, which can be exposed for attack. In this instance the structure contains an ADPβN, 
instead of ATP.  The CA domain is also connected to the DHp domain via a mobile hinge, 
which has been observed in other HKs to adopt multiple conformations for phosphotransfer. 
The H260 side chain is exposed to the surface of the protein and there is a sulphate ion in the 
structure bound to H260, mimicking the phosphorylated histidine.       
 
As HKs are homodimeric, there are two mobile phosphorylating domains (CA) and two 
phospho-accepting exposed His residues (DHp). Therefore cis- or trans-phosphorylation 
could occur. Cis-phosphorylation is the phosphorylation of one HK monomer by itself, 
whereas trans-phosphorylation is phosphorylation of one HK monomer by the other. In the 
HK853 structure, the His residue and ATP binding site are 19Å apart, requiring a rotation of 
domains of 70
o
 for trans- phosphorylation (Marina et al., 2005). This is not consistent with 
26
o
 rotations observed in HAMP domains, so cis-phosphorylation is the preferred model.  
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However, there has been debate over which model applies, since e.g. EnvZ and DesK 
(Tomomori et al., 1999; Trajtenberg et al., 2010) autophosphorylate in a trans-mechanism, 
whereas HK853 and PhoR (Casino et al., 2009; 2010) autophosphorylate in cis. In fact, a 
recent paper has demonstrated that the mechanism of autophosphorylation is independent of 
the cis- or trans-directionality since the catalytic centre of HK853 and EnvZ appear identical 
in functional and structural data (Casino et al., 2014), and that the directionality is dependent 
on the left or right handedness of the DHp α1 and α2 helices. 
 
(iii) Dimerisation Domain to Response Regulator 
 
The crystal structure of the HK853-RR468 complex is shown in Figure 1.5.5.3, and shows 
that the response regulator molecules are positioned on opposite sides of the DHp domain 
dimer and sit below the phosphorylatable His260 residue. 
 
 
 
 
Figure 1.5.5.3: Ribbon representation of the crystal structure of the HK853-RR468 
complex. Adapted from Casino et al., 2009. The complex is viewed perpendicular to the 
DHp axis, and one RR molecule is shown in the structure for clarity. Each subunit of the HK 
is coloured in blue or light brown, and the RR is in green.  
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In this orientation the Asp53 site of the RR is aligned with a phosphoryl mimic and the H260 
site of the HK (shown by spheres), favouring phosphoryl transfer (Casino et al., 2009). The 
RR clings to the helical stem of one HK subunit by inserting the α1 helix of the RR next to 
the two helices of the HK, forming a six-helix bundle (Wang, 2012).  
 
Overall the crystal structures of HK853 with and without bound RR, show conformational 
changes in accordance with the different functional states (phosphorylated by ATP, and 
phosphotransfer to the RR). These contacts should vary with the reaction occurring and 
confer specificity between the HK and its cognate RR. Similar interactions are observed for 
the catalytic domains of other histidine kinases with their cognate response regulators, e.g. in 
the Spo0B-Spo0F complex in B. subtilis (Zapf et al., 2000) and in the ThkA-TrrA complex 
in T. maritima (Yamada et al., 2009). Based on the HK853-RR468 complex and previous 
structures, Casino et al., (2009), propose a model for TCS signalling (see Figure 1.5.5.4).  
 
 
 
 
Figure 1.5.5.4: Signal transduction model, adapted from Casino et al., (2009). Signal 
transduction involves rotation of coiled coils at the top of the DHp domain, altering its 
packing. This causes the CA domain to either approaches the His residue, activating the 
kinase (centre), or moves away to generate site for unphosphorylated RR, for 
phosphotransfer (right), or phosphorylated RR, triggering phosphatase function (left).   
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1.5.6 A Full-Length Histidine Kinase 
 
 
During these studies, the first structure of a full-length histidine kinase, a photosensor kinase 
YF1, was published by Diensthuber et al., (2013) (see Figure 1.5.6.1). The group 
demonstrated that a ‘rotary-switch’ mechanism is involved in its function, whereby rotation 
of helical connectors and coiled coils (e.g. PAS domains) is crucial to transduce signals to 
the kinase domain, to effect a response under different light conditions. YF1 is an engineered 
histidine kinase whereby the oxygen-sensitive PAS-B domain of the B. japonicum FixL HK 
is replaced with a light-oxygen-voltage (LOV) photosensor domain which also adopts a PAS 
fold, and is activated by binding flavin-mononucleotide (FMN) ligands. The resulting YF1 
protein phosphorylates the cognate FixJ RR with similar activity to FixL in the dark. Upon 
exposure to blue light, the LOV sensor domain binds FMN, and compared to FixL, YF1 has 
a 1000 times increased phosphatase activity. Therefore the kinase and phosphatase states can 
be easily distinguished by switching from dark to light conditions. 
 
In the structure, upon light absorption, a signal is transduced from the A’α helices (N-
terminus) which modulate the activity of the LOV (PAS) domain. Crucially the A’α and Jα 
coiled coils are precisely aligned and form a continuous helical spine, which rotates around 
the central axis to transduce signals, resulting in an increase in the crossing angle at the A’α 
domains and Jα. This rotary-switch model has also been proposed to occur in other HKs e.g. 
the Af1503 HK (Ferris et al., 2012), involving HAMP domain signalling. It therefore 
appears that the alterations in the helical connectors and coiled coils (such as DHp, PAS and 
HAMP domains) are crucial to signal transduction. It has been shown in several studies that 
point mutations in coiled coil regions (Havranek & Harbury, 2003, Skerker et al., 2008, 
Ferris et al., 2012, Diensthuber et al., 2013) can completely alter or ‘rewire’ the signal 
response of receptors, and this reprogramming could be used to engineer proteins in the same 
way as YF1, and perhaps act as a route to inhibit histidine kinase function, for instance those 
involved in bacterial antibiotic resistance.  
[51] 
 
 
Figure 1.5.6.1: Ribbon diagram of the X-ray crystal structure of the dark-adapted sensor 
kinase YF1 (PDB: 4GCZ). Adapted from Diensthuber et al., 2013 and drawn in PyMol.  
 
1.5.7 Cross-Talk within Two Component Systems 
 
Most bacterial genomes encode dozens of TCSs to response to a variety of stimuli. As a 
result, multiple HK/RR proteins are present from paralogous gene families. This makes it 
possible for cross-phosphorylation or ‘cross-talk’ between proteins in different TCS 
pathways, at highly similar DHp and REC domains (Gao & Stock, 2009). Cross-talk is 
different from ‘cross-regulation’ which occurs in branched TCSs, through necessity for a 
proper response by the organism. For instance cross-regulation occurs in ‘one-to-many’ 
systems such as the CheA HK chemotaxis system, which can phosphorylate CheY and CheB 
to control motility (Laub & Goulian, 2007). Cross-talk by comparison involves a deviation 
from a specific pathway by cross-phosphorylation from another TCS, and can be detrimental 
to cellular response. Several groups have reported cross-talk to non-cognate substrates in 
vitro, but usually only after protein overexpression, so it is not clear to what extent it occurs 
in vivo, but it is likely minimal to ensure specificity (Laub & Goulian, 2007). 
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One example of cross-talk is between VanS and the response regulator PhoB in E. coli, 
which only occurs in the absence of the PhoR histidine kinase (Fisher et al., 1995; Silva et 
al., 1998). Similarly the kinase, PhoR, can cross-talk to VanR, but only in the absence of 
VanS (Fisher et al., 1996; Haldimann et al., 1997). Therefore cross-talk is likely a 
consequence of eliminating the phosphatase activity normally provided by the other HK. In 
the VanS-VanR TCS in enterococci, VanS was also found to phosphorylate VanR with a 
10,000-fold preference over non-cognate PhoB (Fisher et al., 1995; 1996), demonstrating the 
inherent preference of a kinase for its cognate substrate, to prevent cross-talk. 
 
1.6 Strategies for the Discovery and Development of Novel Antimicrobials 
 
1.6.1 Platforms for Antibiotic Discovery 
 
As stated in section 1.1.1, the discovery of the first aminoglycoside, streptomycin, by 
Selman Waksman in the 1940s was the first example of a robust discovery platform. The 
Waksman platform involved simply screening soil-derived streptomycetes for antimicrobial 
activity against a susceptible test organism by detecting zones of inhibition on an overlay 
plate. This platform of mining soil-derived actinomycetes was widely used by the 
pharmaceutical industry and produced most of the major classes of antibiotics during the 
golden era (Lewis et al., 2013), but after 20 years of success, the returns diminished due to 
the rediscovery of known compounds. In the 1990s, the pharmaceutical industry de-
emphasised its microbial screening programs and focussed on developing synthetic 
antibiotics using high-tech screening approaches based on genomics, high-throughput 
screening (HTS) using robotic technologies, and rational drug design. It was thought that 
essential conserved bacterial proteins identified through genomics would serve as targets for 
HTS and drug design with the aim of producing novel antibiotics. However, since the 
discovery of daptomycin, no novel drugs with broad spectrum activity against important 
pathogens have emerged from this platform (Clardy et al., 2006).   
[53] 
 
A recent comprehensive HTS program of chemical libraries by GSK in 2007, examining 
500,000 small molecules against a range of antibacterial targets did not find any new drugs 
worthy of development (Payne et al., 2007). However, bedaquiline, a novel diarylquinoline 
antibiotic (Figure 1.6.1.1), was obtained through a focussed high-throughput screen using a 
commercially available library, and has been FDA approved for MDR-TB treatment (FDA, 
2012). These focussed libraries, more suited for a specific target class, could hold more 
promise. For instance, the discovery of natural product platensimycin from Streptomyces 
platensis, with new terpenoid scaffold architecture (see Figure 1.6.1.1) was made by 
scientists at Merck using their old collection that had been previously screened for growth-
inhibitory activity against S. aureus (Wang et al., 2006; Young et al., 2006).  
 
Platensimycin was discovered by a targeted ‘smart’ screen using gene ‘knock-downs’, which 
lower the level of essential gene expressions in MRSA, one at a time, and render a particular 
step in a pathway rate limiting. A knockdown of the FabF and FabB enzymes in the fatty 
acid biosynthetic pathway made FabF the rate-limiting step in S. aureus lipid biosynthesis, 
and made bacterial growth sensitive to inhibition of this step (Walsh & Wencewicz, 2014).  
 
There is a clear need to develop reliable discovery platforms, using focused compound 
libraries for HTS discovery and the use of structure-based rational design. X-ray structure 
and NMR structure determination of small-molecule ligands bound to target proteins has 
become a widely used tool for drug discovery, and in silico-based modelling methods 
supplement this (Clardy et al., 2006). These techniques allow design of potential inhibitors 
that can be synthesised and evaluated in targeted biochemical screens. Structure-based 
approaches were responsible for revealing that platensimycin binds specifically to the FabF 
acyl-S-intermediate, and a C163Q mutant of E. coli FabF mimicked the acyl-enzyme 
conformation well-enough to provide crystals in complex with platensimycin, revealing the 
unique structural features of platensimycin (Wang et al., 2006).  
 
[54] 
 
 
 
Figure 1.6.1.1: Structures of Platensimycin and Bedaquiline. Platensimycin has an 
unusual pentacyclic terpenoid-like structure, whereas bedaquiline has two naphthalene-like 
rings and is a novel class called diarylquinolines.    
 
1.6.2 Underexplored antibiotic targets 
 
There is potential to re-explore conventional targets to develop antimicrobials, given the 
wealth of new structural data available on drug targets and new mechanistic data on 
antibiotic action.  For instance, in the early 2000s, a high resolution structure was published 
of the 50S ribosomal subunit from the archaeon Haloarcula marismortui (Ban et al., 2000), 
and the 30S ribosomal subunit from Thermus thermophilus (Wimberly et al., 2000). This 
could enable improved drug targeting at these sites by structure-based approaches. Recent 
data on the mechanism of action of the prototype lantibiotic nisin, which targets Lipid II, has 
also shown a new, additional mode of function. The lantibiotics, along with glycopeptides, 
mannopeptimycins and ramoplanins are thought to bind Lipid II preventing one or more 
steps in the Lipid II cycle or blocking peptidoglycan precursors from crosslinking (Breukink 
& Kruiff, 2006). New NMR evidence shows that the A and B rings of nisin form a 
pyrophosphate cage which binds the pyrophosphate of Lipid II, and that nisin uses Lipid II 
as a docking molecule to create a pore, disturbing cell integrity and leading to cell death 
(Hsu et al., 2004). Nisin has promising activity against clinical isolates of MRSA and VRE, 
so nisin or its derivatives could be used therapeutically (Brumfitt et al., 2002).  
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One advance of particular relevance to this PhD is the work of Boger’s group (Xie et al., 
2011; James et al., 2012) who generated a new synthetic version of the vancomycin 
aglycone: an amidine derivative (see Figure 1.6.2.1). The design took inspiration from the 
lowered affinity of vancomycin for D-Ala-D-Lac-terminating cell wall precursors. The loss 
of a critical hydrogen bond is compensated in the amidine derivative. This version shows 
activity against VRE, and retains acceptable activity against D-Ala-D-Ala PG precursors. 
Addition of the disaccharide moiety back onto the amidine aglycone could therefore lead to a 
new generation of glycopeptide antibiotics, to combat VRE, and perhaps VRSA infections. 
Further insight into the mechanism of binding of vancomycin to VanS (which is a major 
focus of this PhD) could therefore help improve structure-based design of novel 
glycopeptide antibiotics.  
 
 
 
Figure 1.6.2.1: A synthetic amidine vancomycin aglycone which binds to D-Ala-D-Lac. 
Adapted from Walsh & Wencewicz, 2014. The modification of a carbonyl group allows a key 
hydrogen bond (red) to be restored for high affinity in vancomycin resistant strains.    
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1.7 Aims and Outline of Thesis 
1.7.1 Aims 
 
The literature review above details advances in the field of drug discovery and development 
to combat the continued threat posed by antimicrobial resistance. The intricate architecture 
of two-component systems in bacteria shows how they have become tuned to sense slight 
changes in their environment and adapt through expression of individual genes or even on a 
whole cell level. The VanS-VanR TCS is one such example, which responds to the presence 
of glycopeptide antibiotics through expression of van resistance genes to alter the structure 
of the antibiotic target. This has led to the emergence of glycopeptide resistance in clinically 
relevant Enterococcal strains (GRE/VRE), and in more virulent S. aureus strains (VRSA). 
Vancomycin resistance has also been observed in soil-dwelling bacteria e.g. Streptomyces, 
which are often intrinsically resistant. The increasing emergence of glycopeptide resistance 
is a public health concern, and is particularly alarming given vancomycin’s current status as 
a drug of last defence against serious Gram-positive infections e.g. MRSA. There is 
therefore a need to develop novel antimicrobials to combat infections from MRSA, VRE and 
VRSA, and to improve understanding of the associated resistance mechanisms. 
 
Using a structural biology based approach, improved knowledge of the structure and 
function of different VanS proteins could contribute toward rational design of novel 
inhibitors. If successful these inhibitors could be used in conjunction with current antibiotics 
or as stand-alone therapies to combat glycopeptide resistance mechanisms. Towards this 
general aim, the work of this thesis focuses on the study of the sensor histidine kinase, VanS, 
derived from two bacterial strains (E. faecium and S. coelicolor), by biophysical and 
biochemical methods. These strains were chosen represent two different antibiotic resistance 
phenotypes (VanA and VanB-type respectively), and therefore proteins derived from these 
may interact with glycopeptide antibiotics by different mechanisms. Proteins derived from E. 
faecium are termed ‘VanSA’, and those from S. coelicolor, are termed ‘VanSSC’ throughout.   
[57] 
 
Literature on the VanS-VanR TCS demonstrates current knowledge of how extracellular 
glycopeptide and non-glycopeptide antibiotics activate VanS directly or indirectly via 
another signalling molecule such as Lipid II, and improvements in the understanding of 
structure-activity relationships for these systems. However, there are many questions that 
remain unanswered (see below). These are summarised schematically in Figure 1.7.1.1. 
 
1. What is the atomic structure of the VanS membrane protein?   
 
As a membrane protein, a long-term goal of any studies would be to determine the structure, 
function and dynamics of this protein kinase. In particular structure-function studies could 
reveal how vancomycin and other potential ligands activate VanS proteins in different 
species. Towards this goal, attempts were made to crystallise the full-length VanS protein 
and analyse the structure (and antibiotic binding properties) of its sensor domain by NMR 
spectroscopy.  
 
2. What is the nature of the inducer that activates VanS, and if induced by a direct binding 
to the antibiotic, where are the binding sites located?  
 
Biochemical screens for antibiotic inducers of the Enterococcal VanSA protein are not 
consistent (see section 1.4), and biophysical experiments are required to provide conclusive 
evidence for a direct or indirect induction mechanism. Fluorescence- and NMR-based 
titration experiments are described in this thesis to test for a direct interaction between VanS 
and potential vancomycin ligands. Titration studies are conducted with VanS proteins 
derived from S. coelicolor (VanSSC) to act as a positive control when assessing VanS 
proteins derived from E. faecium (VanSA), since VanSSC has recently been shown to bind 
directly to a vancomycin analogue (see section 1.4.2). NMR-based titration data is analysed 
to determine which residues (if any) can interact directly with vancomycin antibiotics. 
  
[58] 
 
3. By what mechanism are signals transduced across the transmembrane domain, upon 
induction by glycopeptide antibiotics? 
 
There is evidence in many two-component systems that conformational changes are 
propagated throughout the sensor kinase upon induction. It is therefore likely that the sensor 
domain alters its conformation to propagate a signal downstream to the kinase domain. The 
transmembrane helices are positioned between these domains and could either associate with 
one another, or exhibit displacements/rotations relative to the bilayer to transduce this signal. 
To examine the propensity of these helices to self-associate, in vivo oligomerisation assays 
(ToxCAT) are conducted, with the aim of improving understanding of signal transduction 
across this domain.  
 
 
 
Figure 1.7.1.1: Schematic diagram showing the predicted topology of VanS, which is 
activated by vancomycin antibiotics, to transduce a signal to VanR. Vancomycin is known 
to bind to Lipid II to inhibit cell wall biosynthesis, but it is not clear whether VanS indirectly 
senses the action of vancomycin on the cell wall, or if it binds to vancomycin directly.   
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1.7.2 Outline 
 
The expression and purification of full-length VanS membrane proteins from two bacterial 
species (E. faecium and S. coelicolor) with different phenotypic backgrounds is discussed in 
Chapter 3. Appropriate vectors are chosen for selective purification of VanS proteins by 
affinity chromatography and subsequent tag cleavage. Detergent-solubilised VanS proteins 
are assessed for their autophosphorylation activity using coupled enzymatic assays 
developed within the Warwick group, and tag-cleaved proteins are placed into crystallisation 
trials (using membrane protein screens). The main aim of these studies was to obtain a 
diffraction-quality crystal of a VanS protein, with improved resolution, compared to crystal 
hits identified (8Å) during previous studies by Dr. Michael Williams (Warwick University).  
 
Chapter 4 describes cloning techniques used to modify the vanS gene sequence, in order to 
isolate the VanS sensor domain for use in NMR studies (see Figure 2.4.2.1). The main goal 
of which is to provide structural data on the sensor region and conformational changes at this 
domain upon titration of potential glycopeptide ligands. Routes towards overexpression and 
purification of this domain in isotopically labelled media, as required for NMR, are outlined. 
NMR spectral quality is also optimised by screening detergent, pH and buffer conditions.  
 
In Chapter 5, fluorescence assays are applied to qualitatively test for any interaction between 
VanS proteins and a labelled vancomycin analogue. NMR-based titration experiments are 
then conducted to determine any residues that interact between the VanS sensor domain and 
vancomycin. These NMR assays involved the use of 
15
N-labelled VanS protein, and 
monitored for changes in peak chemical shift of the protein (on 
1
H-
15
N HSQC spectra) upon 
titration of unlabelled vancomycin antibiotic. Additionally, oligomerisation assays are 
presented which aimed to further elucidate the mechanism by which signals are transduced 
from the sensor domain across the membrane, upon ligand activation. These assays quantify 
association between VanS transmembrane helices using an in vivo ToxCAT reporter system.  
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2 Materials and Methods 
2.1 Suppliers of Chemicals and Reagents 
 
All chemicals and reagents used were of analytical grade, and were obtained from the 
following sources unless otherwise stated: 
 
Promega Corporation; Madison, Wisconsin, USA    
Sigma-Aldrich Company ltd.; Dorset, UK    
New England Biolabs (UK) ltd; Hitchin, Hertfordshire, UK   
Perkin Elmer; Waltham, Massachusetts, USA     
Affymetrix (formerly Anatrace); Maumee, Ohio, USA    
GE Healthcare; Little Chalfont, Buckinghamshire, UK    
Avanti Polar Lipids, Alabaster, AL, USA   
Integrated DNA Technologies, Coralville, Iowa, USA    
Roche, Basel, Switzerland     
Invitrogen Life Technologies Ltd., Paisley, UK    
 
2.2 Escherichia coli Strains 
2.2.1 Bacterial Growth Media 
 
LB Broth (Bertani, 2004) was composed of 10 g Tryptone, 5 g Sodium Chloride, 5 g Yeast 
Extract, prepared to one litre in water and autoclaved. 
 
Super Optimal Broth with Catabolites (SOC) (Hanahan, 1983) was composed of  20 g 
Tryptone, 0.5 g Sodium Chloride, 5 g Yeast Extract, 0.2 g Potassium Chloride, 3.6 g Glucose 
and 1 g Magnesium Chloride and made up to 1 L with double-distilled water and autoclaved. 
 
[61] 
 
LB Agar Plates were composed of LB media, to which 15 g of bacto-agar was added to 1 L 
of media and autoclaved. Mediums were cooled to around 50
o
C at which point appropriate 
antibiotics were added and poured into sterile Petri-dishes and stored at 4
o
C until use. 
 
5x M9 salts (Sambrook, 1989) were composed of 85 g Na2HPO4.12H2O or 64 g 
Na2HPO4.7H2O, 15 g KH2PO4, 2.5 g NaCl, prepared to one litre in water and autoclaved. 
 
2.2.2 Bacterial Strains 
 
 
Table 2.2.2.1   E. coli strains used in this project 
Strain Genotype Reference 
TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 
nupG recA1 araD139 Δ(ara-leu)7697 galE15 galK16 
rpsL(Str
R) endA1 λ- 
Grant et al., 
1990 
DH5α F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG 
Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK
-
 mK
+), λ– 
Hanahan, 
1985 
NT326 F-araDI39ΔlacUl69 rpsL thiΔmalE444 recAl Treptow et 
al., 1985 
C41(DE3) Derivative of E. coli BL21(DE3): F
-
 ompT hsdSB (rB
-
 mB
-
) 
gal dcm (DE3). Contains at least one uncharacterised 
mutation - prevents cell death associated with expression of 
toxic recombinant proteins.  
Miroux & 
Walker, 1996 
C43(DE3) Derivative of C41 (DE3) obtained using F-ATPase subunit 
gene.  
Miroux & 
Walker, 1996 
BL21 
(DE3) 
F
–
 ompT gal dcm lon hsdSB(rB
-
 mB
-) λ. An E. coli strain with 
DE3, a λ prophage carrying the T7 RNA polymerase gene 
and lacI
q
. Transformed plasmids containing T7 promoter 
driven expression are repressed until IPTG induction of T7 
RNA polymerase from a lac promoter. 
Studier & 
Moffat, 1986 
BL21 
(DE3) 
pLysS 
F
-
 ompT gal dcm lon hsdSB(rB
-
 mB
-) λ(DE3) pLysS(cmR). The 
pLysS plasmid is chloramphenicol resistant, and encodes T7 
phage lysozyme, an inhibitor for T7 polymerase which 
reduces and almost eliminates expression from transformed 
T7 promoter containing plasmids when not induced. 
Moffatt & 
Studier, 1987 
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2.2.3 Preparation of Chemically Competent Bacterial Cells for Transformations 
 
Based upon the protocol outlined by Hanahan (1985), several methods for competent cell 
production exist. To produce ultracompetent cells, a method was followed using Promega 
Protocols and Applications Guide (Doyle, 1996). 10 ml of sterile Luria broth (LB) 10:5:5 
was inoculated with 100 μl of the required E. coli strain from a glycerol stock (stored at -
80
o
C) and incubated at 37
o
C with shaking at 180 rpm overnight, until mid-OD phase. 
  
250 mL sterile LB was inoculated with 2.5 mL of the overnight culture and incubated at 
37
o
C with shaking at 180 rpm until the optical density at 600 nm reached between 0.4 and 
0.6. The culture was then centrifuged at 4,500 g for 10 minutes to pellet cells, and 
resuspended in 100 ml of TFB1 buffer (30 mM potassium acetate, 10 mM calcium chloride, 
50 mM manganese chloride, 100 mM rubidium chloride, 15% (v/v) glycerol, pH 5.8), 
centrifuged and resuspended in 10ml of TFB2 buffer (10 mM MOPS or PIPES pH 6.5, 75 
mM calcium chloride, 10 mM rubidium chloride, 15% (v/v) glycerol. Competent cells were 
snap-frozen in 200 μl aliquots in liquid nitrogen and stored at -80oC. 
 
2.3 DNA Transformation of E. coli 
 
Chemically competent cells (prepared as described in section 2.2.3) were thawed on ice and 
100 μL of cells was incubated with 10-100 ng of plasmid DNA for 20 minutes. Cells were 
heat-shocked at 42°C for 45 seconds and returned to ice for 2-3 minutes. 500 μL of 
autoclaved LB media or 300 μL of autoclaved SOC buffer was added and cells were 
incubated at 37°C, with shaking at 180 rpm, for 30-45 minutes. 100 μL of transformation 
mixture was plated using aseptic technique onto LB agar plates containing the appropriate 
antibiotic selection for the transformed plasmid. Plates were incubated at 37°C overnight. 
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2.3.1 Preparation of Glycerol Stocks 
 
5 mL sterile LB was inoculated with a single E. coli colony from a fresh transformation (see 
section 2.3) and grown to mid-log phase in the presence of appropriate antibiotic for plasmid 
selection with shaking at 37°C. 0.8 mL of culture was aseptically mixed with 0.2 mL sterile 
analytical reagent grade 80% (v/v) glycerol in a Corning cryo-vial and frozen at -80°C. 
 
2.4  DNA Manipulation and Cloning Techniques 
 
Oligonucleotides were designed against the appropriate gene target with relevant restriction 
enzyme sites included and ordered from Integrated DNA Technologies (IDT) or Invitrogen.   
 
Table 2.4.1: Synthesised oligonucleotide sequences used in this project.  For -forward (5’) 
primer; Rev- reverse (3’) primer, FL- Full-length gene, 4aa/3aa – Section of DNA encoding 
for 4 or 3 amino acids of an enzymatic cleavage site, Tm- melting temperature. Primers for 
VanSA and VanSSC were designed against E. faecium ‘VanA’ phenotype and S. coelicolor 
‘VanB’ phenotype respectively. Restriction sites are underlined, mutations highlighted, and 
stop codons in red. CCATGG:- NcoI, AAGCTT:- HindIII. 
 
Primer Name Sequence 5’ to 3’ Tm 
(
o
C) 
Use in 
Project 
pttQ18 For CAT CGG CTC GTA TAA TGT GTG G 60.3 Sequencing 
pttQ18 Rev GGC GAA AGG GGG ATG TGC TG 63.4 Sequencing 
pProEx For AGC GGA TAA CAA TTT CAC ACA GG 55.7 Sequencing 
pProEx Rev CTG CGT TCT GAT TTA ATC TGT AGG C 63.7 Sequencing 
VanSAFL For TTT GCG CCA TGG TTA TAA AAT TGA 
AAA ATA AAA AAA ACG ACT ATT CC 
61.4 Construct 
Creation 
VanSAFL Rev TTT GCG  AAG CTT AGG ACC TCC TTT 
TAT CAA CCA AGT CTG GCA TCG CTG  
69.1 Construct 
Creation 
VanSSCFL For TTT GCG CCA TGG ATA GGC GCC CCG 
GTC TGA GCG TCC GCC TCA AG 
75.2 Construct 
Creation 
VanSSCFL Rev TTT GCG AAG CTT ACC TGC CGG TGT 
GCG GAG CGG CCG CGG GCA G 
77.1 Construct 
Creation 
VanSA110 Rev GCG GCG AAG CTT TTA AAT GCC GGT 
ATT TAT CTC GTC AAA GTA TTT TGC 
GAA TTT 
66.8 Construct 
Creation 
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VanSA120 Rev GCG GCG AAG CTT TTA TTG TTT ATC 
TTC GTT CTG AAT AAG TAC ATC AAT 
GCC GGT 
67.0 Construct 
Creation 
VanSA130 Rev GCG GCG AAG CTT TTA CAT AAC ATC 
CAT TTC CGC AGA AAG CTC AAT TTG 
TTT AGC 
67.7 Construct 
Creation 
VanSsc100 Rev GCG GCG AAG CTT TTA GCG GGT GGC 
CTC GGT GAT GCG GTC CAG GGG 
76.0 Construct 
Creation 
VanSsc110 Rev GCG GCG AAG CTT TTA CCG GTG GGA 
GAG GGA TCC GGT CGC CGC CGT GCG 
76.8 Construct 
Creation 
VanSsc120 Rev GCG GCG AAG CTT TTA GTA CTC GTC 
CCT GCG GCC CGG CAG CCG GAT GCG 
GTG 
76.5 Construct 
Creation 
VanSA3C 4aa For TTC CAG GGA CCT ATT GAG CTT TCT 
GCG GAA ATG GAT GTT ATG GAA 
67.0 Mutagenesis 
VanSA3C 4aa Rev CAG CAC CTC CAG TTG TTT ATC TTC 
GTT CTG AAT AAG TAC ATC AAT GCG 
GG 
66.4 Mutagenesis 
VanSATEV 4aa For TAC TTC CAG AGT ATT GAG CTT TCT 
GCG GAA ATG GAT GTT ATG GAA C 
65.0 Mutagenesis 
VanSATEV 3aa 
Rev 
CAG GTT CTC TTG TTT ATC TTC GTT 
CTG AAT AAG TAC ATC AAT GCC GG 
64.2 Mutagenesis 
VanSSC3C 4aa For TTT CAA GGA CCT AGG GAC GAG TAC 
CGA GAA CTC GCC GAT GCC  
68.6 
 
Mutagenesis 
VanSSC3C 4aa Rev CAG CAC CTC CAG GCG GCC CGG CAG 
CCG GAT  
70.0 Mutagenesis 
pccKan For CCT TCA TCA GCC ACT GTA GTG AAC 66.0 ToxCAT 
pccKan Rev CGA CTT CAG CGA GAC CGT TAT AG 66.0 ToxCAT 
VanSA TM1 For CTA GCC TGT ATA TGT ATA TTG TGG 
CGA TTG TGG TGG TGG CGA TTG TTG 
TGC TGT ATA TTG G 
67.0 ToxCAT 
VanSA TM1 Rev GAT CCC AAT ATA CAG CAC AAA CAC 
AAT CGC CAC CAC CAC AAT CGC CAC 
AAT ATA CAT ATA CAG G 
67.0 ToxCAT 
VanSA TM2 For CTA GCA TTT TTA TTT ATG TGG CGA 
TTG TGA TTA GCA TTC TGA TTC TGT 
GCC GCG TGA TGC TGA GCG G 
68.0 ToxCAT 
VanSA TM2 Rev GAT CCC GCT CAG CAT CAC GCG GCA 
CAG AAT CAG AAT GCT AAT CAC AAT 
CGC CAC ATA AAT AAA AAT G 
68.0 ToxCAT 
VanSSCTM1 For CTA GCG GCT TTC TGA CCC TGG CGG 
GCG TGC TGC TGC TGG TGG CGG TGG 
GCG TGT TTC TGC TGG G  
78.0 ToxCAT 
VanSSCTM1 Rev GAT CCC CAG CAG AAA CAC GCC CAC 
CGC CAC CAG CAG CAG CAC GCC CGC 
CAG GGT CAG AAA GCC G 
78.0 ToxCAT 
VanSSCTM2 For CTA GCT GGG TGA TGG CGT TTC TGC 
TGG TGT TTG GCC TGG TGG GCG GCT 
GGT TTC TGG CGG GCG G 
68.0 ToxCAT 
VanSSCTM2 Rev GAT CCC GCC CGC CAG AAA CCA GCC 
GCC CAC CAG GCC AAA CAC CAG CAG 
AAA CGC CAT CAC CCA G 
68.0 ToxCAT 
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2.4.1 Polymerase Chain Reaction (PCR) 
 
DNA amplification was carried out using the specific enzymes for each PCR according to 
the manufacturer's guide. Initially Accuprime High-Fidelity Taq polymerase (Invitrogen) and 
Accuprime GC-rich Taq polymerase (Invitrogen) were used to amplify full-length or 
truncated vanS genes and clone into pProEx vectors. Each PCR reaction contained 5 μL of 
10x Accuprime PCR buffer I (containing 2mM dNTPs, 20mM MgSO4), 2 μL of a mix of 
forward and reverse primers from Table 2.4.1 (stock concentration 10 μM), 1 μL of vanS 
template DNA (25-50 ng/μL) and 0.2 μL of Taq polymerase, and were made up to 50 μL 
with nuclease-free water. Reaction mixtures were centrifuged briefly at 10 krpm, before 
heating in an Eppendorf Mastercycler Gradient thermal cycler with an initial denaturation of 
95
o
C for 2 minutes, then cycling 25 times from 94
o
C for 30 seconds, to annealing at 58-68
o
C 
(i.e. 5
o
C below the lowest Tm of the primer pair) for 45 seconds, to extending at 68
°
C for 90 
seconds. 
 
For PCR reactions involving site-directed mutagenesis, Phusion High-Fidelity polymerase 
(NEB) was used according to the manufacturer’s guide. Each PCR reaction contained 10 μL 
of 5x Phusion HF or GC-rich buffer (containing 15mM MgSO4), 1 μL of dNTPs (stock 
concentration of 10 μM), 5 μL of a mix of forward and reverse primers (stock concentration 
of 10 μM), 1.5 μL DMSO and 0.5 μL Phusion DNA polymerase, and were made up to 50 μL 
with nuclease-free water. Reaction mixtures were centrifuged briefly at 10 krpm, before 
heating in an Eppendorf Mastercycler Gradient thermal cycler with an initial denaturation of 
98
o
C for 45 seconds, then cycling 30 times from 98
o
C for 10 seconds, to annealing and 
extending at 72
o
C (i.e. 5
o
C below the lowest Tm of the primer pair) for 90 seconds.  
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2.4.2 Site-directed Mutagenic PCR (‘Round-the-Horn’) 
 
This ‘Round-the-Horn’ technique is based on the protocol created by Sean Moore 
(http://openwetware.org/wiki/’Round-the-horn_site-directed_mutagenesis), and the phrase 
originally referred to “Rounding Cape Horn”; a very difficult but rewarding journey. The 
method enabled insertion of a TEV or 3C proteolysis site directly into the vanS gene 
sequence, for subsequent cleavage, after expression and purification of the full-length 
protein. A primer pair e.g. “VanSa 3C 4aa For” and “VanSa 3C 4aa Rev” (see Table 2.4.1) 
was mixed with template DNA (pProEx::vanSA), and used in a PCR reaction. These primers 
do not fully base-pair with template vanS gene sequences (highlighted in Table 2.4.1), and 
amplification results in linear mutated strands that have to be blunt-end ligated (see Figure 
2.4.2.1). After blunt-end ligation, the first 4 amino acids of the 3C cleavage site (‘4aa For’) 
and the last 4 amino acids of the 3C cleavage site (‘4aa Rev’) join to form the full cut site.  
  
PCR reactions were set up as given in section 2.4.1, using Phusion HF polymerase and the 
phosphorylated, mutagenic primers. To exclude that the template plasmid is transformed, it 
had to be removed before transformation. The template plasmid is isolated from an E. coli 
strain with active Dam methylase. This enzyme methylates the internal cytosine residues of 
DNA (plasmids). Because of this, it was possible to selectively digest the template DNA 
with the restriction enzyme DpnI, which only cleaves when its recognition site is methylated. 
PCR products were digested with DpnI at 37
o
C for 1 hour, before running a preparative gel 
(see section 2.4.6), excising the band and purifying (see section 2.4.5). Purified, linear 
mutated strands were subsequently circularised by blunt-end ligation overnight at 25
o
C using 
T4 DNA Ligase (see section 2.4.7). The ligation mixture was transformed into E. coli Top10 
competent cells (Invitrogen) and DNA minipreparations were extracted from positive 
transformants (section 2.4.4). Extracted plasmids were restriction digested (section 2.4.3) 
and analysed by agarose gel electrophoresis (section 2.4.6) to determine the presence of a 
correctly-sized insert. 
[67] 
 
 
 
Figure 2.4.2.1: 3C site insertion by “Round-the-Horn” mutagenic PCR. The direction of 
transcription (arrows) of the forward (highlighted yellow) and reverse (highlighted red) 
mutagenic primers designed is shown, as well as the position of insertion into the protein.  
 
 
  
2.4.3 Restriction Enzyme Digestion of DNA 
 
Restriction digests (including double digests containing two restriction enzymes) were 
carried out using restriction enzymes (NEB, UK) in the appropriate buffer system, according 
to the manufacturer's guide. 1 μl of restriction enzyme and 100-500 ng of plasmid DNA or 
PCR product was used and reactions incubated at 37
o
C for 1-2 hours.  
 
2.4.4 Preparation of Plasmid DNA 
 
Plasmid DNA was extracted from E. coli TOP10 cells grown overnight in LB broth and 
appropriate antibiotics. Plasmid DNA was extracted using Fermentas or Qiagen miniprep 
extraction kits or purified by Promega Wizard DNA purification kit, according to the 
manufacturer's instructions. These kits employ the alkaline lysis method, where DNA is 
purified by adsorption to a silica matrix under high salt conditions. 
 
  
 
 
 
 
5’ For:  TTC GAG GGA CCT 
5’ Rev: CAG 
CAC CTC CAG   
vanS DNA
Template
Mutagenic primer
…
…
 
 
      Mut 5’ (For primer)   
Protein:        N      E      D      K      Q       I      E       L       S       A 
DNA Sense:       5’ -  AAC GAA GAT AAA CAA ATT GAG CTT  TCT  GCG 3’ 
DNA Antisense:       3’ - TTG  CTT  CTA  TTT  GTT TAA CTC GAA AGA CGC 5’ 
                                       Mut 5’ (Rev primer)  
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2.4.5 Purification of DNA from PCR and Restriction Digests 
 
DNA was purified to remove polymerases and endonucleases after PCR and restriction 
digests using the Promega Wizard PCR Extraction kit or Qiagen PCR purification kit, 
according to the manufacturer's instructions. Both methods purify DNA by adsorption to a 
silica matrix as used in the mini-prep kits above. 
 
2.4.6 Agarose Gel Electrophoresis 
 
A 0.8% (w/v) solution of high-melting point agarose (Sigma-Aldrich) was prepared by 
dissolving   0.4 g of agarose into 50 mL of 1x Tris-acetate-EDTA (TAE) buffer and heating 
for 3 minutes in a microwave oven. The solution was cooled to touch and 5 μL of Ethidium 
Bromide (10 mg/ml stock) was added. The solution was poured into a gel cast and left to set. 
The gel was submerged in a gel tank containing 1x TAE buffer, and DNA samples were 
loaded into wells with 1 μL of 6x DNA loading dye (Fermentas) per 5 μL of DNA sample. 5 
μL of a DNA standard 100 bp or 1kb GeneRuler ladder  or 1 kb Quick-Load ladder (pre-
mixed with loading buffer) (Thermoscientific) was loaded to allow size determination of 
DNA samples. Electrophoresis was carried out at 100V for 30 minutes, and samples 
visualised with ultraviolet light using a Syngene G:Box gel illuminator, attached to a camera 
to allow imaging. 
 
2.4.7 Ligation of DNA Fragments with Complementary Ends 
 
Ligation reactions either involved blunt-end ligation or ligation of ‘sticky ends’. Restriction 
digestion of plasmid DNA and PCR-amplified insert yielded DNA fragments with 
complementary ‘sticky ends’. Digestion was confirmed by visualisation on an agarose gel, 
and the plasmid DNA band was excised and purified using a QIAquick Gel Extraction Kit, 
whilst PCR inserts were purified using a Qiagen PCR purification kit. Plasmid DNA and 
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insert were ligated at a nanogram ratio of 3:1 PCR insert: DNA plasmid, in the presence of 
T4 DNA ligase (Fermentas) according to the manufacturer's instructions, in a volume of 10 
μL. For blunt-end ligation, only T4 DNA ligase was added. Reaction mixtures were 
incubated at 25
o
C for 4 hours or overnight.  
 
The ligation mixture was used to transform E. coli TOP10 cells as described in section 2.3. 
Transformed colonies were picked and cultured overnight in 5ml LB with appropriate 
antibiotics and plasmid DNA extracted by minipreparation (section 2.4.4). Extracted 
plasmids were restriction digested (section 2.4.3) and analysed by agarose gel 
electrophoresis (section 2.4.6) to determine the presence of a correctly-sized insert. 
 
2.4.8 DNA Sequencing of Plasmid Constructs 
 
To check that a cloned gene had been inserted correctly into the plasmid vector, start and 
stop codons were present and no mutations were incorporated by PCR errors, constructs 
were sequenced. 100 - 250 ng of plasmid DNA and 5-10 pmol of primer per sequencing 
reaction was mixed together and submitted to the Genomics Facility (University of 
Warwick) or GATC Biotech (London). Primers were either those used in the initial PCR, or 
specific for pProEx HTa vectors. Reactions were carried out using an ABI PRISM 3130xl or 
3730xl Genetic Analyser. Resulting sequences were blasted against a database 
(www.uniprot.org/blast) and aligned with the database sequence using ClustalW (Larkin et 
al., 2007) to check for point mutations introduced by PCR. Sequences were also manually 
checked (using BioEdit by Tom Hall, Ibis Biosciences from www.mbio.ncsu.edu/bioedit) to 
identify the presence of start and stop codons and correct gene orientation. 
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Table 2.4.8.1   Initial gene constructs and constructs created. Note: For details on the 
creation of vanS gene truncates (e.g. vanSA100-130) and rationale behind their selection, 
refer to section 4.3. 
Construct Antibiotic 
gene 
Description 
pTTQ18::vanSA Ampicillin pTTQ18 vector containing E. faecium vanSA wild-type 
gene 
pGEM-T::vanSSC Ampicillin pGEM-T Easy vector containing S.coelicolor vanSSC 
wild-type gene 
pProEx::vanSSC Ampicillin pProEx HTA vector containing E. faecium vanSA wild-
type gene 
pProEx::vanSSC Ampicillin pProEx HTA vector containing S. coelicolor vanSSC 
wild-type gene 
pProEx::vanSA110 Ampicillin pProEx HTA vector containing E. faecium vanSA gene 
truncated after 110
th
 residue (Met-1 to Ile-110) 
pProEx::vanSA120 Ampicillin pProEx HTA vector containing E. faecium vanSA gene 
truncated after 120
th
 residue (Met-1 to Gln-120) 
pProEx::vanSA130 Ampicillin pProEx HTA vector containing E. faecium vanSA gene 
truncated after 130
th
 residue (Met-1 to Met-130) 
pProEx::vanSSC100 Ampicillin pProEx HTA vector containing S. coelicolor vanSSC 
gene truncated after 100
th
 residue (Met-1 to Arg-100) 
pProEx::vanSSC110 Ampicillin pProEx HTA vector containing S. coelicolor vanSSC 
gene truncated after 110
th
 residue (Met-1 to Arg-110) 
pProEx::vanSSC120 Ampicillin pProEx HTA vector containing S. coelicolor vanSSC 
gene truncated after 120
th
 residue (Met-1 to Tyr-120) 
pProEx::vanSA-
TEV 
Ampicillin pProEx HTA vector containing E. faecium vanSA gene 
with an inserted TEV-specific proteolysis site 
pProEx::vanSA-3C Ampicillin pProEx HTA vector containing E. faecium vanSA gene 
with an inserted 3C-specific proteolysis site 
pProEx::vanSSC-
TEV 
Ampicillin pProEx HTA vector containing S. coelicolor vanSSC 
gene with an inserted TEV-specific proteolysis site 
pProEx::vanSSC-3C Ampicillin pProEx HTA vector containing S. coelicolor vanSSC 
gene with an inserted 3C-specific proteolysis site 
pccKan::vanSATM1 Ampicillin pccKan vector encoding for the predicted first 
transmembrane helix of E. faecium vanSA gene 
(residues L19 to I37) with an N-terminal ToxR domain 
and C-terminal MBP domain (see section 5.5.2) 
pccKan::vanSATM2 Ampicillin pccKan vector encoding for the predicted second 
transmembrane helix of E. faecium vanSA gene 
(residues I78 to S97) with an N-terminal ToxR domain 
and C-terminal MBP domain (see section 5.5.2) 
pccKan::vanSSC 
TM1 
Ampicillin pccKan vector encoding for the predicted first 
transmembrane helix of S. coelicolor vanSSC gene 
(residues G19 to L37) with an N-terminal ToxR 
domain & C-terminal MBP domain (see section 5.5.2) 
pccKan::vanSSC 
TM2 
Ampicillin pccKan vector encoding for the predicted second 
transmembrane helix of S. coelicolor vanSSC gene 
(residues W68 to G86) with an N-terminal ToxR 
domain & C-terminal MBP domain (see section 5.5.2) 
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2.5 Membrane Protein Expression and Purification 
2.5.1 Protein Over-Expression 
 
Proteins were expressed (from gene constructs in Table 2.4.8.1 above) in E. coli strains 
grown in LB media, at levels amenable to purification by Immobilised Metal Affinity 
Chromatography (IMAC, see section 2.6.6). Increased levels of soluble protein was achieved 
by modifying these protocols, and allowed expression of both proteins in M9 minimal media.  
Recombinant proteins were over-expressed in a number of E. coli strains (Table 2.2.2.1) 
using IPTG induction. Strains were made competent (section 2.2.3) and transformed with an 
expression plasmid containing the recombinant gene (section 2.3) (in some cases with a 
second plasmid to aid expression) and plated on LB agar plates with appropriate antibiotics.  
 
(i)  Overexpression in LB media 
 
A single colony was picked for a small-scale pre-culture and grown, at 37
o
C, 180 rpm, 
overnight in 5 or 10 ml of LB media and appropriate antibiotics. The pre-culture was diluted 
at 1 in 50 or 1 in 100 into LB media containing the appropriate antibiotics (and 0.2% glucose 
for VanSA), and grown at 37
o
C, 180 rpm, before induction with IPTG to a final concentration 
of 0.2 mM or 1 mM when the optical density of a culture, at a wavelength of 600nm, was 
between 0.5 and 0.6. Expressions were initially grown for 4 hours at 37
o
C, but it was found 
that 12-16 hours at 25
o
C (for VanSA) or 20-24 hours at 16
o
C (for VanSSC) gave higher yields 
of soluble protein, before harvesting at 10,000g, 15 mins using a Beckmann JA14 rotor. 
 
Cell pellets were washed in ice-cold phosphate-buffered saline (PBS) and the pellet was 
resuspended in 3 mL of resuspension buffer per gram of wet cell weight. To prevent protein 
degradation, protease inhibitors (2μM leupeptin, 2μM pepstatin, 0.2mM PMSF final 
concentrations) were added. Resuspended cells were snap-frozen and stored at -80
o
C. 
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(ii)  Overexpression in M9 Minimal Media 
 
Both pProEx::vanSA and pProEx::vanSSC were transformed onto LB plates containing 100 
μg/ml of ampicillin and 35 μg/ml of chloramphenicol (see section 2.3). A scraping of 
colonies was taken using an inoculation loop, and added to 10 mL starter cultures in LB 
containing the appropriate antibiotics with addition of 2 g/L glucose for those containing 
vanSA. Starter cultures were grown at 37
o
C for 12-14 hours and used to inoculate 800mL 
cultures at a starting optical density at 600nm of ~0.01. These larger cultures were grown at 
37
o
C until an optical density at 600nm of ~ 0.7-0.8, at which point media was switched to 
M9 (see section 2.2.1) from LB, by pelleting at 3000 g for 10 minutes in a Beckmann 
benchtop centrifuge, washing and resuspending twice in M9 media. In the final resuspension 
step, the pellet was resuspended in either 800ml (‘1x’), 400ml (‘2x’), or 200ml (‘4x’) of M9 
minimal media containing: 1x BME vitamins (Sigma), 1 g/L unlabelled or 
15
N-labelled 
NH4Cl, 4 g/L glucose, 0.1 mM CaCl2, 2mM MgSO4, 50 μM FeCl3, 1x M9 salts, 100 μg/ml 
Ampicillin, 35 μg/ml Chloramphenicol and pH adjusted to 7.5 or 8.0 for higher buffering 
capacity.  
 
Cells were incubated at the induction temperature for 1-2 hours prior to induction to 
discharge unlabelled metabolites, and overexpressed with IPTG for 16-20 hours (0.2 mM 
IPTG and 25
o
C for VanSA and 1mM IPTG and 18
o
C for VanSSC). Cultures were then 
pelleted at 3000 g for 10 minutes, and aliquots taken for SDS-PAGE (section 2.6.1) and 
Western Blot analysis (section 2.6.3). Cell pellets were resuspended in 10 mL/L of 
resuspension buffer, and to prevent protein degradation, protease inhibitors (2μM leupeptin, 
2μM pepstatin, 0.2mM PMSF final concentrations) were added. Resuspended cells were 
snap-frozen and stored at -80
o
C. 
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2.5.2 Preparation of Membrane Protein Lysates 
 
For small-scale production, membrane protein lysates were prepared, as described in Ward et 
al. (2000), using the ‘Water Lysis’ method. 100 mL of an overnight expression (section 
2.5.1) was centrifuged at 10,000 g, 10 mins at 10
o
C in a JA14 rotor with the cell pellet 
resuspended in 0.2 M Tris-HCl (pH 7.8). At time zero, 9.7 mL of sucrose buffer (1M 
sucrose, 1mM EDTA, 0.2M Tris-HCl, pH7.8) was added, followed by 1 mL of 1.3 mg/mL 
lysozyme at 1.5 minutes and 20 mL of deionised water at 2 minutes and left to shake for one 
hour at 25
o
C to form spheroplasts, due to the high osmotic shock experienced by the cells. 
Spheroplasts were sedimented at 20,000 g, 20 mins at 10
o
C in a Beckman JA25.50 rotor. The 
pellet was re-suspended, using a hand-held homogeniser, in 30 mL of water until cloudy and 
no lumps present and left to stand for 30 minutes at 25
o
C.  
 
Membranes were sedimented at 30,000 g, 20 mins at 4
o
C in a JA 25.50 rotor and the 
resulting pellet resuspended in membrane resuspension buffer (0.1 M Sodium phosphate, pH 
7.2, 1 mM 2-mercaptoethanol). Membranes were washed twice in 15 mL of membrane 
resuspension buffer using a hand-held homogeniser each time to resuspend the pellet. Finally 
washed membranes were resuspended in 1 – 5 mL (depending on the weight of protein 
obtained) of membrane resuspension buffer containing 1 mM MgCl2 to which DNase was 
added to a final concentration of 20 μg/mL. Preparations were incubated at 37oC for 30 
minutes before addition of EDTA to a final concentration of 1 mM. Preparations were 
analysed using SDS-PAGE (section 2.6.1) and stored at -80
o
C. 
  
2.5.3 Large-Scale Membrane Protein Preparations 
 
Large-scale membrane protein preparations followed the protocol given by Quigley (2010). 
The expressed cell pellet (from one or more litres of culture) was mixed with resuspension 
buffer (20 mM HEPES pH 7.8 or 50 mM phosphate buffer pH 7.5, 300 mM NaCl) in the 
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ratio of 3mL per gram of wet cell pellet, before snap-freezing and storing at -80
o
C. Upon 
thawing, DNase (20 μg/ml final concentration, Roche), magnesium chloride (10 mM final 
concentration) and chicken egg lysozyme (2.5 mg/ml final concentration, Calbiochem) were 
added. After rocking at 4
o
C for 30 mins, cells were lysed by passing through a continuous 
cell disrupter (Constant Cell Disruption Systems) three times at 30 kpsi and 4
o
C. Lysate was 
centrifuged at 10,000g for thirty minutes using a Beckman JA14 rotor to pellet cell debris 
before the supernatant was transferred to ultracentrifuge tubes and centrifuged at 40 krpm for 
two hours using a Beckman Ti45 rotor in an ultracentrifuge (Beckman Optima L90K) to 
pellet the membrane fraction. Membranes were resuspended in 20 mM HEPES pH 7.8, 300 
mM NaCl, 20 mM Imidazole and 20% Glycerol, in 10 mL of buffer per litre for VanSA or 
per three litres for VanSSC, before storing at -80
o
C. 
 
2.5.4 Protein Solubilisation using Membrane Mimetics 
 
Membrane proteins are naturally embedded in a complex and dynamic lipid bilayer, limiting 
their analysis by standard biophysical techniques. In vitro studies are reliant on successful 
solubilisation of membrane proteins, using appropriate membrane mimicking environments. 
These must consist of a solubilising component and satisfy the hydrophobic nature of TM 
segments, while bringing loop regions into contact with an aqueous phase. Therefore lipid 
and detergent systems are often chosen.  
 
Detergents are amphipathic with polar head groups and a single hydrophobic tail, and can 
spontaneously form spherical, micellar structures (Seddon et al., 2004) above a Critical 
Micelle Concentration (CMC) (Bhairi, 1997). The number of solubilised monomers 
contained in a micelle is known as the mean aggregation number (a), and is related to bulk 
molar detergent concentration (d) and micelle concentration (m) by Equation 1.  
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d C
m
a

     (1) 
Detergents tested include dodecylphosphocholine (DPC) (a = 56 and CMC = 1.1-1.2 mM) 
(Wüthrich, 1986), dodecylmaltoside (DDM) (a = 98 and CMC = 0.17-0.3 mM), 
octylglucoside (OG) (a = 84, CMC = 18-20 mM) (Bhairi, 1997) and sodium dodecyl 
sulphate (SDS) (a = 62 and CMC = 8-14 mM, at 298K) (Nishikido, 1983).  A full list of all 
detergents tested is given in Appendix Table 1. 
 
Prepared membranes were thawed and detergent added to a final concentration of 0.5-1% 
w/v, before membranes were incubated at 4
o
C on a roller rocker for two hours. Solubilised 
membranes were centrifuged at 40 krpm for 45 mins using a Beckman TLA 100.3 rotor and 
benchtop ultracentrifuge (< 20ml volume) or Beckman Ti45 rotor and Beckmann T90K 
ultracentrifuge (< 350ml volume). The resulting supernatant was added to charged nickel, 
high performance agarose (Qiagen) or sepharose (GE Healthcare) slurry (ratio of 1mL slurry 
per mg of expected VanS protein) pre-equilibrated in 20 mM HEPES pH 7.8, 300 mM NaCl, 
10% Glycerol, 20 mM Imidazole, 0.1% w/v detergent). This protein-resin mix was left to 
rock for 1-2 hours at 4
o
C before pouring into a column and allowing the resin bed to settle.  
 
2.6  Protein Analysis and Detection 
2.6.1 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
 
For SDS-PAGE experiments, either a Tris-Glycine buffer system (Laemmli, 1970) or Bis-
Tris system (Invitrogen) was used to separate and visualise polypeptides under denaturing 
conditions on a discontinuous gel system. For the Tris-Glycine system, the resolving gel is at 
pH 8.8 and the stacking gel at pH 6.8. 11 mL of 355 mM Tris-HCl pH 8.8, 0.1% SDS and 
12% or 15% acrylamide: bis-acrylamide (29:1) was prepared allowing resolution of proteins 
between 4 and 100 kDa. Gels were cast using the Hoeffer Mighty Small gel kit, polymerised 
with 10 μL TEMED and 120 μL 10% APS, then overlaid with ethanol to remove the 
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meniscus. 3.5 mL stacking gel mix was prepared with 610 mM Tris-HCl pH 6.8, 0.1% SDS 
and 3% acrylamide:bisacrylamide (29:1), polymerised with 10 μL TEMED and 50 μL 10% 
APS and pipetted on top of the polymerised resolving gel, where a plastic comb was added 
to form the wells. For the Bis-Tris system, which was used for Blue Native PAGE and prior 
to anti-MBP Western blots (see section 2.6.4), NuPAGE Novex 12 % Bis-Tris 10-well 
precast gels were used. Gels were run in an Invitrogen XCell SureLock Mini-Cell 
electrophoresis kit according to manufacturer’s instructions.  
 
Protein samples were usually standardised to 20 μg/ml concentration per lane (unless 
specified), and prepared in 6 x loading buffer (62.5 mM Tris-HCl pH 6.8, 10% glycerol, 
0.1% SDS, 2.5% bromophenol blue and 5% β-mercaptoethanol) and either heat denatured at 
60
o
C in a heat block for 5 minutes or 37
o
C for 15 minutes. The gel comb was removed, wells 
were washed with SDS-PAGE running buffer (25 mM Tris, 192 mM Glycine, 0.1% SDS pH 
8.3) to remove unreacted and samples were pipetted into the wells. Gels were run in SDS-
PAGE running buffer at 180V for 1 hour or until the gel front reached the cast base. SDS-
PAGE ladders used were either LMW-SDS standard (GE Healthcare, 14-90 kDa range), 
SeeBlue Plus2 Standard (Invitrogen, 3-188 kDa), or the ColorPlus Broad Range Marker 
(NEB, 7-175 kDa). SDS-PAGE gels were stained to visualize protein bands in either 
Coomassie Brilliant Blue or Instant Blue stain (see section 2.6.9). 
 
2.6.2 Blue Native PAGE 
 
VanS protein samples that had been purified in detergent micelles, by IMAC and Gel 
Filtration Chromatography (see section 2.6.7) (conducted at 4
o
C), were analysed using the 
NativePAGE Novex Bis-Tris system (Invitrogen). This system is based on the blue native 
polyacrylamide electrophoresis (BN-PAGE) technique developed by Schägger and von 
Jagow (1991), and allows an estimation of the oligomeric states of native proteins and their 
protein complexes relative to molecular weight markers. 
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Samples were applied to a 4 - 16 % precast Bis-Tris gradient gel, and proteins are separated 
based on size under electrophoresis at  4
o
C in NativePAGE running buffer (1M Bis-Tris-HCl 
pH 7.0, 1M Tricine pH 7.0). Sample migration through the gel involves addition of a non-
denaturing Coomassie G-250 dye to protein samples, at 1/4 to 1/10
th
 of the detergent 
concentration, which confers a net negative charge while maintaining the proteins in their 
non-denatured native state. Protein molecular weights were estimated relative to prestained 
markers (High MW Standards, Amersham).  After electrophoresis, separated proteins were 
either analysed by Coomassie Brilliant Blue staining (see section 2.6.9), or by Western 
blotting. For Western blotting, bands were transferred onto a PVDF membrane (Hybond-P, 
GE Healthcare) under an applied current of 110 mA for 90 mins in an X-Cell II Blot Module 
(Invitrogen). After transfer membranes were incubated in 8% acetic acid for 15 mins, rinsed 
with de-ionised water and air-dried, then rewet in methanol (to remove background dye) and 
rinsed once more before blocking with 10% milk powder. Immunodetection followed the 
same protocols outlined in section 2.6.3. 
 
2.6.3 Western Blotting for Histidine-tagged proteins 
 
The method for Western blotting was originally developed by Towbin et al., (1979).  The 
procedure allows determination of protein molecular weights and quantification of relative 
amounts of proteins in each sample. Initially, proteins are separated by SDS-PAGE (section 
2.6.1) then protein bands in the gel are directly transferred under an applied voltage onto a 
nitrocellulose or PVDF membrane which is placed on top of the gel, all within a transfer 
cassette. All sites except protein bands are then blocked in a milk solution, and a primary 
antibody is added which binds to specific protein tags. A secondary antibody containing an 
attached alkaline phosphatase or horseradish peroxidase enzyme is then added which binds 
to the primary. This enzyme allows detection of tagged protein bands by chromogenic 
techniques or electrochemical luminescence, in a reaction between enzyme and developing 
reagents, which can be visualised on X-ray films or directly depending on technique used.    
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In this study, Western blotting procedures have been used and optimised to reduce 
background and decrease experiment time, using the methods below.  Proteins were resolved 
by SDS-PAGE or NativePAGE as described in section 2.6.1or 2.6.2, against His-tagged 
protein markers (Benchmark or MagicMark, Invitrogen) or prestained markers (High MW 
Standards, Amersham) or and the resulting gel was washed in transfer buffer (100mM Tris 
base, 80mM Glycine and 20% methanol). Polypeptides were transferred from the gel to a 
PVDF membrane (Hybond-P, GE Healthcare) at a constant voltage of 120 V in transfer 
buffer for 70 mins, using a BioRad electroblotting kit.  
 
Before transfer, the membrane was activated by placing in methanol for 5 mins, washing 
with deionised water then adding to transfer buffer for 2 mins.  After transfer, membranes 
were blocked in 25 mL of 10% Milk powder in TBS containing 0.1% Tween-20 (TBST-T) 
and rocked for 1 hour, before washing with 20mL of TBS-T for a further 15 min. The TBS-T 
wash step was repeated twice more. 20mL of TBS-T containing 20μL of anti-his IgG mouse 
monoclonal non-preferential antibody (Roche) or 8 μl anti-His IgG mouse monoclonal N-
terminal preferential antibody (Sigma, H1029), and left to shake for one hour. Three 20 mL 
TBS-T wash steps of 15 mins each followed. Subsequently, 10 mL of TBS-T containing 5 μl 
of anti-mouse IgG conjugated to horseradish peroxidase derived from sheep (Sigma, A5906) 
was added and left to shake for two hours before three further TBS-T wash steps.  
 
For the final wash step, membranes were left to rock overnight to reduce background from 
unbound proteins. For development either 5 mL of blotting reagent 1 (GE Healthcare) and 5 
mL of blotting reagent 2 (GE Healthcare), or 1ml of ECL Solution A (Biological Industries) 
and 1ml of ECL Solution B (Biological Industries) was added to the membrane and allowed 
to develop for 90 seconds. Membranes were dried on their edge on a tissue held by tweezers 
then wrapped in cling film and exposed to X-ray films (Super-RX NIF, Fujifilm), generally 
for 10 seconds to 5 mins, but sometimes up to 30 mins. Observed bands resulted from 
electrochemical luminescence (ECL). 
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2.6.4 Western blotting for MBP-tagged proteins 
 
Western blotting antibodies were chosen depending on the protein tag involved. Both the 
TOXCAT constructs and the 3C enzyme construct, encoded for an MBP-tag, therefore anti-
MBP western blots were run. Proteins were resolved by SDS-PAGE using a 12% NuPAGE 
gel, against ColorPlus prestained markers (7-175 kDa) or SeeBlue Plus2 Prestained markers 
(3-188 kDa) and the resulting gel was washed in transfer buffer (see section 2.6.3).  
 
Polypeptides were transferred from the gel to a Nitrocellulose or PVDF membrane (Hybond, 
GE Healthcare) at a constant voltage of 120 V in transfer buffer for 90 mins, using an X-Cell 
II Blot module. Before transfer, the membrane was activated by placing in methanol for 5 
mins (for PVDF membranes only) then washed with deionised water, and added to transfer 
buffer for 2 mins.  After transfer, membranes were blocked in 20 mL of 3-5% Milk powder 
in TBS containing 0.1% Tween-20 (TBS-T) and rocked for 1 hour, before washing with 20 
mL of TBS-T for a further 15 mins. The TBS-T wash step was repeated twice more. 10 mL 
of TBS-T containing 2.5 μL of anti-MBP antibody (Sigma) was added, and left to shake for 
one hour. Three 20 mL TBS-T wash steps of 15 minutes each followed. Subsequently, 10 
mL of TBS-T containing 1 μl of anti-mouse IgG conjugated to alkaline phosphatase (Sigma) 
was added and left to shake for two hours before three further TBS-T wash steps.  
 
3mL of SigmaFAST BCIP/NBT (5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue 
tetrazolium) chromogenic solution was added to the membrane and allowed to develop for 
between 1 - 2 mins, before washing with distilled water and immersing in 1x TBS-T. 
Observed bands resulted from electrochemical luminescence (ECL).    
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2.6.5 Detergent Screening by Western Blotting 
 
VanS proteins were expressed on a large-scale (2-6 L) in LB media and membranes 
extracted and resuspended in 10-20 mL total buffer (see section 2.5.3). Membrane samples 
(1-2 mL) at a total protein concentration of 3 mg/ml were dissolved in 1% w/v detergent 
(except for octylglucoside detergent, which has a high CMC, so 1.8% was used) and 
centrifuged at 100,000 g (~35000 rpm) in a TLA100.3 rotor in a benchtop Beckmann 
ultracentrifuge. The supernatant was pipetted off, and the pellet remaining was resuspended 
to the same initial volume (prior to centrifugation) in HEPES buffer (20 mM HEPES pH 7.8, 
300 mM NaCl) with a homogeniser in order to obtain a homogenous mixture for loading 
onto SDS-PAGE gels or Western blots.  
 
For Western blots, a known fixed volume (of either 10 or 20 μL, depending on band 
intensity) was added into each lane in order to ~20 μg of total protein per lane.  For each 
detergent, the soluble (supernatant) fraction was loaded next to the pellet fraction, both with 
the same volume but not necessarily the same concentration, as this is dependent on 
solubility in the selected detergent. Blotting was carried out according to the protocol in 
section 2.6.3. Bands on the X-ray films were imaged and analysed for each detergent using a 
band-sizing technique (quantified by ImageJ analysis software), to determine the relative 
amounts of VanS protein in supernatant and pellet fractions, and therefore establish the 
protein’s solubility in each detergent. Detergents were selected from three classes: anionic, 
zwitterionic and non-ionic, and those used were commonly tested in detergent screens in the 
literature (Bhairi, 1997; Newby, 2009; Oliver et al., 2013), either prior to NMR experiments 
or crystallisation trials. A full list of all detergents used in this thesis and their properties is 
given in Appendix Table 1. 
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2.6.6 Immobilised Metal Affinity Chromatography 
 
The concept of immobilized-metal affinity chromatography (IMAC) was first formulated 
and its feasibility shown by Porath et al. (1975). It was based on the known affinity of 
transition metal ions such as Ni
2+
 and Co
2+
 for histidine and cysteine residues in aqueous 
solutions. In the 1980s, improvements in the design of chelating ligands provided 
nitrilotriacetic acid (NTA) (Hochuli et al., 1987) and recombinant proteins were produced 
containing genetic modifications to their DNA template to give His-tagged polypeptides that 
could be purified on NTA-based supports (Hochuli et al., 1988) (see Figure 2.6.6.1).  
 
 
Figure 2.6.6.1:  Model of the interaction between Ni NTA and a His-tag. Adapted from 
Block et al., 2009.  
 
 
In this study, pProEx HTa constructs were used with encode for a TEV-cleavable N-terminal 
hexahistidine tag in front of the vanS gene. Purification of hexahistidine-tagged proteins was 
carried out using chelating high performance Nickel NTA agarose (Qiagen) or Chelating 
Sepharose (GE Healthcare), with the exception of his-tagged 3C protease which was purified 
with Cobalt resin (TALON, ClonTech). Columns were resolved by gravity-flow using 
imidazole-containing buffers which compete for the his-tag to bind to Nickel (II) ions. Resin 
was added at a ratio of 1 mL slurry per mg of expected VanS protein.  
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Chelating sepharose resin required charging with Nickel prior to use, according to the 
manufacturer’s guide. Resin was added to the column and washed with 20 column volumes 
(CV) of water then charged with 1 CV of a 0.2 M NiCl2 solution. Excess nickel chloride was 
then washed off with 10 CV of water and 5 CV of 50 mM sodium acetate pH 4.0 added. The 
column was then equilibrated with 5 CV of the binding buffer (20 mM HEPES pH 7.8, 300 
mM sodium chloride, 20 mM imidazole pH 8.0, 10% glycerol and 0.1% detergent). Ni-NTA 
resin was charged by washing with 20 CV of water, and 10 CV of binding buffer. 
 
Once equilibrated, solubilised protein-resin mix was loaded onto the column and the flow-
through collected under gravity and retained for analysis before the column was developed 
by washing with gradient steps of equilibration buffer and elution of the hexahistidine-
tagged protein. Initially, 30 CV of low imidazole wash buffer (20 mM HEPES pH 7.8, 400 
mM NaCl, 10% Glycerol, 0.075% w/v detergent and 20 mM Imidazole pH 8.0) was added.  
This was followed by a wash step with this buffer but containing high salt (1M NaCl, 20 
CV), and a final wash step with this buffer but containing intermediate imidazole (50 mM 
Imidazole pH 8.0, 15 CV), before elution with 2.5 ml volumes of the buffer containing high 
(250 mM) Imidazole pH 8.0. The high salt wash removes ionically bound proteins, and the 
intermediate imidazole wash removes weakly bound histidine-rich E. coli proteins. Eluted 
fractions were retained for analysis using SDS-PAGE. Eluted protein was desalted 
immediately (and imidazole removed) in a desalting PD10 gel filtration column (GE 
Healthcare). A final wash with 500 mM Imidazole pH 8.0 removed any residual protein.  
 
After use, affinity chromatography columns containing chelating sepharose were stripped 
with 5 CV of stripping buffer (20 mM NaPO4 pH 7.4, 50 mM EDTA and 0.5 M NaCl) to 
remove any chelated metal ions with bound protein, followed by 3 CV of 0.5 M NaCl to 
remove residual EDTA, then 10 CV of water. Ni-NTA resin was washed with 1 CV of 0.5 M 
NaOH for 30 mins, then 10 CV of water. Resins were stored at 4
o
C in 20% filter-sterilised 
ethanol solution. Columns were recharged as described above. 
[83] 
 
2.6.7 Analytical Gel Filtration Chromatography 
 
Proteins were separated based on their molecular size using a Superose 6 or Superose 12 
resin (GE Healthcare), on a 10/300 mm GL, 24mL bed volume column, attached to a GE 
Healthcare AKTA Prime system. Superose resin consists of a composite of highly cross-
linked porous agarose beads. Columns were washed with 2.5 CV of distilled water, then 
equilibrated with 2.5 CV of the appropriate buffer (20 mM HEPES pH 7.8, 200 mM NaCl, 
0-10% glycerol, and 0.05-0.1% detergent) before samples were loaded (using a Hamilton 
syringe and adaptor), via an injection loop in volumes of 0.2 or 0.5 mL to prevent loss of 
resolution due to sample smearing. Buffer was pumped through the column at a rate of 0.3 
mL/min under an isocratic gradient of 100% Buffer A for 1.5 column volumes and 0.3 ml 
fractions collected, with absorbance traces recorded at wavelengths of 280 nm and 254 nm. 
Fractions collected were analysed for purity by SDS-PAGE. 
 
After each run, the column was washed with 1.5 CV of water, then 1.5 CV of 20% ethanol 
for storage. After 10-20 runs, rigorous cleaning was conducted, involving washing with 1 
CV of 0.5 M NaOH at 0.3 mL/min, prior to a water/ethanol wash for storage.  
   
2.6.8 Protein Sample Desalting, Concentrating and Dialysing 
 
To exchange buffers or to remove imidazole from protein samples that had been purified by 
IMAC techniques, a PD10 Desalting column (GE Healthcare) was used. All protein samples 
were initially solubilised with DPC or DDM detergent, and purified with the same detergent 
throughout (to avoid the formation of mixed micellar species). The eluted 2.5 mL fractions 
from IMAC were directly applied to the PD10 Desalting column, which had been 
equilibrated with 25 mL of detergent-containing buffer. Once applied, the flow through was 
collected and discarded, and 3.5 mL of the equilibration buffer applied to the PD10 to elute 
the protein sample in the new buffer.   
[84] 
 
For detergent exchange, protein purified in DPC micelles (after IMAC at 0.075 % w/v) was 
diluted to below the CMC for the detergent (<1mM) with an appropriate buffer. This was 
applied to a PD10 desalting column equilibrated with the new detergent-containing buffer 
(containing detergent at 2-5 times its CMC). Proteins purified in DDM detergent were not 
exchanged in these studies (as they have a micellar size greater than most concentrators). 
 
Protein solutions that had been desalted were subsequently concentrated using either Corning 
centrifugal concentrators, with polyethersulfonate (PES) membranes at a molecular weight 
cut-off (MWCO) of 10, 30, 50 or 100kDa, depending on the size of detergent molecules 
bound. Concentrators were washed twice by centrifuging for 10 minutes at 3000g and 4
o
C in 
a bench-top centrifuge (Labofuge 400R, Heraeus Instruments) filled with MilliQ water, then 
the water was discarded and the concentrators were centrifuged once more, filled with 
detergent-containing buffer for 10 minutes at 3000 g, prior to addition of protein solution and 
centrifugation at 3000g. Protein solution was concentrated to ~0.5 ml for application to a gel 
filtration column or ~0.1 mL for application to 96-well membrane protein crystallisation 
trays. In general, activity assays, NMR and gel filtration required protein at between 2 and 
10 mg/mL and crystallography trials required protein ~10mg/ml.  
 
For protein samples, dialysis was not routinely used as it would require large amounts of 
detergent, which is not cost-effective. However, for soluble proteins e.g. 3C protease, 
dialysis was conducted immediately after IMAC, to remove all imidazole and exchange into 
an appropriate buffer for long-term storage. Dialysis tubing (19 mm and 12-14 kDa MWCO) 
was pre-boiled, and stored in 10 mM EDTA pH 7.4, 0.05% sodium azide solution. The 
tubing was rinsed with and immersed in 1L of distilled water, and one end tied before use. 
The solution to be dialysed was added into the open end by pipette, and air bubbles removed 
before tying the other end. The tubing was immersed in 1L of buffer to exchange into, stirred 
for 1 hour, then placed into 1L of fresh buffer and stirred for a further hour. 20% w/v ice-
cold glycerol was added to the dialysed solution, which was aliquoted and stored at -80
o
C.  
[85] 
 
2.6.9 Staining of SDS-PAGE Gels 
 
Proteins resolved by SDS-PAGE were stained overnight in Colloidal Coomassie stain 
(Neuhoff et al., 1988) or for 1 hour in Instant Blue stain (Expedeon Protein solutions, UK) 
before destaining for overnight in MilliQ water. For NativePAGE, gels were fixed for 30 
minutes (50% methanol, 10% acetic acid), stained overnight in Coomassie Brilliant Blue 
(0.01g Coomassie blue R-250, 4ml acetic acid, in 40ml of deionised water), and destained 
over several hours (20% methanol, 7% acetic acid). Gels were imaged using a Syngene 
G:Box illuminator, attached to a camera under a yellow UV filter. 
 
2.6.10 Determination of Protein Concentration 
 
Three methods for protein concentration determination were conducted. The BioRad reagent 
method, is based on a protein’s reaction to Coomassie  Brilliant Blue G-250 dye, which has 
an absorbance maximum at 465 nm, which shifts to 595 nm once it binds protein. 2-10 μL of 
protein solution was added to 200 μL BioRad reagent in a cuvette and topped up to 1000 μL 
total volume, mixed and the absorbance measured at 595 nm using a Phamacia Biotech 
UltraSpec 2000. For protein solution giving a reading greater than the linear range of the 
assay (> 0.6), solutions were diluted and readings repeated. Protein concentration (in μg 
protein per mL) was calculated using Equation 2, according to manufacturer’s instructions.  
 
[Protein] (μg/mL)  =   
                   
   
  x 1.95 x dilution factor x 
    
            
              (2) 
 
The second method involved directly measuring concentrated protein solutions at 280 nm, 
using 1 mL of undiluted protein in a quartz cuvette, or adding 2 μL to a NanoDrop ND2000 
(ThermoScientific) device. The extinction coefficient was assumed to be 1.0 cm
-1
mg
-1
mL 
and the protein concentration was directly calculated from the absorbance at 280 nm.  
[86] 
 
The preferred assay though was the BCA (bicinchoninic acid) assay, which is not affected by 
the presence of detergent in protein samples and therefore gives the most accurate 
representation. This method follows the reduction of Cu
2+
 to Cu
+
 by proteins in an alkaline 
medium (the biuret reaction) with the colorimetric detection of the cuprous cation using a 
reagent containing bicinchoninic acid. The BCA assay was carried out as described by the 
manufacture’s (Pierce) guide. Reagents A and B were mixed at a 50:1 ratio for 1 minute and 
1mL of subsequent working reagent was added to a known volume of each protein sample in 
a 1.5ml Eppendorf, and vortexed to mix. Reactions were left to incubate at 37
o
C in a water 
bath for exactly 30 mins before allowing to cool to room temperature. Absorbance was 
measured against a blank (exposed to similar conditions) at 562 nm using a Pharmacia 
Biotech Ultraspec 2000. Protein concentrations were calculated based upon a BSA (bovine 
serum albumin) standard curve. The assay working range is between 20 and 2000 μg mL-1. 
 
2.7  ToxCAT assays 
 
The TOXCAT assay is used to quantify transmembrane (TM) helix-helix self-association in 
the E. coli inner membrane. It can discriminate between strongly associating and weakly 
associating transmembrane α-helices within a natural membrane environment (Russ & 
Engelman, 1999). Fusion constructs are designed to contain wild-type (wt) TM domains of 
interest flanked by a C-terminal maltose binding protein (MBP) domain and an N-terminal 
DNA binding domain from ToxR, within the ToxCAT plasmid, pccKan (see Figure 2.7.1.1).  
 
In these studies, oligonucleotides encoding individual predicted TM domains of VanS 
proteins were cloned into the pccKan plasmid (provided by Prof. Donald Engelman (Yale 
University) (see section 2.7.1). The resulting chimera were then expressed in E. coli strain 
NT326, and quantitative CAT assays were performed using the FAST CAT kit (Invitrogen) 
(see section 2.7.6). In these assays, activation of the CAT reporter gene depends on the 
extent of TM-driven dimerization, which is measured by fluorescence intensity.  
[87] 
 
Prior to performing ToxCAT assays, membrane insertion of all constructs was confirmed 
using the malE complementation assay (see section 2.7.2), and correct orientation of the 
chimera in the membrane was confirmed via protease sensitivity in a spheroplast assay as 
described in Russ & Engelman (1999) (see section 2.7.4). Expression levels for all constructs 
were similar and confirmed via Western analysis against the MBP domain (see section 
2.7.3). The extent of TM dimerization as a function of chloramphenicol resistance was 
determined by Disk Diffusion assays (by measuring the zone of inhibition) (see section 
2.7.5), and quantified by measuring CAT activity in cell-free extracts (see section 2.7.6). All 
resulting CAT activities were normalized to total fusion protein expression levels using the 
ImageJ software (Abramoff et al., 2004) by analyzing band intensities after anti-MPB 
western blotting, and percentage error calculated over three repeat measurements.  
 
2.7.1 Cloning VanS transmembrane domains into the ToxCAT plasmid 
 
The chimeric pccKan construct is composed of the N-terminal DNA binding domain of 
ToxR (a dimerization-dependent transcriptional activator) fused to a transmembrane domain 
(TM) of interest and a monomeric periplasmic anchor (MBP) (see Figure 2.7.1.1). TM 
association causes ToxR-mediated activation of a reporter gene encoding chloramphenicol 
acetyltransferase (CAT), the level of which indicates the strength of oligomerisation.  
 
 
Figure 2.7.1.1: Expression of chimeric fusion proteins using the pccKan plasmid. (left) 
pccKan plasmid with inserted VanS TM domain of interest between Nhe1 and BamH1, which 
expresses (right) a chimeric fusion protein with C-terminal MBP (blue circle) and N-
terminal ToxR’ (green square) domains flanking the TM section (red helix).  
[88] 
 
(i) Phosphorylation and Annealing of ToxCAT primers 
 
Oligonucleotides listed in Table 2.4.1 were used as inserts for the DNA ligation reaction, 
along with double-digested (BamH1, Nhe1) pccKan vectors. Primers were designed to insert 
into the digested pccKan vector by having ‘sticky ends’ (Figure 2.7.1.2), and all sequences 
were optimised by removing any rare codons present. Primers were initially phosphorylated 
and annealed to create double-stranded inserts. 5 μL of each primer (at 10 μM concentration) 
was added to 2 μL of 10x T4 PNK reaction buffer, 1 μL of 10mM ATP, 2 μL of T4 PNK 
(Fermentas) and 10 μL of water.  The tubes were briefly sonicated before incubation for 30 
mins at 37
o
C, followed by 10 mins at 56
oC to quench the reaction.  From each tube, 4 μL of 
forward primer and 4 μL of reverse primer were added together, along with 2 μL of 
annealing buffer (made with 200 μL 1M Tris-HCl pH7.5, 20 μL 1M MgCl2, 166 μL 3M 
NaCl and 614 μL water) and 10 μL of water into PCR tubes. Primer mixes were incubated at 
95
o
C for 7 minutes to denature any base pairing, before cooling to room temperature over 
time to anneal strands. Annealed oligonucleotides were ligated and stored at -20°C. 
 
5’CTAGCctgtatatgtatattgtggcgattgtggtggtggcgattgtgtttgtgctgtatattGG 
3’    GgacatatacatataacaccgctaacaccaccaccgctaacacaaacacgacatataaCCCTAG 
 
Figure 2.7.1.2: Example of annealed oligonucleotide sequences of the VanSA TM1 
domain for inserting into pccKan plasmids. ‘Sticky ends’ (highlighted in yellow) are 
produced which consist of complementary codons to those at the BamH1 and Nhe1 
restriction enzyme sites, to ligate with digested pccKan plasmids. A ‘G/C’ base (highlighted 
in red) was also required in the primer design, to ensure codon reading was ‘in-frame’.  
 
(ii) pccKan Plasmid Preparation and Digestion 
 
The plasmid used to carry out the ToxCAT assay was pccKan. In this study, modifications of 
the pccKan plasmid were carried out as follows: the Kan cassette was cut out of the plasmid 
and transmembrane domain (TM) sequences of interest were cloned in. These constructs 
were then used in quantitative CAT assays to examine the strength of homo-oligomerisation. 
[89] 
 
A scraping was taken using an inoculation loop from a glycerol stock containing pccKan 
plasmids in E. coli DH5α cells, and added to 5 mL of LB in a universal tube, under sterile 
atmosphere. After overnight incubation at 37
o
C, plasmid DNA was harvested by 
minipreparation (see section 2.4.4).  The plasmid was digested with both restriction enzymes 
(see section 2.4.3), with the addition of 4 μL of Tango buffer (Thermo Scientific) to prevent 
‘star activity’ of the enzymes (under non-standard reaction conditions, some enzymes cleave 
sequences which are similar, but not identical, to their defined recognition sequence). In 
order to check that the plasmids were correctly digested at both sites an agarose DNA gels 
was run (see section 2.4.6) (see Figure 2.7.1.3). The digested vector was subsequently 
excised and purified with the Qiagen gel extraction kit (see section 2.4.5).  The 
phosphorylated, annealed TM insert could then be ligated into the digested pccKan vector 
using the method outlined in section 2.4.7. Finally the ligation mixture was transformed into 
E. coli DH5α competent cells (see section 2.3) and DNA minipreparations were extracted 
from positive transformants (section 2.4.4). Extracted plasmids were restriction digested 
(section 2.4.3) and analysed by agarose gel electrophoresis (section 2.4.6) to determine the 
presence of a correctly-sized insert, which was confirmed by Sanger sequencing using 
pccKan primers (see section 2.4.8). 
 
 
 
Figure 2.7.1.3: A 0.8% agarose gel stained with ethidium bromide, showing undigested 
pccKan plasmid, and double-digested pccKan plasmid. MR - GeneRuler 1kb DNA ladder. 
The kanamycin gene which is cut out from the pccKan plasmid appears as a band at 1.7 kbp. 
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2.7.2 Maltose malE Complementation assay 
 
To establish whether chimeric fusion proteins for the ToxCAT assay were inserting into E. 
coli membranes with the correct topology, a malE complementation assay was conducted. 
NT326 cells which lack endogenous MBP cannot transport maltose into the cytoplasm for 
metabolism and therefore cannot grow on maltose/agar plates. However, if the ToxCAT 
chimera are correctly inserted into the inner membrane, the periplasmic MBP domain will 
complement the NT326 malE-deficient phenotype and support growth on maltose.  
 
Maltose plates were prepared as follows: 100 ml of 5x M9 salts, 1M MgSO4, 1M CaCl2 and 
20% w/v maltose, were prepared separately by filter sterilising or autoclaving. In another 
flask, 78 ml water and 1.5 g agar were also autoclaved. The agar/water mix was melted in a 
microwave and cooled to touch, then 20 ml of 5x M9 salts, 0.2 ml of 1M MgSO4, 2 ml of 
20% maltose and 0.01 ml of 1M CaCl2 were added, and the solution poured into petri dishes 
and allowed to solidify. A single colony from an LB plate transformed with NT326 cells 
containing cloned pccKan plasmids was streaked onto the plate and incubated for 2-3 days at 
37
o
C. Negative controls were also streaked, containing only untransformed NT326 cells. 
 
2.7.3 Expression check 
 
Before conducting the quantitative ToxCAT assay, tests were performed to check that 
chimeric fusion proteins were being expressed in NT326 cells. Differences in expression 
level also affect the amount of dimerization, and were therefore determined by Western 
blotting. An overnight culture of cells was inoculated (1 in 100) into fresh LB, and incubated 
in a shaker until mid-exponential phase (OD600 = 0.6). An aliquot of these cells was taken 
and diluted to give 1 ml samples at an OD of 0.3. Cells were centrifuged at 13000 rpm and 
resuspended in 80 μl 1x SDS sample buffer, before loading onto an a NuPAGE 12% Bis-Tris 
gel in an XCell SureLock Mini-Cell electrophoresis kit (section 2.6.1).  
[91] 
 
After running, gels were placed in an XCell II Blot Module, and bands transferred under an 
applied voltage to a Nitrocellulose membrane (Invitrogen LC2000) in 1x transfer buffer (see 
section 2.6.4). Membranes were then blocked (in 3% w/v milk solution), anti-MBP 
antibodies bound and blots developed (see section 2.6.4).   
 
2.7.4 Proteolysis of Spheroplasts 
 
To verify that interactions within the membrane are responsible for the observed CAT 
activity, the membrane insertion and orientation of the MBP chimerae was measured by 
protease sensitivity assays. The protease sensitivity of a chimera is assayed in cells that have 
been stripped of their outer membrane and cell wall (spheroplasts). MBP should be 
detectable in the spheroplast fraction as it is associated with the inner membrane via TM and 
ToxR domains, and a protease (proteinase K) will liberate the MBP domain from the TM 
domains as it should be exposed on the periplasmic side of the membrane.  SDS-PAGE 
analysis of proteolysed spheroplast fractions will therefore show MBP as a lower molecular 
weight fragment. 
 
Overnight cultures containing the chimerae in NT326 cells, were diluted to an OD600 of 0.6, 
and 1 mL of each sample was centrifuged at 13.4 krpm for 1 minute then resuspended in ice-
cold buffer (100 mM Tris-acetate pH 8.2, 0.5 M sucrose, 5 mM EDTA). 6μL of 10 mg/mL 
ice-cold lysozyme was added to lyse cells open by dissolving the cell wall, and left to stand 
for 1 minute. To the lysed samples, 0.5 mL of ice-cold deionised water was added and 
samples left to stand for 4 minutes (to form spheroplasts from osmotic shock). 20 μL of 1 M 
MgSO4 was then added to each sample to stabilise the spheroplasts, before pelleting by 
centrifugation at 13.4 krpm for 1 minute.  
 
  
[92] 
 
The supernatant will contain the periplasmic fraction, and the pellet can be used to make up 
three fractions – a spheroplast fraction (sp), a proteolysed spheroplast fraction (sp*) and a 
broken spheroplast fraction (bp).  The pellet was resuspended in 300 μL of ice-cold buffer 
(10 mM HEPES pH 7.6, 2 mM EDTA) and split into three aliquots of 100 μL each. The ‘sp’ 
fraction was subjected to TCA precipitation. This involved incubation in 1 mL of 10% TCA 
for 30 minutes, centrifugation at 13.4 krpm for 15 minutes, and the resultant pellet incubated 
in 1 mL acetone for 5 minutes. The reaction mixture was centrifuged at 13.4 krpm for 10 
minutes, and the pellet fraction dissolved in 80 μL of SDS loading buffer.  The ‘bp’ fraction 
was freeze-thawed in liquid nitrogen then 37
o
C water, five times, to break open spheroplasts.  
 
Now both the ‘bp’ fraction and ‘sp*’ fraction were digested with 2.7 μL of 19.6 mg/mL 
ProteinaseK enzyme for 30 minutes on ice, and TCA precipitated and dissolved in SDS 
loading buffer as above. For each chimera, all three fractions were analysed on SDS-PAGE 
to examine the membrane insertion and orientation of the MBP chimerae.   
 
2.7.5 Disk Diffusion Assay 
 
As a measure of the TM-mediated dimerization of different chimerae, prior to quantitative 
CAT analysis, disk diffusion assays were carried out. An overnight culture containing 
chimerae in NT326 cells were diluted to an OD600 of 0.1 in a final volume of 1 mL. A 100 μL 
aliquot was plated on an LB/ampicillin plate and allowed to dry for 1 hour at room 
temperature. A chloramphenicol soaked disk was then placed in the centre of the plate 
(prepared by adding 42 μL of a 90 mg/mL stock of chloramphenicol in ethanol to a 2 mm 
Whatman filter-paper disk and allowed to dry for 1 hour).  The diameter of the clear zone of 
inhibition of growth around the disk was then recorded, and the size of the inhibition zone is 
directly dependent on the strength of TM-dimerisation in the chimera (increased 
dimerization confers greater CAM resistance, thereby decreasing the diameter of the zone of 
inhibition).  
[93] 
 
2.7.6 Quantitative CAT Assay 
 
To quantify the strength of TM-dimerisation, CAT activity was measured in cell-free 
extracts. Dimerisation of helices brings the ToxR domains into contact and activates the ctx 
promoter, resulting in high levels of CAT expression. The assay is based on the Invitrogen 
FAST CAT (deoxy, green) system, using xylene phase extraction to isolate product, as 
described by Seed and Sheen, (1988). The rate of transfer of a butryl group from butryl-CoA 
to chloramphenicol is detected by the rate of color change (at ~520 nm) associated with the 
reaction of the resulting free coenzyme A with BODIPY-FL-deoxychloramphenicol 
(Molecular Probes, Cat. No. F6616). 
 
An overnight culture of cells was diluted 1 in 100 and grown to an OD600 of 0.7. From these, 
a 200 μl aliquot of cells was taken and centrifuged at 13.4 krpm for 1 minute to pellet the 
cells. The pellet was resuspended in 500 μl of 100 mM Tris-HCl pH 8.0 and vortexed, before 
adding 20 μl of lysis solution (100 mM EDTA, 100 mM DTT, 50 mM Tris-HCl pH8.0) and 
a drop of toluene. Samples were incubated at 30
o
C for 30mins to lyse, and then used in the 
CAT assay. 10 μl of fluorescent CAM (BODIPY-FL-deoxyCAM) was added and incubated 
at 37
oC for 5 minutes. 10 μl of 5 mg/ml butyryl CoA solution was added (Amersham) and 
samples returned to 37
o
C for 90 minutes. Samples were centrifuged briefly before 
terminating reactions by adding 300 μl xylene and vortexing for 30 seconds and centrifuged 
for a further 3 minutes to collect the upper phase. To this phase, 300 μl Tris buffer was added 
and samples vortexed for 30 seconds and this procedure repeated.  The sample was then 
assayed for fluorescence by excitation at 495 nm and emission monitored by scanning 
between 500 and 600 nm, with slit settings = 3.5/2.5 nm. Fluorescence values at the 
maximum (~520 nm) were recorded and normalized against expression levels. 
 
[94] 
 
2.8  Mass Spectrometry  
2.8.1 Full-length protein identification by Mass Spectroscopy 
 
Full-length tag-cleaved (wild-type) VanS protein samples were analysed for their identity 
using ESI-TOF mass spectrometry experiments, with the assistance of the Integral 
Membrane Protein group at the Structural Genomics Consortium (Oxford University). 
Samples at 0.5 mg/ml in detergent were diluted by 1 in 50 with 0.1% formic acid, and 40 μl 
aliquots of these were loaded onto a C3 column and run in methanol/formic acid/water 
mobile phase on an Agilent LC MSD TOF system. The 0.1% formic acid was added to the 
analyte solution to enhance protonation and sensitivity. The resulting total ion count (TIC) 
data (summed intensity across the entire range of masses being detected at every point in the 
analysis) was extracted and mass averaged in the region containing VanS proteins, and 
deconvoluted between 4 and 100 kDa using Agilent MassHunter software.  
 
2.8.2 Protein Identification by Tryptic Digest and nanoLC-ESI-MS/MS 
 
Coomassie stained gel pieces were sent to the Warwick/Waters Centre for BioMedical Mass 
Spectrometry and Proteomics (University of Warwick), where they were processed and 
tryptically digested using the manufacturer’s recommended protocol on the MassPrep 
robotic protein handling system.  The extracted peptides from each sample were analysed by 
means of nanoLC-ESI-MS/MS using the NanoAcquity/Ultima Global instrumentation 
(Waters) using a 30 minute LC gradient.  All MS and MS/MS data were corrected for mass 
drift using reference data collected from the [Glu
1
]-Fibrinopeptide B (human - F3261 Sigma) 
sampled each minute of data collection. The data was used to interrogate the E. coli BL21 
database (http://www.ebi.ac.uk/integr8) using the full-length protein sequence using 
ProteinLynx Global Server v2.5.1.   
 
[95] 
 
2.9  Protein Activity Determination using Coupled Enzymatic Assays 
 
2.9.1 Continuous ADP Release Assay  
 
This assay is based on the production of ADP via ATP hydrolysis linked to NADH 
oxidation, by the coupling enzymes: pyruvate kinase and lactate dehydrogenase (PK/LDH) 
as described by Wampler and Westhead (1968). If active, VanS proteins should hydrolyse 
ATP to ADP, and pyruvate kinase will phosphorylate ADP by the catalytic conversion of 
phospho-enolpyruvate (PEP) to pyruvate, thus regenerating ATP. Lactate dehydrogenase 
uses pyruvate and converts it to lactate, by oxidising NADH to NAD
+
 (see Figure 2.9.1.1). 
 
 
Figure 2.9.1.1: Reaction pathway involved in ADP production by ATP hydrolysis, as 
described by Wampler and Westhead (1968). VanS or ATP can be used to initiate the 
reaction, and ATP is catalytically regenerated by pyruvate kinase. The reaction is followed 
at 340 nm on a UV spectrophotometer, by monitoring oxidation of NADH to NAD
+
.  
 
A reaction mixture typically consisted of 50 mM HEPES pH 7.6, 10 mM MgCl2, 50 mM 
KCl, 2.5 mM phosphor-enolpyruvate (PEP), 0.3 mM NADH (freshly prepared daily), 1 μl of 
pyruvate kinase/lactate dehydrogenase (PK/LDH, Sigma), 3 mM ATP, and 20 μL to 80 μL 
of purified VanS (at 2-8 mg/ml or 10 nmol final concentration) in 0.03-0.07% w/v detergent, 
all in a final volume of 200 μL. Assays were performed on a Cary 100 spectrophotometer. 
VanS VanS  -PO4
ATP ADP
Pyruvate Kinase
PEPPyruvate
Lactate 
Dehydrogenase
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NADH NAD+ A340nm
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All components except ATP were added to a 1 cm path-length UV-visible quartz cuvette 
(Hellma), mixed and placed in the cell changer of the spectrophotometer with the 
temperature controller set at 20
o
C for all experiments.  The cuvette was allowed to 
equilibrate to 20
o
C before setting the absorbance at 340 nm to zero. Sample absorbance was 
followed for 1 – 5 minutes, until a flat baseline, after which the cuvette was quickly 
removed, ATP substrate added and mixed and placed immediately back into the cell changer. 
The reaction was followed for at least 60 minutes, up to 300 minutes, and the resulting 
absorbance changes over the time-course of the assay were recorded using Varian Kinetics 
software. To demonstrate the dependence of the absorbance decrease on both VanS and ATP 
components, assays were also initiated by addition of VanS.   
 
2.9.2 Continuous Inorganic Phosphate Release Assay 
 
This assay is based on the utilisation of any free inorganic phosphate by the enzyme MESG 
(2-amino-6-mercapto-7-methylpurine ribonucleoside) and its subsequent conversion by PNP 
enzyme (purine nucleoside phosphorylase) to methylthioguanine and ribose-1-phosphate, 
effecting an increase in absorbance, which may be observed at a wavelength of 360 nm, as 
detailed by Webb (1992). The MESG enzyme has a strong absorbance at 330 nm, whereas 
methylthioguanine has an absorbance maximum at 360 nm, therefore a change in absorbance 
occurs which can be followed spectrophotometrically (see Figure 2.9.2.1).  
 
This assay was conducted as a second measure of protein activity, to complement the ADP 
production assay. It also enabled quantification of the amount of phosphate released by VanS 
after autophosphorylation and therefore allowed calculation of how much ATP is turned over 
from this, giving relative stoichiometries, corrected for any free phosphate release.  
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Figure 2.9.2.1: Reaction pathway involved in inorganic phosphate release by ATP 
hydrolysis, as described by Webb (1992). VanS or ATP can be used to initiate the reaction, 
but ATP is not regenerated. The reaction is followed at 360 nm on a UV spectrophotometer, 
by monitoring conversion of MESG to methylthioguanine by PNP enzyme.  
 
All components except ATP were added to the quartz cuvette (Hellma), mixed and placed in 
the cell changer of the spectrophotometer with the temperature controller set at 20
o
C for all 
experiments.  The cuvette was allowed to equilibrate to 20
o
C before setting the absorbance at 
360 nm to zero. Sample absorbance was followed for 1 – 5 minutes, until a flat baseline, 
after which the cuvette was quickly removed, ATP substrate added and mixed and placed 
immediately back into the cell changer. The reaction was followed for 20-60 minutes and the 
resulting absorbance changes over the time-course of the assay were recorded using Varian 
Kinetics software. To demonstrate the dependence of the absorbance decrease on both VanS 
and ATP components, assays were also initiated with VanS enzyme. 
 
A reaction mixture typically consisted of 50 mM HEPES pH 7.6, 10 mM MgCl2, 0.2 mM 
MESG, 1 μL of PNP (160 units/mL), 3 mM ATP, and 20 μL up to a limit of 80 μL of 
purified VanS enzyme (at 2-8 mg/ml or 10 nmol final concentration) in 0.03-0.07% w/v 
detergent, all in a final volume of 200 μL. Assays were performed on a Cary 100 
spectrophotometer (Varian). In both assays, careful pipetting was required to reduce air 
bubbles or bubbles in detergent containing samples. 
VanS VanS  -PO4
ATP ADP
PNP
MESG + PiMethylthioguanine
+ Ribose-1-Phosphate
A360nm
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2.9.3 Identification of Assay products by Anion Exchange Chromatography 
 
To identify products of the reaction between VanS and ATP, simplified experiments were 
conducted involving only VanS enzyme and ATP substrate (i.e. ATP is not regenerated). A 
reaction mix consisted of 50 mM HEPES pH 7.6, 1 mM MgCl2, 1 mM KCl, 0.03% DDM 
detergent, 10 nmol of VanS enzyme purified in 0.03% DDM and 3 mM ATP in a final 
volume of 200 μL. The reaction time was monitored, from the point at which ATP was 
added, and all 200 μL samples (aliquoted from a master mix) were maintained at 20oC in a 
PCR machine for direct comparison with activity data. Control samples were also run and 
tested simultaneously. These control samples were in-house standards of AMP, ADP or ATP 
(at 3 mM final concentration) in a reaction mix containing 50 mM HEPES pH 7.6, 1 mM 
MgCl2 with a final volume of 200 μL. A reaction mix was also tested involving VanS and 
ADP; 50 mM HEPES pH 7.6, 1 mM MgCl2, 1 mM KCl, 0.03% DDM detergent, 10 nmol of 
VanS enzyme purified in 0.03% DDM and 3 mM ADP in a final volume of 200 μL. 
 
For all samples, a 200 μL aliquot was removed from the PCR machine at specific time points 
(0, 30, 60, 120, 240, 360 or 480 min) and the reaction was quenched with 25 mM (final 
concentration) of EDTA pH 8, which chelates to any magnesium ions present. The sample 
was then applied to a new 5 kDa MWCO concentrator, and concentrated for 20 minutes at 
4000 g, to obtain the VanS protein in the upper chamber and the DNA in the lower chamber. 
nucleotide products of the reaction could then be analysed by Anion Exchange 
Chromatography (IEX), and identified against standards (AMP/ADP/ATP). 80 μL of the 
flow through from the concentrator was diluted with 1.3 mL of buffer A (10 mM ammonium 
acetate pH 7.6), and applied via a 1 mL injection loop onto a pre-equilibrated MonoQ 5/50 
GL column (Amersham) on an AKTA purifier at 1 mL/min flow rate. Absorbance at 280 and 
254 nm was recorded, and ~10 mL was passed through the column to elute any unbound 
compounds, before a gradient was started of 100% B (1M ammonium acetate pH 7.6), over 
30 minutes, and held at 100% B for 10-15 minutes. 
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Once all compounds had been eluted, the gradient was lowered to 0% B and the next sample 
was loaded onto the column when the conductivity reached 0 mS/cm. Absorbance traces 
were recorded for each sample, and the integrals of all peaks and their retention time 
(relative to standards) enabled percentages of AMP/ADP/ATP to be calculated. 
 
2.10 Circular Dichroism  
 
To determine the secondary structure in solution and extent of helicity of VanS proteins in 
different membrane mimetic environments, and for tagged or tag-cleaved samples, Circular 
Dichroism (CD) experiments were conducted. This phenomenon arises from the difference 
in absorption of left and right circularly polarized light (Correa & Ramos, 2009). When 
plane polarized light enters a chiral molecule it is resolved into two perpendicular vibrating 
waves that propagate at different velocities. Retardation of the slow wave relative to the fast 
wave generates a phase difference upon emergence. Circular dichroism arises because not 
only does the phase shift, but the amplitude of incident left and right-hand circularly 
polarized light changes, giving positive or negative values. Therefore circular dichroism can 
be measured by the difference in absorbance of the material for circularly polarized light, 
∆A, (where )RL AAA  , calculated from the Beer-Lambert Law (using A= ()cl).  
This difference in absorption is easily converted to ellipticity units, θ, and typically spectra 
are generated by the CD spectropolarimeter as a function of θ (in millidegrees) against 
wavelength (nm). To provide data of publishable quality, it was converted into standard units 
of Mean Residue Ellipticity (MRE). To calculate this from raw data (in millidegrees, θ), the 
equation below was used (Equation 3) (Rodger & Norden, 1997) which incorporates mean 
residue weight (Mr), concentration (‘c’ in mg/ml), path length (‘l’ in cm) and sequence 
length. NA is the number of amino acids per peptide and units of MRE are mdeg cm
2
 dmol
-1
. 
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CD spectra were measured using a Jasco 815 spectropolarimeter (Jasco UK, Great Dunmow, 
UK) at room temperature and using 1.0 mm path-length quartz cuvettes (Starna; Optiglass 
Ltd., Hainault, UK). All spectra were recorded at room temperature between 190-260 nm, 
using a data pitch of 0.2 nm, bandwidth of 2 nm, scanning speed of 100 nm/min, response 
time of 1 second, and either 16 or 32 accumulations. Data was initially acquired in 10 mM 
HEPES containing 2 mM dodecylphosphocholine (DPC; Avanti Polar Lipids), at a protein 
concentration of 0.2 mg/ml as measured by BCA assay (section 2.6.10) but required 
truncation in the region of 195-200 nm and below. To reduce minimal light scattering and 
obtain data to 190 nm, samples were prepared by exchanging from HEPES buffer into 
10mM phosphate buffer using a PD10 column, containing 2 mM DPC. However, for 
analysing protein samples prior to NMR spectroscopy, the buffer conditions were maintained 
as much as possible. For NMR samples, an aliquot of protein (2-10 μL) in the NMR buffer 
(HEPES/ sodium acetate/ phosphate) was diluted to a final volume of 200 μL with that 
buffer but containing 20 mM NaCl and 2 mM detergent (DPC, LMPG or LPPG).  
 
To stabilise the α-helical fold, and increase the strength of helicity, concentrated protein 
samples were also diluted to 0.2 mg/ml with 100% 2,2,2-trifluoroethanol (TFE) (containing 
2 mM detergent to determine the difference between samples with and without TFE), as this 
reagent is known to induce α-helix formation (Arunkumar et al., 1997). The helicity in TFE 
could then be compared to that in each detergent to analyse the relative protein folds.  
 
Micelle:protein ratios varied depending on detergent, but were in the range of 3-10, for 
solubilisation in DPC detergent, (assuming a CMC for DPC of 1.1 mM and an aggregation 
number of 56) (Wüthrich, 1986).  During scans, the high tension voltage remained below 
600V down to 200 nm, and often to 190 nm, to obtain reliable, publishable data.  
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2.11 Fluorescence Spectroscopy 
 
Fluorescence spectroscopy was used as a qualitative test for an interaction between a 
fluorescently labelled vancomycin probe and a VanS protein. The phenomenon is defined as 
the re-emission of light by a substance that has absorbed radiation at a fixed wavelength. 
Photochemically, fluorescence can occur when an orbital electron of an atom or molecule, 
relaxes to its ground state (S0) by emitting a photon of light, after being excited to a higher 
state (S1, the first excited state). For a full review, see e.g. Sharma & Schulman, (1999).  
 
For these studies, a vancomycin analogue was chosen which was available in the laboratory 
and had been previously used for imaging SDS-PAGE gels (Abrahams, 2011) containing 
transglycosylated polymerised Lipid II molecules of different chain lengths (visualised under 
a fluorescent light filter). The vancomycin analogue contains a BODIPY (Boron-
dipyrromethene) molecule covalently linked to vancomycin, and is a class of fluorescent dye 
(BODIPY-vancomycin, Molecular Probes, V-34850) (Figure 2.11.1).  The BODIPY-
vancomycin dyes have sharp excitation and emission wavelengths at ~504 nm and ~512 nm.     
 
 
Figure 2.11.1: BODIPY-Vancomycin structure, drawn in IsisDraw. BODIPY (red) is 
covalently bonded to the amine group on a sugar moiety of vancomycin, well away from the 
lipid binding heptapeptide core.  
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BODIPY-vancomycin powder showed high solubility in water, and was resuspended in 1mL 
of 20 mM HEPES pH 7.8 buffer, and centrifuged to remove any undissolved powder, 
aliquoting the supernatant into a 1.5 mL Eppendorf shielded from light by wrapping in foil. 
The concentration was determined by testing the absorbance at 504 nm of a number of 
samples with differing dilution factors, in a 0.1 cm path length quartz cell in a UV 
spectrophotometer, using the extinction coefficient of 78000 M
-1
 cm
-1
 for BODIPY-
vancomycin (Zlotnick et al., 2007), and applying the formula:  
 
[      ]  
    
     
      (4) 
 
The concentration was determined to be ~ 100 μM.   Initially, BODIPY-vancomycin at 10 
μM in 20 mM HEPES pH 7.8 was excited at 504 nm with monochromatic light and the 
emission spectrum collected by measuring the emission intensity between 500 and 600 nm. 
The slit width was 1 nm, and the scan speed was 50 nm/min, and all samples were collected 
at 20
o
C on a Perkin Elmer LS50 fluorimeter. The effect of micelles on the emission spectrum 
of the vancomycin analogue was next tested by adding microliter volumes (5 -10 μL) of a 
2% w/v (40mM) DPC solution in buffer, mixing thoroughly and measuring the emission 
spectra. Once the concentration of DPC was significantly above the CMC, VanS proteins or 
Lipid II-Lys molecules were added.  
 
VanS proteins were purified from DPC-solubilised membrane pellets by IMAC techniques 
(see section 2.6.6), which were applied to a PD10 column and exchanged to a buffer 
containing 20 mM HEPES pH 7.8 and 2 mM DPC (see section 2.6.8) and then concentrated 
to 3-6 mg/ml. Lipid II-Lys was synthesised in-house by the Bacwan facility (School of Life 
Sciences, University of Warwick) and its concentration determined by assay as 660 μM, in 
chloroform/methanol/water (2:3:1).  
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For samples containing BODIPY-vancomycin, DPC and Lipid II, an aliquot of Lipid II was 
pipetted (from a parafilmed glass vial), into a clean glass vial, immediately dried under 
nitrogen to a film and resuspended with the 200 μL solution of BODIPY-vancomycin in 
DPC detergent (10 μM BODIPY-vancomycin in 20 mM HEPES pH 7.8, 2 mM DPC), and 
vortexed thoroughly to resuspend the Lipid II fully. Further aliquots of Lipid II were added 
in the same way, to final concentrations of 10, 20, 30 μM, and the emission spectra of all 
samples measured.  For samples containing BODIPY-vancomycin, DPC and VanS, an 
aliquot of VanS in 20 mM HEPES pH 7.8, 2 mM DPC was added directly to 200 μL 
containing 10 μM BODIPY-vancomycin in 20 mM HEPES pH 7.8, 2 mM DPC, mixed 
thoroughly and the emission spectrum measured. Further aliquots of VanS were added in the 
same way, until no appreciable changes in the emission spectra were observed. 
 
 
2.12 Site-specific Enzymatic Tag-Cleavage  
2.12.1 Enzymatic digestion with in-house synthesised TEV protease  
 
After IMAC purification of His-tagged VanS proteins, elution fractions were digested with 
in-house synthesised histidine-tagged tobacco etch virus (TEV). The gene encoding for TEV 
protease (within a pRK793 vector) was obtained from the David Waugh laboratory deposit at 
Addgene, and was the S219V mutant version, containing an N-terminal polyhistidine tag and 
C-terminal polyarginine tag (His6-TEV (S129V)-Arg5). TEV protease was expressed in-
house from this gene, under assistance from the Roper group (University of Warwick). The 
gene was expressed in E.coli BL21(DE3)pRIL cells in Terrific Broth (12 g Tryptone, 24 g 
Yeast extract, 4 mL Glycerol per litre of H2O), and purified by IMAC on a pre-packed nickel 
His-trap column followed by Gel Filtration Chromatography (data not shown). 
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Cleavage experiments were conducted for 8-12 hrs at room temperature or overnight at 4
o
C, 
at a 1:1 ratio of [protein]:[TEV], in 20mM HEPES pH 7.5, 200mM NaCl, 10% glycerol, 20 
mM Imidazole and 2 mM DPC. The mixture was rebound to pre-charged nickel resin over 1 
hour rocking, prior to IMAC purification. The flow through was collected, and any weakly 
bound, cleaved VanS protein was selectively removed from the resin in a low imidazole 
buffer (20mM HEPES pH 7.5, 200mM NaCl, 10% glycerol, 40 mM Imidazole and 2mM 
DPC). TEV protease and uncut VanS were only eluted under high imidazole (250 mM). 
  
2.12.2 3C Protease Expression and Purification 
 
Constructs encoding for N-terminal polyhistidine, and C-terminal MBP-tagged 3C protease 
(N-His6-3C-MBP-C) tagged protease were sourced from Jim Brannigan’s lab in York 
University. 1L of protease was overexpressed in BL21(DE3) cell line with pRARE codon 
optimisation, according to published protocols (Alexandrov et al., 2001). All steps were 
carried out at 4
o
C. The cell pellet was resuspended in 40mL of buffer A (40mM sodium 
phosphate pH 7.8, 200 mM NaCl, 5 mM BME, 5% glycerol). Lysozyme was added to 1 
mg/ml, and DNase to 2 μg/ml, as well as 1 mM PMSF, 0.2 μM leupeptin, 0.2 μM pepstatin. 
Cells were sonicated on ice by three bursts of 30 seconds on and off. The lysate was 
subsequently centrifuged at 17000 g for 30 minutes and rotated for 2 hours with 5 mL bed 
volume TALON affinity resin (pre-equilibrated with buffer A). The resin was then pelleted 
at 1500g for 2min, supernatant decanted and washed with 50 mL of buffer A containing 
20mM Imidazole, 3 times, each time pelleting at 700g, 2mins. 
 
To elute the protease, 5mL of buffer A containing 1M imidazole was added and the sample 
was rotated for 20 mins at 4
o
C. The eluent was collected and dialysed twice for 1 hour each 
in 1L of buffer A (see section 2.6.8). After adding ice-cold glycerol to a final volume of 
20%, the protease was divided into 0.5 mL aliquots (at 3 mg/ml) and stored at -80
o
C. Total 
yield was 60 mg protease per litre, with some protease remaining in the flow through.  
[105] 
 
2.12.3 Enzymatic Digestion with 3C Protease 
 
After IMAC purification of hexahistidine-tagged VanS proteins, elution fractions were 
digested with in-house synthesised 3C protease (N-His6-3C-MBP-C) (see section 2.12.2). 
Cleavage experiments were conducted for 10-12 hrs at room temperature or overnight at 4
o
C, 
at a ratio of 1:1 [protein]:[3C], in buffer A (20mM HEPES pH 7.2, 800mM NaCl, 10% 
glycerol, 1mM DTT, and 2mM DPC). After digestion, the mixture was bound to 10 mL bed 
volume of pre-charged amylose resin (NEB, UK) (washed with 50 mL of 20mM Tris-HCl 
pH 7.5, 200mM NaCl, 10% glycerol, 1mM EDTA and 1mM 2-mercaptoethanol) over 2-3 
hours rocking at 4
o
C, in order to remove the MBP-tagged 3C protease.  
 
Once the flow through had been collected, the resin was washed with 20 mL of buffer A to 
remove residual VanS protein. Fractions were concentrated from ~25 to 2.5mL, and applied 
to a pre-equilibrated PD10 column (20 mM HEPES pH7.5, 300 mM NaCl, 10% glycerol and 
2mM DPC) to remove EDTA which would affect binding to nickel resin.  
 
The elution fraction from the PD10 was then rebound to nickel resin (to remove the C-
terminal untagged region) by adding 20mM Imidazole and rocking in 1-1.5mL bed volume 
of nickel sepharose charged resin for 2 hours. After the rebind, flow through was collected 
under gravity, the column was washed with 20mL of buffer containing 20mM Imidazole, 
20mM HEPES, 300mM NaCl, 10% glycerol and 2mM DPC, then 20mL of this buffer but 
containing 50mM Imidazole, and finally the protein was eluted with the N-terminal product 
as the major band using 2.5mL of buffer containing 250mM Imidazole. The product was 
then applied to a PD10 column before concentrating to 0.5 mL for gel filtration 
chromatography (section 2.6.7), and applying onto a Superose 6 10/300 GL column, under 
an isocratic gradient of 100% A (20mM HEPES, 300mM NaCl, 10% glycerol, 2mM DPC).  
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2.13 Protein Crystallisation 
 
X-Ray crystallography is an effective tool for generating atomic resolution structures of 
protein structure. However, the rate limiting step is the production of diffraction quality 
protein crystals, especially when studying membrane proteins, because solubilized protein-
detergent complexes do not often form ordered crystal lattices (Newby et al., 2009). It is 
difficult to rationalise why some proteins crystallise easily and others do not. However, by 
understanding the crystallisation process, better methods for crystal growth can be created.  
 
The science of crystal growth began in the 1980s and is termed crystallogenesis (Giege & 
Mikol, 1989). The three stages of crystallisation that are followed by all molecules are 
nucleation, crystal growth and termination of growth (Russo Krauss et al., 2013). Protein 
crystal formation requires that interactions between associating molecules are specific, 
directional and organised to provide the three-dimensional lattice.  The full growth process 
can be visualised in a two-dimensional phase diagram (see Figure 2.13.1).  
 
 
 
Figure 2.13.1: Two-dimensional Phase diagram for Crystal growth. Adapted from Russo 
Krauss et al., 2013. The arrow shows the route required for optimal crystal growth by 
vapour diffusion; the protein solution should reach supersaturation and nucleate, but a 
crystal only forms if the concentration drops and growth continues in the metastable zone.  
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As the concentration of a protein solution is brought above the solubility limit, it becomes 
supersaturated. Depending on the degree of supersaturation, growth will proceed in either the 
“precipitation” zone (as amorphous aggregates), the “nucleation” zone (where growth and 
nucleation can occur) or the “metastable” zone (where only growth is supported). There are 
many factors that affect crystal growth, which include pH, buffer, temperature, viscosity, 
protein concentration (Table 2.13.1).  Any of these can greatly affect success of crystallising 
a protein, but several effects can be minimized by obtaining highly pure (single band on 
SDS-PAGE or > 95% purity), homogenous proteins at concentrations of around 10 mg/ml. 
 
In order to rapidly assess a number of conditions, and control some of these factors, sparse 
matrix screens of 24 to 96 wells can be adopted, and allow determination of conditions that 
provide crystal ‘hits’. There are also general protocols for the expression, isolation, 
solubilisation and purification of membrane proteins, with a view towards identification and 
refinement of conditions suitable for crystallisation (Newby et al., 2009). 
 
Table 2.13.1 Factors affecting crystallisation. Adapted from Russo Krauss et al, (2013). 
Physical Factors Chemical Factors Biochemical Factors 
Temperature (affects 
vapour diffusion and 
protein stability) 
Precipitant choice and 
concentration 
Sample purity and 
Degradation rate 
Time (equilibration time 
and growth rate) 
pH and Buffer type (affects pI 
of protein and solubility) 
Sample homogeneity and 
Oligomeric State 
Viscosity Detergents (affects crystal 
contacts and stability) 
Sequence modifications e.g. 
tags or mutations 
Methodology Sample concentration and drop 
ratio (affects supersaturation) 
Aggregation 
Nucleants present Ionic strength and Purity of 
chemicals 
Ligands, co-factors  
 
A final parameter required for crystallisation is the method chosen to form crystals, which 
includes Batch, Dialysis, and most the commonly used, Vapour Diffusion.  
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2.13.1 Vapour Diffusion Crystallisation 
 
Vapour diffusion techniques utilise the evaporation and diffusion of water between a small 
droplet (10 μL or less) containing protein, buffer and precipitant, and a well solution, under a 
sealed environment. The well contains similar buffers and precipitant, but at higher 
concentrations with respect to the droplet. The droplet is equilibrated over the well by a 
hanging, sitting or sandwich drop method (Figure 2.13.1.1), to allow a slow increase in both 
protein and precipitant concentration which could cause supersaturation and crystal growth.  
 
 
Figure 2.13.1.1: The Vapour diffusion method. Adapted from Russo Krauss et al., 2013. In 
the ‘Hanging’ drop technique, the droplet is placed on a cover glass, and turned over to face 
the well. In the ‘Sitting’ drop technique, the droplet is placed on a small island inside the 
well. In the ‘Sandwich’ drop technique, the droplet is placed between two cover slips, one of 
which seals the reservoir.  
 
 
2.13.2 Sparse Matrix Screening 
 
Sparse matrix screens are routinely used when studying a new protein since each protein will 
often crystallise in different and sometimes multiple conditions. It is therefore a necessity to 
screen a variety of solutions, and these matrix screens are developed based on documented 
conditions which have yielded successfully diffracting protein crystals.  
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Often conditions contain a variety of precipitants such as polyethylene glycols (PEG), as 
well as salts, buffers such as Tris-HCl or HEPES, or solvents that have shown high success 
rates. Modern day screens are set-up in 96-well plate format and although there are >30 
possible matrix screens, only a few bias towards conditions for membrane protein 
crystallisation. These include screens developed by the Iwata group, known as MemGold, 
MemStart, and MemSys (Carpenter et al., 2008). Robotic tools are also available at high-
throughput facilities e.g. the Membrane Protein Laboratory (MPL) at Diamond Light Source 
(UK), which allow automated crystallisation screen set-up and imaging analysis.  
 
During this project, Memgold and MemStart (Molecular Dimensions) matrix screens were 
tested, which were set-up in 96-well MRC plates, using a 100 μL volume of precipitant per 
well. Sitting-drops were dispensed by a Honeybee 963 (University of Warwick) or a 
Mosquito robot (Structural Genomics Consortium, Oxford University) and consisted of 0.2 
μL of protein mixed with precipitant, at drop ratios of either 1:1, 2:1 or 0.5:1 
protein:precipitant, to test a range of concentrations, up to an effective concentration of 28 
mg/ml protein. Each 96-well plate therefore required at least 30 μL of protein solution. All 
trials were carried out at 18
o
C. 
 
2.13.3 Data Collection 
 
Microcrystals and nanocrystals of potential hits were collected and transported to Diamond 
Light Source (Harwell, UK) and exposed to a synchrotron beam line to test for crystal 
diffraction, under the assistance of the Integral Membrane Protein Department at the 
Structural Genomics Consortium (Oxford). 
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2.14 Solution State Nuclear Magnetic Resonance Spectroscopy 
 
NMR spectroscopy can provide three-dimensional structure determination of proteins in the 
solution phase. In addition, it provides a useful tool for the study of kinetic and ligand 
binding reactions at the atomic level. In this study, two-dimensional solution state NMR was 
used as a quantitative test for the interaction between a vancomycin or teicoplanin antibiotic 
and a VanS protein, to establish if binding was occurring and determine binding affinities.  
 
NMR spectroscopy examines chemical properties by studying individual nuclei. Only those 
nuclei with a half-spin e.g. 
1
H, 
13
C or 
15
N will exhibit NMR absorption spectra. The nucleus 
will have two possible spin states: m = +½ or m = -½, which when placed in a magnetic 
field, will align with or against the applied field (B0), and the nucleus will precess about the 
magnetic field on its axis of rotation (in the z-axis). This results in an energy difference with 
a small population bias toward the lower state, as described by the Boltzmann distribution. 
 
When the correct resonance frequency (matching the Larmor frequency) of radiation is 
applied to equal the energy difference, at right angles to the external magnetic field, those 
nuclei in the +½  state are excited into the higher -½ state. This excitation shifts the net 
magnetisation away from the z-axis and toward the x-axis, where the nuclei will precess in 
the x-y plane, before returning to equilibrium by relaxation processes (see Figure 2.14.1).  
 
 
Figure 2.14.1: Representation of nuclear spin relative to an axis of rotation, upon 
irradiation with a 90
o 
pulse at the Larmor frequency (rf).  
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These are non-radiative relaxation processes and there are two major relaxation processes: 
spin-lattice (longitudinal) relaxation (‘T1’), in the z-direction and spin-spin (transverse) 
relaxation (‘T2’), in the x-y plane.  The relaxation mechanism is a first order process, so the 
‘rf’ signal emitted by the sample decays exponentially, by free induction decay (FID).  Each 
FID signal, generated as excited protons relax, can be stored and averaged, and then 
converted by Fourier Transform from a time domain signal to a frequency domain spectrum.  
 
By selecting appropriate pulse programs, we can obtain structural information on proteins. A 
basic one dimensional NMR experiment consists of a simple pulse sequence, involving a 
delay time (d1), or a presat pulse (p19) in the case of ‘zgpr’ water suppression pulse, prior to 
excitation (p1), and acquisition (t2). For two-dimensional NMR experiments, there is also an 
evolution time, and mixing time, prior to collection of the FID data (see Figure 2.14.2).  
 
 
Figure 2.14.2: An example 2D COSY pulse program. The program consists of preparation 
(p1) and mixing (p2) periods of single 90° pulses separated by evolution time (t1), and the 
resonance signal from the sample is read during the detection period over a time range (t2). 
 
 
As stated above, two-dimensional solution state NMR was used for these studies, to identify 
any interaction of glycopeptide antibiotics with VanS proteins. 
1
H-
15
N Heteronuclear Single 
Quantum Coherence (HSQC) experiments were conducted to obtain information on protein 
fold, in different buffers, detergents, pH environments, temperatures, and determine the 
optimal conditions. Under these conditions, it was then possible to measure changes to peak 
chemical shift upon addition of potential ligands such as vancomycin and teicoplanin.    
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Experimental measurements for all samples (in 10% D2O, and fixed temperature), involved 
locking the proton signal, tuning and shimming, then collecting an initial 1D 
1H ‘zgpr’ 
presaturation pulse sequence (which provided the ‘p1’value). This was followed by a 
‘zggpwg’ Watergate pulse sequence which provided water suppression and gave information 
on peaks of the protein. From these experiments, values (e.g. p1, o1, sw) were inserted into 
the ‘hsqcetf3gpsi’ pulse program for the 2D 1H-15N HSQC experiment.  
 
2.14.1 2D 
1
H-
15
N HSQC NMR Spectra of VanS proteins in detergent micelles  
 
Proteins were overexpressed in M9 minimal media, containing 
15
N ammonium chloride, as 
required for NMR experiments (see section 2.5.1). Membrane proteins were extracted by cell 
disruption and ultracentrifugation (see section 2.5.3), and solubilised in 0.5-1% w/v DPC 
detergent. After IMAC purification the protein was cleaved with 3C protease at a 1:1 ratio of 
protein:protease, and the N-terminal His-tagged VanS sensor domain was selectively 
purified away from the protease and C-terminal domain (see section 2.12.3). At this point 
detergents were either exchanged on the IMAC resin, or the protein was further purified by 
Gel Filtration Chromatography. Similarly, the pH, salt and buffer could be altered during 
IMAC exchange or after it by applying to a pre-equilibrated PD10 column (section 2.6.8).  
 
The 
15
N labelled VanS N-terminal sensor domain was then concentrated to ~200 μL or >100-
200 μM, centrifuged at 13 krpm for 10 minutes in a Beckmann benchtop centrifuge, to pellet 
any aggregated material, before pipetting into 3mm BrukerMATCH NMR tubes. 10% v/v 
D2O was then added to samples, prior to analysis by solution state NMR on a 500 MHz 
Bruker NMR spectrometer with a tbi probe, or a 700 MHz Bruker NMR spectrometer with a 
cyroprobe. Samples were inserted into the spectrometer, and locked, tuned and shimmed, as 
detailed above, and a 1D 
1
H ‘zgpr’ experiment was conducted. These 1D experiments, 
provided ‘p1’ and ‘o1’ values required to conduct 2D 1H-15N HSQC experiments.    
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2D 
1
H-
15
N HSQC spectra were collected for VanS samples in different detergents, pHs and 
temperatures, to determine the optimal conditions for protein fold and to obtain sharp, well-
resolved NMR peaks with uniform intensities. Three detergents were analysed: DPC, LMPG 
and LPPG, and a pH range between 4.6 and 6.9, and temperature range between 288K and 
418K was tested. Samples were also buffered in either 50mM sodium acetate (pH 4.6-5.6), 
50mM sodium phosphate (pH 5.6-6.6), or maintained in 20mM HEPES buffer throughout 
(pH 6.6-6.9). These experiments informed decisions on appropriate conditions for 
conducting ligand-based titration experiments, as detailed in section 2.14.2.      
 
2.14.2 Ligand-based Titrations by 2D 
1
H-
15
N HSQC spectroscopy 
 
2D 
1
H-
15
N HSQC spectra were acquired for samples containing isotopically labelled VanS 
proteins solubilised in micelles, in a known buffer (as detailed above), to which glycopeptide 
antibiotics were added. The glycopeptide antibiotics tested were vancomycin hydrochloride 
(Sigma) and teicoplanin (Molekula), which were dissolved in buffer, containing detergent 
micelles (at a concentration >>CMC). For instance, a VanS protein sample at ~ 200 μM, 
solubilised in 50 mM DPC, in 50 mM sodium acetate pH 5.6, was analysed by HSQC NMR 
spectroscopy. A vancomycin solution of 10-20 mM was prepared by dissolution in this 
buffer (but containing 5 mM DPC) and titrated into the sample, at 1:1 ratio of 
[protein]:[Vancomycin]. The pH was measured before and after addition of antibiotic on a 
calibrated pH meter, and adjusted accordingly with microliter volumes of 0.1 M acetic acid 
or hydrochloric acid, or 0.1 M sodium hydroxide, to within 0.05 pH units (over all titrations).  
 
Each new titration sample was centrifuged to pellet any insoluble material and aggregated 
protein, and allowed to equilibrate for 15-30 minutes, before being placed into the 
spectrometer and locked, tuned and shimmed. A new ‘p1’ value was obtained using 1D 1H 
‘zgpr’ pulse sequences, before collecting another set of HSQC spectra. The Watergate pulse 
sequence (‘zggpwg’) was also collected to examine protein degradation between samples.  
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NMR samples were also prepared for VanS proteins in the presence of vancomycin and 
Lipid II-Lys (from Gram-positive bacteria), to determine the effects of interaction of VanS 
proteins with a complex of vancomycin and Lipid II cell wall precursor by HSQC NMR. 
Lipid II-Lys was obtained from the Bacwan facility (Warwick) as dissolved lyophilised 
powder at a concentration of 660 μM.  An aliquot of Lipid II was dried to a film in a glass 
vial under nitrogen, and the NMR sample containing 
15
N labelled detergent-solubilised VanS 
protein and vancomycin was added and vortexed thoroughly to resuspend the lipid. Samples 
were allowed to equilibrate for several hours before analysis. Due to the high cost of the lipid 
(1 mg ~ £1000), the molar ratio of vancomycin : protein : Lipid II used in experiments was 
4:1:0.5, but this should be sufficient to form a complex with the excess vancomycin present. 
 
2.14.3 Analysis of NMR-based ligand titration data 
 
NMR data from the 500 or 700 MHz Bruker NMR spectrometer was collected in Topspin 2. 
This data was exported into Sparky 3.114 program for analysis of HSQC NMR spectra. The 
2D 
1
H-
15
N HSQC NMR spectra acquired at each titration point were overlayed in Sparky 
and exported into Microsoft Expression Design 4 for publishing. HSQC spectra were 
analysed in Sparky by peak picking with all peaks tabulated and numbered according to their 
chemical shift (δ), in order of ascending 1HN value.  Changes in the chemical shift (δ) of each 
peak during ligand titrations were calculated using a Chemical Shift Perturbation (CSP) 
analysis. For full details of CSP analyses see section 5.4.1. Briefly, this involved calculating 
the difference in 
1
H (  
 ) or 
15
N (  
 ) chemical shift value of each peak (at each titration 
point), by subtracting against the chemical shift value of the corresponding peak in the 
spectrum containing only the protein in detergent (i.e. at 0:1 [ligand]:[protein]). The relative 
chemical shifts of the 
1
H and 
15
N nuclei were then weighted, and the chemical shift change, 
(Δδ), calculated according to Equation 4 (see section 5.4.1).  By calculating the chemical 
shift change (Δδ) for each peak, a bar graph was then produced of peak number against CSP, 
to demonstrate the number and magnitude of shifts observed (e.g. see Figure 5.4.1.5). 
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3 Cloning, Expression, Purification and Functional 
Characterisation of VanS proteins from Enterococci and 
Streptomyces 
 
3.1 Introduction 
 
VanS is an integral membrane protein and sensor histidine kinase, which forms part of a two 
component system (TCS) (section 1.5), with its cognate cytosolic response regulator, VanR. 
This system regulates inducible transcription of the genes responsible for glycopeptide 
resistance in pathogenic strains such as enterococci (GRE) (section 1.3), as well as in some 
actinomycetes e.g. Streptomyces. In the presence of a glycopeptide antibiotic e.g. 
vancomycin, VanS binds ATP molecules at its cytoplasmic ATP-binding domain and auto-
phosphorylates a conserved histidine residue in an adjacent α-helix (Walsh et al., 1996) 
(Figure 3.1.1). The phosphate is subsequently transferred to a conserved aspartate residue on 
VanR, resulting in a conformational change in the protein. This increases its affinity for a 
specific promoter region, effecting transcription of a number of genes (vanHAX), responsible 
for glycopeptide resistance (Walsh et al., 1996; Healy et al., 2000) (section 1.3.3).   
 
The structural genes for this system are found in many bacteria and their identity can vary 
depending on the bacterial species concerned, for instance additional vanJ and vanK genes 
are required for resistance in Streptomyces coelicolor (Hutchings et al., 2006; Hong et al., 
2008) (section 1.3.5), but generally the vanRSHAX resistance genes are conserved 
throughout all bacterial phenotypes for the core two component systems and D-alanine to D-
lactate or D-serine peptidoglycan metabolism. Each phenotype has a different antibiotic 
sensitivity, for instance in enterococci, the most clinically relevant phenotypes are VanA and 
VanB. Bacteria carrying the VanA phenotype confer resistance to vancomycin and 
teicoplanin, whereas those carrying VanB are resistant to vancomycin but sensitive to 
teicoplanin. In actinomycetes, some species such as S. coelicolor bacteria can also be 
considered as having VanB-type resistance i.e. resistant to vancomycin but not teicoplanin.  
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Figure 3.1.1: Model of phosphotransfer relay in the VanS-VanR two-component system. 
Adapted from Walsh et al., 1996; Healy et al., 2000. VanS is proposed to consist of a small 
extracytoplasmic loop region bound by two membrane spanning helices (shown as cylinders) 
and a large cytoplasmic domain containing the ATP binding site and conserved His residue. 
Residues shown relate to proteins of the Enterococcal VanA strain (VanSA and VanRA). 
 
Biochemical evidence to support the VanRS mechanism includes studies by Wright et al., 
(1993) on E. faecium VanSA/RA proteins, Depardieu et al., (2003) on E. faecalis VanSB/RB 
and Hutchings et al., (2006) on S. coelicolor VanSSC/RSC. Wright et al., (1993) showed that a 
fusion protein consisting of maltose binding protein (MBP) linked to the cytosolic domain of 
the Enterococcal VanA species (VanSA) at Met95, could catalyse both autophosphorylation 
and rapid phosphotransfer to purified VanRA using radiolabelled [γ-
32
P]ATP assays. The rate 
of autophosphorylation of MBP-VanSAΔ95 was calculated as 0.17 min
-1
 over a reaction time 
of one hour. However, even under saturating levels of ATP, only 10-15 % of the protein 
could be phosphorylated. This suggests the actual fraction of active protein was only ~0.1. 
Phosphotransfer from MBP-VanSA~P to VanRA was also found to exhibit ratio of 0.1-0.15 
for phosphate bound to VanRA, thus indicating a 1:1 transfer from active VanSA to VanRA.  
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In a reverse experiment; adding P~VanRA to MBP-VanSA, the group also illustrated the role 
of VanSA as a VanRA–specific phosphatase, which increased the rate of dephosphorylation 
of VanRA by 6-fold when present.  Similar experiments by Depardieu et al., (2003) showed 
that the cytosolic domain of Enterococcal VanSB (Met159 to Lys447) also possesses kinase 
activity and acts as a VanRB-specific phosphatase, increasing its dephosphorylation by 11-
fold when present. Furthermore, Hutchings et al., (2006), showed that the cytosolic domain 
of S. coelicolor VanSSC (Ala85 to Arg364) can autophosphorylate and catalyse rapid 
phosphotransfer to S. coelicolor VanRSC, and subsequent dephosphorylation of VanRSC~P in 
vitro. Biochemical data therefore suggests that VanS is a bifunctional protein that can self-
regulate between kinase and phosphatase activities, and can be represented as follows:  
 
1) Autophosphorylation:        VanS-H  +  ATP          ↔   VanS-H~P  +  ADP 
2) Phosphotransfer:            VanS-H~P  +  VanR-D   ↔   VanS-H       +  VanR-D~P 
3) Phosphatase:                  VanR-D~P  +  H2O          ↔   VanR~D     +   Pi 
 
Further evidence for the phosphatase function of VanS includes experiments involving 
deletion of vanS in S. coelicolor (Hong et al., 2004) and in enterococci (Arthur et al., 1997), 
and the use of a vanH-lacZ reporter system (Haldimann et al., 1997). Deletion of vanS 
results in constitutive expression of the vanHAX resistance genes, indicating that VanS 
negatively regulates VanR in the absence of vancomycin. VanR~P can therefore be produced 
independently of VanS, with VanS acting as a phosphatase in the absence of the antibiotic. 
In the lacZ reporter system (Haldimann et al., 1997), PvanH promoters (expressing VanHAX) 
drive lacZ expression, which can be monitored by β-galactosidase production. It was found 
that strains expressing VanRA only were activated by phosphorylation with donor acetyl 
phosphate molecules, showing increased β-galactosidase production. By contrast, expression 
of VanRS reduced β-galactosidase levels, showing that VanSA interferes with the activation 
of VanR by acetyl phosphate, and illustrating its role as a phosphatase. These experiments 
indicate that separate mechanisms exist for the phosphatase and kinase activities of VanS. 
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Sequence alignments of VanS proteins derived from different species shows a number of 
conserved motifs in the cytoplasmic domain (Figure 3.1.2), which are known to be important 
to protein function, whereas there are large deviations in sequence identity between the 
extracytoplasmic sensor domains. The Enterococcal VanSA and VanSB proteins are 
structurally related, but have only ~23%  overall sequence identity (Depardieu et al., 2007), 
and no relation in sequence in their sensor loop regions (see Figure 3.1.3), or the length of 
their sensor loops (103 residues for VanSB vs. 37 residues for VanSA) (Hong et al., 2008). 
Enterococcal VanS proteins are also very divergent from their streptomycete equivalents 
(~15% identity in pairwise comparisons) (Hong et al., 2008). Between actinomycetes there is 
higher structural similarity, e.g. S. coelicolor and S. toyocaensis have ~65% identity, but 
again these differ greatly in the sensor regions (Figure 3.1.3). Structural differences between 
VanS sensor domains may suggest why each species exhibits a different response to 
glycopeptide antibiotics (see section 1.4.3), whereas conservation of sequence motifs in the 
cytoplasmic domain (e.g. the H, N, G1, F, G2 boxes, see section 1.5.3), means that the 
overall kinase functional mechanism remains the same.   
 
 
Figure 3.1.2:  Schematic representation of the VanS protein and predicted topology. 
Adapted from Depardieu et al., 2003; 2007. The putative membrane-bound sensor domain 
(orange) containing transmembrane (TM) helices (blue boxes) is linked to the putative 
cytoplasmic kinase domain (green) containing conserved sequence motifs (H, N, G1, F, G2). 
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Figure 3.1.3: CLUSTALW2 sequence alignment of the VanSA, VanSB and VanSSC protein 
sequences.  Extracellular sensor loops are highlighted in green text. Transmembrane-
spanning helices are highlighted in red text. HAMP domains are highlighted in blue text. 
Conserved motifs are outlined in boxes – ‘H’ in brown, ‘N’ in green, ‘G1’ in purple, ‘F’ in 
pink and ‘G2’ in orange.  Transmembrane helices shown were predicted using TMPred 
software (Hofmann and Stoffel, 1993) (and checked against other software e.g. TopPred 
(von Heijne, 1992) and PSIPred (Jones, 1999). HAMP domains were predicted using 
SMART bioinformatic software (Letunic et al., 2012). 
 
Figures 3.1.2 and 3.1.3 show the sequences of conserved regions (H, N, G1, F, and G2 
boxes) which identify the proteins as histidine kinases. These regions are involved in 
autophosphorylation and contain residues that directly interact with ATP. The direct link 
between the H-box and other four boxes categorises them as class I HKs (Dutta et al., 1999). 
VanSb --MERKGIFIKVFSYTIIVLLLLVGVTATLFAQQFVSYFRAMEAQQTVKSYQPLVELIQN 58
VanSsc --MDRRPGLSVRLKLT--------------------------------LSYAGFLTLAG- 25
VanSa MVIKLKNKKNDYSKLER-------------------------------KLYMYIVAIVVV 29
:. :       .                                    *  :: :   
VanSb SDRLDMQEVAGLFHYNNQSFEFYIEDKEGSVLYATPNADTSNSVRPDFLYVVHRDDNISI 118
VanSsc ---VLLLVAVGVFLLDQG----WLLTNERGAVRATPGT---------------------- 56
VanSa A-IVFVLYIRSMIRGKLGDWILSILENKYDLNHLDAMK---------------------- 66
: :    .::  .       :  :: .     .                        
VanSb VAQSKAGVGLLYQGLTIRGIVMIAIMVVFSLLCAYIFARQMTTPIKALADSANKMAN--L 176
VanSsc ---------VFLRSFAPTAAWVMAFLLVFGLVGGWFLAGRMLAPLDRITEATRTAATGSL 107
VanSa ---------LYQYSIRNNIDIFIYVAIVISIL---ILCRVMLSKFAKYFDEINTGIDVLI 114
:   .:      .: . :*:.::   ::.  * : :    :  ..     :
VanSb KEVPPPLERKDELGALAHDMHSMYIRLKETIARLEDEIAREHELEETQRYFFAAASHELK 236
VanSsc SHRIRLPGRRDEYRELADAFDEMLARLEAHVA--------------EQRRFAANASHELR 153
VanSa QNEDKQIELSAEMDVMEQKLNTLKRTLEKREQD-------AKLAEQRKNDVVMYLAHDIK 167
..         *   : . :. :   *:                   :. .    :*:::
VanSb TPIAAVSVLLEGMLENIGD-YKDHSKYLRECIKMMDRQGKTISEILELVSLNDGRIVPIA 295
VanSsc TPLAVSKAILD--VARTDP-HQDPGE-IIDRLHAVNTRAIDLTEALLLLSR-AGQRSFTR 208
VanSa TPLTSIIGYLSLLDEAPDMPVDQKAKYVHITLDKAYRLEQLIDEFFEITRYNLQTITLTK 227
**::     *.      .   .: .: :   :.        : * : :            
VanSb EPLDIGRTVAELLPDFQTLAEANNQRFVTDIPAGQIVLSDPKLIQKALSNVILNAVQN-T 354
VanSsc EQVDMSLLAEEATETLLPFAEKHGVTLETRG-HVTLALGSPALLLQLTTNLVHNAIVHNL 267
VanSa THIDLYYMLVQMTDEFYPQLSAHGKQAVIHAPEDLTVSGDPDKLARVFNNILKNAAAY-S 286
:*:     :    : .  . :.            . ..*  : :  .*:: **     
VanSb PQGGEVRIWSEPGAEKYRLSVLNMGVHIDDTALSKLFIPFYRIDQARSRKSGRSGLGLAI 414
VanSsc PGRGRVWIHTAAGPRTTRLVVENTGDLISPHQASTLTEPFQRGTERIHTDHPGVGLGLAI 327
VanSa EDNSIIDITAGLSGDVVSIEFKNTG-SIPKDKLAAIFEKFYRLDNARSSDTGGAGLGLAI 345
. : * :  .     : . * *  *     : :   * *  :    .    ******
VanSb VQKTLDAMSLQYALEN-TSDGVLFWLDLPPTSTL------ 447
VanSsc VNTITQAHDGTLTLTPRHSGGLRVTVELPAAAPHTGR--- 364
VanSa AKEIIVQHGGQIYAES-NDNYTTFRVELPAMPDLVDKRRS 384
.:      .         ..   . ::**. .        
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Interestingly, the VanSA protein does not contain a HAMP domain (Hulko et al., 2006), 
whereas VanSB and VanSSC proteins do. These domains are believed to possess a role in 
regulating phosphorylation of kinases by transmitting conformational changes in the 
periplasmic sensor domain to the cytoplasmic kinase domain (see section 1.5.5). HAMP 
domains could therefore be implicated in the observed activity of each VanS protein. 
 
Currently, there are no structures of a VanS sensor histidine kinase in the Protein Data Bank 
(PDB), which would be highly beneficial in order to characterise the structural and 
mechanistic basis of VanS catalysis. Several crystal or NMR structures do exist though for 
the soluble cytoplasmic domains of histidine kinases, with and without bound response 
regulators (Casino et al., 2009; Marina et al., 2005; Tanaka et al., 1998), which have 
provided structural information on the architecture of the kinase domain and its interaction 
with the response regulator receiver domain (see section 1.5.5). Recently, the first structure 
of a full-length histidine kinase (YF1) was published (Diensthuber et al., 2013), which 
shows that coiled coil regions like those in HAMP domains, are crucial in signalling (section 
1.5.6). However, there is little sequence similarity between VanS and YF1, and the precise 
mechanism of ligand binding and autophosphorylation of VanS is not fully understood, in 
particular with relation to the nature of the signalling molecule that induces VanS activity. 
 
This chapter details the cloning, expression, purification and crystallisation of full-length 
VanS enzymes in detergent environments, for structural and mechanistic characterisation, 
with comparison to previous data by Quigley, (2010) and Wright et al., (1993). The main 
goal of this work is to obtain a more detailed understanding of the atomic structure of VanS 
proteins derived from enterococci and Streptomyces bacteria and increase knowledge of the 
signalling mechanism that underpins glycopeptide resistance. This could contribute toward 
rational design of novel inhibitors of Two-Component Systems and more targeted therapies 
to combat bacterial resistance mechanisms, which are in critical need due to the recent 
emergence of VRE and more virulent, VRSA in hospitals (Murray, 2000; Hiramatsu, 2001). 
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Previous work by Dr. Andrew Quigley at the University of Warwick (Quigley, 2010), 
provided some biochemical characterisation of full-length VanS from Enterococcus faecium 
(VanSA) and of truncates containing only the cytoplasmic kinase domain (MBP-VanSAΔ95 
and VanSAΔ110 – Δ155). Full-length and truncated VanSA proteins were shown to be active 
with respect to autophosphorylation and phosphotransfer using coupled enzymatic assays 
(see section 2.9) or radiolabelling assays using [γ-32P]ATP. VanS proteins from E. faecium 
(VanSA) and S. coelicolor (VanSSC) were therefore expressed and purified, and tested in the 
phosphorylation assays developed within the Warwick group (Quigley, 2010) to increase 
understanding of the mechanism of autophosphorylation in different VanS species.  
   
Prior to Dr. Andrew Quigley, studies were carried out by Dr. Michael Williams at the 
University of Warwick (Williams, 2007), in collaboration with Dr. Marek Brzozowski and 
Justyna Korcynska (University of York), which provided several potential crystals of C-His-
tagged VanSA proteins, the best of which diffracted to 8Å. By analysing the conditions that 
yielded these crystal hits, attempts were made to improve crystal growth and obtain higher 
resolution diffraction patterns crystals by selecting appropriate membrane mimetics. 
 
3.2 Aims 
 
(i) To clone vanS genes from two different backgrounds (E. faecium, S. coelicolor) 
into new, tag-cleavable vectors for high level expression and selective 
purification of wild-type VanS proteins by affinity chromatography. 
(ii) To test the activity of purified VanS proteins using coupled-enzymatic assays, to 
improve upon knowledge of the phosphorylation mechanism in different species.  
(iii) To obtain active, homogenous and natively folded wild-type (tag-cleaved) VanS 
protein samples for use in crystallographic studies on 96-well plates.  
(iv) To crystallise tag-cleaved VanS proteins (and improve upon the 8Å crystals 
previously obtained for C-His-tagged VanSA in DDM) by testing conditions that 
yielded these hits and by screening for hits in other detergent classes.  
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3.3 Cloning vanS genes into Expression Vectors 
  
Full-length wild-type vanS genes derived from Enterococcus faecium (termed vanSA) and 
Streptomyces coelicolor (termed vanSSC) were provided by Dr. David Roper. These genes 
were contained within a pTTQ18 vector (for vanSA) or a pGEM T-easy vector (for vanSSC). 
Previous studies at Warwick University by Quigley (2010) aimed to obtain crystals of the 
VanSA protein by expression and purification from pTTQ18::vanSA constructs. The pTTQ18 
vector encodes a C-terminal hexa-histidine tagged protein, but the tag cannot be removed. 
Therefore, in these PhD studies the vanSA and vanSSC genes were amplified by Polymerase 
Chain Reaction (PCR, section 2.4.1) and cloned into pProEx HTa vectors (Addgene) for 
recombinant expression. These vectors encode an N-terminal hexa-histidine tag and contain 
a TEV-cleavable linker in front of the vanS gene sequence (Figure 3.3.1). In this way, the   
N-terminal hexa-histidine tag aids expression of the resulting protein and enables selective 
purification by immobilised metal affinity chromatography (IMAC, see section 2.6.6), and 
the tag can subsequently be cleaved (by TEV protease) to obtain the wild-type protein. 
Cleavage of the His-tag is preferential to obtain protein samples with a more native fold (and 
to remove impurities) for use in activity assays and crystallisation trials.  
 
251 ACACAGGAAACAGACCATGTCGTACTACCATCACCATCACCATCACGATTACGATATCCCAACGACC 
              Start                                His6  
318 GAAAACCTGTATTTTCAGGGCGCCATGGATCCGGAATTCAAAGGCCTACGTCGACGAGCTCAACTAG 
        TEV protease site                  NcoI  
385 TGCGGCCGCTTTCGAATCTAGAGCCTGCAGTCTCGAGGCATGCGGTACCAAGCTTGGCTGTTTTGG 
                              HindIII  
 
Figure 3.3.1: Restriction map of the pProEx HTa plasmid between bases 251 and 450. 
Restriction sites are in red, and start codon (ATG), His6 and TEV cleavage site are 
underlined.  The vanS genes were cloned between the two restriction sites, with the region 
between these sites removed by enzymatic digestion of the pProEx HTa plasmids.  
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To insert the vanS genes into pProEx vectors, forward and reverse oligonucleotides were 
designed against template vanS sequences (Table 2.4.1), incorporating either an NcoI 
restriction site (5’ end, forward primer) or a HindIII restriction site (3’ end, reverse primer). 
This allowed amplification of plasmid DNA by PCR (section 2.4.1) (Figure 3.3.2) with 
restriction sites at either end of the gene. The PCR products were then double-digested 
(NcoI, HindIII) (section 2.4.3) alongside pProEx HTa plasmids, and provided compatible 
sticky ends for ligation. The high GC content of Streptomyces vanS, relative to Enterococcal 
vanS required higher annealing temperatures (68
o
C) and the use of GC-rich Taq polymerases 
in order to obtain gene products. 
 
 
 
Figure 3.3.2: A 0.8% agarose gel (inverted image) showing the PCR amplification of (a) 
vanSA and (b) vanSSC genes. MR - GeneRuler 1kb DNA ladder, MR’  - Quick-Load 1kb 
ladder, (a) Lane 1-3 vanSA gene (1152 bp length) (b) Lane 1-3 vanSSC gene (1104 bp length), 
showing intense bands of DNA obtained using the GC-rich Taq polymerase.   
 
Double-digested PCR products and pProEx plasmids were then ligated (section 2.4.7), and 
the mixture used to transform E. coli TOP10 cells (Table 2.2.2.1) (section 2.3) and extract 
DNA from positive transformants by minipreparations (section 2.4.4). To check the vanS 
insert was present, minipreparations were digested with NcoI and HindIII enzymes (Figure 
3.3.3), and sequence identity was confirmed by Sanger sequencing (section 2.4.8), which 
showed in-frame vanS sequences, without DNA mutations. 
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Figure 3.3.3: An 0.8% agarose gel (inverted image) showing correctly-sized gene 
sequences after NcoI/HindIII double-digestion. MR – Quick-Load 1Kb ladder; Lane 1 – 
control pProEx plasmid containing ape gene from Neisseria gonorrhoeae, Lane 2 - digested 
pProEx::vanSA gene, Lane 3 – digested pProEx::vanSSC gene. Each digestion shows a gene 
insert at ~1100 bp (red arrow), and a cut linear vector at ~5000 bp (blue arrow). 
 
3.4 Expression of VanS constructs 
 
Previous work by Dr. Andrew Quigley showed that expression from the pTTQ18::vanSA 
construct (for C-His6-VanSA) using the “Walker strains” (Miroux & Walker, 1996) (C43 or 
C41(DE3)) co-transformed with pRIL plasmids (Table 2.2.2.1) improved expression level of 
Enterococcal VanS proteins, as they are more tolerant to toxic proteins. Therefore the 
pTTQ18::vanSA construct was used as a guide to test previous conditions, prior to optimising 
conditions for the new pProEx::vanS constructs. C41 and C43(DE3).pRIL cell lines were 
tested for expression from pTTQ18::vanSA constructs by using small-scale trials and 
analysing on SDS-PAGE gels (see section 2.6.1) (Figure 3.4.1). C41 or C43 cells were added 
to overnight cultures and used to inoculate 100 ml LB containing ampicillin and 
chloramphenicol, as described in section 2.5.1.  VanS proteins were overexpressed with 
IPTG for 4 hours at 37
o
C (as previously used by Dr. Andrew Quigley (Quigley, 2010) in the 
Warwick group), and analysed by SDS-PAGE after extraction of the membrane fraction 
from whole cells using a technique known as Water Lysis (Ward et al., 2000) (see section 
2.5.2), which produces membrane proteins via an osmotic shock procedure.  
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Figure 3.4.1: A 12% SDS-PAGE gel showing proteins overexpressed in C41 or C43 (DE3) 
pRIL cell lines after Water Lysis preparations. VanS proteins overexpressed with IPTG (+) 
are highlighted in red boxes (~ 44 kDa), against uninduced (-) controls. Mr - Protein ladder 
(LMW-SDS, GE Healthcare), lanes 1 – 3 - C41 cell line, lanes 4 – 6 – C43 cell line. For 
lanes 2-3 and 5-6, 0.2 mM IPTG inducer was added. 
  
These membrane preparations showed that VanS proteins were not the major band on SDS-
PAGE gels, but were being overexpressed, therefore further optimisation of current protocols 
was required.  It is known that membrane proteins can be toxic to the cell, and these Walker 
strains can help prevent this, as they are able to tune the rate of transcription to harmonise 
with translation, such that saturation of the Sec translocon does not occur, and proteins are 
inserted correctly into the membrane (Wagner et al., 2008). However, transcription prior to 
induction with IPTG can occur, known as “leaky expression”, in which the cell uses carbon 
sources such as glycerol to stimulate transcription. This can be reduced by the “glucose 
effect” or “catabolite repression”, which lowers transcription from the lac promoter (Kolb et 
al., 1993). Therefore 0.2% w/v autoclaved glucose was added and small-scale expression 
trials repeated. Furthermore, a cell growth curve was constructed to determine the optimal 
level of inducer (IPTG) for the VanSA expression system. Growth curves were monitored at 
different concentrations of IPTG relative to an uninduced control, and the resulting 
preparations were analysed by SDS-PAGE experiments (Figure 3.4.2). 
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Figure 3.4.2: (a) An SDS-PAGE gel showing overexpressed proteins from pttQ18::vanSA 
in C41pRIL cells at varying [IPTG] and (b) corresponding growth curves. Samples loaded 
had been processed by Water Lysis, and VanS proteins overexpressed with IPTG (+) are 
highlighted in red boxes (~ 44 kDa), against uninduced (-) controls. MR – Protein ladder, 
lane 1 – 0 mM IPTG added, lane 2 – 0.2 mM IPTG added, lane 3 – 1 mM IPTG added. For 
the growth curves, each line is a concentration of IPTG inducer; 1 mM (blue line), 0.2 mM 
(green line), 0 mM (red line).  
 
These trials showed a dramatic effect on expression level upon adding glucose, producing C-
His6-VanSA proteins as the major species (~ 45kDa, theoretically 43,916 Da); with 
concomitant reduction in ‘leaky’ expression of other E. coli proteins (see Figure 3.4.2). The 
Water Lysis method also provided a clear visualisation of the protein expression level, as it 
extracts only soluble proteins in the membrane fraction, and therefore reduces interference 
from other naturally expressed cytosolic proteins.  Growth curves monitored over 4 hours 
post-induction indicated that upon addition of IPTG, the rate of increase of optical cell 
density (OD, measured at 600 nm) was lowered, hence the cells were under strain to 
overexpress VanS proteins. Furthermore, 0.2 mM IPTG inducer gave greater cell densities 
and increased VanS yield, relative to 1 mM IPTG inducer, and was therefore the optimum 
concentration of inducer. 
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With this information in hand, small-scale expression was trialled for the novel 
pProEx::vanSA and pProEx::vanSSC constructs (encoding N-His6-VanSA), overexpressed in 
LB media, with addition of 0.2% w/v glucose and both ampicillin and chloramphenicol 
antibiotics (section 2.5.1), and processed by Water Lysis (Figure 3.4.3).  
   
 
 
 
Figure 3.4.3: 12% SDS-PAGE gel showing overexpression from pProEx::vanSA or 
pProEx::vanSSC constructs in C41pRIL cells, after Water Lysis. VanS proteins 
overexpressed with 0.2 mM IPTG (+) are highlighted in red boxes and labelled, against 
uninduced (-) controls. Mr – Protein Marker (GE), lanes 1-2 – expression from 
pProEx::vanSA and lanes 3 – 4 – expression from pProEx::vanSSC . 
  
 
Figure 3.4.3 shows that the major expressed protein bands were at ~45 kDa, which 
corresponds to the molecular weight of His6-TEV-VanSA (47,012 Da theoretically), and at 
~40 kDa, which corresponds to the molecular weight His6-TEV-VanSSC  (42,620 Da 
theoretically). However, to confirm that these observed bands were indeed the His6-tagged 
VanS proteins, anti-histidine Western blots were required, which are discussed section 2.6.3. 
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As a final experiment, the temperature for induction was lowered and cells were grown over 
a longer time, to reduce the propensity for protein misfolding or unfolding. If proteins are 
highly overexpressed in E. coli but misfolded, this can lead to formation of insoluble 
aggregates known as inclusion bodies. Therefore the temperature for inductions was lowered 
to 25
o
C and small-scale expressions were induced as before at mid-log phase, but allowed to 
grow for 12-16 hours to increase cell density. SDS-PAGE analyses (Figure 3.4.4) showed 
marginal increases in expression level of soluble protein compared to those grown at 37
o
C, 
and VanS proteins are still the major species. Protein unfolding is increased at higher 
temperatures, therefore the fold at 25
o
C is likely to be better stabilised, and was selected in 
future expressions. 
 
 
 
Figure 3.4.4: A 12% SDS-PAGE gel showing expression from pProEx::vanSA at 25
o
C 
overnight prepared by Water Lysis. MR – Protein ladder (GE Healthcare), Lane 1 – 0 mM 
IPTG, Lane 2 – 0.2 mM IPTG, Lane 3 – 1 mM IPTG.  
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3.5 Western Blotting for His-tagged VanS proteins 
 
To confirm the expression of His-tagged VanS proteins, anti-His Western blots were 
performed (section 2.6.3) and run alongside SDS-PAGE gels for direct comparison. At this 
point expression was still carried out at 37
o
C for 4 hours to confirm the observed bands were 
indeed VanS proteins. Initial Western blots used primary anti-His antibodies (Roche) to bind 
to polyHis-tagged proteins, and were developed (after addition of secondary antibody) by 
electrochemical luminescence (ECL) as described in section 2.6.3. Two SDS-PAGE gels 
were run simultaneously with identical samples loaded, one of which was blotted.  
 
The positions of bands in the blot corresponded well with SDS-PAGE bands of proposed 
VanS proteins, and it was observed that C-terminal His-tagged (pTTQ18) VanSA and N-
terminal His-tagged (pProEx) VanSSC were visible from the blot, but no bands were 
observed for the N-terminal His-tagged (pProEx) VanSA protein (Figure 3.5.1).  
 
Figure 3.5.1: (left) 12% SDS-PAGE gel of Water Lysis preparations, and (right) 
equivalent Western blot developed using Roche non-specific anti-His antibodies. All vanS 
constructs were transformed into C41pRIL cells, and either not induced (-) – Lanes 1, 3, and 
5, or induced with 0.2mM IPTG (+) – Lanes 2, 4, and 6 for 4 hours at 37oC. Lanes 1 & 2 
were transformed with pTTQ18::vanSA, Lanes 3 & 4 were transformed with pProEx::vanSA 
and Lanes 5 & 6 were transformed with pProEx::vanSSC. MR –Protein marker (GE), MR’ – 
Benchmark His-tagged Ladder (Invitrogen). VanS proteins are highlighted by red boxes.  
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Since all three VanS proteins appear to be expressed and only one VanS proteins was not 
visible on the blot, it was likely that there was reduced interaction between the antibody and 
the tag, e.g. the protein fold rendering the binding site inaccessible. The manufacturer’s 
instructions stated that these anti-His antibodies were ‘non-specific’, i.e. can bind to N- or C-
terminal His-tags if exposed. By examining commercially available antibodies, it was found 
that anti-His antibodies have also been designed which bind preferentially to N-terminal tags 
(Sigma). VanS protein samples were loaded onto SDS-PAGE gels, and analysed by blotting, 
using the same protocol but adding the novel anti-His primary antibodies (Figure 3.5.2).  
 
The SDS-PAGE gels and corresponding blots demonstrated that the N-terminal His-tagged 
VanSA protein was being expressed and the bands were much clearer for the N-terminal 
tagged proteins, compared to C-terminal, demonstrating the preference of the antibody. 
Therefore hexa-histidine tagged VanS membrane proteins were being expressed, without 
cleavage in vivo, and in a soluble form, and could now be selectively purified using this tag.  
 
Figure 3.5.2: (left) 12% SDS-PAGE gel for Water Lysis preparations, and (right) 
equivalent blots developed using Sigma N-term preferential anti-His antibodies. All vanS 
constructs were transformed into C41pRIL cells, and either not induced - Lanes 1, 3, and 5, 
or induced with 0.2mM IPTG – Lanes 2, 4, and 6 for 4 hours at 37oC. Lanes 1 & 2 were 
transformed with pProEx::vanSA, Lanes 3 & 4 were transformed with pProEx::vanSSC and 
Lanes 5 & 6 were transformed with pTTQ18::vanSA. MR – Benchmark His-tagged Ladder 
(Invitrogen). VanS proteins are highlighted by red boxes.  
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3.6 Purification of VanS Membrane Proteins by IMAC 
 
Attempts were now made to purify VanS proteins by extracting them from the E. coli inner 
membrane and then selectively purifying the histidine-tagged proteins by immobilised metal 
affinity chromatography (IMAC). For small-scale purification, published Water Lysis 
methods, developed in Professor Peter Henderson’s laboratory (Leeds University) were used 
(Ward et al., 2000) (see section 2.5.2). These involve formation of spheroplasts by lysing 
cells under osmotic shock and subsequent centrifugation (at ≤ 50,000g) to pellet membranes. 
However, previous work carried out in the Warwick group by Quigley (2010), showed that 
scale-up and the use of sucrose gradients (to separate inner and outer membranes), gave low 
yields of C-His-tagged VanS, due to apparent localisation of VanS to the outer membrane. 
 
By working at the Membrane Protein Laboratory (MPL, Harwell), Quigley (2010) found that 
higher yields could be obtained by lysing the expressed cell pellet with a continuous cell 
disruptor (shears cells by forcing them through a mesh), obtaining membrane pellets by 
ultracentrifugation and solubilising the membranes directly in (DDM) detergent prior to 
IMAC. This method can impinge on final purity as it gives the opportunity for further 
contaminants to be solubilised, but extraction with detergents is widely used for membrane 
proteins both within the research group and wider science community, reflecting its success.  
 
Expressed cell pellets containing N-terminal His-tagged VanSA proteins were therefore 
treated this way (see section 2.5.3).  Large-scale expressions (1-6 L, section 2.5.1) were 
induced at 25
o
C for 12 hours, and cells pelleted, and lysed by cell disruption. Membranes 
extracted from the lysate by ultracentrifugation were solubilised in 1% w/v DDM overnight. 
The protein-detergent mix was then ultracentrifuged in order to pellet and remove insoluble 
material (not bound to detergent micelles), and the supernatant (soluble fraction) was applied 
to pre-charged, pre-equilibrated nickel-nitrilotriacetic acid (Ni-NTA) agarose resin, at a ratio 
of 1 mL bed volume of resin per 1 litre of expressed cell pellet.  
[132] 
 
The mix was allowed to rock for two hours then poured into a column, flow through 
collected and the resin was washed as described in section 2.6.6, before eluting VanSA in a 
high-imidazole buffer. Fractions collected were then analysed by SDS-PAGE (Figure 3.6.1). 
The Ni-NTA agarose resin was used as it allows high binding capacity and minimal non-
specific binding, up to 5-10 mg of His-tagged protein per mL of resin.   
 
 
Figure 3.6.1: A 12% SDS-PAGE gel showing N-His6-VanSA purification by affinity 
chromatography. Membranes were solubilised in 1% DDM from 5L of expressed cells 
containing VanSA, and purified in buffer containing 0.05% DDM. Lane 1 – 20mM Imidazole 
eluate, Lane 2 – 50mM Imidazole eluate, Lane 3-6 – 300mM imidazole eluates (2.5 mL 
volume each). VanSA protein bands are highlighted.  
 
Unfortunately, even from a 5L expression relatively low yields of around 1-2 mg of purified 
N-His6-VanSA membrane protein were being obtained, as calculated using the BCA protein 
concentration assay (see section 2.6.10), which was lower than that obtained for the C-His6-
VanSA protein previously (~1 mg per Litre by Quigley, 2010), and the purity appeared 
reduced, due to some non-specific binding. By assessing protein yield at each stage, it was 
found that even after solubilising a freshly expressed and processed membrane pellet in 
DDM detergent, only ~ 40 % of protein remained in the soluble fraction (Figure 3.6.2), 
therefore the N-His6-VanS protein was not stable in DDM micelles.  
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Figure 3.6.2: A 12% SDS-PAGE gel of N-His6-VanSA extraction into DDM micelles. 
Membranes were extracted in 1% DDM  from 1L of cells containing VanSA, (lane 1) and 
ultracentrifuged at 40 krpm. Lane 2 – soluble fraction, Lane 3 – insoluble fraction.  
 
In order to select a better detergent for solubilisation, a detergent screen (see section 2.6.5 
and Appendix Table 1) was set-up for VanSA as well as VanSSC proteins (extracted from 
membranes by the same method as before, as detailed in section 2.5.3). These screens 
included higher purity ANA-GRADE DDM (Affymetrix), to ensure the low solubility was 
not a function of the SOL-GRADE DDM (Melford) used. Detergents tested were chosen 
based on their success in the literature to extract and reconstitute membrane proteins (Newby 
et al., 2009). These included LDAO and maltoside detergents (DM, DDM), which are 
commonly used in protein extraction prior to crystallisation, and DPC detergent, which is 
routinely used in solution state NMR studies. The selection of a particular detergent for 
crystallographic study is based on its ability to extract a large quantity of soluble, as well as 
stable and active protein. In comparison, a suitable detergent for NMR studies is one that has 
a small micelle size in order to permit rapid tumbling of the associated protein-micelle 
complex in solution (giving long T2 spin-spin relaxation rates). For this reason, DDM, which 
forms micelles of 50-70 kDa is only used in crystallography studies, whereas e.g. DPC 
detergent, which forms micelles of 15-25 kDa, can be used in both crystallographic and 
NMR studies. 
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Detergent screens essentially involved solubilising a fixed volume (1 – 2 mL) of a 
resuspended membrane pellet in a detergent solution, then ultracentrifuging at 100,000 g, 
and collecting the supernatant (soluble fraction), and pellet (insoluble fraction). Aliquots of 
the soluble and insoluble fractions were then loaded onto an SDS-PAGE gel and transferred 
to PVDF membrane for Western blot analysis (Figure 3.6.3). All lanes contained a fixed 
volume of protein to directly measure the ratio of VanS proteins in soluble and insoluble 
fractions, and all pellet fractions were resuspended to the same initial volume in buffer. 
Unfortunately, LDAO detergents smeared on gels, so these samples were not blotted.  
 
 
 
Figure 3.6.3: (a) Western blots showing detergent solubilisation of VanSSC (left) or VanSA 
(right) membrane pellets, and (b) corresponding bar charts of the relative percentages of 
soluble and insoluble protein.  Soluble supernatant fraction – S, blue bar, insoluble pellet 
fraction – P, red bar. Solubilisation (%) was calculated from band sizing of the VanS band 
(red arrow) using ImageJ software. MR – MagicMark His-tagged ladder. Western blots for 
VanSSC showed reduced background as they were washed overnight before developing. 
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From these detergent screens, it was concluded that the non-ionic maltoside detergents (DM, 
DDM) could only solubilise ~40% of the VanS proteins, whereas zwitterionic DPC detergent 
(dodecylphosphocholine) gave the highest protein solubilisation at ~80%. This difference in 
solubility could be attributed to the head-group, since DPC and DDM have the same 
hydrocarbon chain, but DPC has a more native, lipid-like PC head-group (Figure 3.6.4).  
 
 
 
Figure 3.6.4: Molecular structures of DPC and DDM detergents, drawn in ISISDraw. 
 
 
Previous attempts to crystallise the C-His-tagged VanSA protein by Dr. Marek Brzozowski 
and Justyna Korczynska at York University (see Figure 3.6.5) identified several crystal hits 
in the presence of 0.05% w/v DDM, but the group could only achieve low resolution 
diffraction patterns (> 8Å) in this detergent. Further screening by Dr. Andrew Quigley 
(2010) using the same crystallisation conditions could not repeat these protein crystals, and 
he concluded that reduced crystal packing, possibly due to the large steric size of DDM 
micelles (50-70 kDa), may have prevented hydrophilic regions from forming protein-protein 
contacts in the crystal (and hence giving low diffraction-quality crystals).  
 
From the detergent screens conducted in this thesis, it appears that VanS proteins are 
relatively unstable in DDM, and the use of other detergents e.g. DPC may provide better 
conditions for crystal growth. DPC detergents form smaller micelles than those of DDM, 
which could allow closer protein-protein contacts within the crystal, thereby increasing 
crystal stability. This does however makes the assumption that the micelle size of each 
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detergent will be affected in a similar way upon insertion of the protein, but this could only 
truly be quantified experimentally e.g. by Dynamic Light Scattering (DLS). Both the mass 
and hydrodynamic radii of micelles will be affected by the addition of the protein, which 
inserts its transmembrane domains into the hydrophobic core of the micelle, thus altering the 
packing of the hydrocarbon tails and polar headgroups (Bond et al., 2004). Therefore the 
actual micelle size is not necessarily predictable once the protein is added to the micelle. As 
a check of the average micelle size for VanSA proteins extracted into DPC detergents, DLS 
measurements were briefly made using a Nano-Series Zetasizer (Malvern). This gave mean 
particle diameters (termed as ‘Z-average’) of ~13 nm and a particle size distribution 
dominated by a single population at ~ 10 nm (see Appendix Figure 1), which is within the 
range expected for DPC micelles (which have hydrodynamic radii of ~3.5 nm before 
addition of any protein) (Oliver et al., 2013).  
   
Based on the high solubility of VanS proteins in DPC micelles and the favourable 
hydrodynamic radii of their associated protein-micelle complexes, attempts were therefore 
made to purify N-His-tagged VanSA (and VanSSC) proteins in DPC, with a view towards 
conducting crystal screens in this detergent. As noted earlier, the best detergent for 
crystallization purposes is one that can solubilise protein at high concentrations, but also 
provides a homogeneous, stable and functionally-active protein sample. With this in mind, 
prior to crystallisation trials, VanS proteins were also analysed by Gel Filtration 
Chromatography (section 3.7); to test for a single sharp (homogeneous) peak, by CD 
spectroscopy (section 3.10); to test for a native protein fold, and by spectrophotometric 
assays (section 3.11); to test for functional activity of the kinase.  
[137] 
 
 
Figure 3.6.5: Crystallisation conditions for C-His6-VanSA at 18
o
C, identified by Dr Marek 
Brzozowski and Justyna Korczynska at York University. (A): VanSA in 0.05% DDM, 10% 
PEG 4000 (w/v), 10% Glycerol, 0.1M Tris/HCl, pH8.5, (B): VanSA  in 0.05% DDM, 14% 
PEG 2000 (w/v), 0.1M NaCl, 0.1M LiSO4, 0.1M Tris/HCl pH8.5, (C): VanSA  in 0.05% 
DDM, 10% PEG 3350 (w/v), 0.1M NaAc pH 4.5, (D): VanSA in 50mM BOG, 30% PEG 400 
(w/v), 0.1M LiSO4, 0.1M Sodium Citrate pH 4.5. 
 
 
First of all, N-His6-VanSA proteins had to be purified by metal affinity chromatography. 
Samples were solubilised in 1% w/v DPC detergent and applied to Ni-NTA agarose pre-
charged, pre-equilibrated resin, and purified using the protocol given in section 2.6.6. 
Proteins were eluted in 0.075% DPC (~1.5x CMC), to compare with elution fractions 
obtained using DDM detergent (0.05%, ~2x CMC), and the resulting fractions were analysed 
on SDS-PAGE gels, loaded at 20 μg/ml per lane, or if lower concentration, the maximum 
volume for the lane (~25 μl) (see Figure 3.6.6). As observed from the gel in Figure 3.6.6, the 
quantity of purified VanSA protein was vastly greater than in DDM, with around 3-4 mg of 
pure VanS per litre of culture.  
[138] 
 
 
Figure 3.6.6: A 12% SDS-PAGE gel showing the purification of N-His6-VanSA by affinity 
chromatography. Membranes were solubilised in 1% DPC from 2L of expressed cells of 
VanSA, and purified in buffer containing 0.075% DPC. MR – Ladder (GE), Lane 1 – Flow 
through, Lanes 2-5 – 20 - 50mM Imidazole, Lane 6-8 – 300 mM Imidazole (2.5 mL volumes).    
 
 
In contrast, attempts to purify N-His6-VanSSC proteins under the same protocols did not 
provide any protein in IMAC elution fractions. Examination of the yield of protein at each 
stage of purification by Western blotting (Figure 3.6.7), revealed that most of the protein 
expressed at 25
o
C (or 37
o
C) was insoluble, and pelleted with cell debris after lysing by cell 
disruption. In light of this poor solubility, the induction temperature was further decreased to 
16
o
C for 18 hours and overexpressed cells containing VanSSC proteins were purified and 
blotted (Figure 3.6.8). A much higher proportion of soluble protein was obtained (~50-60%) 
after cell disruption, which localised to the membrane fraction (lane 6). The resulting 
membrane pellet was subsequently solubilised in 1% w/v DPC and purified by IMAC and 
aliquots loaded onto SDS-PAGE gels (Figure 3.6.9). 
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Figure 3.6.7: Western blot showing attempted purification of N-His6-VanSSC proteins 
expressed at 37
o
C.  Lane 1 –Cell pellet, Lane 2 – Insoluble protein after cell disruption, 
Lane 3 – Soluble protein after cell disruption, Lane 4 – Supernatant from 40 krpm spin, Lane 
5 – Pellet from 40 krpm spin (resuspended in a smaller volume) MR – Benchmark ladder.  
 
 
Figure 3.6.8: Western blot showing attempted purification of N-His6-VanSSC proteins 
expressed at 16
o
C. Lane 1 –Cell pellet, Lane 2 –Proteins after cell disruption, Lane 3 – 
Soluble protein, Lane 4 – Insoluble protein, Lane 5 – Supernatant from 40 krpm spin, Lane 6 
– Pellet from 40 krpm spin (resuspended in a smaller volume). MR – Benchmark Ladder.  
 
VanSSC protein purified by these methods gave about 1 mg of pure protein per litre in DPC, 
which is reasonable considering it is one of several major expressed bands and had to be 
overexpressed at low temperatures. In addition, studies by Koteva et al., (2010), found that 
VanSSC expressed in their constructs in BL21 (DE3) pLysS was toxic to the cell and also 
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required induction at 16
o
C. Therefore the culture size had to be increased to 6L or more to 
obtain enough protein for biochemical and biophysical studies (see Appendix Figure 2).  
 
 
Figure 3.6.9: A 12% SDS-PAGE gel showing purification of N-His6-VanSSC proteins by 
affinity chromatography. 1L of cells expressing VanSSC were purified to membranes and 
solubilised in 1% DPC. Lane 1: Soluble fraction, Lane 2: Insoluble fraction, Lane 3: Flow 
through, Lane 4-6 : 20 mM Imidazole, Lane 7-9: 300 mM Imidazole (2.5 mL elutions). 
 
3.7 Purification of VanS proteins by Gel Filtration Chromatography 
 
Elution fractions from IMAC containing VanS protein were next applied to PD10 desalting 
columns (see section 2.6.8) and further purified by Gel Filtration Chromatography (GFC) 
(see section 2.6.7). Improved separation of VanS proteins was achieved by applying samples 
that had been concentrated using 30 kDa MWCO concentrators (see section 2.6.8) to a 
Superose 12 Gel Filtration column (separation range 1-300 kDa), under an isocratic gradient 
of 100% B. As shown in Figure 3.7.1, the protein eluted as a single peak at elution volumes 
of 11.5 mL for VanSSC and 11.8 mL for VanSA (as identified by SDS-PAGE, see Figure 
3.7.3). There is one other peak at 9 mL elution time, which contains aggregated protein at 
high molecular weight (>300 kDa), and represents the void volume of the column (VO, 9.0 
mL). The single peaks at ~11-12 mL indicate that the protein is predominantly stable in DPC 
micelles, and should be amenable for crystallisation studies. Since the retention times of both 
proteins are similar, this could indicate that they exist also in the same oligomeric state.  
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Figure 3.7.1: Gel Filtration Chromatograms for protein samples of VanSA (black) and 
VanSSC (red) applied to a Superose 12 column. An isocratic gradient of 100 % B was used 
(B: 20 mM HEPES pH 7.8, 300 mM NaCl, 0.075% w/v DPC).  
 
By applying Gel Filtration standards to the column and running at the same flow rate and 
with the same buffer (Appendix Figure 3), it was possible to create a calibration curve of 
log(molecular weight) against elution volume, assuming a void volume of 9.0 mL (Figure 
3.7.2). Plotting the relative retention times of VanSA and VanSSC proteins on this curve gave 
predicted molecular weights of around 80-90 kDa, and therefore it is expected the proteins 
migrate as dimers. However, all standards run were globular proteins, which may migrate 
differently to VanS membrane proteins, so the molecular weights are only a prediction. 
 
 
Figure 3.7.2: A calibration curve of gel filtration standards, plotted by the log of their 
weights against their elution times (Ve), relative to a void volume (Vo). Standards (blue 
dots) were applied to a Superose 12 column under an isocratic gradient. For full standard 
names see Appendix Figure 3. Using the equation for the line, values for the log(molecular 
weight) of VanSA (red) and VanSSC (green) were calculated and added. 
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SDS-PAGE analysis of gel filtration samples collected under the main peak confirm a pure 
band of VanS protein at ~40 -45 kDa, (Figure 3.7.3). There is also an impurity at ~100 kDa 
which is present throughout purifications, and could not be removed by Gel filtration 
chromatography. This could be AcrB (110 kDa), a histidine-rich E. coli expressed protein 
which co-elutes with many proteins during IMAC purifications (Veesler et al., 2008). It is a 
further reason for choosing a construct that has an enzymatic cleavage site after the His-tag, 
since any AcrB impurities can be removed due to their high affinity for nickel resin, whilst 
the cleaved VanS wild-type protein is collected in the flow through.  
 
 
 
 
Figure 3.7.3: A 12% SDS-PAGE gels showing aliquots of 0.3 mL gel filtration elutions 
collected under the main peak (~10 -12 mL). N-His6-VanSA (a) and N-His6-VanSSC (b) 
proteins are indicated by red arrows.  
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3.8 Histidine Tag Cleavage for Crystallisation Trials 
 
As mentioned above, in a number of studies, it has been observed that AcrB proteins 
spontaneously bind to IMAC resin and co-elute with the protein of interest. AcrB proteins 
also crystallise preferentially over membrane proteins, even at low concentrations (Bolanos-
Garcia & Davies, 2006; Veesler et al., 2008). Therefore by cleaving the His-tag, and 
subjecting the digest to a further round of IMAC purification, impurities like AcrB can be 
removed, to improve the chances of crystallising VanS proteins. Experiments to cleave the 
tag using tobacco etch virus (TEV, 27 kDa) (see section 2.12.1), found that relatively high 
concentrations were required to access the cut site, possibly due to its close proximity to the 
micelle surface (Figure 3.8.1). SDS-PAGE gels demonstrate the cleavage, with a mass 
reduction of ~3 kDa (the His-tag), and show that even 1:2 [TEV]:[protein] ratios did not 
provide 100 % cleavage (as some uncleaved protein remains bound to the resin).  
 
 
 
 
 
Figure 3.8.1: A 12% SDS-PAGE gel to test conditions for VanSA tag-cleavage. VanSA 
protein was bound to pre-charged nickel sepharose resin, and digested on-column with 
different ratios of [TEV]:[protein] (in different columns). Lane 1 – 20 mM Imidazole wash to 
remove non-specifically bound proteins, Lanes 2, 4, 6 – Flow through after cleavage, Lane 
3, 5, 7 – Proteins on the resin after cleavage, Lane 8 – N-His6-VanSA uncut control, Lane 9 – 
His6-TEV protease control. Lane 2/3 – 1:2 [TEV]:[protein], Lane 4/5 – 1:4 [TEV]:[protein], 
Lane 6/7 – 1:8  [TEV]:[protein]. MR – Protein ladder (GE). 
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Upon discussion with collaborators in the Integral Membrane Protein facility at the 
Structural Genomics Consortium (SGC, Oxford University), it was found that they often use 
1:1 and even 2:1 [TEV]:[protein] ratios in their purifications and overnight cleavage is 
preferable to achieve optimal yield. Protein samples were therefore cleaved at 1:1 ratios (see 
section 2.12.1) and run on SDS-PAGE gels (Figure 3.8.2), which showed complete cleavage.  
 
 
Figure 3.8.2: A 12% SDS-PAGE gel showing tag-cleavage of VanSA with TEV. Lane 1 – 
After overnight cleavage with TEV, Lane 2 – before cleavage. Band sizes were ~47 kDa for 
tagged-VanS and ~44 kDa for tag-cleaved VanS, relative to a GE marker. 
 
Digestion products were subsequently rebound to nickel resin, to remove his-tagged 
impurities (e.g. AcrB and TEV) and collect cleaved VanS proteins in the flow through. As a 
final measure, the wild-type VanS proteins were purified by gel filtration chromatography 
(see Appendix Figure 4), and samples were concentrated to 200 μL for use in crystallisation 
trials (see Appendix Figure 5), which showed that the possible AcrB contaminant at ~100 
kDa had been removed. Concentrated samples were also analysed by mass spectrometry (see 
section 2.8.1), to confirm their exact protein identity and by CD spectroscopy (see section 
2.10), to ensure the purified proteins remained in their native helical fold.   
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3.9 Identification of Full-length VanS Proteins by Mass Spectrometry 
 
To confirm the identity of purified VanS proteins, samples were analysed after TEV 
digestion, by mass spectrometry. An aliquot of tag-cleaved VanS protein purified in DPC 
detergent was analysed under positive-mode electrospray ionisation on an Agilent LC-MSD 
TOF instrument (see section 2.8.1). Resulting spectra were averaged and deconvoluted using 
MassHunter software, as shown in Figure 3.9.1. 
 
 
 
Figure 3.9.1: Mass averaged, deconvoluted ESI-TOF mass spectra of  tag-cleaved wild-
type VanSA (a) and VanSSC (b) proteins. The view is enlarged in the m/z region of the 
molecular ion peak. Major species identified including the [M+H]
+
 peak are annotated.  
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Full-length tag-cleaved VanS proteins were identified at the exact molecular mass predicted 
+/- 1 Dalton, containing the wild-type sequence and an additional two residues (glycine and 
alanine) prior to the gene sequence (resulting from cleavage at glutamine/glycine in the TEV 
recognition site). For VanSA the [M+H]
+
 ion was observed at 44044.6 Da (expected 
molecular ion mass including the two residues is 44043.9 Da) and for VanSSC at 39652.9 Da 
(expected molecular ion mass including the two residues is 39651.5 Da). Spectra showed 
some impurities remaining after gel filtration, but the highest intensity peak was the [M+H]
+
 
peak, and shoulder peaks resulting from sodiated species e.g. [M+Na]
+
 (e.g. 39674.0 Da) and 
[M+2Na-H]
+
 (e.g. 39697.4 Da). Therefore purified VanS proteins had the correct mass and 
were being cleaved by TEV protease at the correct site, and despite any impurities, did not 
appear to show any post-translational modifications. 
 
3.10 Secondary structure of VanS proteins by Circular Dichroism 
 
As a pre-requisite to crystallisation and NMR studies, VanS protein samples were analysed 
by Circular Dichroism (CD) (section 2.10) to ensure the proteins were properly folded, and 
to compare secondary structure characteristics of both proteins. CD provides information 
about molecular conformation and protein stability. In the instance of proteins, there are 
spectral signatures characteristic of alpha-helical, beta-sheet and random coil secondary 
structures, and fitting software can determine the relative percentages of each in the sample.  
 
Each protein sample was prepared as described in section 2.10. Scans were made in the far 
UV range (190 - 260 nm) at all data was collected at 20
o
C. Initially, samples were prepared 
from VanS proteins that had been purified by gel filtration in a buffer containing 20 mM 
HEPES pH 7.5, 2 mM DPC, diluted in the same buffer to give a final concentration of 0.1-
0.15 mg/ml in 200 μL (4-5 μM). However, it was found that HEPES can cause high 
scattering at wavelengths around and below 200 nm (Figure 3.10.1) and preferred buffers 
used in the literature are sodium phosphate, Tris or sodium acetate (Kelly et al., 2005). 
[147] 
 
Therefore samples in HEPES buffer were exchanged into 20 mM phosphate buffer pH 7.5 
(containing 2 mM DPC) using a PD10 column, and diluted to ~0.1 mg/ml, in order to collect 
data to 190 nm (which is required for most fitting software) (see Figure 3.10.1). 
 
 
 
Figure 3.10.1: CD spectra of 5 μM N-His6-VanSA and N-His6-VanSSC in HEPES or 
phosphate buffer pH 7.5, containing 2 mM DPC.  VanSA in phosphate buffer – red line, 
VanSSC in HEPES buffer – green line, VanSA in HEPES buffer – blue line.   
 
 
Examination of the CD spectra above for VanSA and VanSSC in DPC detergent shows strong 
peaks at around 208 nm and 222 nm, characteristic of a predominantly α-helical protein. 
Analysis of the CD data for VanSA in phosphate buffer, using fitting software (Dichroweb, 
CDSSTR) (Whitmore & Wallace, 2004) confirms this (60% α-helix, 13% β-strand and 26% 
β-turn/random coil), and is in close agreement with the predicted secondary structure (using 
PredictProtein software) (Rost et al., 2004) for the protein sequence alone. Samples of 
VanSSC could not be analysed by a fitting program due to light scattering below 200 nm, but 
appear to show the characteristic α-helical fold, and have similar MRE values to VanSA, as 
predicted from protein sequence alone (50% α-helical using PredictProtein software).  
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In order to assess any changes in secondary structure upon histidine-tag cleavage, tag-
cleaved VanS samples purified by gel filtration (see section 3.7) were also analysed under 
the same conditions, exchanged into phosphate buffer (Figure 3.10.2). Furthermore, 100% 
2,2,2-trifluoroethanol (TFE) was added to his-tagged VanSA samples in DPC, as it is known 
to induce α-helicity (Shiraki et al., 1995; Arunkumar et al., 1997), in order to provide a 
measure against which to compare the helicity observed in DPC detergent alone. 
  
 
 
Figure 3.10.2: CD spectra of 5 μM N-His-tagged and tag-cleaved VanSA in phosphate 
buffer pH 7.5 or TFE, containing 2 mM DPC.  His-tagged VanSA in buffer – red line, tag-
cleaved VanSA in buffer – green line, His-tagged VanSA in TFE solvent – blue line.   
 
 
Fitting software for tag-cleaved VanSA gave values of 64% α-helix, 11% β-strand and 25% 
β-turn/random coil, therefore the cleavage did not greatly affect the fold, and may even 
improve protein stability. Addition of TFE further stabilises the fold, but only marginally, 
giving approximately 70% α-helicity, therefore the proteins were well folded in the DPC 
detergent chosen, and could be placed into crystallisation trials. 
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3.11 Determination of VanS Protein Activity by Coupled Enzymatic Assays  
 
Although the VanS protein samples are highly pure and well-folded, the ability of the protein 
to function as a kinase or phosphatase is often reduced when it is extracted from the bacterial 
membrane. Previous studies within the Warwick group (Quigley, 2010; Williams, 2007) 
found that the addition of detergent greatly hampered or prevented detection of the 
autophosphorylation and dephosphorylation rate of VanS proteins. Therefore it was critical 
to assess the activity of purified VanS proteins within a detergent environment prior to 
crystallisation or NMR studies, especially if potential ligands were to be added to samples.     
 
The first biochemical characterisation of VanSA autophosphorylation was conducted by 
Wright and co-workers (Wright et al., 1993), and similar autophosphorylation assays were 
adopted by Hutchings et al., (2006) to characterise VanSSC proteins. By adding radiolabelled 
[γ-32P]ATP into autophosphorylation reactions, both groups measured the amount of labelled 
VanS protein present after an incubation period, on SDS-PAGE gels. Phosphotransfer was 
also shown from the 
32
P-radiolabelled VanS protein to a VanR protein after a co-incubation 
period.  In order to avoid the potential difficulty of re-solubilising full-length VanS proteins, 
the groups studied the soluble C-terminal domain of each protein. Wright et al., (1993) 
expressed and purified the cytoplasmic C-terminal region of VanSA (VanSAΔ95) containing 
an N-terminal MBP-tag to assist protein folding, whereas Hutchings et al., (2006), expressed 
and purified the cytoplasmic domain of VanSSC (VanSSCΔ84) assisted by an attached His tag.  
 
Incubation of MBP-VanSAΔ95 or His-VanSSCΔ84 with [γ-
32
P]ATP, in the presence of Mg
2+
 
ions, allowed transfer of the labelled phosphoryl group to the protein, and phosphorylation 
was essentially complete after ~ 60 minutes. Kinetic parameters for the MBP-VanSA protein 
were determined by autoradiography and showed that the initial rate was first-order with 
respect to ATP, and analysis of the total 
32
P incorporated demonstrated that 10-15% of the 
protein was phosphorylated after one hour under saturating levels of [γ-32P]ATP.  
[150] 
 
A previous PhD student in the Warwick group, Dr. Andrew Quigley (2010), studied 
truncates of the VanSA protein using radiolabelling assays, to verify these kinetic parameters 
and examine the role of structural features in the kinase domain on activity. These truncates 
(and a control protein, MBP-VanSAΔ95) contained only the cytoplasmic domain (VanSAΔ95 
to VanSAΔ155) and were all active with respect to autophosphorylation, provided that the 
histidine site (H164) was present (see Figure 3.11.1). They also showed that ~15% of the 
MBP-VanSAΔ95 was phosphorylated after 60 minutes, but significantly less phosphorylation 
occurred for the truncates. Critically, no autophosphorylation could be observed for the full-
length kinase (C-His6-VanSA) purified into detergent micelles, and it was concluded that the 
His-site may have been occluded by the presence of excess detergent micelles.  
 
  
Figure 3.11.1: 14% acrylamide SDS-PAGE gel phosphoimage of VanSAΔ110 
autophosphorylation with time, reproduced from Quigley (2010). An equivalent  
SDS-PAGE stained gel was used to quantify band position (lane L1).  
 
Although radiolabelling methods are widely used in the literature to determine the activity of 
sensor kinases (Hastie et al., 2006), the technique does suffer from being non-continuous, 
and as such the value of the observed autophosphorylation is often undercalculated. The 
phospho-histidine bond is labile in acidic conditions, such as those during SDS-PAGE 
analysis, and phosphate can potentially be lost. For instance, Wright et al., (1993), showed 
by HPLC that the percentage of phosphorylation was underestimated by ~25%. 
[151] 
 
A more continuous measure of autophosphorylation can be obtained by spectrophotometric 
assays which can account for phosphate loss. These include quantification of ADP 
production using a coupled enzymatic assay, as developed by Wampler and Westhead, 
(1968) (see section 2.9.1), by monitoring changes in absorbance during oxidation of NADH 
to NAD
+
, as a result of ADP release. This can be coupled to a phosphate release assay, as 
developed by Webb, (1992), to account for any phosphate loss due to the lability of the 
phospho-histidine bond (see section 2.9.2). The ADP release assay assumes that resultant 
ADP is released after autophosphorylation (Marina et al., 2005), and the amount released 
enables quantification of autophosphorylation rate and stoichiometry. These assays were also 
tested by Quigley (2010), who found that against expectations, autophosphorylation was 
observed for purified full-length C-His-VanSA protein in DDM detergent (see Figure 3.11.2). 
 
 
Figure 3.11.2: ADP release profile of C-His6-VanSA full-length (green), VanSAΔ110 (blue) 
and VanSAΔ155 (red), extracted from Quigley (2010).  
 
To assess autophosphorylation activity of the N-His6-VanSA and N-His6-VanSSC proteins 
expressed in this PhD, a combination of ADP release and phosphate release assays were 
conducted for the full-length proteins purified into detergent micelles. Detergents chosen 
included DDM as a control, in which activity had already been observed for C-His-tagged 
VanSA, and DPC, as this was used throughout the PhD for crystallography and NMR studies.  
[152] 
 
3.11.1 ADP Release Assay 
 
Using the two continuous spectrometric assays, attempts were made to measure the 
autophosphorylation of purified VanS proteins in terms of ATP turnover. The assays 
measure phosphorylation indirectly by recording the release of ADP and inorganic 
phosphate. By subtracting the molar quantity of inorganic phosphate released from the molar 
quantity of ADP produced, a value can be obtained, which should correspond to the 
percentage phosphorylation of VanSA, provided no other products form. This relationship is 
shown in Reaction Scheme 1, as proposed by Wright et al., (1993). 
 
 
 
Reaction Scheme 1 
 
The assays are represented in Figure 3.11.1.1 ((a) – ADP release, (b) phosphate release). In 
the ADP release assay a decrease in absorbance at 340 nm is observed, whereas in the 
phosphate release assay, an increase in absorbance at 360 nm is seen. It is worth noting that 
the ADP release assay is cyclic as it involves regeneration of ATP, which provides a closer 
approximation to Michaelis-Menten kinetics.  By maintaining the level of ATP present in the 
cyclic reaction, the reverse reaction should be prevented, and should not affect 
autophosphorylation kinetics.  
 
 
VanS + ATP 
k1
k2
VanS  ATP. k3
k4
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k5 k6
Phos-VanS  + ADP
[153] 
 
 
Figure 3.11.1.1: Reaction pathways involved in (a) ADP production by ATP hydrolysis 
and (b) inorganic phosphate release by ATP hydrolysis. The assays are based on enzymes 
and substrates described by Wampler and Westhead (1968) and Webb (1992). VanS or ATP 
can initiate the reaction, which can be followed at 340 nm by monitoring oxidation of NADH 
to NAD
+ 
during ADP release, or at 360 nm by monitoring production of methylthioguanine 
during phosphate release. In the former reaction, ATP is catalytically regenerated by 
pyruvate kinase, whereas in the latter, all ATP is converted to ADP.  
 
ADP release was monitored at 340 nm on a UV spectrometer as detailed in section 2.9.1 for 
VanSA and VanSSC full-length proteins which had been purified (by IMAC) in 0.03% DDM 
(for comparison with activity data collected by Quigley, 2010), or in 0.07% DPC detergent 
(chosen from solubility screens) (Figure 3.11.1.2). Both proteins appeared active in these 
detergents, although the observed activity varied depending on how much detergent was 
present, and concentrating the samples sometimes led to unmeasurable rates of activity. It 
was found that provided the detergent concentration was minimized to 1.5x to 2x CMC (i.e. 
0.03% DDM and 0.07% DPC), the rate of ADP release could still be observed over a 
reasonable timescale. These experiments indicate that ADP is being released from VanS 
before VanR binding takes place.  
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As anticipated for a biochemical reaction involving a single substrate, the reaction curves 
display Michaelis-Menten kinetics, and asymptotically approach a maximum rate, indicating 
all enzyme has bound to substrate. However, the phosphorylation reaction is only around 
50% complete at 60 minutes. This much slower than the reaction observed by Wright et al., 
(1993) when assessing kinase activity of the cytoplasmic domain of VanSA, and by Quigley, 
(2010), when assessing the ADP release activity of full-length VanSA (see for Figure 3.11.2), 
who both found that phosphorylation reactions were essentially complete after 1 hour. It 
should be noted though, that the presence of excess micelles in the samples of detergent-
solubilised VanS proteins, is likely to hamper the ability of the VanS catalytic region to 
phosphorylate the conserved His-164 site.  
 
 
 
Figure 3.11.1.2: ADP release profile for full-length VanSA protein in 6 mM DDM (0.03 %, 
red) or 2 mM DPC (0.07%, green), and VanSSC protein in 2 mM DPC (0.07%, blue). 
nmoles of ADP released were calculated from the change in absorbance observed at 340 nm, 
as a result of NADH oxidation to NAD
+
 in the coupled reaction, using an extinction 
coefficient of 6220 M
-1
cm
-1
 at 340 nm for NADH. The reaction was initiated by the addition 
of 3 mM ATP into the final mix containing 50 μM (10 nmol) of VanS protein, and monitored 
over 300 minutes or until completion.     
  
[155] 
 
The rate and number of nmoles of ADP produced was found to be highest in DDM, over 
DPC detergent, but the reaction is slow in both detergents, and complete phosphorylation is 
only observed after ~ 2 hours. Furthermore, the nmoles of ADP produced is much higher 
than the nmoles of VanS protein used (10 nmoles) in assays, for instance VanSA in DPC 
detergent attained a maximum turnover of ATP of 29 nmoles. This indicates that the VanS 
protein may be losing phosphate at a high rate, which can be tested using the phosphate 
release assay (see section 3.11.2). It is assumed that the observed change in absorbance 
occurs from ADP release, and that this release is due to the action of VanS, which is likely, 
as the protein samples appeared relatively pure by SDS-PAGE, however this cannot be 
proven without an additional assay technique. As such, the nucleotide products from the 
reaction were also assessed by Anion Exchange Chromatography (see section 3.11.4).   
 
As a control measure for the ADP release assays, reactions were initiated by addition of ATP 
or VanS, to demonstrate that the absorbance changes observed are representative of a real 
event. The reversibility of this system is confirmed in Figure 3.11.1.3, which shows that the 
reaction can proceed by addition of enzyme or substrate, and ~60 moles of ADP are released 
in the reaction. There is however a slight difference in the profiles of the reactions, which 
could be due to differences in the rate of mixing in each reaction; a different volume of 
enzyme (20 μL) was added compared to substrate (6 μL) to initiate the reaction. The 
temperature for reactions in the spectrophotometer was also controlled and set at 20
o
C 
throughout, and the amount of protein per assay was fixed at 10 nmoles, in order to make 
direct comparisons with data previously collected by Quigley, (2010).   
 
 
[156] 
 
 
Figure 3.11.1.3: ADP release profile for full-length VanSA protein in 6 mM DDM (0.03 
%) produced upon initiation by either enzyme (green) or substrate (red). nmoles of ADP 
released were calculated from the change in absorbance observed at 340 nm, as a result of 
NADH oxidation to NAD
+
 in the coupled reaction, and using an extinction coefficient of 
6220 M
-1
cm
-1
 at 340 nm for NADH. The reaction was initiated by the addition of VanSA 
enzyme at 50 μM (10 nmoles, green line) or ATP at 3 mM (red line) into the final mix.    
 
3.11.2 Phosphate Release Assay 
 
The phosphate release assay was conducted as described in section 2.9.2 for the VanSA and 
VanSSC proteins, using consistent amounts of protein (10 nmol) (see Figure 3.11.2.1). In 
contrast to the ADP release reactions, all phosphate release appeared to be complete within 
30 minutes, and reaction profiles all started quickly initially then slowed after the first few 
minutes, reaching a maximum phosphate release between 6 and 12 nmol at around 25 
minutes, which must be related to the enzyme (VanS) or substrate (ATP) present, since the 
total MESG present in the reaction is 40 nmoles. This suggests that no more phosphate is 
released after 30 minutes.  
 
[157] 
 
For the VanSA protein in DDM detergent, 1.2 nmoles of phosphate is released for every 1 
nmol of protein, which suggests that either the phospho-histidine bond is extremely labile 
under these conditions, or a secondary reaction is taking place that also produces phosphate. 
 
    
 
Figure 3.11.2.1: Phosphate release profile for full-length VanSA in 6 mM DDM (0.03 %, 
red) or 2 mM DPC (0.07 %, green), and full-length VanSSC in 2 mM DPC (0.07%, blue). 
nmoles of phosphate released were calculated from the absorbance change observed at 360 
nm upon conversion of MESG to methylthioguanine in the coupled reaction, and an 
extinction coefficient for free phosphate of 10,000 M
-1
cm
-1
 at 360 nm.  
 
3.11.3 Assessing the Autophosphorylation of VanS 
  
The ADP release assay continues over a longer time course than the phosphate release assay, 
which could occur for several reasons. Firstly this could reflect the stability of the ADP 
bound state (VanS-ADP), over the phosphate bound state (His-P). In the structures of the 
cytoplasmic domains of histidine kinases (e.g. HK853 from T. maritima, see Figure 1.5.5.2), 
the His site on the dimerisation domain (DHp) is more exposed than the nucleotide binding 
site in the catalytic binding domain (CA) (see section 1.5.5) and the phospho-His bond 
[158] 
 
appears very labile (as shown in Figure 3.11.2.1). Therefore the rate of exchange of bound 
ADP for ATP is unlikely to the same as the rate of phosphate release. It is possible that VanS 
exists in an ADP bound state for a long time, and may be quite stable in that state. As the 
assay continues, the amount of free ATP to exchange with will reduce, and the assay will 
reach completion, but only after a long time.  
 
Secondly, the ADP release reaction continues even after all phosphate appears to have been 
released, which means that ATP should still be being turned over to ADP and phosphate, but 
this phosphate could remain bound to the protein (and not released). This could occur if there 
are multiple phosphorylation sites in the VanS protein, and would also help explain the very 
high percentage of protein phosphorylated (> 100 %) in Table 3.11.3.1 below.  
 
To analyse the amount of ADP and inorganic phosphate released during the reaction of VanS 
with ATP, values are tabulated at timepoints in both assays (see Table 3.11.3.1). Values for 
ADP release are tabulated at 25 minutes (at the end of the phosphate release reactions), and 
at 60 and 120 minutes. Approximately half the ADP release reaction was complete for both 
proteins at 60 minutes, and almost all ADP release had occurred by 120 minutes for VanS in 
DPC. The values at these timepoints were used to calculate the amount of phosphorylated 
protein, to compare with data obtained by Wright et al., (1993) and Quigley (2010) for the 
VanSA protein. Theoretically, the ratio of ADP release to phosphate release should be 1:0 if 
all phosphates are transferred to VanS, but it is known from the literature that some 
phosphate is released (Fisher et al., 1996), so the ratio may be expected to be slightly higher 
(up to 1:0.5 according to Fisher et al., 1996).  
 
  
[159] 
 
Table 3.11.3.1: ADP and phosphate release per assay for VanSA in DDM or DPC and 
VanSSC in DPC, recorded at 25, 60 or 120 minutes. NB Data for phosphate release is given 
at a 25 min timepoint, at the apparent completion of the reaction.  
 
 
 
Data in Table 3.11.3.1 shows that over the first 25 minutes, the ratio of ADP:phosphate was 
around 1:1, and the percentage of protein phosphorylated (except for VanSA in DPC) is 
predicted to be around 30%, which indicates a single phosphorylation event. However, the 
ADP release reaction did not reach completion at this point, which could reflect the stability 
of the ADP-VanS bond. By 60 minutes, the calculated ratio of ADP:phosphate is around 
2.5:1, suggesting a secondary product may also be forming.  Dr. Andrew Quigley, (2010) 
calculated a similar ADP:phosphate ratio (of 3:1) for the MBP-VanSAΔ95 protein over 60 
minutes, and showed that this could result from secondary product formation, by identifying 
the production of AP4 (adenine 5’-tetraphosphate) (see section 3.11.4). Finally, by 120 
minutes, the ratio of ADP:phosphate was 4:1, leading to a calculated percentage of 
phosphorylated VanS protein of 350%. This high ratio could simply indicate that ATP 
hydrolysis is occurring independently of VanS kinase activity, but it does raise the 
possibility of phosphorylation at multiple sites or the formation of secondary nucleotide 
products.  
Assay 
Time 
(min) 
Protein; Detergent ADP 
release 
(nmol) 
Pi 
release 
(nmol) 
Protein 
phosphorylated  
ADP:Pi 
ratio 
nmol % 
 
 
25 
VanSA; DDM 14.40 11.57 2.83 28 1.2:1 
VanSA; DPC 6.78 6.75 0.03 0 1:1 
VanSSC; DPC 11.88 7.95 3.93 39 1.5:1 
 
 
60 
VanSA; DDM 29.45 11.57 17.88 180 2.5:1 
VanSA; DPC 17.96 6.78 11.18 110 2.5:1 
VanSSC; DPC 23.77 7.95 15.82 160 3:1 
 
 
120 
VanSA; DDM 46.20 11.57 34.63 346 4:1 
VanSA; DPC 28.93 6.78 22.15 222 4.3:1 
VanSSC; DPC 31.81 7.95 23.86 239 4:1 
[160] 
 
Overall the data indicates that the purified VanS proteins are able to turnover ATP and 
exhibit autokinase activity, but there may be secondary reactions occurring or the protein 
may be phosphorylated at sites other than the conserved histidine site (His-164 in VanSA). 
Although multiple-site phosphorylation could not be assessed within the timecourse of these 
studies, anion exchange chromatography techniques were conducted to identify the 
nucleotide products in these reactions, including any secondary products, as detailed below. 
Methods to analyse phosphorylation at sites other than the active histidine site are outlined in 
the discussion in section 3.13.4. 
 
3.11.4 Identifying Nucleotide products using Anion Exchange Chromatography 
 
To identify nucleotide products formed during the reaction between VanS and ATP, reaction 
mixes containing the enzyme and substrate were set up and products formed were analysed 
by anion exchange chromatography. It was observed in previous autophosphorylation assays 
(Quigley, 2010) that a secondary product, AP4, was formed as identified by tandem MS 
analysis (see Figure 3.11.4.1). This nucleotide product can occur from addition of phosphate 
onto ATP. Under certain conditions, some enzymes involved in biosynthetic pathways have 
been shown to produce AP4, such as MurD (Bouhss et al., 1999) and MurE (Blewett, 2005). 
Formation of AP4 could explain the high ratio of ADP:phosphate release observed, and why 
the ADP release reaction continues to occur over 2 hours, whereas phosphate release appears 
to stop at 30 minutes, since phosphate produced could recombine with ATP and hence not be 
observed.   
[161] 
 
 
Figure 3.11.4.1: MS-MS spectra of ATP phosphorylation reaction of VanSA100 630 m/z, 
reproduced from Quigley (2010). Molecular weights can be assigned to fragments of ATP 
and there is a fragmentation pattern of the suspected AP4, confirming its formation. 
 
Simplified experiments were conducted involving only VanS enzyme and ATP substrate (i.e. 
ATP is not regenerated), and products were analysed for the presence of e.g. AP4, by anion 
exchange chromatography. Full details are given in section 2.9.3, but essentially, a reaction 
mix consisted of identical concentrations of VanS enzyme (10 nmol) and ATP (3mM) in the 
same buffer as that of the ADP release reaction.  Magnesium and potassium ions (important 
in complex formation) were also present, and the final volume was maintained at 200 μL and 
the incubation temperature set at 20
o
C. The reaction was monitored upon initiation with 
ATP, and all 200 μL samples were aliquoted from a master mix.  
 
At timepoints of between 0 and 480 minutes, a 200 μL aliquot was taken and quenched with 
25 mM EDTA (final concentration) pH 8, which chelates to the magnesium ions present. 
The sample was then applied to a fresh 5 kDa MWCO concentrator, and concentrated for 20 
minutes at 4000 g, to obtain the nucleotide products from the reaction in the flow through.  
[162] 
 
These products were then analysed by Anion Exchange Chromatography (IEX) on a MonoQ 
5/50 GL column, and identified against standards (AMP/ADP/ATP) (see Figure 3.11.4.2). 
To apply samples onto the loop, a fixed volume (of 80 μL) from the concentrator flow 
through was diluted with 1.3 mL of buffer A (10 mM ammonium acetate pH 7.6), and 
injected. Samples were applied under an isocratic gradient of 100% B over 30 minutes, and 
the absorbance at 280 and 254 nm was recorded.   
 
 
Figure 3.11.4.2: Anion-exchange chromatography profiles for nucleotide standards (200 
μM) applied to a pre-equilibrated MonoQ 5/50 GL column. Standards were run under a 
linear gradient of 0 to 100% B over 30 minutes, and remained at 100% B to elute any bound 
nucleotide products. A: 10 mM ammonium acetate pH 7.6, B: 1M ammonium acetate pH 7.6.  
 
For protein-containing samples, it was important to quench the reaction at the exact 
timepoint, and to use a fresh concentrator for each sample to avoid carryover of nucleotide 
products. This should enable the same amount of nucleotides to be present in each assay (i.e. 
the same total integral). The integrals of each peak at 254 nm and their retention time 
(relative to standards) allowed percentages of AMP/ADP/ATP/AP4 to be quantified (see 
Table 3.11.4.1A and Appendix Figure 6). Absorbance traces recorded for the ATP standard 
(0 min), or samples from reaction between protein and ATP are shown in Figure 3.11.4.3. 
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Figure 3.11.4.3: Overlayed anion exchange chromatograms collected at timepoints during 
reaction of VanSA with ATP, showing the relative amounts of nucleotide products. 
Timepoints (in minutes) are coloured as follows: 0  – purple, 60 – cyan, 120  – green, 360  – 
red and 480 – orange. The gradient of 0 – 100% B over 30 minutes is shown as a black line 
against a secondary axis.  
 
 
Table 3.11.4.1A: Relative peak integrals of nucleotide products observed over time by 
anion exchange chromatography upon addition of ATP to VanSA. The relative retention 
time of each peak is noted in the table at each timepoint.   
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Aliquot 
(min) 
AMP ADP ATP 
Peak 
(min) 
Area 
(%) 
Peak 
(min) 
Area 
(%) 
Peak 
(min) 
Area 
(%) 
0 12.2 0.0 20.2 5.9 27.1 94.0 
60 12.2 1.1 19.5 20.1 27.3 78.8 
120 12.2 5.8 19.6 28.8 27.4 65.4 
360 12.4 8.1 19.5 65.6 27.3 26.3 
480 12.4 9.5 19.4 71.3 28.0 19.2 
[164] 
 
The overlayed chromatograms of nucleotide products in Figure 3.11.4.3 illustrate the 
decrease in ATP present and concomitant increase in ADP formation. The turnover of ATP 
to ADP by the VanSA kinase is even more apparent when the percentage integrals of each 
nucleotide product are plotted graphically, as shown in Appendix Figure 6. In the graph, the 
change in ATP over time is exactly mirrored in the increase in ADP over time, 
demonstrating that the VanSA kinase is active with respect to ATP turnover.  
 
Detailed analysis of the reaction products, finds that at 60 minutes around 15% of the ATP 
moles had been converted to ADP moles (see Table 3.11.4.1A; ATP: 94.0 to 78.8%, and 
ADP: 5.9 to 20.1%). This reflects well with the stoichiometry of phosphorylated VanSA 
reported by Wright et al., (1993) for the VanSAΔ95 truncate, which showed ~15% of the 
protein was phosphorylated in one hour. By 120 minutes the level of ADP produced doubled 
to ~30% (and 30% reduction in ATP present), which also fits well with the activity data in 
Table 3.11.3.1 (ADP nmoles doubled from 60 to 120 minutes for VanSA in DDM).  
Unfortunately no AP4 reaction products could be observed using this technique, which 
would elute with a retention time >30 minutes (although a standard was not available to test), 
but it is possible AP4 may still be produced and requires another technique for identification.   
 
It is worth noting though that the level of AMP increased over time, from 0 to 10 % by the 
final sample, which may indicate a secondary reaction. To check that this was not just the 
result of ADP hydrolysis to AMP, control experiments were set up involving only the ATP 
standard (no VanS present) under identical conditions, which found that the level of AMP 
did not change significantly (data not shown). This indicated that the VanS protein may have 
been responsible for the increase in AMP present from ADP. To test this hypothesis, a 
reaction mix was set up containing 10 nmoles VanS and 3 mM ADP, in the same buffer and 
to the same final volume of 200 μL. Aliquots were quenched and nucleotide products 
analysed by anion exchange at each timepoint as before. Overlayed chromatograms are 
shown in Figure 3.11.4.4 and the integrals of each peak are recorded in Table 3.11.4.1B.  
[165] 
 
 
Figure 3.11.4.4.: Overlayed anion exchange chromatograms collected at timepoints during 
reaction of VanSA with ADP, showing the relative amounts of nucleotide products. 
Timepoints are coloured (in minutes) as follows: 0  – purple, 120 – cyan, 240 – green, 360  – 
red and 480  – orange. The gradient of 0 – 100% B over 30 minutes is shown as a black line 
against a secondary axis. Identified peaks of AMP and ADP products are staggered by 0.25 
min (15 s) between each set of peaks, in order to show peak changes more clearly.  
 
 
Table 3.11.4.1B: Relative peak integrals of nucleotide products observed over time by 
anion exchange chromatography upon addition of ADP to VanSA. The relative retention 
time of each peak is noted in the table at each timepoint.   
 
 
Aliquot 
(min) 
AMP ADP 
Peak (min) Area (%) Peak (min) Area (%) 
0 11.0 11.6 17.6 88.4 
120 11.2 15.2 18.0 84.8 
240 11.5 18.1 18.3 81.9 
360 11.8 20.1 18.6 79.9 
480 12.0 21.0 18.8 79.1 
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It is apparent from the overlayed chromatograms in Figure 3.11.4.4 that in the presence of 
ADP, there is a correlation between the level of AMP produced and the reduction in ADP 
present. As observed for the VanS sample in the presence of ATP, the level of AMP present 
increases by ~10% by the final sample. To test for ADP hydrolysis, control experiments 
were again set up involving only ADP standards (no VanS present), under identical 
conditions, which also did not show any appreciable changes in ADP or AMP present (data 
not shown). Therefore the AMP produced must result from a reaction between the VanS-
containing sample and ADP. There are no reports in the literature of a histidine kinase that is 
able to convert ADP to AMP, as this would involve removal of a high energy phosphate, and 
would not be beneficial to cellular response or growth. It therefore remains unclear how the 
purified VanS protein could cause AMP production. 
 
One kinase that is known to convert ADP to AMP is adenylate kinase, which is present in E. 
coli bacteria (Krishnamurthy et al., 2005) (and in mammalian cells), and responds to a 
reduction in the level of ATP available in the cell. When the ATP in the cell is consumed 
faster than it can be replenished (or in this experiment, is not regenerated), and the 
concentration of ADP is increased, adenylate kinase responds by converting two molecules 
of ADP, into ATP and AMP. This supplies the cell with energy, and lowers the ADP 
concentration, with the by-product of AMP. Therefore it is possible that in the anion 
exchange experiments conducted, an expressed E. coli protein such as adenylate kinase may 
be present in the detergent-solubilised VanS sample, which increases the level of AMP, in 
the limit of high ADP and very low ATP concentrations. If this is the case, AMP is unlikely 
to be a secondary product in the ADP release reaction, as ATP is constantly regenerated.   
 
Further techniques are required to identify suspected secondary products in the ADP release 
reaction, which could include tandem MS analyses, or the use of radiolabelled assays to 
determine if other impurity proteins extracted in the detergent micelles are also responsible 
for the high ADP:phosphate ratio calculated and nmoles of ADP produced.   
[167] 
 
Overall both N-His-tagged VanS proteins have been shown to be active with respect to 
autophosphorylation, and anion exchange data clearly shows that ATP is being converted by 
VanSA to ADP. This indicates that in the presence of detergent micelles, the kinase can still 
bind ATP molecules and turnover ADP. Crystallisation trials were conducted with the active 
VanS proteins (after cleavage of the His-tag), with a view to determine the structure of the 
kinase or fix it into a single state. Active His-tagged protein was also used in NMR titration 
studies, to assess the potential of antibiotics to bind to VanS (as discussed in chapter 5).  
 
3.12 Crystallisation Screens 
 
Crystallisation trials were set up on 96-well MRC or Greiner plates at either at the University 
of Warwick using a Honeybee 963 crystallisation robot, or at the Integral Membrane Protein 
facility, at the Structural Genomics Consortium (Oxford) using a Mosquito robot. MemGold 
and MemStart screens designed towards crystallisation of membrane proteins were tested, 
both of which use the sitting drop method of vapour diffusion crystallisation (see section 
2.13.1). Initially, active tag-cleaved VanSA purified in 0.07% w/v DPC detergent (from gel 
filtration chromatography) was concentrated in a 50 kDa MWCO PES concentrator, and 
added to MemGold plates using the Mosquito robot (SGC) to give sitting drops of 0.2 μL of 
protein mixed with mother liquor (100 μL per well), at drop ratios of 1:1, 2:1 or 0.5:1 
(protein:precipitant) (effectively 7, 14 and 28 mg/ml). All trials were carried out at 18
o
C, as 
this temperature gave hits in previous studies of C-His6-VanSA (Williams, 2007). 
  
On a second plate, the same drop ratios were used but with addition of AMP-PNP (an ATP 
derivative, Figure 3.12.1) (Wikstrӧm, 2005) to a final concentration of 5 mM. The ATP 
derivative is a stable non-hydrolysable analog of ATP, and was used to try to fix the VanS 
into an active phosphorylated conformation, and provide a ‘snapshot’ of this state during the 
catalytic cycle. This approach has been successful in studies of other histidine kinases e.g. 
PhoQ (Marina et al., 2005), HK853 (Marina et al., 2001) and CheA (Bilwes et al., 2001).  
[168] 
 
It was hoped that by purifying the tag-cleaved VanSA protein into DPC detergent at the 
min1.5x CMC), greater protein-protein contacts could be formed than that in DDM 
detergent, as used in previous trials (see Figure 3.6.5), which could increase stability of the 
crystal packing.  
 
 
 
Figure 3.12.1: AMP-PNP structure. This differs from ATP by replacement of an oxygen 
between β- and γ-phosphate groups with a nitrogen (red), which is very slowy hydrolysed. 
 
 
Crystal trays were therefore set up at the SGC (Oxford) at 18
o
C, containing the tag-cleaved 
VanSA proteins in DPC (from the pProEx::vanSA construct), in the presence or absence of 
AMP-PNP. Some potential crystals or crystallites formed in DPC detergent (see Figure 
3.12.2), which were analysed on a beam line at Diamond Light Source (UK), with help from 
collaborators at the SGC. However, these were all found to be detergent crystals. 
Crystallisation trials were repeated with freshly purified tag-cleaved VanSA proteins using 
MemStart or MemGold screens at the University of Warwick, in DPC (9.1 mg/ml), or in 
DDM (6.4 mg/ml) (see Table 3.12.1). But again these also did not provide any crystals. 
Protein samples in DDM showed a large proportion of clear drops on crystal trays and may 
not have reached supersaturation, as the concentration was relatively low. Furthermore drop 
dispensing using the in-house Honeybee 963 crystallisation robot was not uniform due to the 
presence of detergent bubbles.  
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Table 3.12.1:  Concentrations of detergent-purified, tag-cleaved VanSA proteins used in 
crystallisation screens. All proteins were purified in detergents at 1.5-2 times their CMC. 
 
   Construct Detergent Screen chosen Concentration in Screen 
VanSA 0.07% DPC MemGold 13.8 mg/ml, 9.1 mg/ml 
VanSA 0.07% DPC MemStart 13.8 mg/ml, 9.1 mg/ml 
VanSA 0.03% DDM MemGold 6.4 mg/ml 
VanSA 0.03% DDM MemStart 6.4 mg/ml 
 
 
 
 
Figure 3.12.2:  A selection of promising crystallisation conditions for VanSA proteins 
solubilised in 0.07% DPC on MemGold 96-well screens. (A) 0.02 M CaCl2 /0.01 M MgSO4 
/0.02 M NaCl, 0.02 M MES pH 6.5, 7.7% PEG 1500 (w/v), (B, C and D) 0.1 M CaCl2, 0.1 
Tris pH 6.5, 13% PEG 2000 MME (w/v), (E) 0.2 MgCl2, 0.1 M Tris pH 8.5, 25 % PEG 4000 
(w/v), (F) 0.1 M NaCl/0.325 M Sodium Acetate, 0.1 M Tris pH 8.0, 21 % PEG 400 (v/v). 
 
A selection of crystallites which appeared promising, and their conditions is given in Figure 
3.12.2. In the figure, the crystal in panel A appeared promising, but did not diffract and was 
found to be a salt crystal. In panels B – D, crystallites appeared at low concentration (D - 7 
mg/ml) but more structured crystals were formed at 14 mg/ml and above (B/C). All of these 
were tested on the beam line but found to be detergent crystals. In panels E and F (14 
mg/ml), coloured crystallites formed after several weeks. These were not tested at the time, 
(A) (B) (C)
(D) (E) (F)
[170] 
 
but examination by eye of the crystal hits obtained at York University using the C-His-
tagged VanSA sample, finds that either cuboid (Figure 3.6.5 C/D, pH 4.5) or a dipyramid-like 
crystallites formed (Figure 3.6.5 A, pH 8.5), and the possible hits in Panels E and F above 
(Figure 3.12.2 E/F, pH 8 – 8.5) appear to show a similar dipyramid-like shape. Therefore 
crystal shape may depend on pH, but the use of DPC detergent does not seem to improve 
conditions compared to DDM, and the crystal hits obtained previously still appear the most 
promising. Crystallisation of the VanS membrane protein with or without bound ligand 
(ATP) clearly requires a wider screen of detergents such as maltosides, glucosides and other 
classes. Further collaboration with membrane protein research groups such as those at the 
Structural Genomics Consortium is needed to have a chance of crystallising this protein, as 
they can provide the specialist expertise and state-of-the-art equipment needed to rapidly 
screen multiple detergents and conditions for crystal hits.      
 
3.13 Discussion 
 
Recombinant E. faecium VanSA and S. coelicolor VanSSC proteins were successfully cloned 
into pProEx HTa vectors, and overexpressed as N-hexahistidine-tagged proteins with tag-
cleavable TEV linkers, in E. coli C41(DE3).pRIL cells. Both proteins were purified to 
homogeneity by two chromatographic steps: immobilised metal affinity chromatography, 
followed by size exclusion chromatography, and their identities confirmed by LC-MS data. 
Autophosphorylation activity of purified N-His6-VanS proteins was assessed by a 
combination of ADP release and phosphate release spectrophotometric assays and found to 
be active in DDM and DPC micelles. The protein activity was dependent on the detergent 
chosen, with a reduced rate observed in DPC micelles, but overall the time course for ATP 
turnover was ~ 2 hours. Subsequent cleavage of active protein with TEV protease gave the 
wild-type protein, and a final purification step provided relatively pure (>90%) protein 
samples, which were applied to sparse matrix screens and allowed to form crystals by vapour 
diffusion crystallisation, in an attempt to improve on the 8Å resolution previously obtained.  
[171] 
 
3.13.1 Approaches to express and purify VanS proteins for crystal studies  
 
N-His-tagged VanSA and VanSSC recombinant proteins were successfully expressed by using 
the C41 Walker strain, which is optimised for membrane proteins, and by adding 0.2% w/v 
glucose, to prevent ‘leaky’ expression. The use of anti-His Western blots showed that VanS 
protein expressed at 37
o
C (in line with previous protocols in the Warwick group) was often 
insoluble and not visible on anti-His antibodies (presumably as the His-tag was occluded). It 
was found that the level of soluble VanS proteins could be greatly increased by lowering the 
induction temperature (to 16
o
C for VanSSC and to 25
o
C for VanSA) and growing overnight. 
The use of novel ‘N-terminal preferential’ anti-His antibodies also improved visualisation of 
the N-His-tagged VanS proteins during all stages of purification. In addition, detergent 
solubilisation of VanS proteins was optimised through screening, and selecting DPC 
detergent, which was found to solubilise much greater quantities of VanS protein than 
previously adopted maltoside detergents. This enabled yields of purified VanSA protein to be 
increased to 3 mg/L, compared to ~1 mg/L observed by Quigley (2010) in DDM. The high 
solubility of VanS proteins in DPC is very desirable for NMR studies (see Chapter 5) since a 
large number of membrane protein NMR structures have been solved in this detergent.  
 
High yields of VanS proteins of potential crystallisation-quality were produced in DPC 
detergent. These proteins exhibited all the desired qualities for crystallisation; they were 
homogenous, with the correct helical fold and appeared active with respect to 
autophosphorylation. The use of a TEV cleavable linker in the expressed protein also 
enabled cleavage and purification of the wild-type protein for use in crystal trials. This 
avoided any potential contamination with histidine-rich proteins such as AcrB which often 
crystallise preferentially. Despite these efforts, no VanSA crystals were obtained in these 
studies in DPC or DDM detergents tested, which is a large set back in improving the 8Å 
resolution of the VanSA diffraction pattern. The overriding issue appears to be the formation 
of detergent crystals in crystal screens.  
[172] 
 
3.13.2 Screening crystallisation of VanS proteins from multiple species 
 
Another approach towards obtaining an X-ray crystal structure is to screen a protein target 
from multiple species (Benvenuti & Mangani, 2007). It would have been useful to screen 
VanS proteins derived from S. coelicolor (and other species such as E. faecalis). However, 
expression of soluble VanSSC protein proved more difficult than VanSA, for which initial 
expression protocols had already been given (Quigley , 2010). Although not discussed at 
length in this chapter, a number of different routes were pursued to improve VanSSC 
expression including different cell lines such as BL21(DE3).pLysS, as previously used in 
expression studies by Koteva et al., (2010), and the use of chaperonins: the GroEL-GroES 
double-ring system of E. coli (Xu et al., 1997, PDB: 1AON) to assist in protein folding. 
Unfortunately, the level of soluble protein expressed was not greatly increased by these 
changes, and growth under multiple antibiotics in the GroEL-GroES system actually led to 
reduced yields. The optimal expression conditions were found to be 16
o
C in C41 (DE3) 
pRIL cells for ~ 20 hours (see Figure 3.6.8), which produced around 1 mg of purified 
VanSSC per litre of culture. As a result of the low yield, crystal trials were not attempted with 
VanSSC, but if yields could be further improved, it could be a candidate in future screens. It 
should be noted that the vanSSC gene was not codon-optimised, and contained several rare 
codons, so this could improve expression levels of soluble protein. 
 
Another possibility for crystallising VanS proteins would be to add a fusion tag. Membrane 
protein-GFP fusions allow monitoring of the protein directly throughout the purification 
process (Drew et al., 2008) for instance in fluorescence size-exclusion (FSEC) studies. This 
allows analysis of the effects of different detergents on the chromatogram shape, in order to 
select those with sharp, single peaks for use in crystal trials (Kawate & Gouaux, 2006). In 
addition, MBP fusions can be used as ‘scaffolds’ to induce crystallisation (Smyth et al., 
2003), e.g. for proteins such as SarR (Liu et al., 2001). MBP crystallises readily and can be 
attached to proteins of interest to induce crystal contacts and provide co-crystal structures. 
[173] 
 
3.13.3 Activity of VanS and its crystallisation is affected by detergent micelles 
 
Crystallisation assays have been affected by the presence of excess detergent, which has led 
to a lack of protein crystals in the screen, and a large number of detergent crystals. Attempts 
were made to lower the detergent concentration to 2x CMC (0.03 % w/v DDM or 0.07 % 
w/v DPC), and use appropriate concentrators e.g. 100 kDa MWCO concentrators for samples 
in DDM detergent (micelle size: 50-70 kDa) to avoid concentrating the detergent. However, 
no protein crystals were observed in any membrane protein screens.   
 
Activity assays also appeared to be affected by the presence of detergent, which increased 
the reaction time for autophosphorylation, as measured by ADP release assays, from 60 
minutes for the cytoplasmic domain of VanSA (MBP-VanSAΔ95 tested by Quigley (2010), 
(see Figure 3.11.2) to ~120 minutes for the full-length VanSA protein in DPC micelles (see 
Figure 3.11.1.2). This may be due to reduced access to the ATP binding site, in the presence 
of excess detergent micelles, or possibly a long-lived ADP bound state (see section 3.11.3).  
 
The activity data presented in this thesis is however qualitative and requires additional 
experiments to determine the kinetic parameters for the binding of ATP to VanS, such as the 
Michaelis-Menten constant (KM), the turnover number of substrate to product (KCAT) and the 
maximal velocity (VMax). These values could be obtained by measuring the rate of activity at 
increasing concentrations of ATP (around the KM value of 0.62 mM observed by Wright et 
al., 1993) e.g. 0.25 to 6 mM, and plotting the resulting substrate versus velocity profile. 
Attempts were made to obtain this data, however measurements of ADP release for VanSA 
and VanSSC proteins gave variable rates even at constant ATP concentrations, since the 
detergent-containing sample was difficult to accurately pipette without creating air bubbles 
during experiments. Therefore there is a need to obtain consistent measurements in a specific 
detergent before a full kinetic analysis can be achieved.  
[174] 
 
In addition to ADP/phosphate release assays, a new antibody has just been developed which 
allows identification of phospho-Histidine bonds by Western blotting (Kee et al., 2013). 
Despite the development of a number of assays to identify phosphorylation of serine, 
threonine and tyrosine kinases, there has been a lack of available tools to study histidine 
kinase phosphorylation, which has been attributed to the chemical instability of the 
phosphoramidate linkage at the histidine residue to acid.  However, Kee et al., (2013), have 
raised antibodies which are specific to the pHis modification, and showed that this antibody 
could be used to detect histidine phosphorylation of the HK KinB in vitro and in vivo (in 
native cell lysates) on Western blots. Anti-pHis Western blotting would enable higher 
throughput studies of the VanS histidine kinase, and is therefore suggested as future work 
(see section 6.6) to act in place of more hazardous radiolabelling studies using [γ-32P]ATP. 
 
3.13.4 Possibility of secondary reactions during VanS autophosphorylation  
 
ADP and phosphate release assays recorded for purified VanSA and VanSSC proteins gave a 
ratio of ADP:phosphate of around 1:1 over the first 25 minutes (see Table 3.11.3.1). 
However, although all phosphate appeared to be released within this time, ADP release did 
not reach completion until much later. Indeed, the ratios of ADP:Pi were calculated as 4:1 by 
the completion of the ADP release reaction, and the percentage of VanS phosphorylated was 
calculated as ~300%. These values are much higher than anticipated, and possible 
explanations include: the formation of secondary (nucleotide) products, which will affect the 
observed UV absorbance at 340 nm, or perhaps phosphorylation of VanS at multiple sites, 
including the active His site, thereby increasing the percentage phosphorylation above 100%.    
 
  
[175] 
 
In order to investigate the possibility of secondary product formation during 
autophosphorylation, reactions involving samples of VanSA enzyme and ATP substrate were 
analysed over a time course by anion exchange chromatography. By adding a fixed amount 
of ATP into reactions (i.e. ATP is not regenerated), it was shown by this technique that the 
percentage increase in ADP nucleotides directly correlated with a percentage decrease in 
ATP substrate present (see Appendix Figure 6).  
 
It was hoped that AP4 formation could be observed using this method, which is a secondary 
product that had been observed during autophosphorylation of VanSA in previous studies 
(Quigley, 2010). This can form by the recombination of free phosphate with ATP molecules, 
and would reduce the amount of free phosphate present, and thereby fit with the observed 
phosphate release data. However, AP4 could not be identified by this method, and instead 
the only secondary product that was observed was AMP, which formed even upon addition 
of ADP (rather than ATP) to purified VanS samples. There are no reports of histidine 
kinases that can convert ADP to AMP, and the only known enzyme that catalyses this 
reaction is adenylate kinase, so it remains unclear how AMP is produced in the reaction, and 
it may only occur in response to conditions of low ATP availability (refer to section 3.11.4). 
The formation of AP4 may still be occurring, which may be identified by other techniques 
such as mass spectrometry, and secondary reactions would account for the high percentages 
of VanS phosphorylation calculated (> 100%) and ADP:phosphate ratios observed. With 
hindsight, it would also have been useful to see if the ADP release reaction could be 
abolished by addition of EDTA (which complexes to Mg
2+
 ions), to see if secondary 
reactions were occurring, and causing a higher than expected absorbance change. 
 
The second possibility for the observed activity data is multiple-site phosphorylation. This 
was not assessed in these studies due to time restrictions, but is known to occur for some 
protein kinases, and at sites other than histidine such as serine, threonine or tyrosine, e.g. the 
serine/threonine kinase MSK1 is phosphorylated on at least six sites (McCoy et al., 2005). 
[176] 
 
Multiple-site phosphorylation could be tested by two routes. Firstly, tandem mass 
spectrometry techniques could be used to identify residues that have been phosphorylated.  
In the simplest site mapping experiment, a purified protein is proteolytically digested at 
defined sites to produce small peptides, and tandem mass spectrometry can be used to 
measure the masses of intact peptides and fragment ions. Computer algorithms are then used 
to identify phosphopeptides by matching the experimental data to theoretical spectra derived 
from sequence databases (that consider all possible phosphorylated versions of the peptide). 
(Dephoure et al., 2013).  Secondly, site-directed mutagenesis could be used to identify other 
phosphorylation sites in the absence of the active histidine residue. Studies by Haldimann et 
al., (1997) have already shown that replacement of the His-164 site in VanSA with a 
glutamine residue (H164Q) led to a loss of kinase activity. Therefore the creation of this 
mutant could provide support for the observed activity data; no activity should be expected 
for the detergent-purified VanSA H164Q mutant unless a secondary phosphorylation reaction 
is occurring that does not require the presence of the conserved histidine residue.       
 
  
[177] 
 
4 Structural Studies of the VanS sensor domain by solution-
state NMR spectroscopy 
 
4.1 Introduction 
 
Membrane proteins include receptors, ion channels, transporters, and enzymes, and 
constitute a significant fraction (20%–30%) of the proteome (Fagerberg et al., 2010). 
However they are highly underrepresented, and make up less than 1% of all protein 
structures solved. As of July 2014, there were 878 published reports of membrane protein 
structures (491 unique)  solved by NMR or crystallographic techniques 
(http://blanco.biomol.uci.edu/mpstruc/), out of a total of 100,000 protein structures deposited 
in the Protein Data Bank (PDB) (http://www.rcsb.org/pdb/). This is not due to a lack of 
biological importance, since membrane protein receptors represent the targets of over half of 
all known drugs (Bakheet & Doig, 2009; Yildirim et al., 2007), but due to the challenges 
associated with expressing and purifying large enough quantities for structural study.     
 
By nature, integral membrane proteins (IMPs) contain hydrophobic regions, and are often 
flexible and unstable, which causes difficulties in studying them. The proteins are embedded 
in a lipid membrane which varies in composition and constitutes only ~10% of the cytosolic 
volume (or ~5% for the plasma membrane) (Alberts et al., 2002) therefore the environment 
for transmembrane protein function is highly specialized, and there is a need to select 
appropriate membrane mimetics in order to structurally characterise each membrane protein.  
 
Of the membrane protein structures deposited, structures of the membrane-spanning sensor 
domains of histidine kinases are poorly represented. Structural analysis by both NMR and X-
ray methods is hampered by inherent difficulties. The mobility of TM helices causes strong 
broadening of NMR signals and reduces spectral quality and resonance assignment, and 
diffraction quality crystals are hard to obtain because solubilised protein-detergent 
complexes do not usually form ordered lattices (Maslennikov et al., 2010).  
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However, a few NMR structures have been obtained for the transmembrane domains of 
histidine kinases e.g. ArcB, QseC, KpdD (Maslennikov et al., 2010) (see Figure 4.1.1). 
There are also X-ray crystal structures for HK sensor domains e.g. PhoQ, NarX, TorS 
(Cheung & Hendrickson, 2009; Moore & Hendrickson, 2009) (see section 1.5.3).  
 
Figure 4.1.1: NMR backbone structures of TM domains of two classes of histidine kinase. 
QseC (class I, PDB: 2KSE) and ArcB (class II, PDB: 2KSD) are drawn in cartoon form.   
 
 
Significant advances in expertise relating to the handling and analysing of membrane 
proteins in vitro over the past few decades have contributed to the solution of membrane 
protein structures. By screening buffer, pH and detergent conditions in protein analysis, the 
aggregation (or oligomerisation) state of the material can be monitored using gel filtration, 
electron microscopy or ultracentrifugation (Gutmann et al., 2007) in order to choose a 
detergent that extracts a large quantity of soluble, active, homogeneous and stable protein. In 
addition, improved methods are being developed to address bottlenecks in expression and 
solubilisation, such as the use of GFP or MBP-fusion constructs (Drew et al., 2008) and 
novel detergents e.g. lyso-phospholipids (derivatives of natural E. coli lipids) (Krueger-
Koplin et al., 2004), and in crystallisation, the use of robots for high-throughput screening. 
The effect of these advances is highlighted by the exponential increase in the number of 
membrane protein structures deposited in the PDB, since the first structure was added 
(Deisenhofer et al., 1985) (see  http://blanco.biomol.uci.edu/mpstruc/). Therefore membrane 
proteins have become more realistic targets for NMR or crystallographic study.  
ArcBQseC
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This chapter details the structural study of the sensor domains of VanS histidine kinases 
derived from E. faecium and S. coelicolor by solution state NMR techniques, using a number 
of these buffer, pH and detergent screens, in order to obtain homogeneous, well-folded and 
stable proteins. To the best of knowledge, there are currently no NMR structures of VanSA or 
VanSSC proteins in the literature, or any details of protocols to overexpress and purify the 
two proteins in labelled media, as required for NMR analyses. Therefore the data presented 
in this chapter illustrates a route for high yields of isotopically (
15
N) labelled VanS proteins 
and provides the first high resolution NMR spectrum of VanSA and VanSSC sensor domains. 
 
The full-length VanSA/VanSSC proteins are 40-47 kDa in size and would therefore not be 
easily amenable to study by solution NMR, since the spin-spin relaxation rate (T2) would be 
very rapid, causing significant line broadening and overlapping signals from the nuclei. An 
ideal protein size would be around 10 - 20 kDa (or ~100 residues), to enable individual peak 
shifts to be discerned and assigned by two- and three-dimensional NMR techniques, 
especially since solubilisation in detergent micelles will further reduce tumbling rates in 
solution and hence decrease spectral resolution. Therefore, although the structure of a full-
length VanS kinase would be beneficial to understand structural aspects of VanS catalysis, 
the main area of focus has been to obtain structural information on the isolated sensor 
domain of the VanS protein, and to examine binding of glycopeptide ligands to this domain. 
It should be noted that the recent development of TROSY (Transverse Relaxation Optimized 
Spectroscopy) techniques (Tian et al., 2005; Eletsky et al., 2001) has allowed two-
dimensional NMR analyses of proteins above 30 kDa in size, and towards 100 kDa (Riek et 
al., 2002; Tugarinov et al., 2004), but significant reduction in protein yields are often 
observed since TROSY techniques usually require protein labelling with addition of 
2
H, by 
growing bacteria in D2O, and were therefore not tested in this study.  
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Experiments by Koteva et al., (2010) have indicated that S. coelicolor VanS proteins bind 
directly to vancomycin derivatives (see section 1.4.2), therefore this protein could act as a 
positive control in NMR-based ligand binding experiments, to establish whether VanSA 
proteins are also activated by direct binding or if they are activated via an indirect route. 
NMR studies were therefore conducted on the VanS sensor domain of each protein (without 
the C-terminal kinase domain), since this is below 20 kDa in size and contains the 
extracellular loop region of the protein, which is the only domain accessible region to 
glycopeptide antibiotics. Expression and purification of the isolated sensor domain would 
then enable protein-ligand binding studies using isotopic labelling methods and two-
dimensional solution-state NMR methods. Since it was not known how any ligand binding 
would affect the conformation of the protein, it was beneficial to study the isolated sensor 
domain which (due to its size) should allow individual peak shifts to be observed. 
   
4.2 Aims 
 
(i) To genetically modify vanS sequences in order to obtain the isolated sensor 
domain for structural study by solution state NMR.  
(ii) To provide a route for overexpression and purification of VanS sensor domains 
in labelled M9 minimal media, for use in solution state NMR studies. 
(iii) To obtain high resolution NMR spectra of the VanS sensor domain in detergent 
micelles, using two-dimensional NMR methods, and to optimise spectral quality 
by screening detergents, buffers, pH and temperatures.  
(iv) To assign individual amino acids in the VanS protein using 3D NMR methods.   
[181] 
 
4.3 Gene Modification of vanS sequences to create NMR-relevant constructs 
 
Constructs were created which encoded only the VanS sensor domain, by using PCR 
techniques (section 2.4.1) to amplify the N-terminal section of the full-length vanS gene, 
contained within pProEx::vanS constructs (see section 3.3). PCR reactions were set up using 
pProEx forward primers (‘pProEx For’), and reverse primers that encoded amino acids in the 
vanS sequence directly after the second TM domain (e.g. ‘VanSA110 Rev’, see Table 2.4.1). 
These reverse primers terminated in a Stop codon, and therefore PCR amplification would 
provide the N-terminal sensor domain, containing both transmembrane helices, followed by 
the stop codon. The transition from transmembrane to cytoplasmic residues is predicted to 
occur after Ser-97 in VanSA and after Gly-86 in VanSSC sequences, but as this is only a 
prediction, amplified sections of the genes were chosen to include (approximately) a further 
10 amino acids after these residues to ensure both transmembrane domains would be 
complete in the final constructs. Therefore the first PCR products encoded vanS gene 
residues from Met-1 up to Ile-110 (for VanSA) and Met-1 up to Arg-100 (for VanSSC).  
 
It was also important to design different length vanS truncates, and quantify the level of 
expressed protein from each, since the amount of protein expressed will be reduced when 
residues in the extramembranous domains are truncated, and the resultant protein may be 
inserted into the membrane incorrectly or improperly folded. Proper assembly of a truncated 
membrane protein depends on features charge and hydrophobicity, and other factors e.g. the 
rate of folding. TM domains have high overall hydrophobicity, and are flanked by 
hydrophilic loop residues as governed by the “positive inside” rule (non-translocated loops 
are enriched in positively charged residues compared to translocated loops) (von Heijne G., 
1992). Therefore the TM domains reduce protein solubility, whereas the loop regions 
increase the overall solubility. For these reasons, two additional PCR products were designed 
from VanSA and VanSSC sequences, to include residues up to Gln-120 or Met-130 for VanSA 
and Arg-110 or Tyr-120 for VanSSC, (see Table 2.4.1) to compare expression levels of each.  
[182] 
 
PCR products were generated for the N-terminal sensor domains of VanSA and VanSSC by 
amplification from the full vanS length gene (section 2.4.1), which was subsequently purified 
(section 2.4.5) and analysed by agarose gel electrophoresis, as shown in Figure 4.3.1. The 
resulting shortened vanS genes were ~400 bp in length, and required further purification by 
gel extraction. These were ligated into fresh, double-digested (NcoI, HindIII) pProEx HTa 
vectors, to test expression of the VanS sensor domain (as detailed previously in section 3.3).  
 
 
 
Figure 4.3.1: Purified PCR products from amplification of vanSA, encoding the N-
terminal His6 tag, TEV site and the first 110, 120 or 130 amino acids of the protein 
sequence. MR – 1 kb GeneRuler DNA ladder, Lane 1 - SA110, Lane 2 - SA120, Lane 3 - 
SA130. Position of the N-terminal VanSA bands is indicated by a red arrow at ~400 bp.   
 
 
The ligation mixture was used to transform E. coli TOP10 cells (Table 2.2.2.1) (section 2.3) 
and extract DNA from positive transformants by minipreparations (section 2.4.4), which 
were analysed by Sanger sequencing (section 2.4.8), both to confirm sequence identity and 
ensure the vanS sequences were in-frame and without DNA mutations. These constructs 
were then tested for recombinant expression of the isolated sensor domain in a range of E. 
coli cell lines and at different [IPTG], using the protocol in section 2.5.1. The resulting 
overexpressions were analysed by Western blotting (section 2.6.3), as shown in Figure 4.3.2.  
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Figure 4.3.2: Western blots showing levels of overexpression of VanSA110, 120 or 130 
after Water Lysis preparation. 40mL cultures were grown overnight at 25
o
C and 
resuspended in 2ml of phosphate buffer pH7.5 and blotted. Induction was with 0.2mM IPTG 
(lanes 1, 3, 5) or 1mM IPTG (lanes 2, 4, 6), in BL21(DE3) (Lanes 1, 2), C43(DE3) (Lanes 3, 
4) or C41pRIL(DE3) (Lanes 5, 6). MR – Benchmark His-tagged ladder (Invitrogen). 
Overexpressed full-length N-His6-VanSA was added as a positive standard (+). 
 
In contrast to the positive standard (full-length N-His6-VanSA annotated as ‘+’), which was 
expressed under the same conditions and loaded at the same volume, the expression levels 
for VanSA proteins were greatly reduced, which shows the impact of the soluble C-terminal 
domain upon expression. In terms of expression level, the SA120 construct produced the 
highest yield, and as observed with the full-length proteins, 0.2 mM IPTG inducer was again 
the optimal concentration (see for Figure 3.4.2).    
 
By analysing vanS gene sequences using RONN (Regional Order Neural Network) disorder 
prediction software, it was found that disordered regions are predicted to exist for VanSA 
between residues 130-155, and for VanSSC between residues 97-120 and 141-171 (Figure 
4.3.3). These disorder predictions suggest a reason why SA130 expresses at far lower levels 
than SA120, and similarly why SSC 120 expresses better than SSC110 (data not shown). It is 
also likely that SA110 does not express as highly as SA120, because this truncation is closer 
to the membrane-spanning residues and could affect protein insertion or folding.   
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(a) 
 
(b) 
 
 
Figure 4.3.3: Disorder prediction plots for VanSA (a) and VanSSC (b) using RONN 
software. Major regions of disorder predicted for VanSA were M130-L150, and for VanSSC 
were E97-Y120, Q141-H171 and L294-I314.  
 
In an attempt to increase expression level of the VanS sensor domain, further concentrations 
of IPTG inducer were screened for the most promising constructs (SA120 and SSC120) and 
cell line (C41(DE3) pRIL), and the temperature for induction was lowered to 16
o
C to allow 
time for proper insertion and folding in the membrane (e.g. see Figure 4.3.4). BL21(DE3) 
pLysS cell lines were also screened for expression, since they encode the gene for T7 
lysosyme, a natural inhibitor of T7 RNA polymerase which serves to suppress basal 
expression of the polymerase prior to induction (Sivashanmugam et al., 2009).  
[185] 
 
 
 
Figure 4.3.4: Western blot showing overexpression of SA120 at 16 or 25
o
C, at varying 
IPTG concentrations. 100 ml cultures were grown overnight and resuspended in 2ml 
volume, processed by Water Lysis and blotted. Lane 1 – 0.05 mM IPTG added, Lane 2 – 0.1 
mM IPTG added, Lane 3 and 4 – 0.2 mM IPTG added. Lanes 1-3 - 16oC induction, Lane 4 – 
25
o
C induction. Overexpressed full-length VanSA was added as a positive standard (+).  
 
Figure 4.3.4 shows that of the three IPTG concentrations tested, 0.2 mM IPTG was still 
optimal, and more soluble protein was produced by induction at 25
o
C, and over a shorter 
period, than at 16
o
C. However, the level of soluble protein from these constructs was much 
lower than that of their full-length counterparts, and would not produce enough yield of 
protein after purification. From the RONN plots it was apparent that lengthening the sensor 
domain to e.g. 140 or 150 residues would be likely to only increase disorder for both 
proteins, and may not improve expression level. It is concluded that expression of the sensor 
domain requires increased solubility, afforded by the C-terminal cytoplasmic domain.  
 
With this in mind, a new approach was adopted, in which the full-length proteins could be 
expressed using the already optimized protocols, and subsequently cleaved between the 
sensor and cytoplasmic kinase regions, to produce the desired sensor domain in a high yield. 
Using the knowledge gained from the vanS truncates, the best position to cleave the protein, 
and obtain a soluble sensor region, was around the 120
th
 residue of the wild-type sequence. 
This cleavage would need to be highly specific to avoid multiple digestion products, and 
require a method to selectively purify the sensor domain or remove the C-terminal domain. 
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One of the advantages of cloning into the pProEx HTa plasmid, was that the encoded VanS 
proteins are His-tagged at the N-terminus, and when digested will produce a tagged N-
terminal product, and an untagged C-terminal product. The N-terminal product can be 
selectively purified by Nickel affinity chromatography, and the C-terminal domain will be 
removed (in the flow through). Furthermore, by choosing an appropriate digestion enzyme, 
e.g. one that is tagged with e.g. MBP or GST (i.e. not His-tagged), the enzyme can be 
removed after cleavage using amylose or glutathione resin respectively. Another possibility 
is to use the His-tagged TEV protease for cleavage. This enzyme will cleave the expressed 
VanS proteins at the inserted site ~120
th
 residue, and at the TEV-cleavable linker (between 
the His-tag and vanS gene sequence) (see Figure 4.3.5). The TEV protease can then be 
removed by affinity chromatography, and the remaining untagged N-terminal domain and C-
terminal cytoplasmic domain can be separated by size using gel filtration chromatography.  
 
Within the Roper laboratory, glycerol stocks were available which encoded digestion 
enzymes such as thrombin, enterokinase, 3C, and TEV, each of which act at specific 
cleavage sites, consisting of a defined sequence of five or more amino acids. Although the 
serine proteases, enterokinase and thrombin, used to be reagents of choice for removing 
affinity tags (Waugh, 2011; Gasparian et al., 2003), and should cleave with high specificity, 
there are several reports of fusion proteins that were cleaved by these proteases at locations 
other than the designed site (Waugh, 2011). By contrast, few if any reports exist of cleavage 
at non-canonical sites in designed fusion proteins by the viral proteases, TEV and 3C. This 
specificity is probably attributed to their low turnover rates (low kcat) (Kapust et al., 2001; 
Long et al., 1989). For this reason, TEV and 3C enzymes were selected for cleavage of VanS 
proteins in these studies. The TEV protease is His-tagged and the 3C protease is tagged at 
either end with Histidine and MBP, so they can both be selectively purified by affinity 
chromatography, and easily removed on resin after use. The only practical ramification of 
this choice is that more viral protease than serine protease is required to digest a fixed 
amount of protein, but far greater expression of viral proteases is achievable in E. coli. 
[187] 
 
A new route was therefore devised to insert a TEV or 3C site into the vanS gene sequence 
(after the second transmembrane helix), as shown in Figure 4.3.5, to cleave with high 
specificity using the respective enzyme and selectively purify the sensor domain.  
 
 
Figure 4.3.5: Schematic representation of a VanS protein and the proposed position for 
insertion of an enzymatic cleavage site. VanS has a predicted N-in, C-in topology with two 
transmembrane domains, and the inserted 3C/TEV cleavage site would proceed these in a 
solvent-exposed region (outside the micelle).  
 
Enzymatic cleavage would be conducted on detergent-solubilised, purified full-length VanS 
proteins, and hence a further requirement is that the cleavage site must be inserted into a 
solvent-exposed region (i.e. not enclosed in the micelle), within the cytoplasmic domain. To 
confirm that this site would be in a solvent-exposed region, protein samples that had been 
purified in DPC detergent, were digested with trypsin or chymotrypsin, which cleave at 
multiple positions in the protein, and would show accessible regions. Trypsin cleaves peptide 
bonds mainly at the carboxyl side of Lys or Arg residues, whereas chymotrypsin 
preferentially cleaves peptide bonds where the carboxyl side of the bond contains a large 
hydrophobic residue e.g. Tyr, Trp or Phe. 
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Digestion experiments were set up with a 1:50 ratio of [tryptic enzyme]:[protein], and 
aliquots of the mixture were taken at different timepoints and resolved on 15% SDS-PAGE 
gels and corresponding Western blots (see Figure 4.3.6). The blots would enable 
identification of peptide fragments containing a His-tag, and therefore fragments from the N-
terminal region. Although several bands were observed on SDS-PAGE gels from digestion 
with chymotrypsin, none of them appeared to be His-tagged proteins (data not shown). 
Whereas, digestion with trypsin produced two major his-tagged bands (see arrows in Figure 
4.3.6 at ~22 and ~16 kDa), which were present at both 1:20 and 1:50 cleavage ratios. The 
two his-tagged proteins were excised from the corresponding SDS-PAGE gels, and sent for 
identification by means of fragmentation and mass spectrometric analysis (using nanoLC-
ESI-MS/MS, section 2.8.2). Similar bands were observed during trypsin digestion of 
detergent-solubilised VanSSC proteins which were also sent for identification. From the 
MS/MS fragmentation data, peptide residues in the cleaved products were identified and 
mapped onto the full-length sequence (see Figure 4.3.7).   
 
 
 
Figure 4.3.6: (left) A 15% SDS-PAGE gel containing digested samples of N-His6-VanSA 
collected over timepoints, (right) the corresponding Western blot. Samples were collected 
after 2, 4, 6 and 16 hours tryptic digestion (labelled 1-4 respectively), at a ratio of 1:50 
[trypsin]:[protein]. MR - Prestained SeeBlue Plus2 marker (Invitrogen). Two major 
digestion products were observed, which were his-tagged (green and red arrow).  
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Figure 4.3.7: Map of peptide fragments identified by MS/MS analysis of excised gel bands 
from digestion of VanSA or VanSSC. Maps are shown for the His-tagged VanSA band 
observed on SDS-PAGE at ~22 kDa (a) and the His-tagged VanSSC band observed at ~17 
kDa (b). Peptide fragments are highlighted, and predicted TM domains are underlined.  
 
Maps of peptide fragments identified from excised gel bands show accessible regions either 
in the periplasmic loop region between the two predicted TM domains, or in the cytoplasmic 
domain that follows the second TM helix. Importantly, both VanSA and VanSSC are being 
cleaved by trypsin at ~20 – 30 residues after the predicted second TM helix (at Q120 for 
VanSA and E122 for VanSSC), so a site inserted around this region should be cleavable by the 
viral proteases. Initial expressions showed that SA120 and SSC120 were the most soluble 
expressed proteins, so cleavage at ~120
th
 residue should give stable N-terminal products.  
 
Bioinformatic analyses of the protein sequences using PSIPred (and JPred3) software (Jones, 
1999; Cole et al., 2008) also revealed that both VanSA and VanSSC sequences exhibited 
relatively unstructured, coiled regions in the region of the 110-120
th
 residue (see Figure 
4.3.8). A digestion site in the coiled region should not affect protein secondary structure, and 
will hopefully cleave to leave two separated sections, without any unwanted hydrophobic 
interactions maintaining the protein structure. The full-length protein should also still 
express, insert into membranes and obtain its native fold with the cleavage site present. 
(a)
(b)
[190] 
 
Proposed positions to insert cleavage sites were therefore chosen between Q120 and I121 in 
VanSA, and R116 and R117 in VanSSC (see peptide map in Figure 4.3.7). 
 
 
 
Figure 4.3.8: Secondary structure prediction for VanSA (a) and VanSSC (b) proteins 
between residues 80-160, generated using PSIPred software. Predicted secondary 
structural elements in the protein sequence (‘AA’) are illustrated as either α -helical 
(represented as cylinders, or ‘H’), β-strand (represented as arrows, or ‘E’) or coiled 
(represented as a line, or ‘C’).  The confidence level of secondary structure identified for 
each amino acid is also represented by bars (highest confidence shown by tallest bars).    
 
With knowledge of the intended position of the site in the gene, cloning protocols were 
designed for insertion of the required sequence of amino acids to form the cleavage site. 
Conventional mutagenesis techniques such as QuikChange (Stratagene), allow insertion of 1 
or 2 amino acids per reaction, and would take several reactions to insert the site. However, a 
less common mutagenesis technique known as ‘Round-the-Horn’ PCR, can provide a 
method for inserting large peptide sequences (e.g. 5-10 residues) directly into a gene.  
(a)
(b)
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In this protocol, two primers are designed with different sequences, which do not fully base 
pair with the template DNA and amplify the template sequence in opposite directions. This 
results in linear mutated strands with blunt-ends which can be ligated (and re-circularised), 
to obtain the gene, containing the full stretch of inserted amino acids. For full details and a 
diagram of the method applied to vanS genes, see section 2.4.2. 
 
After transformation of the ligation mixture into E. coli TOP10 cells (section 2.4.7), and 
extraction of positive transformants by minipreparation, the presence of a correctly sized 
insert was determined from restriction digests (section 2.4.3). DNA sequencing (section 
2.4.8) was then used to confirm the addition of a TEV or 3C site, correctly orientated within 
the vector and in the correct reading frame.  3C and TEV sites were successfully 
incorporated into both vanSA and vanSSC genes (e.g. in Figure 4.3.9) and expression from the 
constructs could now be tested, prior to digestion at the sites. 
 
 
 
Figure 4.3.9: Sequencing data showing a section of the VanSA DNA sequence containing 
an inserted TEV site (GAG AAC CTG TAC TTC CAG AGT) encoding for ENLYFQS. 
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4.4 M9 Minimal Media Expression of vanS genes 
 
For isotopic labelling of recombinant VanS proteins, a standard version of the M9 minimal 
media protocol was followed (Sambrook et al., 1989), which employs 
15
N ammonium 
chloride for nitrogen labelling, and if required 
13
C glucose can be used for carbon labelling, 
and deuterium oxide for deuteration (see section 2.5.1). Supplements can also be added to 
the media such as trace metal mixtures and vitamins, which can enhance growth and 
expression (Jansson et al., 1996; Kainosho, 1997; Cai et al., 1998). For these studies, Basal 
Medium Eagle (BME) vitamins (Sigma) were chosen which consist of vitamins such as 
thiamine, riboflavin and folic acid, to stimulate cell growth. The only trace metals tested 
were calcium chloride and magnesium sulphate, which are commonly used alongside M9 
metal salts in minimal media preparations. However, in later expression trials, the addition of 
iron (III) chloride to media was also analysed.  
 
Isotopically labelled media is expensive, and optimisation of expression conditions and 
growth media is a necessary requirement, before addition of labelled ammonium chloride 
and/or glucose. Therefore, expression trials were conducted for the full-length His-tagged 
VanS proteins in unlabelled M9 minimal media (prior to site insertion). M9 salts were 
prepared as detailed in section 2.2.1 and used to make a minimal media (see section 2.5.1). 
This media contains a source of ions (1x M9 salts), a source of carbon for growth (glucose) 
and a source of nitrogen to synthesise bases and amino acids (ammonium chloride), other 
metals (CaCl2, MgSO4), vitamins, and antibiotics, as suggested by (Sambrook et al., 1989).   
 
Traditionally for protein NMR, constructs are transformed into E. coli and grown on M9 
plates, with single colonies used to inoculate M9 starter cultures, which in turn can be used 
to inoculate larger cultures e.g. 1L. At this point M9 salts are supplemented with metals, 
vitamins, and labelled ammonium chloride or glucose. The advantage of this route is that 
cells grow in M9 media throughout, providing a high yield of uniformly labelled protein. 
[193] 
 
However, unlike rich Luria Broth media, minimal media excludes yeast and other nutrients, 
and supplies only the exact nutrients needed for bacteria to grow. Therefore slower growth 
rates are observed, which can result in reduced expression due to cytotoxic effects associated 
with the plasmid exerting selective pressure (Baneyx, 1999) and reduced viability of cells to 
overexpress proteins. In a number of recent papers, authors have shown that rich LB media 
can be used for transformation, inoculation and growth of large-scale cultures then switched 
to M9 minimal media at the point of induction for overexpression of labelled proteins 
(Marley et al., 2001; Cai et al., 1998; Sivashanmugam et al., 2009). In this way, high level 
protein expression can be achieved, in a time-efficient manner by utilising the fast doubling 
rates of E. coli cells in the media. Media is switched by gently pelleting the cells once at the 
mid-log phase, washing and resuspending in the minimal media, and allowing cells to 
equilibrate in the new media (usually for one hour) before inducing.  
 
Using this method, Cai et al., (1998) monitored cell growth in fermentors, and measured the 
decrease in oxygen consumption (which occurs upon exhaustion of essential nutrients) to 
precisely time the switch between unlabelled and labelled nutrients. Similarly, Marley et al., 
(2001) monitored cell growth in regular shaker incubators, and found optimal expression 
levels by growing in unsaturated LB media and exchanging around the mid-log phase (OD600 
~0.7). However, when exchanging media, they also concentrated the cell suspension to 1/2, 
1/4 or 1/8
th
 of its original volume, before transferring the bacteria into isotopically labelled 
media for expression. They stated that exchanging cells into fresh media immediately prior 
to induction can increase protein expression levels by removing byproducts (e.g. unlabelled 
metabolites) inhibitory to growth and expression, and prevent problems arising from cells 
going into the stationary phase. Furthermore, the optimal cell density for induction differs for 
freshly exchanged media, and allows ‘high-cell-density’ expression (by concentrating the 
cells). Overall, a concentration factor of four times (25% of original volume) conferred 
maximal protein expression for those studied, but this is protein dependent.  
 
[194] 
 
Finally, Sivashanmugam et al., (2009) went a step further to generate improved methods for 
triple-labelled protein expression (incorporating D2O) and examined two high-cell-density 
bacterial expression methods: an autoinduction method by Studier (2005), and the IPTG-
induction method. The Studier method was advantageous as it achieved high cell densities 
with minimal handling, as there was no need to monitor growth for induction, however, 
results were inconsistent with OD600 values reaching 8-20, but no protein yield observed. By 
comparison, the high-cell-density method allowed induction and harvesting of cells (after 4 
hours growth at 37
o
C) within a normal working day, and gave high yields (OD600 5-10 from 
growth in LB media). For isotopic labelling the group state that a longer period of exchange 
time e.g. two hours, at a reduced temperature is preferable. This allows clearance of 
unlabelled metabolites and slows down bacterial growth during the exchange period, 
preserving nutrients for protein synthesis after IPTG-induction. Two further alterations were 
the buffer pH in the media and the culture volume. Typically during expression, the pH 
drops from 7.2 to ~6 at the point of harvest, and should be set a log higher (pH ~8) to 
increase buffering capacity and prevent plasmid instability and degradation of ampicillin. 
Cultures volume should also be limited to 1/5
th
 of the flask volume to increase aeration.  
 
Using this literature information, it was possible to combine protocols, to examine high-cell-
density protein expression levels in M9 minimal media at different induction temperatures, 
and with addition of trace metals. The pH for the M9 minimal media was set at pH 8 for 
higher buffering capacity, and ampicillin was added to initial cultures and in the M9 media 
to maintain selection pressure. All cultures were grown at 37
o
C in LB media, and the 
temperature was reduced for expression in M9 media to obtain high yields of soluble, 
isotopically labelled proteins. A schematic representation of the optimised, high-cell density 
method used in these studies, based on literature protocols is given in Figure 4.4.1. 
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Figure 4.4.1: A diagram of the optimised high-cell-density method used for production of 
uniformly 
15
N-labelled VanS proteins. Adapted from methods by Marley et al., (2001) and 
Sivashanmugam et al., (2009). Constructs are transformed on LB/agar plates, and single 
colonies added to 10mL starter cultures, which are grown overnight to an OD600~ 1-1.5. In 
this way, 800mL cultures of LB media can be inoculated at 1/100 dilution, and grown until 
mid-log phase (OD600~0.6-0.7) before gentle pelleting, and washing in M9 salts. In the final 
wash, cells are resuspended at ½ or ¼ of the original volume in 
15
N labelled M9 media 
containing metals, vitamins and antibiotics to achieve high cell density. The culture is then 
equilibrated at the induction temperature for 1-2 hours, before induction and growth. 
 
 
Using the high-cell-density method, expression was initially tested for full-length VanS 
proteins using unlabelled M9 minimal media (section 2.5.1) and under similar conditions to 
those that gave favourable expression in E. coli C41pRIL. The media was switched from 
cultures grown in LB to M9 minimal media, (initially without concentrating) and induced 
with IPTG at an OD600 of 0.6-0.7. The cells were allowed to grow at 25
o
C overnight for 
VanSA or 18
o
C overnight for VanSSC and overexpressions were analysed on SDS-PAGE gels 
and Western Blots as shown in Figure 4.4.2. 
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Figure 4.4.2: (left) A 12% SDS-PAGE gel of VanSA and VanSSC overexpression in M9 
minimal media, at different IPTG concentrations, and (right) corresponding Western blot. 
MR – GE LMW-SDS marker, MR’ – Benchmark His-tagged marker, Lane 1 – 0.2 mM IPTG 
added, Lane 2 – 0.5 mM IPTG added, Lane 3 – 1mM IPTG added. Bands relating to VanSA 
(green arrow) and VanSSC (red arrow) are indicated. 
 
 
These experiments demonstrated that both VanSA and VanSSC proteins could be 
overexpressed in M9 media, with similar levels to those observed in LB. To further optimise 
the expression yield, different concentration factors were tested (1x, 2x and 4x), and trace 
amounts of iron were added to improve bacterial growth. The addition of iron was suggested 
in an article by Cambridge Isotope Laboratories entitled “Top Ten Tips for Producing 13C 
15N Protein in Abundance” (Berthold et al., undated), who stated that, in the absence of trace 
metals, 50-100 μM FeCl3 alone will provide the nearly the same increase in expression level 
(Studier, 2005). 800 mL cultures in 2L flasks were inoculated and grown to an OD600 ~ 0.6, 
and exchanged into 800, 400 or 200 mL of 
15
N-labelled M9 minimal media, with and 
without supplementary iron (III) chloride. After overnight induction at a fixed IPTG 
concentration (0.2 mM), the resulting expression levels were analysed by SDS-PAGE and 
quantified by band sizing on the corresponding Western blots (Appendix Figure 7). A plot of 
normalised expression level relative to the unconcentrated, unsupplemented sample is shown 
in Figure 4.4.3.  
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Figure 4.4.3: A bar chart showing relative band intensities for full-length VanSA proteins 
overexpressed under different conditions in 
15
N M9 minimal media. The intensities were 
quantified from Western blots using ImageJ analysis and normalised against the sample 
grown in media without iron supplement or concentrating (1x). The concentration factor was 
either equal to that in LB (1x) or concentrated to half (2x) or quarter (4x) of the initial 
volume. Some expressions were also supplemented with 75 μM iron (III) chloride (red bars).  
 
In agreement with studies by Marley et al., (2001), concentrating the cell culture during 
exchange into minimal media significantly increased the expression yield of soluble VanS 
protein, but above a concentration factor of 2, the level of expression appears to decrease. 
High-density bacterial cells require more nutrition in the medium for overexpression, 
therefore an increased amount of carbon source (glucose) could enable healthy cell growth at 
high concentration factors. Indeed, Sivashanmugam et al., (2009), believe that the amount of 
glucose is critical for high-cell-density expression, and showed that they could increase cell 
density at concentration factors of 8x by adding up to 10 g/L of glucose in minimal media. 
Therefore the addition of 4 g/L of glucose was used in all future expression trials (in place of 
2 g/L), to ensure cells would have sufficient nutrients to overexpress VanS proteins upon 
concentrating two-fold or four-fold. In addition, cells supplemented with iron also increased 
their expression level, demonstrating it can act in place of a mixture of trace metals. 
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These findings led to the optimised M9 minimal media expression protocol, as given in 
Figure 4.4.1 and section 2.5.1. It was now possible to use this protocol to overexpress 
mutagenic 
15
N-labelled VanS proteins, containing the newly inserted enzymatic cleavage 
sites, which could be subsequently digested to obtain the desired 
15
N-labelled sensor domain. 
 
4.5 M9 Minimal Media Expression of mutant vanS genes for Enzymatic Cleavage 
and Purification of the isolated VanS sensor domain 
 
After cloning in the TEV and 3C sites, expression trials were conducted for the full-length 
His-tagged VanS proteins in 
15
N-labelled M9 minimal media. VanS proteins were 
overexpressed and allowed to grow at 25
o
C (for VanSA-3C or VanSA-TEV) or 18
o
C (for 
VanSSC-3C or VanSSC-TEV) overnight. Expression was assessed using SDS-PAGE and 
Western Blots as shown in Figure 4.5.1. 
 
 
 
Figure 4.5.1: (left) A 12% SDS-PAGE gel showing overexpression of VanSA and VanSSC 
mutants in 
15
N-labelled M9 minimal media, and (right) the corresponding Western blot. 
VanSA and VanSSC proteins are indicated by boxes. Lane 1 – VanS containing TEV site, Lane 
2 – VanS containing 3C site, MR – LMW-SDS Protein Ladder, MR’ – Benchmark his-tagged 
ladder. VanSA and VanSSC proteins were induced at an [IPTG] of 0.2 and 1mM respectively 
 
These experiments demonstrate that both VanSA and VanSSC mutants can be overexpressed 
in 
15
N-labelled M9 media, with similar levels to that of the wild-type proteins in LB media. 
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The blots show only marginally higher expression yields for the VanS-3C proteins 
(compared to VanS-TEV) even though by SDS-PAGE, VanSA-3C appears by far the most 
expressed. VanS-TEV and VanS-3C proteins were next solubilised in DPC micelles and 
purified by nickel affinity chromatography, before digestion with in-house synthesised TEV 
(section 2.12.1) and 3C protease (sections 2.12.2 & 2.12.3), for the respective constructs. 
The ratio of [protease]:[protein] was fixed at 1:1. Products were analysed during digestion by 
SDS-PAGE and Western blotting (see Figures 4.5.2 & 4.5.3, and Appendix Figure 8).  
 
 
Figure 4.5.2: (left) A 15%  SDS-PAGE gel showing initial products from digestion of 
VanSA-3C after 4 hours, (right) corresponding western blot. Key bands are labeled with 
arrows. MR : LMW-SDS Protein Marker, MR’ - MagicMark XP ladder.  Lane 1: VanSA-3C 
protein, Lane 2: 3C protease (~ 66 kDa), Lane 3: 1:1 Digestion mixture.  
 
 
 
Figure 4.5.3: (left) A 15% SDS-PAGE gel showing initial products from TEV digestion of 
VanSA-TEV after 4 hours, (right) corresponding western blot. Key bands are labeled with 
arrows. MR : LMW-SDS Protein Marker, MR’ - MagicMark XP ladder.  Lane 1: VanSA-TEV 
protein, Lane 2: TEV protease (~ 27 kDa), Lane 3: 1:1 Digestion mixture. NB: A band for 
TEV should have been visible in the blot in Lane 3, but must not have transferred properly.  
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Figure 4.5.2 shows that during digestion of purified VanSA-3C with 3C protease, two major 
bands are present at ~ 29 kDa and ~ 17 kDa, with the latter visible on Western blots. These 
bands correspond well with the predicted molecular weights of the untagged C-terminal 
cytoplasmic product and the His-tagged N-terminal membrane-bound product. Similar 
digestion products are also observed for purified VanSSC-3C incubated with 3C protease (see 
Appendix Figure 8). In Figure 4.5.3, however, VanSA-TEV is rapidly digested by TEV 
protease and the production of C-terminal and N-terminal products was not easy to identify 
by SDS-PAGE or Western blots. The TEV protease should cleave all tags from the protein 
therefore no protein bands should be visible on a Western blot of the digestion mixture 
(assuming 100% cleavage). Unexpectedly though, the corresponding Western blot indicated 
the presence of a possible N-terminal band (~20 kDa) retaining its his-tag, which suggests 
that the TEV protease accesses the inserted cytoplasmic cut site more readily than the site 
immediately following the his-tag. Attempts to purify the products from TEV digestion did 
not appear to produce any yield of the VanS sensor domain, and therefore purification was 
pursued only for products from 3C digestion.  
 
In contrast to TEV, the 3C protease cleaved the detergent-purified VanS proteins at only one 
site, giving the desired His-tagged N-terminal product and C-terminal cytoplasmic product. 
Since the 3C protease synthesised contained a His-tag and an MBP-tag (as confirmed by an 
anti-MBP blot, see Appendix Figure 9), it was possible to selectively remove the enzyme 
after digestion using amylose resin (section 2.12.3). This resin has a high affinity for MBP 
and allowed removal of the protease from the digestion mixture, with the remaining VanS 
proteins eluting in the flow through and wash steps. This eluent was then rebound to pre-
charged nickel resin to remove the untagged C-terminal cytoplasmic domain (see section 
2.12.3). The flow through was collected and the column was washed with an imidazole 
gradient to elute the 
15
N-labelled N-terminal His-tagged VanS protein (in DPC micelles) 
under high imidazole. An SDS-PAGE gel showing products from the amylose binding and 
subsequent IMAC purification steps is shown in Figure 4.5.4.  
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Figure 4.5.4: A 12% SDS-PAGE gel showing selective purification of the VanSA N-
terminal ‘sensor’ domain away from the C-terminal domain and 3C enzyme. Lane 1 – 1:1 
digest of VanSA-3C with 3C protease overnight, Lane 2 – Flow through upon rocking in 
amylose resin, Lane 3 –Flow through upon subsequent rocking in nickel sepharose resin, 
Lane 4 – 20mM Imidazole wash fraction, Lane 5 – 50mM Imidazole wash fraction, Lane 6 – 
250mM Imidazole elution fraction. MR – ColorPlus Prestained Ladder (10-230 kDa). 
 
The eluted N-terminal VanS sensor domain was then concentrated in a 10 kDa MWCO 
concentrator to 500 μL for final purification by Gel Filtration Chromatography (see section 
2.6.7) on a Superose 6 10/300 GL column, to remove any residual 3C protease and 
undigested VanS. An example of a typical gel filtration profile acquired is given in Figure 
4.5.5, and the overall products from all the purification steps for VanSA are illustrated on an 
SDS-PAGE gel (Figure 4.5.6), with the purified N-terminal sensor domain of VanSA in DPC 
micelles shown in Lane 6.  
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Figure 4.5.5: Gel filtration chromatograms of protein samples containing the N-terminal 
sensor domain of 
15
N-labelled VanSA (black line) or VanSSC (red line) in DPC micelles, 
applied to a Superose 12 10/300 GL column. Plots were drawn in Microsoft Excel. The 
VanS sensor domain eluted at 17-18 mL, and undigested full-length protein and 3C protease 
eluted at 10-16 mL. An isocratic gradient of 100 % B was used to elute the proteins (buffer 
B: 20 mM HEPES pH 6.8 or 50 mM phosphate pH 6.3, 75-100 mM NaCl, 2 mM DPC).  
 
 
Figure 4.5.6: A 15% SDS-PAGE gel showing digestion and subsequent purification of the 
N-terminal ‘sensor’ domain of VanSA.  Lane 1: IMAC purified VanSA-3C, Lane 2: purified 
3C protease, Lane 3: 1:1 Digest of VanSA-3C with 3C protease after 4 hours incubation, 
Lane 4: Digest after removal of 3C protease on amylose resin, Lane 5: Digest after removal 
of C-terminal untagged VanSA by IMAC, Lane 6: VanSA sensor domain purified by GFC.  
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The purified VanS N-terminal product in DPC was eluted from the gel filtration column (at 
an elution volume of 17 – 20 mL) and was further concentrated to ~ 200 μL, for application 
into 3 mm BrukerMATCH NMR tubes, to analyse protein structure and ligand binding 
properties by solution state NMR spectroscopy (see section 2.14). For NMR studies of alpha-
helical membrane proteins such as VanS, the concentration of detergent must be tuned to 
enable sufficient tumbling of the associated protein-micelle complex in solution, whilst not 
being excessively high so as to cause denaturing of the native fold of the membrane protein.  
A list of all current structures for membrane proteins solved by solution state NMR is given 
at http://www.drorlist.com/nmr/. By studying the list of structures it is apparent that the 
detergent and concentration used successfully for solution NMR structure determination 
differ greatly, but DPC is the most commonly used detergent, and concentrations are in the 
order of 50 mM and above (except in mixed micellar systems or nanodiscs). Therefore for 
these studies, the final concentration of DPC detergent in the NMR sample was adjusted 
from 2 mM (after gel filtration) to 50 mM, and all samples were analysed by CD 
spectroscopy (refer to Figure 4.6.4) before analysis in the NMR spectrometer, to ensure the 
alpha-helical protein fold (~ 60% α-helical) was still maintained.     
 
Initially, NMR was used to analyse purified, uniformly 
15
N-labelled VanS sensor domains in 
50 mM DPC detergent in HEPES or phosphate buffer. The pH was maintained near 
physiological values, but was required to be below pH 7, in order to avoid loss of amide 
(NH) signals due to exchange in solution.  From these experiments, several factors required 
optimisation to achieve high resolution 2D 
1
H-
15
N HSQC NMR spectra, with well resolved 
peaks and uniform peak intensities. These included buffer selection, pH, temperature and 
detergent, and are detailed in section 4.6.  
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4.6 2D Solution State NMR studies of the VanS sensor domain and Optimisation of 
Solution Conditions by Temperature, Detergent and Buffer Screening 
  
To find solution conditions required to produce well-folded and homogeneous samples of the 
VanSA sensor domain, the sensitivity-enhanced 
1
H-
15
N Heteronuclear Single Quantum 
Coherence (HSQC) experiment was used (see section 2.14).  A well-resolved HSQC 
spectrum containing sharp, well-dispersed signals is a strong predictor of correct folding and 
is essential for successful structural characterisation. More specifically, when judging the 
suitability of a set of conditions, the following properties of the spectrum were primarily 
considered: peak width (narrow peaks are optimal), the number of observable peaks 
(approximately 112 backbone amide peaks should be observable for VanSA and 107 for 
VanSSC, not including the 39/40 predicted transmembrane residues in each protein), chemical 
shift dispersion (characteristic of a well-folded protein), and homogeneity of peak intensity. 
 
4.6.1 Effect of magnetic field strength and temperature 
 
Initially, the effects of magnetic field strength and temperature were examined for samples 
of the N-terminal domain of VanSA in 50 mM DPC detergent, after gel filtration. 
1
H-
15
N 
HSQC spectra were acquired on 500 and 700 MHz Bruker spectrometers (see Figure 
4.6.1.1A and B).  These spectra contain peaks for the backbone amide NH groups (
1
H ~ 8-9 
ppm) as well as NH-containing functional groups on side-chains of specific residues (
1
H < 
8 ppm).  At 500 MHz, the peaks are broad and difficult to resolve, indicating short spin-spin 
relaxation times (T2) and variable (heterogeneous) peak intensities. The chemical shifts are 
not well-dispersed either, making it difficult to judge the number of peaks in the spectrum.  
The spectrum is improved at 700 MHz (panel B).  In addition to using a higher field strength, 
which improves resolution, the temperature was increased from 25C to 37C, to improve 
tumbling rates in solution, and reduce line broadening due to rapid spin-spin relaxation rates 
(T2). The spectrum shown in Figure 4.6.1.1B clearly contains additional peaks (55 
resolvable), which are narrower and more disperse.   
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Figure 4.6.1.1: 2D 
1
H-
15N HSQC spectrum of 140 μM VanSA sensor domain collected at (a) 298K on a 500 MHz spectrometer, or (b) 310K on a 700 MHz 
spectrometer. Both proteins were purified in 50 mM DPC, 50 mM phosphate buffer pH 6.3, 75 mM NaCl.
(a) (b)
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The optimal field strength (700 MHz) and temperature (37C) obtained from these analyses 
were used to acquire an HSQC spectrum of the VanSSC N-terminal sensor domain, purified 
and prepared under similar conditions as those for VanSA. The resulting spectrum is shown 
in Figure 4.6.1.2.  NMR samples of the purified 
15
N-labelled samples containing VanSA and 
VanSSC sensor domains are given in Appendix Figure 10, which show no obvious impurities, 
and protein samples appeared stable for up to around two weeks of measurements at 310K.  
 
 
Figure 4.6.1.2: 2D 
1
H-
15N HSQC spectrum of 200 μM VanSSC sensor domain in 50 mM 
DPC, collected at 310K on a 700 MHz spectrometer. Protein was purified into 20 mM 
HEPES pH 6.8, 75 mM NaCl. 
 
If anything, the spectrum of 
15
N-labelled VanSSC in Figure 4.6.1.2, is superior in quality to 
the VanSA spectrum (Figure 4.6.1.1B), showing sharp, disperse peaks (78 peaks in total) that 
are similar in intensity.  Overall, it is clear that field strength and temperature are important 
variables to monitor when optimising spectral quality. The composition, concentration and 
pH of buffer components can also affect the quality of the NMR spectrum, but there are 
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currently no firm guides on which buffers are best for a given protein. Unlike sparse matrix 
screens employed in X-ray crystallisation, there are no simple and rapid analogous buffer 
screening protocols for NMR analyses, so spectra must be collected for each condition.  
 
4.6.2 Effect of detergent 
 
As demonstrated above, the sensitivity of the spectrometer, the temperature and the buffer 
choice will influence the spectral quality, but perhaps the most key variable in analysing 
membrane proteins, is the choice of membrane mimetic (the solubilising detergent). The 
spectral resolution of a membrane protein within a detergent micelle is directly dependent on 
the T2 (spin-spin) relaxation rate. Only those detergents which allow rapid tumbling of the 
protein-micelle complex in solution can provide long T2 relaxation times, leading to reduced 
line broadening and increased signal-to-noise.  
 
Although most NMR structures of membrane proteins have been solved in DPC detergent 
(see http://www.drorlist.com/nmr), it is not the optimal detergent for all proteins, and a 
number of other detergent classes provide promising membrane mimetics. For instance, 
Gautier et al., (2010) screened a number of detergents and obtained NMR spectra of a seven-
transmembrane-helix GPCR, pSRII, in diheptanoylphospatidylcholine (DHPC) micelles of a 
quality that would rival those of ‘normal’ soluble proteins, despite the fact that the protein–
micelle complex was found to be over 70 kDa in size.  
 
In addition, studies by Krueger-Koplin et al., (2004) on three test membrane proteins; the 
LH1 β-subunit from R. sphaeroides (a single TM helix), subunit ϲ from E. coli (a two TM 
helix) and the Smr protein from S. aureus (a four TM helix), found that by far the highest 
resolution solution NMR spectra, and most stable protein-micelle complexes were produced 
in lyso-phospholipid detergents e.g. LPPG and LPPC. These detergents are single chain 
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analogues of native E. coli lipids; dipalmitoylglycerolphosphoglycerol (DPPG) and 
dipalmitoylglycerolphosphocholine (DPPC) respectively (see Figure 4.6.2.1).  
 
 
 
 
Figure 4.6.2.1: Molecular structures of LPPG and DPPG detergents, drawn in ISISDraw 
 
It is believed that the ability of these lyso-phospholipids to maintain stable, functional 
protein folds may be closely related to the fact that they are the only class of single-chain 
detergents that resemble the majority of natural phospholipids, in that they have a polar but 
uncharged (glycerol) spacer that links the apolar lipid-like C14/C16 tail to the charged 
headgroup (Krueger-Koplin et al., 2004; Koehler et al., 2010). These long lipid-like tails 
provide a good match for the hydrophobic span of protein transmembrane domains, whilst 
the native phospholipid headgroups form favourable interactions with the membrane protein.  
 
Most interestingly, Krueger-Koplin et al., (2004) found that although the protein-lysolipid 
complexes had diffusion times consistent with molecules > 100 kDa in size, the rotational 
correlation times for proteins within the micelles (as measured by NOE relaxation 
experiments) were surprisingly short; on the order of 8 – 12 ns. This is the time anticipated 
for a 15 – 20 kDa protein tumbling isotropically in solution. It is therefore proposed that the 
lyso-phospholipids may also be fluid enough to permit rotation of proteins within the 
confines of the micelle, thus increasing the tumbling rate in solution (reducing line 
broadening due rapid T2 spin-spin relaxation) and providing high resolution NMR spectra. 
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To examine the applicability of the lyso-phospholipids, DHPC and other detergents classes 
for structural NMR studies, detergent screens were set-up for both VanS proteins. The 
experimental procedure follows that given in section 2.6.5. Briefly, this involved addition of 
1% w/v detergent to a known amount of protein, rocking for 2 hours and then separating the 
soluble and insoluble fractions by ultracentrifugation. These fractions were loaded in equal 
volume onto SDS-PAGE gels and blotted (see Appendix Figure 11). The relative percentage 
of protein solubilised in each detergent (including those tested in section 2.6.5) was 
calculated from the blots by band sizing, and is represented in the bar chart in Figure 4.6.2.2.     
 
 
Figure 4.6.2.2: Bar charts showing the relative percentages of soluble (red) and insoluble 
(blue) protein for (a) VanSA or (b) VanSSC in different detergents. Percentages were 
calculated from the intensity of protein bands on Western blots calculated using ImageJ 
analysis software. Western blots are provided in Appendix Figure 11.  
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By grouping the detergents into their respective classes, it is clear that anionic (and some 
zwitterionic) detergents provide optimal solubilisation of the VanS proteins. This is likely to 
reflect the composition of native E. coli and Enterococcus membranes. In Gram-negative E. 
coli, the inner membrane is mostly composed of zwitterionic phosphatidylethanolamine lipid 
(PE, ~ 70%), anionic phosphatidylglycerol lipid (PG, ~ 20%) and cardiolipin (CL, ~ 10%), 
(Gidden et al., 2009) and there is a net negative charge on the membrane. PE is also 
converted into zwitterionic PC (phosphatidylcholine) lipid by methylation in cells, which can 
be found in the inner membrane of some Gram-negative species.  
 
By comparison, although several Gram-positive bacterial membranes contain PG, PE, and 
CL, they are often enriched with glycolipids (such as lysyl-PG) (Gidden et al., 2009) and 
lipoteichoic acids (Fabretti et al., 2006), so both membranes have an overall negative charge. 
It therefore appears that the highest degree of solubility and stability of both VanS proteins is 
observed in anionic phosphatidylglycerol lipids and some zwitterionic PC lipids, which 
closely resemble the native functional headgroups present in bacterial membranes. 
 
From the screen above, several candidates for protein solubilisation and NMR analysis were 
possible e.g. LPPG, LMPG, LMPC and SDS. SDS is a relatively harsh detergent and would 
destabilise any dimerization of the VanS proteins in solution, which may be required for 
ligand binding. Whereas, the lyso-phospholipids are detergent analogues of native E. coli 
lipids, and allow protein solubilisation without denaturation. Furthermore, studies by 
Krueger-Koplin et al., (2004) indicated that for several membrane proteins, the lyso-PG 
lipids (LMPG/LPPG), provided the highest percentage of resolvable peaks on 2D 
1
H-
15
N 
HSQC NMR spectra, and protein lifetimes of one to two months at room temperature (as 
determined from the quality of 2D 
1
H-
15
N HSQC spectra observed over the period).  
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Therefore, new 
15
N-labelled VanS samples were expressed and purified in lyso-PG 
detergent, and cleaved and purified as before (see section 2.12.3), in order to obtain the 
labelled N-terminal sensor domain in 50 mM LPPG. To compare spectra of VanS proteins in 
LPPG and DPC, the buffer composition was maintained at 50 mM Phosphate pH 6.3, 75 mM 
NaCl, and the temperature fixed at 310K. An overlayed HSQC is shown in Figure 4.6.2.3. 
 
 
 
Figure 4.6.2.3: Overlayed 2D 
1
H-
15
N HSQC spectra of VanSA sensor domain solubilised in 
50 mM DPC at 140 μM (red) or in 50 mM LPPG at 200 μM (green). Both proteins were 
purified into 50 mM Phosphate pH 6.3, and 75 mM NaCl collected at 310K on a 700 MHz 
Bruker spectrometer. 
 
A marked improvement in peak resolution is observed for those samples in LPPG detergent 
(in Figure 4.6.2.3), particularly for those peaks in the backbone amide NH region (
1
H ~ 8-9 
ppm). This may be a function of the increased tumbling rate in solution within the micelle, as 
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postulated by Krueger-Koplin et al., (2004). By peak picking in LPPG, 106 peaks were 
obtained (including side-chain resonances), which is relatively high considering the N-
terminal VanSA protein has 151 residues in total, of which ~ 40 are present in the 
transmembrane domains. Therefore an improved NMR spectrum of VanSA was achieved 
through detergent selection. To further optimise solution conditions, the effect of 
temperature was also screened for both proteins in the new detergent.   
 
According to Krueger-Koplin et al., (2004), the quality of 2D 
1
H-
15
N HSQC spectra for two 
of their membrane proteins in LPPG improved as the temperature was increased above 25
o
C, 
since tumbling rates increased (as observed in DPC in section 4.6.1), however signals were 
irreversibly lost above 50
o
C. In agreement with these studies, the list of known membrane 
protein structures solved by NMR indicates that almost all structures have been produced 
from spectra collected between 25
o
C and 50
o
C. Therefore temperature changes were 
screened for VanSA and VanSSC proteins in LPPG detergent, at specific temperatures 
between 15
o
C and 45
o
C (Figure 4.6.2.4A and B), to qualify the effect on the number of peaks 
observed, and the peak dispersity and intensity.  
 
The number of observable peaks in Figure 4.6.2.4 (A and B) clearly increases with 
increasing temperature (for the same contour level) up to 310K and the peaks are more 
disperse. This indicates more rapid tumbling, improving signal to noise. However, 
comparing the spectra for VanSSC at 310K against that at 318K (in Figure 4.6.2.4B) shows a 
significant reduction in signal, particularly for those peaks in the backbone amide region, so 
a temperature of 310K (37
o
C) is preferential. Protein stability can be reduced at elevated 
temperatures and often the rate of exchange of labile amide protons with water is increased 
(Kwan et al., 2011), resulting in loss of signal intensity. These screens were useful to 
determine the optimal temperature for NMR study, and form a foundation for conducting 
NMR-based ligand binding experiments, which should be at near physiological conditions 
and at 37
o
C, which fortuitously happens to provide the highest quality NMR spectra. 
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Figure 4.6.2.4: Overlayed 2D 
1
H-
15
N HSQC spectra of (a) 200 μM VanSA sensor domain (b) 150 μM VanSSC sensor domain, at selected temperatures 
between 288K and 318 K. Both proteins were purified in 50 mM LPPG, 50 mM Phosphate pH 6.3, 75 mM NaCl and collected on a 700 MHz Bruker 
spectrometer. The resolution of spectra in overlay (b) is greater than (a) as it they were collected over 128 planes, rather than 64 planes for (a).
(a) (b)
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4.6.3 Effect of pH 
 
In addition to temperature screens, pH changes were analysed for both VanS proteins in 
different detergents. NMR spectra can be recorded at any pH value, however, protons that 
are chemically labile (e.g. backbone and side-chain amide protons) can exchange with 
solvent protons, and the rate of this exchange increases logarithmically above pH 2.6 (Kwan 
et al., 2011). Once the exchange becomes too fast, the signal from the labile proton will 
merge with that of the solvent, causing the signal to broaden and become unobservable. For 
these reasons, many studies in the literature are performed at reduced pH, generally between 
pH 4.0 and 7.5.  
 
A range of pHs were tested for both proteins solubilised in LPPG, with spectra collected 
between pH 4.6 and 6.3 and overlayed (Figures 4.6.3.1A and B). Phosphate has a buffering 
capacity in the range of pH 5.8 to 8.0, so to obtain data at lower pH values, the NMR sample 
was diluted, and exchanged into a buffer containing 50 mM sodium acetate, and 
concentrated in a 30 kDa MWCO concentrator to ~ 200 μL. For VanSA protein solubilised in 
LPPG detergent (Panel A in Figure 4.6.3.1), a dramatic increase in peak dispersion is 
observed upon decreasing pH, and the number of resolvable peaks in the backbone amide 
region is increased (to 113 peaks) with most proton resonances discernable in the backbone 
amide region. For VanSSC protein solubilised in LPPG (Panel B in Figure 4.6.3.1), there is 
perhaps a slight improvement is observed in peak dispersion at reduced pH, but much of the 
backbone amide region remained unresolvable at either pH. In order to distinguish individual 
protons in the backbone amide region, it may therefore be necessary to produce samples at 
higher protein concentration, of the order of 0.3-0.5 mM.   
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Figure 4.6.3.1: Overlayed 2D 
1
H-
15N HSQC spectra of (a) 200 μM VanSA N-terminal sensor domain, or (b) 150 μM VanSSC N-terminal sensor domain, 
obtained at selected pHs between pH 4.6 and 6.3 in 50 mM LPPG. Both proteins were purified in 50 mM phosphate pH 6.3 (red) or 50 mM Sodium acetate 
pH 5.5 or 4.6 (green/blue), containing 75 mM NaCl, and collected at 310K on a 700 MHz Bruker spectrometer. 
(a) (b)
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For studies involving ligand addition, a near-neutral pH would be preferable, as it is known 
that glycopeptide antibiotics such as vancomycin have reduced solubility in acidic solutions 
(FDA, 2008). Therefore ideally studies of antibiotic binding to VanS should be conducted at 
pH 5-7. From temperature and pH screens in LPPG detergent, optimal spectra for both 
proteins were acquired at a temperature around 310K, and, for VanSA, at a relatively low pH.  
 
When conducting titrations the pH chosen will depend on the peak shifts observed and if 
required, it can be lowered to increase peak dispersity and reduce peak linewidth of those 
residues involved. Furthermore, pH changes in one detergent will affect the NMR spectra 
differently to those in others, so titrations should be tested for a range of detergents and pHs 
for comparison. Indeed analysis of the VanSA protein in DPC detergent, recorded at a range 
of pH values (Figure 4.6.3.2), illustrates that spectral dispersity is dependent on the detergent 
chosen. Although a reduced pH does improve peak dispersity in Figure 4.6.3.2, the 
resolution of the backbone amide region does not appear improved, and a reduction may not 
be advantageous, since it could destabilise the protein fold. For VanS proteins solubilised in 
DPC, a near-neutral pH may be preferred for NMR-based ligand binding studies, to be 
physiologically relevant and reduce sample degradation and increase sample lifetimes.  
 
By conducting NMR-based ligand binding studies in different detergents, it may be possible 
to identify conserved residues involved in binding to VanS proteins, and hence the position 
of any binding site, based on the chemical shift change upon titration of the ligand (i.e. using 
a Chemical Shift Perturbation (CSP) Analysis) (Williamson, 2013). Essentially, this involves 
measuring and weighting peak shifts in 
15
N and 
1
H on HSQC spectra, and selecting those 
residues for which the weighted shift change is greater than the standard deviation for all 
residues. NMR-based binding studies are detailed in section 5.4, involving VanS proteins 
and potential glycopeptide antibiotic ligands. Antibiotics were titrated in excess into NMR 
samples containing the N-terminal VanS sensor domain, in order to allow approach to the 
binding site, and ensure any binding should be observed. 
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Figure 4.6.3.2: Overlayed 2D 
1
H-
15N HSQC spectra of 140 μM VanSA N-terminal sensor 
domain obtained at selected pHs between 4.6 and 6.3 in 50 mM DPC. Protein was purified 
in 50 mM Phosphate pH 6.3 (red) or 50 mM Sodium acetate pH 5.5 or 4.6 (green/ blue). 
 
4.6.4 Analysis of protein fold in NMR samples 
 
Prior to NMR analyses, CD spectroscopy was used to analyse the secondary structure 
content for samples of VanS proteins purified into detergent micelles. The secondary 
structure of the protein will vary when solubilised in different detergents, as some are 
‘harsher’ than others or do not adequately mimic the native bacterial membrane. Therefore 
as a precaution, VanS proteins were analysed in each detergent by CD spectroscopy. The 
full-length VanS proteins have an alpha-helical fold (~ 60% alpha-helix) which should be 
maintained for the truncated N-terminal sensor domain.  
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An aliquot of the purified protein in 50 mM detergent was diluted to ~ 0.1 mg/ml (~ 5 μM) 
in the appropriate sample buffer (containing HEPES/ sodium acetate/ phosphate buffer), and 
the final detergent concentration was ~ 5 mM (i.e. >> CMC). For each sample spectra were 
measured at room temperature as detailed in section 2.10. A selection of CD spectra 
collected for VanS protein samples solubilised in each detergent, and normalised to MRE 
values, are shown in Figure 4.6.4.1. 
 
Figure 4.6.4.1: Overlayed CD spectra for VanSA and VanSSC sensor domains purified in 
different detergents. The VanSA N-terminal sensor domain was purified in 20 mM HEPES 
pH 6.8, 5 mM DPC (red line), 50 mM Sodium acetate pH 4.6, 5 mM LPPG (green line), or 
50 mM Sodium acetate pH 5.5, 5 mM LMPG (blue line) is shown, and the VanSSC N-terminal 
sensor was purified in 50 mM Sodium acetate pH 4.6, 5 mM LPPG (orange line).       
 
As shown in Figure 4.6.4.1, both proteins maintain an alpha-helical fold in all detergents and 
buffers tested, and across a pH range of 4.6 to 6.8. The spectrum obtained in DPC and 
HEPES buffer, shows strong light scattering below 200 nm, but peaks at ~208 nm and ~222 
nm, characteristic of the alpha helical fold are clearly visible.  An increased alpha-helicity is 
observed in LMPG and LPPG detergents, which may reflect a more lipid-like characteristic 
of these detergents, compared to DPC detergent.  
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This CD data, in conjunction with the corresponding HSQC NMR data, confirms that the 
VanS proteins are well-folded, and the peak dispersity, signal intensity and number of 
resolvable peaks in the NMR spectrum have been optimised through screening buffer, 
temperature, pH and detergent conditions. By using DPC and the lyso-lipid detergents, under 
these optimised conditions, it should be possible to observe the changes in peak chemical 
shift on HSQC spectra during titration experiments with potential antibiotic ligands (as 
detailed in section 5.4), and determine any residues which may be involved in binding. 
 
4.7 Discussion 
 
A novel ‘Round-the-Horn’ PCR technique was used in these studies to insert a 3C enzymatic 
site into full-length vanS gene sequences (from E. faecium and S. coelicolor), and a route 
was devised to cleave specifically at this site, to obtain and purify the isolated N-terminal 
VanS sensor domain for NMR analysis. This is the only region that is accessible to bind to 
glycopeptide ligands, and by truncating the C-terminus, the resulting protein-micelle 
complexes could tumble in solution on an appropriate timescale for NMR analysis.  
Conventional NMR labelling techniques (Sambrook et al., 1989) were applied to produce 
uniformly 
15
N-labelled VanS sensor domains, and expression protocols were optimised, 
based on recent literature methods (Marley et al., 2001; Sivashanmugam et al., 2009). These 
labelled samples provided the first known 
1
H-
15
N HSQC spectrum of a VanS protein from 
enterococci or Streptomyces, and high resolution spectra were achieved by optimising 
detergent choice and solution conditions. These studies have now provided suitable VanS 
proteins and NMR conditions to conduct NMR-based titration experiments (see Chapter 5), 
to determine whether vancomycin and other glycopeptide antibiotics bind directly to VanS, 
or if the sensor is activated indirectly. 
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4.7.1 Optimal routes to obtain and selectively purify the VanS sensor domain  
 
 
Initial routes to obtain the VanS sensor domain by inserting a stop codon into the vanS gene 
sequence, after the second TM domain, and overexpressing the resulting N-terminal product 
did provide some protein yield. However, the expression level was greatly reduced compared 
to that of the full-length control (see Figure 4.3.4), and this was concluded to result from the 
absence of the solubility-enhancing C-terminal cytoplasmic region. Using an unconventional 
‘Round-the-Horn PCR’ approach, an enzymatic cleavage site was instead inserted into the 
vanS gene, which allowed the use of already optimised expression protocols to obtain high 
yields of soluble VanS protein, before truncation of the C-terminus.  
 
The position for the inserted site was also carefully chosen based on disorder prediction plots 
(RONN), secondary structure predictions (PSIPred/JPred3) and a novel tryptic digest 
experiment, in order to make sure it would be in a relatively unstructured, unordered region 
of the protein, and easily accessible for cleavage, without greatly disrupting the overall fold. 
The tryptic digest experiment involved digesting samples of purified VanS proteins (within 
detergent micelles) with trypsin or chymotrypsin, and resolving digestion products by SDS-
PAGE. Individual protein bands were then excised and analysed for their peptide sequence 
by tandem MS, and mapped to the full sequence. These maps showed solvent-exposed 
regions of the VanS proteins, accessible (outside the micelle) for cleavage, and demonstrated 
that an inserted site at ~ 20 amino acids away from the second TM helix in each VanS 
protein (at ~120
th
  residue), would be accessible for enzyme cleavage of the C-terminus.  
 
It was decided that it would be most appropriate to insert 3C or TEV protease sites, which 
are cleaved with high specificity, which were inserted in one step, using an unconventional 
‘Round-the-Horn’ PCR technique. Unfortunately, subsequent TEV digestion of the 
overexpressed VanS protein resulted in a product that could not be easily identified on gels 
or blots, or purified by IMAC. However, cleavage at the 3C site gave an N-terminal His-
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tagged VanS product which was selectively purified from the untagged C-terminal product 
by IMAC, and the MBP-tagged 3C protease was removed by utilising the strong affinity of 
amylose resin for MBP. A schematic representation showing the purification route to obtain 
the isolated purified VanS sensor domain, and the position of the inserted site is illustrated in 
Figure 4.7.1.1.  This route can be applied to study VanS proteins from other species, cloned 
into pProEx vectors, and shows how important it is to choose appropriate protein tags and 
cleavage sites, in order to purify individual proteins domains, and still make use of the high 
solubility afforded by soluble domains in the protein.        
 
 
 
 
 
 
Figure 4.7.1.1: An illustration of the purification route used to express, cleave and purify 
the N-terminal sensor domain of VanS.     
 
One problem encountered with the purification route above was the cost: DPC is not cheap 
compared to most detergents (~£60/g) and large quantities are required for purification of the 
isolated sensor domain. One possible change to the proposed route would therefore be to 
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screen VanS solubility, stability and activity in other, cheaper detergents such as CHAPS, 
sodium cholate, LDAO, and purify in the most suitable candidate. Another possibility would 
be to change the affinity tag in order to reduce the number of purification steps. Sometimes 
the solubility of a recombinant protein can be improved by fusing it to a highly soluble 
partner. In particular, MBP tags have been used in several studies as fusion tags to purify 
aggregation-prone or low solubility polypeptides, by promoting folding of native 
conformations (Pryor & Leiting, 1997; Sachdev & Chirgwin, 1998; Kapust & Waugh, 1999).   
 
In one such system, which is commercially available (the pMAL Protein Fusion and 
Purification System, NEB), a gene can be cloned into a pMAL vector downstream from the 
malE gene (encoding for MBP), and an MBP-fusion protein is expressed. Using a pMAL 
system (e.g. pMAL-p5, NEB), the MBP-fusion protein is expressed which contains a 
polylinker sequence between MBP and the gene of interest, allowing for recognition by a 
specific protease and cleavage of MBP after expression Furthermore, the MBP-fusion 
protein can be selectively purified using amylose resin, and cleaved, without the need for any 
vector-derived residues in the protein (e.g. His-tags) and the fusion protein can be purified in 
one step. This route would reduce the quantity of DPC detergent required and decrease the 
total time required to express and purify 
15
N-labelled VanS proteins for NMR analyses.   
 
4.7.2 Optimised protocols for the expression of  
15
N-labelled VanS proteins 
 
15
N protein labelling strategies conducted were based on M9 minimal media preparations 
detailed in Sambrook et al., (1989), and media was supplemented with vitamins (BME, 
Sigma-Aldrich) and iron (75 μM iron (III) chloride), which was suggested to be sufficient for 
expression of membrane proteins in the absence of a trace metal mix (Studier, 2005). 
Expression trials initially involved full-length (unmutated) His-tagged VanS proteins, and 
expression protocols were optimised by testing different approaches given in the literature.  
[223] 
 
The first of which was a method employed by Cai et al., (1998), in which cell cultures were 
grown in rich Luria broth, up until the point of induction, when the media was switched to 
M9 minimal media containing isotopic labels, which greatly reduces the time required for 
expression. Secondly, Marley et al., (2001), showed that these methods can be further 
optimised by concentrating the cell suspension prior to exchanging media, giving ‘high-cell-
density’ expression which both reduces the amount of labelled media required (and hence the 
cost) and increases protein yield. And finally, Sivashanmugam et al., (2009) stated that the 
time between exchanging media and inducing should be lengthened to around two hours and 
incubating at the temperature for induction, in order to discharge unlabelled metabolites and 
preserve nutrients for protein synthesis. From all this literature information, protocols were 
combined and tested to examine protein expression in M9 minimal media (see Figure 4.4.1).  
 
Using these protocols, both VanSA and VanSSC proteins were overexpressed in 
15
N-labelled 
minimal media and at a similar level to that observed in the much richer LB media. In 
addition, it was shown that both supplementation with iron chloride in expression media, and 
concentrating the media to half its initial volume when exchanging into M9 (‘high-cell-
density’), almost doubled the yield of VanS protein (see Figure 4.4.3), demonstrating just 
how effective these strategies are. Even greater yields of the VanS proteins may have been 
achievable by concentrating cell cultures to 1/4 or 1/8
th
 of their original volume prior to 
induction, providied that the concentration of glucose and other nutrients (e.g. vitamins) was 
sufficient to support cell growth, since these concentration factors have been successful in 
the literature for several membrane proteins (Marley et al., 2001; Sivashanmugam et al., 
2009). Increased protein yields (of the order of 1 mM) would be necessary in order to obtain 
sufficient protein concentrations to assign protons to individual residues in the VanS sensor 
domain, and enable those residues involved in binding to glycopeptide ligands to be 
identified. These NMR assignments involve using three-dimensional HSQC techniques e.g. 
TOCSY-HSQC and NOESY-HSQC (Marion et al., 1989a; 1989b; Zuiderweg & Fesik, 
1989), which assign each proton spin system observed to a specific residue.  
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The assignment procedure simply involves inspecting a series of 2D TOCSY or NOESY 
spectra collected, viewed as 2D 
1
H(F1)-
l5
N(F3) slices, edited with respect to the frequency of 
the 
15
N heteronucleus in a third dimension (F2). Connections between residues can be 
identified from through-space (NOESY) correlations. By collecting 2D slices, those peaks in 
the spectrum with similar or overlapping chemical shift values can be separated in a third 
dimension, allowing residue assignment (Marion et al., 1989a; 1989b). It should be noted 
that assignment of the full sequence, including side chain hydrogen atoms may also require 
additional NMR experiments e.g. HCCH-TOCSY or HCCH-COSY.  
   
4.7.3 Obtaining high resolution 2D NMR spectra of the VanS sensor domain 
 
Initial 
1
H-
15
N HSQC NMR spectra were collected for uniformly 
15
N-labelled VanS sensor 
domains purified in DPC detergent, since this detergent had provided active (full-length 
protein) with respect to autophosphorylation, and appeared to produce stable, homogeneous 
and well-folded samples. HSQC spectra in DPC collected on a 700 MHz spectrometer 
showed that a number of peaks (~50) could be discerned, but further optimisation was 
clearly required in order to observe individual peak shifts during titration experiments. 
Therefore a number of conditions were optimised, including pH, temperature and buffer, and 
critically different detergents were screened to optimise spectral resolution. 
 
Raising the temperature from 298K to 310K did improve spectral quality, resulting in 
increased protein-micelle tumbling in solution, but above 310K significant reductions in 
signal were observed, indicating that 310K (37
o
C) was the optimal temperature for studies. 
This is useful as it reflects physiological conditions within bacterial cells. Reducing the pH 
also increased peak dispersity especially in the lyso-lipid detergent, LPPG, but the result was 
dependent on the detergent chosen, as the pH affects protein fold and stability. Overall, a 
near neutral pH is preferential anyway in ligand titration studies, since glycopeptide 
antibiotics such as vancomycin and teicoplanin are most soluble in the pH range 5 – 7.  
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For selecting the most suitable membrane mimetic for ligand binding studies, a wide 
detergent screen was conducted for both VanS proteins, involving detergents from 3 
different classes: anionic, zwitterionic and non-ionic. These screens showed that VanS 
proteins exhibited highest solubility in anionic (LPPG, LMPG, SDS) and (some) zwitterionic 
detergents (LMPC, DPC), rather than non-ionic ones, which reflects the PC/PG lipid 
composition of Gram-negative E. coli and Gram-positive enterococci and Streptomyces 
bacterial membranes. Of course, the extent of solubilisation is only one measure of a 
detergent’s suitability as a membrane mimetic, and both the stability and activity of the 
protein should ideally be assessed in each detergent. Although these were not tested in these 
screens, literature studies suggested that the lyso-phosphatidylglycerols (LPPG, LMPG) have 
been able to extract many large membrane proteins in a native, functional form and maintain 
their stability under conditions of high temperature and low pH over days to weeks (Foury et 
al., 1981; Huang et al., 1998; Krueger-Koplin et al., 2004). NMR spectra were therefore 
collected for VanS proteins purified into LPPG and LMPG lyso-phospholipid micelles.  
 
The NMR spectral quality of proteins solubilised in LPPG compared to those in DPC was 
markedly improved, as shown in Figure 4.6.2.3. The number of resolvable peaks was 
increased to >100 and the peak dispersity was significantly improved. Under these NMR 
conditions it should now be possible to observe any small conformational changes induced 
during ligand binding. The success of these lyso-lipids in NMR spectroscopy is thought to be 
due to their ability to stabilise protein folds through favourable interactions with their native 
phospholipid headgroups and lipid-like acyl chains, and to permit fluid rotation of proteins 
within the confines of the micelle (Krueger-Koplin et al., 2004; Koehler et al., 2010).  
 
A selection of the best observed spectra for the VanS proteins studied in different detergents 
in given in Figure 4.7.3.1, along with the conditions under which the spectra were obtained.  
Screening a number of factors that affect NMR spectral resolution has now provided optimal 
solution conditions and detergent selections, in order to study changes in peak chemical shift 
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on HSQC spectra during ligand titration experiments with antibiotic ligands (as detailed in 
section 5.4), and determine any residues which may be involved in binding. 
 
 
 
Figure 4.7.3.1: Optimal 2D 
1
H-
15
N HSQC spectra of the N-terminal sensor domains of 
VanSA and VanSSC proteins purified in various detergents and collected on a 700 MHz 
spectrometer at 310K. (A) 600 μM VanSA solubilised in 50 mM DPC, 50 mM NaCl, 20 mM 
HEPES pH 6.85, (B)700 μM VanSA solubilised in 50 mM LMPG, 50 mM NaCl, 50 mM 
sodium acetate pH 5.5, (C) 200 μM VanSSC N-terminal sensor domain solubilised in 50 
mM DPC, 50 mM NaCl, 20 mM HEPES pH 6.8, (D) 200 μM VanSSC N-terminal sensor 
domain solubilised in 50 mM LPPG, 50 mM NaCl, 50 mM phosphate pH 6.1.  
 
(A)
(D)
(B)
(C)
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5 Analysis of Receptor-Ligand Binding and Examination of 
the Role of Oligomerisation State in Receptor Signalling 
 
5.1 Introduction 
  
Protein-protein and protein receptor–ligand interactions play a crucial role in biological 
systems. Testing ligand binding to specific receptors is important both for theoretical studies 
and for drug development research. The main aspects of receptor-ligand binding interactions 
include binding affinity and kinetics, binding thermodynamics and conformations of targets 
(de Jong et al., 2005). Numerous methods are available to study protein-ligand binding, but 
perhaps the most commonly applied include fluorescent-labelled or radioreceptor assays, 
label-free chip-based assays such as Surface Plasmon Resonance (SPR) (Wilson, 2002), 
structure-based assays such as NMR or X-ray diffraction, and thermodynamic assays e.g. 
Isothermal Titration Calorimetry (ITC) (Rajarathnam & Rosgen, 2014). In this thesis, NMR-
based and fluorescence-based ligand binding assays are used to examine the binding of VanS 
to glycopeptide antibiotics. Details of the methodology for NMR spectroscopy are provided 
in section 2.14 and 5.4, and fluorescence spectroscopy techniques are outlined below. 
 
Fluorescence spectroscopy techniques involve excitation of a fluorophore, by unpolarised 
light (or in the case of fluorescence polarisation (FP) (Lea & Simeonov, 2011), linearly 
polarised light), and measurement of the resulting photons re-emitted. Upon ligand binding, 
changes will be observed in the light re-emitted, which usually involves an alteration in the 
emission intensity e.g. due to ‘quenching’, or a shift in emission peak wavelength (de Jong et 
al., 2005).  These fluorescence techniques often do not require separation or washing steps 
before measurement (so called ‘mix-and-measure’) (de Jong et al., 2005), allowing their 
application in high-throughput screening (HTS) experiments (Lea & Simeonov, 2011).  
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In relation to studies in this thesis, one such screening assay was developed by Popienek & 
Pratt, (1987), in which binding was screened for potential glycopeptide ligands to a 
fluorescently-labelled (Dansyl) derivative of the pentapeptide terminus of the cell wall 
precursor (refer to section 1.2). The fluorophore was excited at 330 nm and binding was 
identified from an increase in the intensity of light emitted at 550 nm, upon changes in the 
fluorophore environment. Using similar assays it may be possible to test for changes in 
fluorescence upon addition of potential glycopeptide ligands to VanS protein samples, 
provided that one of the molecules contains a fluorophore. If a direct interaction did occur, 
the environment of the fluorophore would be perturbed, altering its emission properties.  
 
As stated in section 1.4.2, fluorescent labelling strategies have recently been successfully 
applied to study VanS membrane proteins in the presence of glycopeptide ligands. Koteva et 
al., (2010), demonstrated for the first time, a direct covalent binding between a fluorescently 
labelled vancomycin analogue (VPP) and the VanS protein derived from S. coelicolor. Using 
a vanH gene reporter assay it was also shown that VPP was a bioactive ligand of VanS, able 
to induce resistance gene expression in vancomycin-resistant S. coelicolor in vivo. This VPP 
ligand is however synthetic and structurally different from natural vancomycin, so it is 
possible that vancomycin molecules may not interact via the same mechanism. Nonetheless, 
this VanSSC protein could act as a positive control in NMR-based vancomycin binding 
experiments, to establish whether other VanSA proteins are also activated by direct binding.  
 
Despite a number of biochemical assays conducted in the literature to determine the nature 
of the inducing ligand that activates VanS in Enterococcus faecium (VanSA), screens for 
antibiotic inducers of this system are not consistent (see section 1.4.1 and Table 1.4.3.1). 
Inducers have been identified by either assaying VanX activity in cell extracts (Baptista et 
al., 1996; Arthur et al., 1999), by monitoring induction of Lac-containing precursors (Allen 
& Hobbs, 1995), or by coupling the lacZ promoter under control of VanRS to a reporter gene 
(Lai & Kirsch, 1996; Ulijasz et al., 1996; Grissom-Arnold et al., 1997; Mani et al., 1998). 
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Biochemical data from all of these assays suggests that E. faecium VanSA is strongly induced 
by glycopeptide antibiotics, which would suggest a direct binding. However, in some assays 
it is also induced by other structurally unrelated compounds involved in late steps in cell wall 
biosynthesis, in particular, by moenomycin A. This has led to a general consensus in the 
scientific community that VanSA should be activated indirectly, either by sensing 
accumulation of a cell wall intermediate such as Lipid II (as a result of antibiotic inhibition 
of TG activity) or perhaps by interaction with Lipid II in complex with the glycopeptide 
antibiotic (Hong et al., 2008). By close examination of each assay technique, it can be seen 
that the screens provide conflicting evidence (see Table 1.4.3.3), since an inducer in one 
system is often not an inducer in another, for instance Grissom-Arnold et al., (1997), 
concluded that ramoplanin was an inducer whereas Baptista et al., (1996), conclude it is not. 
Even moenomycin A was found to be either weakly inducing (Grissom-Arnold et al., 1997), 
or in some assays, not inducing at all (Arthur et al., 1999; Lai & Kirsch, 1996) (see section 
1.4.1), so it is still possible than VanSA could be activated by direct glycopeptide binding.   
 
By comparison, similar biochemical assays showed that VanS proteins from E. faecalis 
VanSB and S. coelicolor VanSSC (see section 1.4.2 and Tables 1.4.3.2 & 1.4.3.3) were only 
induced by structurally related glycopeptides, and other antibiotics tested failed to activate 
VanS, so it therefore appears that these proteins are activated by direct antibiotic binding (as 
proposed from biophysical studies by Koteva et al., 2010). During this PhD I therefore hope 
to determine by biophysical studies including fluorescence- and NMR-based binding assays, 
whether each VanS protein binds directly to glycopeptide antibiotics or whether another 
signalling molecule or cell wall intermediate is involved in the activation of VanS. I also 
hope to improve understanding of the structures of VanS proteins from Enterococcus and 
Streptomyces using solution NMR spectroscopy.  
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Another question that requires investigation is: how does the VanS protein interacts with its 
ligand, to transduce a signal from the sensor domain to the kinase domain and effect a 
response? The extracytoplasmic sensor domains show little or no sequence homology 
between VanS proteins and yet can respond to multiple signals. By examining published 
structures of HK sensor domains there do, however, appear to be several common structural 
folds, suggesting some conserved signal sensing mechanisms. DHp and CA domains are 
common elements of HKs and have conserved sequence motifs (as discussed in section 
1.5.3) (Dutta et al., 1999). There are also a variety of modular elements that are commonly 
found N-terminal to the catalytic domains, which are believed to be involved in stimulus 
perception and transduction, such as PAS, GAF (see section 1.5.3) and HAMP domains (see 
section 1.5.5). HAMP domains are positioned directly after the second TM domain, and 
consist of two helices that form a four-helix bundle in the homodimeric active state. They are 
thought to transduce signals from the extracytoplasmic sensor domain to the catalytic kinase 
core via either ‘cog-like’ rotations of this bundle (Hulko et al., 2006; Ferris et al., 2012) or a 
‘screw-like’ movement (Airola et al., 2010).  Therefore a multiplicity of domains exist in the 
HK sensor complex, to allow multiple signals to be transduced and effect sensor kinase 
activity. It is likely that structural changes that occur in the extracytoplasmic sensor region 
upon ligand binding, trigger signal transduction through the TM helices to the kinase 
domain, via conformational changes in PAS/GAF/HAMP domains (as proposed in a recent 
TCS signalling model by Casino et al., 2009, shown in Figure 1.5.5.4).  
 
It is still not clear what the role of the TM helices play in the mechanism of signal 
transduction, but rotations or interactions between TM helices have been suggested (Cheung 
& Hendrickson, 2010; Zhang & Hendrickson, 2010). Structures of sensor domains in the 
literature have usually been obtained by truncating these transmembrane regions, and the 
resulting isolated domains are monomers in solution (see Figure 1.5.3.3) (Cheung et al., 
2008; Cheung & Hendrickson, 2009; 2010). However, they are expected to form dimers in 
the context of the whole protein since the DHp and HAMP domains are homodimers. 
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Therefore, homo-dimerisation of the TM domains (and the full-length protein) is likely to 
occur, and requires further investigation to understand its role in the signalling mechanism. 
To this end, gel-based Blue Native PAGE (BN-PAGE) assays are conducted to assess 
oligomerisation of full-length VanS, and in vivo reporter assays (ToxCAT/ GALLEX) are 
tested to analyse homo-dimerisation of VanS transmembrane helices (TM-TM interactions).  
 
Blue Native PAGE (BN-PAGE) techniques can identify native membrane protein complexes 
on PAGE gels, without denaturing the protein (Schagger & von Jagow, 1991) and can be 
conducted in different detergents, in order to determine protein oligomeric state, relative to 
standards. Samples of VanS proteins purified into detergent micelles are analysed by BN-
PAGE to identify their oligomeric state. The detergents tested included those used in 
structural (NMR, Crystallography) and enzymatic assays, and therefore could identify if, for 
instance a homodimeric complex was present, which could be important in ligand binding or 
in signal transduction mechanisms.   
 
The ToxCAT assay (Russ & Engelman, 1999) (see section 2.7) quantifies the strength of 
homo-oligomerisation of TM domains, and the GALLEX assay (Schneider & Engelman, 
2003; Cymer et al., 2013) quantifies either the homo- or hetero-oligomerisation of TM 
domains. The two assays differ in the fusion construct design involved and the assay product 
quantified. For the ToxCAT assay, the TM domain of interest is cloned into a fusion 
construct flanked by a periplasmic MBP anchor and a cytoplasmic ToxR domain, whereas in 
GALLEX the ToxR is replaced by LexA (LEX) protein. Upon dimerization, the ToxR or 
LexA domains come into close contact, and activate transcription of reporter genes encoding 
either chloramphenicol acetyltransferase (CAT) or β-galactosidase (GAL), which can be 
assayed by different methods. There are indications in the literature that TM-TM 
interactions influence downstream signalling to the catalytic kinase domain. For instance 
Jeffery & Koshland, (1994), found that a single substitution of an isoleucine with a 
[232] 
 
phenylalanine in the second TM domain (TM2) of the Tar chemotaxis receptor, led to a 
significant alteration in receptor activation. By conducting ToxCAT and GALLEX assays 
it should be possible to quantify the level of homo- or hetero-oligomerisation for VanS, to 
improve understanding of the role of TM-TM interactions in signalling.   
 
This chapter therefore focuses on trying to answer the following questions: 
- Does vancomycin bind directly to VanS proteins from different species? 
- Do transmembrane helix-helix interactions play a role in signalling and does the 
oligomerisation state of the VanS sensor affect its ligand binding?  
 
5.2 Aims 
 
(i) To determine whether binding can be observed between glycopeptide antibiotics and 
VanS proteins using fluorescence spectroscopy and solution state NMR. 
(ii) To identify any conserved residues in the VanS sensor domain that are involved in 
binding to glycopeptide ligands, by conducting NMR titration experiments, and 
analysing changes in peak chemical shift at each titration point.   
(iii) To determine the oligomerisation state of detergent-solubilised full-length VanS 
proteins using gel-based PAGE techniques, in order to increase understanding of the 
role of oligomerisation state upon ligand binding.   
(iv) To investigate transmembrane helix-helix association, using in vivo reporter assays, 
to improve knowledge of the means by which signals are transduced across the 
bacterial membrane to the kinase core.  
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5.3 Analysis of Ligand Binding by Fluorescence Spectroscopy 
 
Initially, fluorescence spectroscopy was conducted as a qualitative measure to test for an 
interaction between purified VanS proteins and a fluorescently-tagged vancomycin 
glycopeptide. In these studies, the fluorescent vancomycin analogue chosen was readily 
available from Sigma-Aldrich, and was selected based on previous success in the Warwick 
group, in which the fluorescent probe was used to image SDS-PAGE gels (Abrahams, 2011) 
containing transglycosylated polymerised Lipid II molecules of different chain lengths 
(visualised under a fluorescent light filter). The probe contained a BODIPY molecule 
covalently linked to vancomycin, and is a class of fluorescent dye (BODIPY-vancomycin, 
Molecular Probes) (for structure, see Figure 2.11.1).  
 
The major use of BODIPY dyes is in cell imaging studies such as fluorescence imaging 
microscopy (DeDent et al., 2007; Pereira et al., 2007). Despite their small Stokes shift;  
BODIPY-vancomycin has an excitation wavelength of 504 nm and an emission wavelength 
~ 511 nm, the dyes have high fluorescence quantum yields (even in water) and sharp peaks, 
whose position remain almost unchanged in different solvents, making them ideal for ligand 
binding studies in detergent environments. BODIPY-vancomycin was solubilised in HEPES 
buffer and its emission spectrum monitored upon excitation at 504 nm, with and without the 
addition of detergent, to examine its suitability for these studies. The stock concentration of 
BODIPY dye in the buffer was calculated as approximately 100 μM, from its observed 
absorbance at 504 nm using an extinction coefficient of 78000 M
-1
 cm
-1
.  
 
Microliter additions from a 40 mM DPC stock solution were added to the BODIPY-
vancomycin at 10 μM in buffer, mixed thoroughly, and the emission spectra recorded (see 
Figure 5.3.1). As observed from overlayed emission spectra, BODIPY-vancomycin has an 
emission maximum of 510 nm in buffer, which shifts by less than 1 nm in the presence of 
detergent micelles showing the low environment dependence of the BODIPY fluorophore. 
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The CMC of DPC is approximately 1 mM, so all studies were therefore carried out above 
this, at a final concentration of 2 mM (0.1% w/v DPC) which was maintained throughout. It 
should be noted that a second peak at ~ 506 nm is present in all detergent-containing 
samples. However this almost directly overlaps with the excitation wavelength (505 nm) and 
must result from light scattering in the detergent solution. 
 
 
Figure 5.3.1: Overlayed emission spectra upon excitation of BODIPY-vancomycin dye in 
HEPES buffer and/or DPC. Aliquots of a 40 mM DPC solution were added to 10 μM 
BODIPY-vancomycin dissolved in HEPES buffer (red line), to final concentrations of 1 mM 
(green line) or 2 mM (blue line), and allowed to mix before recording emission spectra.   
 
Since the presence of detergent did not greatly affect the emission spectra, it was possible to 
test samples containing detergent-solubilised VanS proteins or Lipid II molecules. Adding 
Lipid II molecules to a solution of BODIPY-vancomycin, would act as a control experiment, 
since vancomycin is known to bind to the D-Ala-D-Ala N-terminus of Lipid II (Walsh et al., 
1996). Binding of proteins to ligands often causes changes in their 3D structures, and if this 
affects the environment of a fluorophore, it can result in measurable changes in the spectrum, 
such as a shift in the position of the emission maximum or the emission intensity (Möller & 
Denicola, 2002). Therefore an interaction between Lipid II and the vancomycin analogue 
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could influence the environment of the BODIPY fluorophore, and could cause a change in its 
emission spectrum. Similarly, if an interaction occurred between VanS proteins and the 
vancomycin analogue, this may also be observed by changes in the spectrum.     
 
Samples were prepared as before by adding DPC detergent into a 10 μM solution of 
BODIPY-vancomycin, up to a final concentration of 2 mM (2 x CMC), and subsequently 
titrating in Lipid II or VanS protein (refer to section 2.11).  For those samples containing 
BODIPY-vancomycin, DPC and Lipid II, an aliquot of Lipid II was pipetted into a glass vial, 
immediately dried under nitrogen to a film and resuspended with vortexing, using the 
solution of BODIPY-vancomycin (10 μM BODIPY-vancomycin in 20 mM HEPES pH 7.8, 
2 mM DPC). Further aliquots of Lipid II were added in the same way, to final concentrations 
of 10 - 40 μM, and the emission spectra of all samples measured (see Figure 5.3.2).   
 
 
Figure 5.3.2: Overlayed emission spectra upon excitation of BODIPY-vancomycin dye in 
HEPES buffer containing DPC, and increasing concentrations of detergent-solubilised 
Lipid II. Aliquots of a 40 mM DPC solution were added and mixed with 10 μM BODIPY-
vancomycin dissolved in HEPES buffer to a concentration of 2 mM (red line), and the 
solution used to resuspend a lipid film to give final concentration of Lipid II of 10 μM (green 
line), 20 μM (blue line), 30 μM (orange line) or 40 μM (purple line). A control spectrum was 
also recorded for the excitation of Lipid II solubilised in 2 mM DPC (dashed line). 
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This experiment showed an appreciable shift in the position of the emission maxima of about 
4 nm, which is an indication that the Lipid II and vancomycin dye are interacting. Successive 
additions of Lipid II did not appear to greatly affect the maxima position, but this may be 
anticipated since only 1 molecule of Lipid II is able to bind 1 molecule of vancomycin at a 
time, and at the first addition, the concentration of vancomycin and Lipid II was 10 μM (1:1 
ratio). The emission intensity also decreases appreciably upon adding Lipid II, but this 
quenching does not necessarily indicate an interaction, since BODIPY dyes also self-quench, 
therefore shifts in the position of the emission maximum are more informative of an 
interaction. Based on the success of these experiments with Lipid II, similar methods were 
applied to samples of vancomycin dye and VanS protein (see Figures 5.3.3 and 5.3.4). 
 
 
Figure 5.3.3: Overlayed emission spectra upon excitation of BODIPY-vancomycin dye in 
HEPES buffer containing DPC, and increasing concentrations of detergent-solubilised 
VanSA. DPC detergent-containing solution was added and mixed with 10 μM BODIPY-
vancomycin dissolved in HEPES buffer to a concentration of 2 mM (red line), to which 
microliter aliquots of purified detergent-solubilised VanSA protein was added at final 
concentrations of 1 μM (green line), 2 μM (blue line), 3 μM (orange line) or 5 μM (purple 
line). A control emission spectrum was also recorded for excitation of VanSA solubilised in 2 
mM DPC (dashed line). 
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Figure 5.3.4: Overlayed emission spectra upon excitation of BODIPY-vancomycin dye in 
HEPES buffer containing DPC, and increasing concentrations of detergent-solubilised 
VanSSC. DPC detergent-containing solution was added and mixed with 10 μM BODIPY-
vancomycin dissolved in HEPES buffer to a concentration of 2 mM (red line), to which 
microliter aliquots of purified detergent-solubilised VanSSC protein was added at final 
concentrations of 1 μM (green line), 2 μM (blue line), 3 μM (orange line) or 4 μM (purple 
line). A control emission spectrum was also recorded for excitation of VanSSC solubilised in 
2 mM DPC (dashed line). 
 
Microliter aliquots of IMAC purified VanS proteins (at 3-6 mg/ml in 20 mM HEPES pH 7.8, 
2 mM DPC) were added directly to a solution of detergent-solubilised10 μM BODIPY-
vancomycin dye. After thorough mixing, the emission spectrum was measured upon 
excitation at 504 nm (Figures 5.3.3 and 5.3.4). Further aliquots of VanS were added until no 
appreciable changes in the spectra were observed, and the total volume change from 
additions was maintained below 10%. Emission spectra of the BODIPY dye in the presence 
of detergent-solubilised VanS proteins did not display the same level of quenching, but 
importantly, the emission maximum still shifted by a significant amount and continued to 
shift with increasing concentration of VanS, up to a limit.  
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For both VanSA and VanSSC, a cumulative shift in peak wavelength of 3-4 nm was observed 
at the final addition (4/5 μM final concentration), which is similar to that of the Lipid II 
control, and suggests that both full-length VanS proteins could be interacting with the 
vancomycin analogue. This is in agreement with binding studies conducted by Koteva et al., 
(2010), who demonstrated covalent binding between VanSSC proteins and a vancomycin 
derivative (a vancomycin photoaffinity probe).  However, no direct binding has been 
previously observed between VanSA proteins and vancomycin, so these results contradict the 
consensus view in the scientific community (based on biochemical data as mentioned above, 
and in detail in section 1.4.1) that VanSA should be activated by an indirect mechanism in the 
presence of vancomycin. The fluorescence data presented therefore suggests a direct 
interaction (whether it be productive or not) between the vancomycin analogue and both 
VanSA and VanSSC proteins. It should however be noted that there are other possible 
explanations for the changes observed in the fluorescence spectra. For instance, the spectra 
are detergent sensitive, so if vancomycin binds directly to the micelle, this will alter the 
micelle structure and dynamics, and indirectly affect the fluorescence observed (rather than 
the changes resulting purely from direct binding).  
 
Much more data still needs to be collected using other biophysical techniques in order to 
ascertain if vancomycin can bind directly to VanS, and whether any direct interaction 
activates the kinase. To this end, the fluorescence data acts as a starting point, prior to more 
quantitative, ligand-binding studies such as SPR, ITC or solution state NMR, the latter of 
which is detailed in section 5.4 below.  
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5.4 Analysis of Ligand Binding by Solution State NMR Spectroscopy 
 
In order to more quantitatively ascertain whether a direct binding is occurring between VanS 
proteins and vancomycin antibiotics, solution state NMR techniques were applied. NMR 
spectroscopy is an attractive technique for studying protein-ligand interactions because many 
molecules have (or can be enriched with) NMR-active nuclei (e.g. 
13
C/
15
N/
1
H) and a single 
analysis can provide a vast amount of structural and binding affinity data without destroying 
the sample (Lucas & Larive, 2004). In addition, unlike fluorescence or spectrophotometric 
techniques, it is less prone to giving false positive results (Williamson, 2013), and can 
provide data on small conformational changes in the protein during ligand binding. 
 
Ligand-based NMR screening and the identification of ligand-binding conformations by 
NMR are becoming routine in the pharmaceutical industry and are important tools in the 
rational drug-discovery process (Lucas & Larive, 2004). Combinatorial libraries of 
thousands of ligands can be synthesised and potential drug candidates screened against a 
specific target such as an enzyme or cell surface receptor for activity. Several solution-state 
NMR techniques have therefore been developed to study protein-ligand interactions, which 
are extensively reviewed in the literature e.g. by Fielding (2003) and Meyer & Peters (2003) 
and the choice of technique is often based on whether the ligand or the protein is labelled.  
 
Protein-based techniques include monitoring changes in chemical shift (δ) by calculating 
Chemical Shift Perturbations (CSP) and require isotopically enriched or selectively labelled 
protein samples. Ligand-based techniques include those based on relaxation (Hajduk et al., 
1997), Saturation Transfer Difference (STD) (Mayer & Meyer, 1999) and Pulsed-field 
gradient (PFG) (Lucas & Larive, 2004) NMR, and can be more desirable as spectra are better 
resolved than those of large proteins. However, all these techniques require labelled protein 
or ligand, which must be expressed or synthesised and although ligand-based assays are 
useful for screening, they cannot identify specific residues of the protein involved in binding. 
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Therefore, in these studies, protein-based techniques were chosen since VanS proteins had 
already been successfully isotopically labelled, purified and solution conditions optimised 
(see section 4.6). Additionally, ligand-based techniques would require the use of labelled 
(
13
C)-vancomycin, which is naturally expressed unlabelled, as a vancomycin hydrochloride 
in Streptomyces orientalis, so the bacteria would need to be grown in media containing [1-
13
C] or [U-
13
C] glucose. Using protein-based methods, the labelled proteins were mixed with 
unlabelled ligands, and protein-ligand binding was analysed. In this instance, the changes in 
protein chemical shifts were analysed by a Chemical Shift Perturbation (CSP) experiment.  
 
5.4.1 Chemical Shift Perturbation NMR Analysis 
 
For CSP experiments, the ligand is titrated into a sample containing the protein, and protein 
chemical shifts are monitored at each stage of the titration by acquiring a series of 2D 
1
H-
15
N 
HSQC spectra. The chemical shift is highly sensitive to structural changes, and can be 
measured accurately, meaning that virtually any genuine binding interaction will produce 
CSPs. The analysis is also relatively simple in its basic form; measure the chemical shifts at 
each titration point; follow the movement of peaks in the 
1
H and 
15
N dimensions; those that 
shift the most are likely to map to the binding site for the ligand. A titration curve (of 
chemical shift vs. concentration of ligand) can also be fitted to obtain a value for the 
dissociation constant of the ligand (KD).  
 
Several issues can still arise from using this analysis technique including scenarios where 
multiple binding modes occur or when the dynamics of the system change upon binding, e.g. 
from fast exchange to slow or intermediate exchange (Williamson, 2013). Additionally, 
several controls must be measured during the titration; the same buffer must be used for both 
protein and ligand (including detergent present), and the pH should remain constant between 
ligand additions (or adjusted if necessary), since even small changes in the pH, salt 
concentration or detergent concentration can alter protein signals and peak positions.  
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CSP experiments were therefore conducted by collecting initial 
1
H-
15
N HSQC spectra of 
15
N-
labelled VanS proteins in an appropriate solubilising detergent and buffer. Next, dissolved 
and detergent-solubilised, vancomycin was titrated into the NMR sample (in the same 
detergent and buffer) (see section 2.14.2 for full experimental details) and chemical shift 
changes were monitored at each titration point. The pH was controlled by maintaining it to 
within 0.05 units over all titrations. Vancomycin stock solutions were prepared at 10-20 mM 
concentrations by dissolution in an appropriate buffer (containing 5 mM detergent) and 
titrated into the NMR sample at [vancomycin]:[protein] molar ratios of 1:1, 2:1, or 4:1.  
 
All NMR titrations were allowed to equilibrate after mixing for 15-30 minutes, before 
centrifuging at 13,000 rpm for 10 minutes in a benchtop centrifuge, to pellet any insoluble 
material, and loading the supernatant into 3 mm BrukerMATCH NMR tubes for analysis. 
Initially, vancomycin was titrated into samples containing the sensor domains of VanSA 
proteins at ~120 μM which had been solubilised in 50 mM DPC, 50 mM sodium acetate 
buffer pH 5.5 (Figure 5.4.1.1). The vancomycin was added to a final concentration of 0.48 
mM and was soluble in NMR buffer at room temperature and at 310K in the spectrometer.  
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Figure 5.4.1.1: Overlayed 2D 
1
H-
15
N HSQC spectra of 120 μM VanSA N-terminal domain 
solubilised in 50 mM DPC, before and after addition of detergent-solubilised vancomycin. 
Both the protein and vancomycin were solubilised in 50 mM Phosphate pH 5.5 and 75 mM 
NaCl. [Vancomycin]:[protein] ratios of 0:1 and 4:1 were tested and spectra collected at 
310K on a 700 MHz Bruker spectrometer. Peaks of interest are highlighted with arrows.  
 
It was anticipated that the addition of excess vancomycin would result in multiple peak 
shifts, and their chemical shifts could be mapped for each titration to conduct a CSP analysis. 
However, no significant peak shifts were observed, and instead several peaks (marked with 
arrows on Figure 5.4.1.1) were observed to disappear in the presence of excess antibiotic.  
It was not possible to determine if those peaks had broadened or become narrower during 
titrations, as a result of interaction with the antibiotic. However, according to Williamson, 
(2013), as a ligand is titrated into a sample containing protein, when exchange is fast i.e. 
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when koff  >> Δδ (of free and bound ligand), the signals will move smoothly from their 
position in the free spectrum to their position in the bound spectrum. By contrast, if the 
exchange rate is slow on the chemical shift timescale i.e. when ‘off rate’ (koff) << Δδ (of free 
and bound ligand), the free signal gradually disappears and the bound signal appears, with 
the intensity of the two peaks reflecting the concentrations of free and bound ligand. In the 
limit of very slow exchange, the peaks may also broaden and disappear. Furthermore, if the 
exchange rate is similar to the chemical shift difference i.e. when koff  ~ Δδ (of free and 
bound ligand), signals will broaden and shift simultaneously. Observed peak changes during 
exchange are illustrated in Figure 5.4.1.2. It is therefore possible that protein-vancomycin 
interactions occur in DPC detergent, but could involve slow exchange to a bound state.           
       
 
Figure 5.4.1.2: The appearance of 2D NMR peak shape under different rates of exchange. 
Adapted from Williamson, (2013). (Left): During fast exchange, peaks move smoothly from 
free (blue) to bound (red) state (see arrows). (Right): During slow exchange, the free peak 
(blue) decreases in intensity as the bound peak (red) increases. 
 
In order to establish whether the peak disappearances observed for VanSA in the presence of 
vancomycin were indicators of ligand binding, and if so, what the rate of exchange between 
free and bound states was, protein samples containing the VanSA sensor domain were re-
tested in either the same detergent (DPC) but at different pH, or solubilised in another 
detergent, and spectra collected.  
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In Figure 5.4.1.1 the solution pH was 5.5, so a more neutral pH of 6.8 was selected for 
further analysis, in order to provide a more physiologically relevant environment for the 
ligand to bind to VanS. All titrations were again performed at 0:1, 1:1 and 4:1 ratios of 
[vancomycin]:[protein] to observe any changes in peak intensity or chemical shift during 
additions (see Figure 5.4.1.3 Panel A). Solubilisation of VanSA protein in DPC detergent at 
the increased pH of 6.8 (Figure 5.4.1.3A) resulted in similar peak changes and 
disappearances (marked with arrows) to those in Figure 5.4.1.1 (at pH 5.5), although the 
higher pH led to reduced peak dispersity. Therefore peak changes observed upon 
vancomycin addition can be seen to occur across the relevant pH range (5-7).  
 
Titrations were next performed for samples of the VanSA sensor domain in different 
detergents (LMPG: Figure 5.4.1.3B, and LPPG: Appendix Figure 12), with the aim to 
investigate antibiotic binding for a range of protein folds. It should be noted that samples in 
the lyso-phospholipids (LMPG and LPPG) were usually solubilised in sodium acetate buffer 
at pH ~5.5, because Krueger-Koplin et al., (2004) had shown that for their membrane 
proteins, sample lifetimes were not significantly affected by buffering in the range of pH 4.5 
to 8.0, and reduced amide broadening could be achieved around pH 5-6.  
 
A comparison of samples of VanSA solubilised in DPC detergent with those solubilised in 
LMPG detergent (Figures 5.4.1.3A and 5.4.1.3B respectively) also shows a number of peaks 
that shift and/or disappear during ligand titrations (marked on both figures with arrows), with 
relatively similar peak positions. In particular, reasonably large peak shifts are observed in 
LMPG detergent (Figure 5.4.1.3B), which could indicate a direct interaction between 
vancomycin and the VanSA protein. The peak shifts also appear to cluster to a particular 
region of the spectrum (see arrows in Figures 5.4.1.3A and B) for VanSA protein samples 
solubilised in different detergents and at different pHs, and therefore may indicate a possible 
binding site (provided that the identity of the peaks indicated are equivalent residues).   
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Figure 5.4.1.3: Overlayed 2D 
1
H-
15
N HSQC spectra of (a) 600 μM VanSA N-terminal domain solubilised in 50 mM DPC, 20 mM HEPES pH 6.85, or (b) 
700 μM VanSA N-terminal domain solubilised in 50 mM LMPG, 50 mM sodium acetate pH 5.5, during titration of detergent-solubilised vancomycin. 
[Vancomycin]:[protein] ratios of 0:1 (red), 1:1 (green) and 4:1 (blue). All spectra were collected at 310K and peaks of interest are highlighted with arrows.
(a) (b)
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As a further test to examine vancomycin binding, samples of VanSSC proteins were 
solubilised in detergent, and HSQC spectra recorded at each titration point. VanSSC proteins 
were solubilised in LPPG or DPC detergent, under similar conditions to those for the VanSA 
proteins, and titrations conducted at identical molar ratios of vancomycin: protein. Peak 
shifts of interest were marked with arrows on Figure 5.4.1.4 (in LPPG) and Appendix Figure 
13 (in DPC), and it is clear that several of the peaks indicated are observed in similar regions 
to those in the VanSA spectra (for the same detergent). It is therefore possible, that 
vancomycin may be directly interacting with both VanS proteins in detergent micelles, and 
perhaps even at residues with similar identity. However, other possibilities for observed  
peak shifts should also be considered. For instance, the position of many peaks in the HSQC 
spectra of the VanS proteins are affected by the detergent chosen (e.g. comparing Figure 
5.4.1.3A with Figure 5.4.1.3B), and if the structure of the detergent micelle is altered e.g. 
upon binding to vancomycin, this could in turn alter the structure of VanS (within the 
micelle) and hence indirectly affect peak chemical shifts, rather than necessarily resulting 
from a direct binding.  
 
In order to identify those peaks which had statistically significant chemical shift changes, 
and hence provide supporting evidence for a direct binding, a Chemical Shift Perturbation 
Analysis was conducted for each protein in each detergent (see Figure 5.4.1.5). This 
identified those peaks with a chemical shift change (Δδ) greater than that of the standard 
deviation for all peaks in the spectrum (using Equation 4, see Figure 5.4.1.5). Ideally, the 
peaks would be assigned to specific residues in the VanS proteins, however efforts towards 
assignment are still underway in the laboratory. Optimisation of protein concentration to 
allow collection of 3D spectra such as TOCSY-HSQC or NOESY-HSQC with improved 
signal-to-noise ratios is required and was not achievable in the time available, despite 
considerable efforts. Therefore further discussion of peak perturbation and broadening in this 
chapter is done in the absence of protein assignments.   
 
[247] 
 
 
 
Figure 5.4.1.4: Overlayed 2D 
1
H-
15
N HSQC spectra of 200 μM VanSSC N-terminal domain 
solubilised in 50 mM LPPG, 50 mM phosphate pH 6.1, during titration of detergent-
solubilised vancomycin. [Vancomycin]:[protein] ratios of 0:1 (red), 1:1 (green) and 4:1 
(blue) were tested. All spectra were collected at 310K and peaks of interest are highlighted.
*
[248] 
 
For each CSP analysis, all peaks in the HSQC spectrum were picked at each titration point 
(0:1, 1:1 and 4:1 [ligand]:[protein] ratios) and the 
1
H and 
15
N peak values were recorded and 
tabulated. The difference in 
1
H (  
 ) or 
15
N (  
 ) chemical shift value of each peak (at each 
titration point) was calculated by subtracting against the chemical shift value of the 
corresponding peak in the spectrum containing only the protein in detergent (i.e. at 0:1 
[ligand]:[protein]). The relative chemical shifts of the 
1
H and 
15
N nuclei were then weighted, 
and the chemical shift change, (Δδ), calculated according to Equation 4 (Grzesiek et al., 
1996; Garrett et al., 1997):  
 
    √    [  
       
  ]    (4) 
 
This equation is standard practice in CSP analysis, and calculates the average (or summed) 
Euclidean distance moved for each peak in 
1
H and 
15
N dimensions, using an appropriate 
scaling factor, α, for values in 15N (Williamson, 2013). Although there is no theoretical value 
for the scaling factor, several groups have taken the chemical shift range for 
1
H and 
15
N, and 
used this to provide a scale. For example, the range of backbone 
15
N chemical shifts for both 
VanSA and VanSSC is approximately 130 – 105 ppm, and the range of 
1
H
N
 shifts is 
approximately 10.4 – 6.8 ppm, so the scale factor should be 3.6/25 or approximately 0.14. 
This is value for α is common in the literature (Williamson, 2013; Williamson et al., 1997), 
and was used throughout CSP analyses of VanS proteins in this study.  
 
By picking and numbering peaks for VanS proteins at each titration point (in ascending 
1
H
N
 
value), and calculating the chemical shift change (Δδ) for those peaks, it was possible to 
produce a bar graph of peak number (as opposed to residue number, for reasons discussed 
previously) against CSP to illustrate the number and magnitude of shifts observed (Figure 
5.4.1.5A and 5.4.1.5B). Peaks displaying the largest CSPs are likely to indicate an amide or 
side-chain proton involved in binding, however, a threshold value had to be calculated to 
decide which shifts were large enough to be considered indicators of the binding site. 
[249] 
 
Generally, the standard deviation of the shift changes (σ) is calculated (Schumann et al., 
2007), to identify residues with significant chemical shift change (i.e. those with Δδ > σ). 
Typically if the ligand binds in a well-defined binding site, there should be chemical shift 
changes in excess of 0.2 ppm in 
1
H
N
. However, if the ligand binds in a less well defined 
orientation, changes will be smaller (Williamson, 2013). For example, Morrison et al., 
(2003) found that a phenylalanine-containing peptide ligand bound to their protein in a 
number of conformations, and the largest chemical shift change (Δδ) was only 0.08 ppm in 
1
H
N
. Therefore, CSP analysis alone only gives an indication of the region involved in 
binding, and the absolute shift measured will vary widely for different systems. The 
chemical shift change calculated also varies depending on the degree of saturation reached, 
for example, larger shifts will be observed at ligand:protein molar ratios of 4:1 versus 1:1. 
This is evident in Figure 5.4.1.5, whereby shift changes increase in Panel B (4:1-0:1) versus 
Panel A (1:1-0:1), because the molar ratio of ligand:protein is greater.  
 
In Figure 5.4.1.5, those peaks with high chemical shift changes during ligand titrations are 
starred and numbered (in increasing 
1
H chemical shift) e.g. 1*, and are annotated onto 
overlayed HSQC spectra in Figure 5.4.1.6, to highlight shifts that indicate genuine binding. 
This bar graph for the analysis of CSP values was created based on a paper by Morrison et 
al., (2003) (mentioned above), who saw similar shifts, often with peak overlap. The group 
picked peaks and plotted them on bar graphs against calculated chemical shift perturbations, 
to determine peak changes of relevance. Based on these methods, CSP analyses were 
conducted for vancomycin titrations into samples of VanSA protein solubilised in DPC, and 
VanSSC protein solubilised in LPPG detergent. Shifts significantly above the threshold value 
(see Appendix Figures 14 and 15) are annotated by stars on the corresponding overlayed 
HSQC spectra, which are shown in Figures 5.4.1.7 and 5.4.1.8 respectively, zoomed in on 
the region containing these starred peaks.  
[250] 
 
 
Figure 5.4.1.5: Chemical shift changes for individual peaks in the 
1
H-
15
N HSQC spectrum 
of VanSA protein in LMPG (Fig. 5.4.1.3B) upon addition of vancomycin, represented by a 
bar chart of peak number (ascending 
1
H
N) against chemical shift change (Δδ). Changes 
for side-chain and backbone 
1
H
N
 protons were calculated using the equation:  
    √    [  
          
  ], against a threshold value (σ, red line). Peaks with significant 
CSPs are annotated by starring. (A) Chemical shift changes upon adding a 1:1 molar ratio 
of  [vancomycin]:[protein] (B) Chemical shift changes upon adding a 4:1 molar ratio of  
[vancomycin]:[protein]. 
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Figure 5.4.1.6: Overlayed 2D 
1
H-
15
N HSQC spectra of 700 μM VanSA N-terminal domain 
in 50 mM LMPG during titration of vancomycin, zoomed in to the region of 7.5-8.4 ppm 
in 
1
H and 127-110 ppm in 
15
N, in Figure 5.4.1.3B. [Vancomycin]:[protein] ratios of 0:1 
(red), 1:1 (green) and 4:1 (blue) were tested at 310K. Peaks with significantly high chemical 
shift changes, according to CSP analysis, are starred and numbered and their positions 
(prior to ligand addition) annotated onto the spectra.  
[252] 
 
 
Figure 5.4.1.7: Overlayed 2D 
1
H-
15
N HSQC spectra of 600 μM VanSA N-terminal domain 
in 50 mM DPC during titration of vancomycin, zoomed in to the region of 7.5-8.2 ppm in 
1
H and 125-110 ppm in 
15
N, in Figure 5.4.1.3A. [Vancomycin]:[protein] ratios of 0:1 (red), 
1:1 (green) and 4:1 (blue) were tested at 310K. Peaks with significantly high chemical shift 
changes, according to CSP analysis (see Appendix Figure 14), are starred and numbered 
and their positions (prior to ligand addition) annotated onto the spectra. Those peaks that do 
not shift, but instead disappear upon addition of vancomycin are indicated by arrows.  
[253] 
 
 
 
Figure 5.4.1.8: Overlayed 2D 
1
H-
15N HSQC spectra of 200 μM VanSSC N-terminal domain 
in 50 mM LPPG during titration of vancomycin, zoomed in to the region of 7.4-8.2 ppm in 
1
H and 123-108 ppm in 
15
N, in Figure 5.4.1.4. [Vancomycin]:[protein] ratios of 0:1 (red), 
1:1 (green) and 4:1 (blue) were tested at 310K. Peaks with significantly high chemical shift 
changes, according to CSP analysis (see Appendix Figure 15), are starred and numbered 
and their positions (prior to ligand addition) annotated onto the spectra. 
[254] 
 
CSP analyses confirmed that several of the perturbations marked with arrows in Figures 
5.4.1.3A and B, and 5.4.1.4A were likely to be significant, as they lie well above the 
calculated standard deviation across all resolvable peaks analysed, and are starred in Figures 
5.4.1.6 to 5.4.1.8. The CSP data provides further evidence for a direct interaction between 
vancomycin and VanS proteins, and several residues (as yet unassigned) in similar chemical 
environments are indicated to be involved. Despite this statement, the magnitude of the shifts 
are small (similar to that presented by Morrison et al., 2003), which could mean the 
vancomycin interacts weakly or transiently with VanS, or presents different conformations 
(i.e. not a well-defined binding site), but the data does suggest an interaction between VanS 
and vancomycin, which causes perturbation of a number of proton signals. 
 
Further insight can be gained by examining individual peak shifts in overlayed HSQC 
spectra. Individual peaks (annotated with stars) were selected from the spectra of VanSA in 
LMPG detergent (Figure 5.4.1.6) or VanSSC in LPPG detergent (Figure 5.4.1.8), and are 
shown in Figure 5.4.1.9, to demonstrate the dependence of chemical shift on vancomycin 
concentration. Overall, most peaks in the spectra did not shift (above the standard deviation), 
and some disappeared with excess ligand, which may have resulted from altered dynamics 
upon binding. However, for those peaks that did display a CSP, the peak position moves 
roughly along a direct line, as a function of increasing antibiotic concentration, with some 
peaks broadening during the titration.  
 
As stated earlier, one might expect to see a chemical shift change of 0.2 ppm or above in 
1
H
N
, and 0.9 ppm or above in 
15
N, for a system in fast exchange between bound and unbound 
state (Williamson, 2013). Therefore the peak shifts observed for both VanSA and VanSSC 
proteins do not represent a system under fast exchange. Instead, several peaks disappear with 
increasing concentration of vancomycin, which is more indicative of an intermediate-slow 
exchange to the bound conformation (see Figure 5.4.1.2). Any peak broadening occurring 
could also result from intermediate-slow exchange or reduced tumbling in solution.  
[255] 
 
For those peaks that do shift, the signal intensity is often reduced at high concentrations of 
vancomycin (tested to a final concentration of 2.8 mM), which may result from slow 
exchange (decreasing peak linewidth), or decreased signal-to-noise (since the antibiotic is 
added in excess into solution). In contrast, the signal intensity for all peak shifts in Figure 
5.4.1.8 does not vary with increasing antibiotic concentration (tested up to 0.8 mM), so 
changes in signal intensity may only result from decreased antibiotic solubility.  
 
As a final note, in Figure 5.4.1.9 below, the peak shifts in Panel F, resulting from addition of 
vancomycin to samples of VanSSC protein in LPPG detergent, show relatively large changes 
in the chemical shift of the peak at ~ 10.4 ppm. This peak must result from the resonance of 
the indole NH ring proton of a tryptophan residue, as this is the only proton present in that 
chemical shift region. This is interesting since the N-terminal sensor domain of VanSSC 
contains only three tryptophan residues (W), at positions 41, 68 and 82 in the wild-type 
sequence, and only W41 should be exposed outside the micelle and therefore accessible to 
interact with vancomycin, since residues W68 and W82 occur in the predicted second 
transmembrane domain (Figure 5.4.1.10).  
 
Additionally, studies by Koteva et al., (2010) which showed the first direct binding of a 
vancomycin analogue to the VanSSC protein, identified that the only section of the protein 
covalently labelled by the vancomycin probe was between residues M1 – W41. This consists 
of the putative first transmembrane helix and the first four residues, DQGW, of the predicted 
extracytoplasmic loop region (Figure 5.4.1.10). Therefore W41 could potentially be involved 
in binding to vancomycin, and the peak at 10.4 ppm is likely to represent that residue (as it is 
the only tryptophan exposed). This provides supporting evidence for a direct interaction of 
vancomycin with the VanSSC protein in vitro.             
[256] 
 
 
 
Figure 5.4.1.9: Overlayed 2D 
1
H-
15
N HSQC NMR spectra for VanS proteins during titration of vancomycin, showing individual peak shifts with high 
calculated CSPs. (A-C): 600 μM VanSA N-terminal domain in 50 mM LMPG pH 5.5, (D-F): 200 μM VanSSC N-terminal domain in 50 mM LPPG pH 6.1.  
[Vancomycin]:[protein] ratios of 0:1 (red), 1:1 (green) and 4:1 (blue) were tested. Peaks were starred and numbered according to data in Figure 5.4.1.5 (A-
C) or Appendix Figure 15 (D-F).
*1 *3 *8
(a) (c)(b)
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Figure 5.4.1.10: Predicted domain positions in the VanSSC protein sequence, showing 
residues 17 to 85. Predicted TM domains (according to TMPred, and Koteva et al., 2010) 
are shown in boxes (residues 17-37 and 65-85) and the extracytoplasmic loop region is 
highlighted in red. The four residues (DQGW) in the loop region that are proposed by 
Koteva et al., (2010) to be involved in binding to vancomycin are underlined, and the three 
tryptophan residues in the sequence are in green. 
 
5.4.2 Analysis of Full-length VanS proteins by NMR Spectroscopy 
 
Sensor histidine kinases such as VanS function as dimers, and in prototypical histidine 
kinases, the cytoplasmic core consists of a dimerisation domain (DHp) and a C-terminal 
ATP binding domain (CA) (see section 1.5.3) (Gao and Stock, 2009). The CA domain alone 
exists as a monomer in solution, and is capable of binding ATP and transferring phosphoryl 
groups to a conserved histidine residue in the dimeric DHp domain. In the presence of an 
inducer such as vancomycin, it is not clear whether VanS interacts with vancomycin in a 
monomeric or dimeric form, but the formation of a dimeric sensor complex is required for 
signal transduction via the dimeric DHp domains to the catalytic domain, to effect kinase 
function. It is therefore likely that any binding that does occur between vancomycin and 
monomeric VanS proteins, will not be productive, i.e. will not cause signal transduction and 
activation resistance gene transcription.  
 
As observed for the VanSA and (to a lesser extent) VanSSC N-terminal sensor domains, the 
addition of vancomycin does perturb the chemical environment of several protons (on 
different residues), and suggests that the presence of vancomycin does alters the 
conformation of VanS. Since the functional form of the VanS kinase is a dimer, if 
YAGFLTLAGVLLLVAVGVFLL DQGWLLTNERGAVRATPGTVFLRSFAP TAAWVMAFLLVFGLVGWFLA
17 37 65 84
TM1 TM2Extracytoplasmic Loop
[258] 
 
vancomycin is added to the full-length form of VanS, which has been shown in section 3.11 
to be functionally active in DPC detergent (with respect to ADP release and phosphate 
release assays), further changes in conformation would be anticipated as interactions could 
be more productive, and enable downstream signal transduction. Therefore, full-length VanS 
proteins overexpressed in 
15
N labelled M9 minimal media were examined (without 
enzymatic cleavage) using 
1
H-
15
N HSQC NMR spectroscopy and spectral changes 
monitored during ligand titrations. Although spectral crowding would be much greater for 
the full-length protein and peak linewidths would likely increase due to the increase in size, 
it was thought that the peaks that had been observed to shift during ligand titrations to 
samples containing the VanS sensor domain would still remain distinguishable; since they 
were well-dispersed from the majority of peaks in the backbone amide region and predicted 
to be in a more flexible region of the protein.  Furthermore, even if peaks could not be easily 
distinguished, the resulting HSQC spectra of the full-length, and isolated sensor domain of 
VanS, could be overlayed to ensure no changes in protein fold were occurring after cleavage 
of the C-terminal domain, which could impinge on antibiotic binding.           
 
Samples of full-length detergent-solubilised VanS proteins in DPC detergent (and in LMPG 
detergent) were purified in the same buffer and detergent conditions as those of the isolated 
VanS sensor domain (see Figure 5.4.2.1A for VanSA and Appendix Figure 16 for VanSSC). 
Overlayed NMR spectra in Figure 5.4.2.1A show that the overall fold of the isolated sensor 
domain of VanS is highly similar to that of the full-length protein, with overlapping peaks in 
the side-chain regions and backbone amide region. Additional peaks are also present for the 
full-length protein, dispersed widely across the 
15
N axis. However, most of the peaks which 
are implicated in antibiotic binding to the isolated VanSA sensor domain (starred and 
annotated), are either not observed in the spectrum of full-length VanSA or appear at a 
different chemical shift value. It is therefore difficult to see if interaction with these residues 
is conserved for the full-length protein.   
[259] 
 
  
 
Figure 5.4.2.1: (a) Overlayed 2D 
1
H-
15N HSQC spectra of 700 μM VanSA N-terminal domain (red) or 600 μM full-length protein (green), (b) Overlayed 
2D 
1
H-
15
N HSQC spectra of the VanSA full-length protein during titration of detergent-solubilised vancomycin. Both protein samples were solubilised in 50 
mM LMPG, 50 mM sodium acetate pH 5.5 collected at 310K. Peaks with significantly high chemical shift changes (according to CSP analyses) during 
vancomycin titration into samples containing the VanSA sensor domain in (a), are starred and numbered and their positions annotated onto the spectrum. 
[Vancomycin]:[protein] ratios of 0:1 (red), 1:1 (green) and 4:1 (blue) were tested in (b), and peaks of interest are highlighted with arrows.
(b)(a)
[260] 
 
Nevertheless, vancomycin was added to samples of the VanSA full-length protein in LMPG 
detergent at molar ratios of 0:1, 1:1, 4:1 (vancomycin:protein). Chemical shift changes were 
monitored during titrations and the resulting overlayed spectra are given in Figure 5.4.2.1B. 
The figure shows a handful of peaks (marked with arrows) that display chemical shift 
changes during the titration, some of which appear in similar chemical environment to those 
in the isolated sensor domain (e.g. near *6, *7 or *3). However, the magnitude of the 
chemical shift changes remains small, despite the presence of the full-length VanSA protein, 
and it appears that any interaction with vancomycin is not altered by the presence of the 
kinase domain. This suggests that any binding between VanSA (whether full-length or 
truncated) and vancomycin involves only a few residues (similar to the DQGW binding 
region proposed by Koteva et al., (2010) for VanSSC) and exchange rate to the bound form is 
likely to be slow.  
 
However, these are in vitro studies using purified and detergent-solubilised proteins, whereas 
direct binding to a VanS protein has only been confirmed in vivo from unpurified membrane 
preparations (Koteva et al., 2010). This raises the possibility that the membrane preparations 
used may still contain cell wall precursors, such as Lipid II, which may also be required in 
order to facilitate binding to the protein. Therefore three distinct models can be proposed: (i) 
direct induction; in which the kinase is activated by direct binding of antibiotic to the sensor 
domain, (ii) indirect induction; in which the kinase is activated by binding a cell wall 
metabolite which is either an intermediate in cell wall biosynthesis or accumulates as a result 
of antibiotic action, or (iii) induction by the vancomycin-cell wall metabolite complex; in 
which the kinase is activated by the glycopeptide antibiotic when it is bound to a D-Ala-D-
Ala-containing cell wall precursor.   
 
In a recent paper by Kwun et al., (2013), in vivo activation of the van cluster in the VanB-
type resistance system of S. coelicolor was found to require vancomycin binding to the D-
Ala-D-Ala termini of cell wall PG precursors, to be perceived by the VanSSC sensor domain.  
[261] 
 
By manipulating the amounts of D-Ala-D-Ala and D-Ala-D-Lac-containing precursors in the 
cell, the group showed that induction of van gene expression by vancomycin was 
significantly reduced in cells where D-Ala-D-Lac-containing precursors were more abundant 
than D-Ala-D-Ala, consistent with model (iii) for VanS sensing. Furthermore, induction of 
vanH transcription was readily observable upon addition of vancomycin to S. coelicolor 
wild-type cells, but when a vancomycin derivative was added, which cannot bind to D-Ala-
D-Ala termini (desleucyl vancomycin, Figure 5.4.2.2), no vanH transcript was detectable. 
This showed that the D-Ala-D-Ala binding pocket of vancomycin is important not only for 
the mode of action but also for inducing the van resistance system, and supports the view 
that a vancomycin-cell wall metabolite complex should be required for activation of VanSSC. 
 
With this knowledge it was important to conduct a further experiment, involving addition of 
Lipid II cell wall precursor to NMR samples containing VanS and vancomycin, in case 
activation is triggered by formation of a vancomycin-cell wall PG precursor complex, which 
could be observed by chemical shift changes in the spectrum.   
 
 
Figure 5.4.2.2: Vancomycin (left) and Desleucyl vancomycin (right) structures, drawn in 
ISISDraw. The desleucyl vancomycin has a modified peptide-binding pocket and is unable 
to bind to the of extracellular PG precursors. The difference in the two structures in 
highlighted by the moiety in red, which forms one of the five hydrogen bonds to the D-Ala-D-
Ala N-terminus of PG precursors. 
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5.4.3 NMR Titration of the Lipid II cell wall precursor 
 
Samples were prepared for VanS proteins in the presence of vancomycin and Lipid II-Lys 
(naturally found in the cell wall of Gram-positive bacteria) and analysed by 2D HSQC NMR, 
in order to test for any interaction of the VanS proteins with a complex of vancomycin and 
the Lipid II cell wall precursor. Lipid II-Lys was obtained from the Bacwan synthesis facility 
(School of Life Sciences, University of Warwick) as a dissolved lyophilised powder (in 
chloroform/methanol/water). An aliquot of Lipid II was dried to a film in a glass vial, and 
the NMR sample containing 
15
N labelled detergent-solubilised VanS protein and 
vancomycin, was added to the vial and vortexed to resuspend the lipid (see section 2.14.2).  
 
HSQC spectra for samples of VanSA protein or VanSSC protein solubilised in DPC detergent 
during titration of vancomycin, and subsequent addition of Lipid II, are overlayed and shown 
in Figure 5.4.3.1A or Figure 5.4.3.1B respectively. For the sample containing VanSA protein, 
only the N-terminal sensor domain was present (since full-length VanS proteins had not been 
tested at this time), and Lipid II was added after vancomycin titrations in order to see if 
further peak shifts were observed. Although one or two peaks (marked with arrows in Figure 
5.4.3.1A) were perturbed by the addition of Lipid II, the overall protein conformation 
remained unchanged. It was therefore not possible to state whether a complex of Lipid II and 
vancomycin are causing the peak shifts observed.  
 
As stated in section 5.4.2, a possible issue with using the VanS sensor domain, is that the 
protein may not be able to dimerise which is important for kinase function, and vancomycin 
might only interact with dimeric VanS. Therefore in a second test, vancomycin was added to 
a sample containing full-length VanSSC protein in DPC detergent (in which the protein 
appeared active), and subsequently Lipid II was added (Figure 5.4.3.1B). This would enable 
interactions to occur between a dimeric VanSSC protein and a vancomycin-lipid complex, 
which is believed to be required for activation of the kinase in vivo (Kwun et al., 2013).  
[263] 
 
 
Figure 5.4.3.1: Overlayed 2D 
1
H-
15
N HSQC spectra of (a) 600 μM VanSA N-terminal sensor domain solubilised in 50 mM DPC, or (b) 500 μM VanSSC 
full-length protein solubilised in 50mM DPC, during titration of detergent-solubilised vancomycin and Lipid II-Lys.  [Vancomycin]:[protein]:[Lipid II] 
ratios of 0:1:0 (red), 4:1:0 (green) and 4:1:0.5 (blue) were tested, and all data collected at 310K. Both proteins were solubilised in 20 mM HEPES pH 6.85. 
(b)(a)
[264] 
 
Minimal changes in the position of peaks in Figure 5.4.3.1B are observed upon addition of 
vancomycin to full-length VanSSC, and no significant changes occurred after subsequent 
addition of Lipid II. It is therefore not possible to ascertain from the data whether 
complexation of vancomycin to Lipid II is required to activate VanSSC or not. It appears that 
technical difficulties associated in working with a membrane-localised sensor protein and a 
lipidated PG ligand, have prevented collection of in vitro data to support the in vivo 
vancomycin-VanSSC binding studies by Kwun et al., (2013) and Koteva et al., (2010). 
Trying to recreate appropriate cell conditions in vitro for ligand binding to occur, will require 
the selection of a more suitable membrane mimetic (e.g. one that provides a more native 
environment for PG lipids) and perhaps the addition of other cell wall metabolites.  
 
5.4.4 NMR Titration of other glycopeptide antibiotics 
 
All NMR studies presented so far have concentrated on interactions between VanS proteins 
and vancomycin, since a direct binding of VanS to a glycopeptide antibiotic has only been 
shown with vancomycin analogues. However, both VanSA and VanSSC are activated by other 
glycopeptide antibiotics, and are classed as VanA- or VanB-type phenotypes based on their 
resistance to teicoplanin antibiotics. VanSA is resistant to teicoplanin, whereas VanSSC is 
only sensitive to teicoplanin, and therefore teicoplanin should only induce kinase activity in 
VanSA. This could therefore provide a useful control experiment in NMR titration studies, as 
changes in the chemical shifts of VanS proteins on HSQC NMR spectra, should only be 
observed upon addition of teicoplanin to VanSA proteins. 
 
NMR ligand titration experiments were conducted as stated previously (see section 2.14.2) 
and teicoplanin was dissolved to a stock concentration of 10-20 mM and solubilised in 5 mM 
LMPG detergent micelles. The teicoplanin was added to NMR samples containing VanSA 
(solubilised in LMPG detergent) at molar ratios of 1:1 and 4:1 of teicoplanin:protein and 
HSQC spectra collected at each titration point and overlayed, as shown in Figure 5.4.4.1. 
[265] 
 
Teicoplanin was obtained from Molekula (Dorset, UK) and comprises of a mixture of 
different compounds, including five major (termed teicoplanin A2-1 through A2-5) and four 
minor (termed teicoplanin RS-1 through RS-4), which all share the same glycopeptide core 
termed A3-1 (a fused ring to which two carbohydrates are attached). The antimicrobial action 
of teicoplanin is tuned by using the proper ratio of A2 and A3 compounds (marketed as 
Targocid by Sanofi Aventis). 
 
 
 
 
Figure 5.4.4.1: Overlayed 2D 
1
H-
15N HSQC spectra of 600 μM VanSA N-terminal domain 
in 50 mM LMPG, 50 mM phosphate buffer pH 6.0, during titration of detergent-
solubilised teicoplanin. [Teicoplanin]:[protein] ratios of 0:1 (red), 1:1 (green) and 4:1 
(blue) were tested and all spectra were collected at 310K. 
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No peak shifts of significance are observed during titration of teicoplanin to VanSA in LMPG 
detergent, in comparison to the many shifts observed during addition of vancomycin under 
similar conditions. The effect if any, of adding the teicoplanin cannot be determined, but a 
possible conclusion that could be drawn is that peak shifts of VanSA proteins are observed in 
the presence of a dimeric glycopeptide antibiotic (vancomycin). Teicoplanin is unique 
among the vancomycin group of antibiotics in that it shows no appreciable propensity to 
dimerise (Gerhard, 1993a) and carries a glucosamine acylated by a C10 or a C11 fatty acid 
(Barna et al., 1984). It is postulated that the fatty acid side chain acts as a membrane anchor, 
to enable the binding of the antibiotic to the pentadyl-D-Ala-D-Ala terminus of a growing 
cell wall to be effectively intramolecular (Beauregard et al., 1995; MacKay et al.,1994). 
Therefore in the membrane mimic chosen (detergent micelles), the teicoplanin may not be 
able to anchor into the membrane and interact with VanS. Additionally, no data to suggest a 
direct interaction of a VanS protein with teicoplanin antibiotic is present in the literature, so 
a lack of peak shifts may have been anticipated.   
 
5.5 The Role of VanS Oligomerisation in Ligand Binding and Signalling 
 
As stated in section 1.5.3, a number of common HK structural motifs have been identified 
(Gao & Stock, 2009) that are believed to possess a role in regulating phosphorylation of 
kinases by transmitting conformational changes in the periplasmic sensor domain to the 
cytoplasmic kinase domain. For instance, ~33% of HKs contain at least one PAS domain 
(Taylor & Zhulin, 1999), and ~31% of HKs contain a HAMP domain (Hulko et al., 2006; 
Szurmant et al., 2007), both of which are implicated in signalling in dimeric sensor kinases, 
by providing movements in the protein which are transduced to the kinase domain. It has 
been proposed that these movements cause conformational changes in the ATP binding 
domain which are necessary to position the histidine residue optimally for phosphotransfer. 
Therefore knowledge exists of conserved features required for signal transduction through 
the kinase, which should be critical to expression of resistance genes. However, little is 
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known about how the signal is transferred across the membrane from the extracytoplasmic 
loop region through the transmembrane helices, to the dimerization domain. Through a 
combination of in vitro and in vivo oligomerisation assays, VanS histidine kinases were 
therefore analysed for their oligomerisation state, and the strength of oligomerisation of their 
transmembrane helices, to improve understanding of the role of oligomerisation in ligand 
binding and in signal transduction.    
 
5.5.1 Analysis of VanS Oligomerisation by Blue Native PAGE  
 
The oligomerisation state of VanS proteins can be investigated by a number of techniques 
such as Analytical Ultracentrifugation (AUC) (Macfarlane, 2007), Native PAGE, Native 
Mass Spectrometry (Laganowsky et al., 2013) and Gel Filtration Chromatography. As seen 
in section 3.7, VanS proteins purified in membrane mimetics appear to elute as dimers by gel 
filtration chromatography (at ~ 90 kDa size relative to gel filtration standards), but further 
methods are required to support this data, one of which is Blue Native PAGE (BN-PAGE). 
This technique provides identification of native membrane protein complexes and 
determination of purity on PAGE gels, without denaturing the protein (Schagger & von 
Jagow, 1991). Coomassie G-250 is present as the charge-shift molecule in the NativePAGE 
Gel system, which binds to proteins and confers a net negative charge while maintaining the 
proteins in their native state (Schagger et al., 1994). BN-PAGE was therefore conducted to 
characterise the oligomeric state of VanS proteins in different detergents, and determine their 
molecular size relative to Native PAGE standards (see section 2.6.2). Samples of VanS 
proteins purified by IMAC techniques were loaded onto NativePAGE gels (Invitrogen) and 
protein bands were visualised by Coomassie staining or Western blotting (see Figure 
5.5.1.1). 
 
[268] 
 
 
 
 
Figure 5.5.1.1: (left) BN-PAGE 4-16% gradient gel loaded with purified His-tagged full-
length VanSA samples in DPC at 0.1% w/v (~2x CMC), or in DDM at 0.05% w/v (~3x 
CMC) (right) corresponding Western blot. In each lane 5μg (1) or 15μg (2) VanS protein 
was loaded, and an estimate of protein molecular weight was provided by a NativePAGE 
protein marker (MR, Amersham), solubilised in DDM and loaded at 0.05% w/v. Bands at 
molecular sizes which would correlate with a monomer, dimer or higher oligomer are 
indicated by arrows.   
 
 
VanS proteins are proposed to be homo-dimeric in their active state and the BN-PAGE gel 
and blot (Figure 5.5.1.1) shows that VanSA exists in DPC in different oligomeric forms, with 
protein sizes indicating dimeric and monomeric, and possibly higher oligomeric states. The 
higher oligomers are unlikely to form in native bacterial membranes, but instead indicate that 
the DPC detergent micelles are able to stabilise trimer or higher oligomeric structures. 
Ideally, however, only one band for VanS (dimer) should be observed, since this is the form 
that has kinase activity. Interestingly VanSA protein in DDM detergent (at roughly the same 
[protein]:[detergent] ratio), appears to be aggregated since very little enters the resolving gel, 
which indicates that either the protein is unstable in the detergent environment, or that it also 
forms high order oligomers. This result helps to explain why a large proportion of the protein 
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pelleted as insoluble material, when testing in DDM detergent during the initial solubility 
screens (see section 3.6), and could be a reason for the poor crystal growth observed in 
previous studies in DDM. 
 
VanSSC proteins in DPC detergent display similar oligomeric complexes to that of VanSA 
(see Figure 5.5.1.2), and indicate that DPC detergent is capable of stabilising VanS proteins 
in a functional dimeric form (although some monomer is also present). There also appears to 
be a higher ratio of dimer to monomer for VanSSC proteins compared to VanSA proteins in 
Figure 5.5.1.2, which could indicate a higher strength of oligomerisation between VanSSC 
monomers or increased oligomer stability.    
 
 
 
Figure 5.5.1.2: BN-PAGE 4-16% gradient gel loaded with purified His-tagged full-length 
VanSA (left) or VanSSC (right)  samples in DPC detergent at 0.1% w/v (~2x CMC). In each 
lane 5 μg (1) or 15 μg (2) of VanS protein was loaded, and an estimate of protein molecular 
weight was provided by a NativePAGE protein marker (MR, Amersham). Bands at molecular 
sizes corresponding to monomer, dimer or higher oligomer are indicated by arrows.  
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5.5.2 Analysis of VanS Homo-Oligomerisation using ToxCAT Assays  
 
Native PAGE and gel filtration data presented indicate that dimeric VanS proteins are one 
species being formed in vitro, and these have been shown to be active with respect to ADP 
release and phosphate release through the use of coupled enzymatic assays (see section 
3.11). As a further test of homo-dimerisation in vivo, another assay was performed, known as 
the ToxCAT assay (Russ & Engelman, 1999). This assay determines whether homo-
oligomerisation is occurring between transmembrane (TM) domains within the VanS protein 
and quantifies the strength of association relative to a strongly dimerising control protein, 
glycophorin A (GpA) (Russ & Engelman, 1999). NMR data has shown that the association 
between GpA TM monomers is mediated by a seven residue motif presented on one face of 
each TM helix (Russ & Engelman, 1999) which is tightly packed at the interface, making it 
an ideal positive control protein of a strongly dimerising system. A point mutation in GpA at 
residue Gly-83 to an isoleucine (G83I) has also been found to disrupt the dimer interface, 
and therefore provides a good negative control in assays. It was hoped that the ToxCAT 
assay would provide an insight into the mechanism of signal transduction across the bacterial 
membrane via the membrane-spanning helices.  
 
In the first instance bioinformatic software was used to predict the position of 
transmembrane residues, and the most appropriate prediction was found using TMPred 
software (Hofmann & Stoffel, 1993), which predicted an anticipated N-in, C-in topology and 
predicted sequences also followed the “positive inside rule” i.e. TM domains had high 
overall hydrophobicity, and were often flanked by hydrophilic residues (von Heijne G., 
1992). This directed the synthesis of corresponding primers (given in Table 2.4.1), which 
were then cloned into a pccKan DNA vector (section 2.7.1), between two restriction sites 
(NheI and BamHI) to create a chimeric fusion protein (refer to Figure 2.7.1.1).  
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Full details of primer phosphorylation, annealing and ligation into digested pccKan plasmids 
are given in sections 2.7.1. The predicted TM sequences are given below, and the residue 
numbers are 19-37 and 78-97 for VanSA proteins, and 19-37 and 68-86 for VanSSC proteins: 
 
 
VanS
SC
 TM1:   GFLTLAGVLLLVAVGVFLL  
VanS
SC
 TM2:   WVMAFLLVFGLVGGWFLAG 
  
VanS
A
 TM1:   LYMYIVAIVVVAIVFVLYI 
VanS
A
 TM2:   IFIYVAIVISILILCRVMLS 
 
 
The pccKan construct is composed of the N-terminal DNA binding domain of ToxR (a 
dimerization-dependent transcriptional activator), termed ToxR’, which is fused to a 
transmembrane domain (TM) of interest (i.e. TM 1 and 2 of VanS) and a monomeric 
periplasmic anchor (the maltose binding protein, MBP) as shown in Figure 5.5.2.1. MBP 
directs the fusion protein across the inner membrane of E. coli and association of TM helices 
results in ToxR’-mediated activation of a reporter gene encoding chloramphenicol 
acetyltransferase (CAT) (Figure 5.5.2.1). Activation of the reporter gene results in acquired 
resistance to the antibiotic chloramphenicol (CAM). Two ways of measuring the extent of 
TM-induced dimerization in the literature are: a disk diffusion assay (see section 2.7.5), 
which measures the zone of inhibition resulting from acquired resistance to the antibiotic 
CAM for each chimera, and a quantitative CAT assay (see section 2.7.6), which measures 
acetylation of CAM by the CAT enzyme by fluorescence spectroscopy. These assays and 
other control experiments are detailed below. 
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Figure 5.5.2.1: A schematic diagram of the basis for the ToxCAT assay. A chimeric fusion 
protein is expressed from the pccKan plasmid, containing a cytoplasmic ToxR DNA binding 
domain. Upon dimerisation, the transmembrane domains bring ToxR’ domains into close 
contact, activating them towards binding to the ctx promoter to effect expression of CAT 
enzyme, the level of which can be monitored in the quantitative ToxCAT assay.  
 
 
To establish whether chimeric fusion proteins were inserting into E. coli membranes with the 
correct topology, a malE complementation assay was first conducted (see section 2.7.2). The 
pccKan plasmid containing the VanS TM was transformed into NT326 cells, which lack 
endogenous MBP. NT326 cells cannot transport maltose into the cytoplasm for metabolism, 
and therefore cannot grow on maltose/agar plates. However, if the ToxCAT chimerae are 
correctly inserted into the inner membrane, the periplasmic MBP domain will complement 
the NT326 malE-deficient phenotype and support growth on maltose. All constructs were 
correctly oriented in the membrane, and grew on maltose plates (Figure 5.5.2.2), unlike 
NT326 negative controls.  
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Figure 5.5.2.2: The malE complementation assay. NT326 cells transformed with pccKan 
plasmids (expressing chimeric VanS fusion proteins) were streaked onto minimal media 
plates containing only maltose as a carbon source, to provide a check for insertion of the TM 
domain (TM1/TM2) across the membrane. Untransformed NT326 cells were streaked as a 
negative control, and a control protein (GpA) and its mutant (G83I) were also streaked. 
 
 
The expression level of the chimeric fusion proteins in NT326 cells was also checked (see 
section 2.7.3). The chimera ToxR’-TM-MBP is constitutively expressed at low levels by the 
toxR promoter and differences in the expression levels will affect the relative amount of 
dimerization, therefore by determining the expression level of the chimerae, ToxCAT data 
can be normalized relative to expression.  To check expression levels, an aliquot of NT326 
cells expressing the chimera was taken (diluted to an OD600 of 0.3), and pelleted by 
centrifugation, before resuspending in SDS sample buffer and loading onto a NuPAGE 12% 
Bis-Tris gel (see section 2.7.3). The gel bands were subsequently transferred to a 
nitrocellulose membrane, blotted with anti-MBP antibodies and developed (refer to section 
2.6.4). The anti-MBP Western blot showing the successful expression and relative levels for 
each construct is given in Figure 5.5.2.3A.  
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Figure 5.5.2.3: Anti-MBP Western blots showing (a) the expression of chimeric fusion 
proteins in NT326 cells (normalised by OD600) or (b) a spheroplast assay for one fusion 
protein. For expression tests a negative control of untransformed NT326 cells was loaded. In 
the spheroplast assay, fractions collected before (SP) and after proteolysis (SP*), or after 
cycles of freeze-thawing (BP) are shown. The molecular weight band corresponding to MBP 
is highlighted by an arrow at ~ 42 kDa. 
 
 
Next, protease sensitivity assays were conducted, in order to measure the membrane 
insertion and orientation of the MBP chimerae and verify that interactions within the 
membrane were responsible for the observed CAT activity (see section 2.7.4). The protease 
sensitivity of a chimera is assayed in cells that have been stripped of their outer membrane 
and cell wall (spheroplasts). As anticipated, MBP was detected in the spheroplast fraction 
(‘sp’) since it is associated with the inner membrane via TM and ToxR domains, and the 
addition of proteinase K (protease) excised the MBP domain from the TM domains as it was 
present on the periplasmic side of the membrane, which can be observed on SDS-PAGE gels 
of proteolysed spheroplast fractions (‘sp*’), as a lower molecular weight fragment (~ 42 
kDa) (see Figure 5.5.2.3B). 
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As a final test of TM-mediated dimerization of different chimerae, prior to quantitative CAT 
assays, disk diffusion assays were carried out. An aliquot of NT326 cells expressing the 
chimerae (normalised by optical cell density) was plated on LB/ampicillin plates and 
allowed to dry, before placing a chloramphenicol soaked disk into the centre of the plate. 
The diameter of the clear zone of inhibition of growth around the disk was then recorded, 
and the size of this zone is directly dependent on the strength of TM-dimerisation in the 
chimera; increased dimerization confers greater CAM resistance, thereby decreasing the 
diameter of the zone of inhibition. Unsurprisingly GpA had the smallest diameter zone of 
inhibition, and G83I, the largest, with the VanS TM-containing chimerae displaying 
inhibition zones in between these values. Three of the plates and their inhibition zones are 
shown in Figure 5.5.2.4.  
 
 
 
Figure 5.5.2.4:  The disk diffusion assay. Clear zones of inhibition occur around a 
chloramphenicol soaked disk on LB/Ampicillin plates transformed with NT326 cells 
containing chimeric fusion proteins; GpA (left), G83I (center) or VanSSC TM1 (right). The 
diameter of the inhibition zone is indicated by arrows, and is directly related to the strength 
of dimerization of the TM domains present in the chimera.    
 
 
To quantify the strength of TM-dimerisation, CAT activity was measured in cell-free 
extracts by the quantitative ToxCAT assay. The assay is based on the Invitrogen FAST CAT 
(deoxy, green) system, using xylene phase extraction to isolate product, as described by Seed 
& Sheen, (1988), and experimental details as given in section 2.7.6.  
G83I SSC TM1GpA
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In this assay, the rate of transfer of a butryl group from butyryl-CoA to fluorescent 
chloramphenicol (CAM) is detected by the rate of color change (at ~520 nm) associated with 
the reaction of the resulting free coenzyme A with BODIPY-FL-deoxyCAM (Molecular 
Probes). Each sample containing an expressed chimera was lysed, and incubated with 10 μl 
of fluorescent CAM, then10 μl of a 5 mg/ml butyryl CoA solution. Samples were centrifuged 
briefly before terminating reactions by adding 300 μl xylene and centrifuging to collect the 
upper phase. This phase was sunsequently assayed for fluorescence by excitation at 495 nm, 
and emission spectra were collected between 500 and 600 nm (see Figure 5.5.2.5).  
 
 
Figure 5.5.2.5: Fluorescence emission spectra collected upon excitation of samples 
containing chimeric fusion proteins at 495 nm. Each fusion protein is labelled and 
coloured as follows: blue - GpA, red - G83I, green –VanSA TM1, purple – VanSA TM2, cyan 
– VanSSC TM1 and orange - VanSSC TM2.  
 
As shown in Figure 5.5.2.5, the fluorescence maxima at ~ 520 nm for the TM domains of 
most VanS proteins display significantly higher intensity than the negative, mutant control 
G83I. However the fluorescence intensity is still only one third to one quarter of the intensity 
of the strongly dimerising positive control, GpA. This suggests that whilst there may be 
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association of TM domain in VanS proteins, the level of dimerization appears to be fairly 
weak. In order to quantify the relative strengths of dimerization of all chimera, the 
fluorescence values at 520 nm were recorded and normalised for any concentration 
differences, against expression levels (by band sizing using the blot in Figure 5.5.2.3A). The 
positive control (GpA) was plotted and data normalised to this value, and the negative 
control (G83I) was also plotted, which should show ~ 10% of the strength of dimerization of 
GpA as a result of the isoleucine mutation (see Figure 5.5.2.6).   
 
 
Figure 5.5.2.6: Normalised ToxCAT activity for each chimeric fusion protein. The bar 
graph shows the CAT activity of each chimera measured by fluorescence at 520 nm and 
normalised to expression levels, plotted relative to a positive (GpA, 1.0) and a negative 
control (G83I, ~ 0.1). Error bars are displayed for each chimera, calculated from the 
standard deviation in the value of fluorescence at 520 nm over three sample repeats.  
 
As a result of the high expression level of VanSA fusion proteins, when the fluorescence 
values were normalised to density values in Figure 5.5.2.6, the overall strength of 
dimerization was diminished, whereas, VanSSC fusion proteins remained relatively 
unaffected. A comparison to the G83I  negative control (density of 0.07), shows that VanSSC 
TM1 (0.20) and TM2 (0.23) have some propensity to dimerise, but VanSA TM1 (0.13) and 
VanSA TM2 (0.06) are within the error values of the negative control.  
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The overall strength of oligomerisation for the VanS fusion proteins is relatively low, which 
implies that TM-TM homo-interactions are weak and may not be a key feature of the signal 
transduction pathway. However, these TM domains were only predicted, and it known that 
optimisation of the lengths of the TM regions within the constructs is often required in order 
to observe TM-TM association (Brosig & Langosch, 1998). For instance, a previous PhD 
student at Warwick University (Jenei et al., 2009) working on Carnitine palmitoyltransferase 
1A (CPT1A), a mitochondrial membrane protein, found that the optimum CPT1A TM1 
length was 24 amino acids, and that reducing to 21 amino acids, resulted in halving the CAT 
activity. By comparison, the length of CPT1A TM2 used that resulted in CAT activity was 
16 amino acids. Interestingly, Jenei et al., (2009) also found that TM1 yielded CAT activities 
that were equivalent to that of the G83I negative control, whereas the TM2 showed a higher 
propensity to form homo-oligomers, yielding CAT activities of at around 40% of the level of 
the positive control, GpA, which is similar to the CAT activity presented here in Figure 
5.5.2.6. The CPT1 protein has two membrane-spanning helices and an identical N-in, C-in 
topology to that of VanS, and based on this data, CAT activity observed for VanSSC TM1 
and TM2 in Figure 5.5.2.6 could indicate TM-TM association. Hetero-oligomeric 
interactions may also occur e.g. TM1-TM2, in the active dimeric form of VanS, which 
would need to be assessed using another in vivo assay; the GALLEX assay (Schneider & 
Engelman, 2003). 
 
Close examination of the protein TM sequences, finds that there are also several small-xxx-
small motifs present (where ‘x’ is any residue) (Kleiger et al., 2002) which are implicated in 
helix-helix interactions as they can provide close-packing of TM domains, promoting homo-
dimerisation (see Figure 5.5.2.7). The most common of these small-xxx-small motifs is 
GxxxG (Russ & Engelman, 2000), but other motifs are known such as AxxxA and VxxxV, 
which can also provide close-packing arrangements of dimer interfaces (Schneider & 
Engelman, 2004).  
[279] 
 
It can be seen that there is a G77-xxx-G81 motif in VanSSC TM2, and other motifs, which may 
increase TM association in VanSSC. In the TM2 helix of some chemotaxis receptors from 
R. sphaeroides bacteria there are also several small-xxx-small motifs (Senes et al., 
2006), which increase association strength, suggesting that TM-TM packing interactions 
are important for function in these and other systems (Hall et al., 2011).      
 
 
 
Figure 5.5.2.7: A comparison of the predicted TM sequences for VanSA and VanSSC 
proteins, highlighting helix-helix packing motifs. Each small-xxx-small motif is starred and 
residues are highlighted in red. 
 
As a final note, the strengths of dimerization of VanS TM domains in vivo (from normalised 
density data), correlate well with the Blue-Native PAGE data in vitro (in DPC detergent). 
The BN-PAGE data shows that a higher percentage of VanSSC dimer appears to be stabilised 
in DPC micelles than VanSA dimer. This would fit with the higher propensity of VanSSC 
helices to dimerise, as presented in the ToxCAT data. Although both the BN-PAGE and 
ToxCAT data need much greater analysis and additional repeats, there may be a correlation 
between the propensity of VanS proteins to dimerise and their observed antibiotic sensitivity. 
For instance, increased strength of dimerisation of the VanS protein may result in increased 
binding of glycopeptide antibiotics, which in turn could affect modulation of signals 
transduced to the kinase domain.   
VanSSC TM1:   GFLTLAGVLLLVAVGVFLL 
VanSSC TM2:   WVMAFLLVFGLVGGWFLAG
VanSA TM1:   LYMYIVAIVVVAIVFVLYI
VanSA TM2:   IFIYVAIVISILILCRVMLS
* *
* ** * *Motifs:
GxxxG
AxxxA
VxxxV
[280] 
 
5.6 Discussion 
 
Both fluorescence techniques involving BODIPY-vancomycin analogues, and NMR-based 
titration data involving vancomycin antibiotics, indicate that VanSSC and VanSA proteins 
appear able to directly interact with vancomycin. This data supports a model for direct 
interaction between vancomycin antibiotics and VanS proteins derived from Enterococcus 
and Streptomyces, and challenges the consensus view that the Enterococcal VanS protein 
should be indirectly activated by vancomycin. Furthermore, a number of significant 
Chemical Shift Perturbations are observed in the 
1
H-
15
N HSQC spectra of 
15
N-labelled VanS 
sensor domains, upon addition of vancomycin, which appear to cluster to a particular region 
of the spectrum, for a range of detergents, and could map to a binding site. The assignment 
of these peaks requires further optimisation of protein concentration to allow collection of 
3D spectra such as TOCSY-HSQC or NOESY-HSQC with improved signal-to-noise.  
 
The role of oligomerisation in VanS activity and signalling mechanisms was also assessed 
using Native PAGE assays, which showed that purified full-length VanS proteins existed in 
to some degree in a dimeric state in DPC detergent. In contrast, in vivo ToxCAT assays, 
found that for fusion proteins studied (containing predicted VanS TM helices) only weak 
homo-oligomeric TM-TM association was observed, and it was concluded that TM-TM 
association is unlikely to be a major mechanism in the two-component signalling 
mechanism, although the possibility of hetero-oligomerisation cannot be ruled out.  
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5.6.1 New evidence for a direct interaction between vancomycin and VanS  
 
BODIPY-vancomycin dyes were chosen as ligands in fluorescence studies based on their 
previous use within the Warwick group, and showed minimal changes in fluorophore 
environment in the presence of DPC detergent micelles. Upon addition of VanS proteins to 
BODIPY-vancomycin solutions, red shifts of 4-5 nm were observed for both proteins (from 
~ 510 nm to ~515 nm), similar to that observed on addition of a Lipid II control. This gave 
an indication that the full-length proteins may be interacting with the vancomycin molecule, 
and further details of residues involved could be obtained by NMR techniques.    
 
Isotopic 
15
N-labelling of VanS sensor domains enabled the first known NMR spectra of a 
VanS sensor domain to be acquired (as detailed in section 4.6). By adding unlabelled 
vancomycin antibiotics to the labelled VanS proteins, it was possible to determine chemical 
shift changes during interaction with the antibiotic using a Chemical Shift Perturbation 
(CSP) analysis. All resolvable peaks in the 
1
H-
15
N HSQC spectra of 
15
N-labelled VanS 
proteins, at each titration point, were picked and tabulated, and enabled a bar graph to be 
produced of chemical shift perturbation (CSP) vs. peak number (see Figure 5.4.1.5). These 
CSP analyses were conducted for VanS proteins in different detergent environments upon 
antibiotic addition, and identified a number of statistically significant peak shifts that 
represent genuine interactions involving conformational changes in the protein (Figures 
5.4.1.6 to 5.4.1.8). Some of these peaks appear to cluster to a particular region of the 
spectrum, across the range of detergents, which could map to a binding site. However the 
identity of the residues has not yet been assigned and will require 3D HSQC-TOCSY or 
HSQC-NOESY NMR techniques, which are currently underway within the Warwick group. 
There is still a possibility that the changes observed in both the fluorescence and NMR 
spectra could result from indirect effects, such as the alteration of the micelle structure and 
dynamics upon binding to vancomycin, which would indirectly affect the chemical shifts of 
the protein and the fluorescence wavelength rather than being a direct binding effect. 
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Therefore supporting data is required using other biophysical techniques such as SPR or 
ITC-based ligand-binding assays (as outlined in section 6.6) to confirm this direct binding 
between VanS and vancomycin. 
    
In terms of the kinetics, individual peak shifts for the NMR spectra of VanS proteins in the 
presence of vancomycin (see Figure 5.4.1.9), show a positive correlation between peak 
chemical shift and vancomycin concentration, which would suggest that vancomycin acts as 
a direct ligand for VanS. The magnitude of these peak shifts is relatively small (~ 0.05 ppm) 
indicating a slow or intermediate exchange to the bound state, but this may be expected since 
the VanS protein is solubilised within a micelle, which could occlude approach of the 
antibiotic. Indeed, this would correlate with the activity data obtained in Chapter 3, which 
showed that the presence of detergent micelles hampered the rate of autophosphorylation (as 
a function of ADP release), increasing the assay time to over two hours in some cases. It 
would have been useful to have obtained a dissociation constant (KD) for this binding; by 
plotting a titration curve of chemical shift change (Δδ) vs. ligand concentration, but 
unfortunately only two points (two ligand concentrations) were tested for each sample. In 
future a greater number of ligand concentrations should be sampled, in order to qualitatively 
determine the dissociation constant for the proposed binding of vancomycin to VanS.        
 
An interesting result from NMR binding studies was the identification of a chemical shift 
perturbation for a tryptophan residue in the VanSSC protein, characterised by a peak for its 
indole ring NH proton at ~10 ppm. This residue must be solvent-exposed, and there is only 
one exposed Trp residue in the expressed VanS sensor protein (Trp-41), so in the absence of 
residue assignment data, this peak is proposed to be Trp-41. This residue is one of the four 
residues (DQWG) predicted to bind directly to vancomycin in studies by Koteva et al., 
(2010), therefore this data indicates that Trp-41 is involved in binding and supports the view 
that VanSSC directly interacts with vancomycin at its extracytoplasmic sensor loop in vivo.  
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A number of questions have been raised as a result of these studies, most importantly, the 
question of whether Enterococcal VanSA proteins do bind directly to vancomycin antibiotics, 
since biophysical ligand-binding techniques conducted in this thesis appear to show a real 
interaction, resulting in conformational changes of several residues. This data contradicts the 
consensus view from previous biochemical assays that VanSA should be induced indirectly 
whereas VanSSC should bind directly; since VanSA can be activated by glycopeptide 
antibiotics and other structurally unrelated antibiotics. Further research is clearly required to 
characterise the interaction observed between VanS and vancomycin, including assignment 
of residues in the sensor domain that show conformational changes upon antibiotic addition.  
 
As a final NMR experiment, HSQC spectra were collected for the full-length VanS proteins, 
since it was thought that addition of vancomycin to functional, full-length VanS would result 
in further observable changes in conformation, compared to those of the isolated sensor 
domain, as interactions could be more productive. However, overlayed NMR spectra of the 
full-length VanSA protein against its isolated VanSA sensor domain (see Figure 5.4.2.1A) 
showed that most of the peaks implicated in antibiotic binding to the VanSA sensor domain 
were either not observed in the spectrum of full-length VanSA or were not visible due to peak 
overlap. Of those peaks that did shift, the magnitude of the shift was low, indicating that any 
interaction of VanS with vancomycin is not altered by the presence of the kinase domain.  
 
5.6.2 The role of transmembrane domains upon signal transduction 
 
It was postulated that transmembrane helix-helix interactions may be involved in 
oligomerisation of the protein, and may provide a route to transduce signals downstream. For 
this reason, ToxCAT homo-oligomerisation assays were conducted to study TM-TM 
interactions as detailed in section 5.5.2. These assays showed that the TM domains of VanSA 
proteins did not show any significant oligomerisation, but there was an appreciable 
association of VanSSC TM domains, and this could be due to differences in the dimerisation 
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interfaces, since a number of GxxxG close-packing motifs are present in VanSSC TMs. 
Overall though the level of association was weak, which suggests that transmembrane 
association is unlikely to feature in the two-component signalling mechanism (unless hetero-
oligomerisation is occurring, which would which require further analysis using GALLEX 
assays). However, conformational changes in the transmembrane region could still be 
occurring to transduce signals across the membrane. 
 
Indeed in a number of studies involving the isolated sensor domains of histidine kinases, it 
has been observed ligand binding at the extracytoplasmic sensor loop causes dimerisation of 
the sensor complex, and results in structural changes that are transduced through the protein. 
This includes conformational changes in the form of piston-like movements or rotations of 
the TM helices (Cheung & Hendrickson, 2010; Zhang & Hendrickson, 2010). For example, 
NarX is activated by nitrate binding to its isolated sensor loop, which induces a displacement 
of its N-terminal helices toward the cell membrane, relative to the C-terminal helix (see 
Figure 5.6.2.1) (Cheung & Hendrickson, 2009). Since these N- and C-terminal helices are 
expected to connect to TM1 and TM2 respectively, the relative movement of the two helices 
would push down TM1 or lift up TM2 (see for Figure 5.6.2.1). These piston-like motions are 
also observed upon ligand binding in Tar HK sensor domain (Falke and Hazelbauer, 2001), 
but the displacements are in an opposite direction.  
 
Furthermore, the direction of helix movement correlates with HK function: nitrate binding in 
NarX promotes a phosphosphorylated state (Williams & Stewart, 1997), and aspartate 
binding in Tar promotes a dephosphorylated state (Jin & Inouye, 1994). These displacements 
are shown clearly in the NMR structures of ligand-free and ligand-bound forms of the CitA 
sensor domain (Sevvana et al., 2008) (see Figure 5.6.2.1). It is found that residues in the β-
sheet region curled up to one side towards the citrate ligand binding site which corresponded 
to an upward movement of the TM2 helices (Sevvana et al., 2008), in the similar manner and 
direction to that observed for the Tar chemotaxis protein (Falke and Hazelbauer, 2001).  
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Figure 5.6.2.1: (a) Overlayed backbone structures of CitA ligand-free monomers 
(magenta) and ligand-bound dimers (green), reproduced from Wang (2012) and (b) the 
hypothetical model of TM signalling in CitA. In the model in (b), citrate binding causes the 
PDC domain to contract (as shown in (a) by the β-sheet moving up towards ligand), which 
triggers a piston-like movement of the TM2 helices, and transduction of the signal to the 
cytoplasmic side. CitA PDB codes for monomer and ligand-bound dimer are 2J80 and 2V9A.  
 
 
Therefore displacements or rotations of TM domains is important for signal transduction in 
histidine kinases and is likely to feature for the VanS kinase, and to a higher degree than 
signalling from transmembrane helix-helix association during protein dimerisation. It is also 
interesting to note that in the structures of isolated sensor domains of HKs in the literature 
e.g. NarX and CitA, the ligand free forms are monomeric, whereas ligand-binding induces 
dimerisation, as seen in Figure 5.6.2.1. It is therefore possible that similar ligand-induced 
binding may occur for the isolated VanS sensor domains, and peak shifts observed in the 
HSQC NMR spectra may reflect conformational changes in the sensor domain upon 
dimerisation. However, the oligomerisation state of the detergent-extracted and purified 
sensor domains of each VanS protein was not deeply investigated during these studies, so 
identification of oligomeric state of both free sensor domain and vancomycin-bound sensor 
by AUC or Native MS techniques would be required to test this theory.  
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Overall, the use of Native PAGE and in vivo ToxCAT assays have provided an insight into 
the protein oligomeric state (in NMR-relevant detergents) and the strength of homo-
dimerisation of VanS transmembrane helices, which has improved knowledge of the role of 
oligomerisation in VanS activity and in the signal transduction mechanism.   
 
5.6.3 The role of vancomycin dimerization in ligand binding 
 
It has been shown in a number of NMR studies (Gerhard et al., 1993b; Pearce et al., 1995, 
Beauregard et al., 1995) that vancomycin and its analogues (e.g. ristocetin, eremomycin) are 
predominantly dimeric in solution and that there is a correlation between the degree of 
dimerization of the glycopeptide and its affinity for peptide ligands. Beauregard et al., 
(1995), calculated from NMR experiments, that dimeric vancomycin increases its affinity for 
D-Ala-D-Ala cell wall precursors by a factor of 1 to 10 and for cell wall fragments by factors 
of 2 to 100. This data suggests that dimerization may have a physiological influence in the 
action of antibiotics of the vancomycin group, and could also affect the extent of their 
interaction with the VanS sensor kinase.  
 
Vancomycin and other glycopeptide antibiotics are known to form noncovalent dimers (Loll 
et al., 1998; Lehmann et al., 2002), sometimes referred to as “back-to-back” dimers, in 
which the dimerization surface is on the opposite side of the molecule from the ligand 
binding pocket (see Figure 5.6.3.1). X-ray studies of vancomycin shows that this back-to-
back dimerisation produces two asymmetric binding sites with different binding affinities, 
due to the positioning of the sugar moieties in each monomer. 
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Figure 5.6.3.1: A back-to-back dimer of the vancomycin aglycone induced by an acetate 
ligand, represented by sticks and a cartoon ribbon. The acetate ligand is shown in orange 
for simplicity and the crystal structure contains only the aglycone. Four independent 
monomers of the vancomycin aglycone (PDB: 1GHG) comprise the crystallographic 
asymmetric unit, forming two asymmetric dimers, one of which is shown. Individual elements 
are coloured as follows: carbon – white, oxygen – red, nitrogen – blue and chlorine – green.  
 
Most interestingly, in the crystal structure in Figure 5.6.3.1, both binding pockets of the 
vancomycin aglycone are occupied by bound acetate ions, which mimic binding of the C-
terminus of nascent cell wall peptides. This could provide an explanation for the observed 
magnitudes of CSPs in the HSQC NMR spectra of VanS proteins in the presence of 
vancomycin in sodium acetate buffer (see Figure 5.4.1.6 and 5.4.1.8), which are larger than 
those in HEPES buffer (see Figure 5.4.1.7).  The acetate ions can increase stabilisation of 
dimeric vancomycin, which in turn may increase interaction with the VanS sensor domain 
(provided that the functional state of vancomycin in NMR titrations was dimeric). 
Thermodynamic data collected by McPhail & Cooper, (1997) (by calorimetric dilution 
experiments), calculated the dimerization constant (Kdim, Equation 5) for vancomycin (‘V’) 
in phosphate buffer at pH 7 and 298K as 475 dm
3
 mol
-1
, whereas in acetate buffer a Kdim of 
860 dm
3
 mol
-1
 was calculated for the same conditions. This equates to a requirement of 
approximately 2.2 mM vancomycin in phosphate buffer in order to form 50% dimer in 
solution, but in acetate buffer, only 1 mM vancomycin is required.  
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Therefore a higher proportion of dimer can be formed in acetate buffer for the same final 
concentration of vancomycin, and would have been present during NMR-based titration 
experiments conducted (e.g. in Figure 5.4.1.6).  In fact, in all titration spectra collected, 
significant changes in the peak chemical shifts of VanS proteins appear to occur upon 
addition of 0.8-1 mM vancomycin (Figures 5.4.1.6 - 5.4.1.8), which would support a 
requirement for interaction of VanS with a dimeric form of vancomycin.   
   
In addition to the dimerisation ability of vancomycin, there are reports of hexameric 
structures of vancomycin, which form when crystallised in the presence of certain cell-wall 
precursor analogues (e.g. N-acetyl-D-Ala-D-Ala (NAAA) and diacetyl-Lys-D-Ala-D-Ala 
(DALAA) (Loll et al., 2009), Nitanai et al., 2009).  These consist of a trimer of dimers 
formed by three vancomycin-ligand complexes containing ‘back-to-back’, ‘face-to-face’ and 
‘side-to-side’ interactions (see Figure 5.6.3.2) (Lehmann et al., 2002; Nitanai et al., 2009).  
 
 
Figure 5.6.3.2: Stereo view of the “face-to-face” dimer present for vancomycins 4 and 6 in 
a six-vancomycin-asymmetric unit (PDB: 1FVM), with hydrogen bonding to DALAA 
ligands. Vancomycin is colored in white or orange, and the ligands in green or cyan. The 
diacetyl-Lys of the ligand chain was removed for clarity.   
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 “Face-to-face” interactions are also observed in balhimycin complexes with cell wall 
mimetics (Lehmann et al., 2002) and are likely to represent a general mode of 
oligomerisation for vancomycin complexes with cell wall peptides. Therefore the 
oligomerisation behaviour of vancomycin may be relevant to its antibacterial mechanism of 
action, especially as it is expected to recognise two types of muramyl peptide targets in vivo; 
those found on Lipid II and those found on nascent peptidoglycan chains (Loll et al., 2009). 
The asymmetric nature of vancomycin complexes may also enable interactions with both cell 
wall precursor peptides and VanS proteins at different interfaces (e.g. face-to-face and back-
to-back), as each face has a different degree of ‘openness’. Furthermore, Kwun et al., (2013), 
stated that although VanSSC proteins should be activated by interaction with a complex of 
vancomycin bound to its cell wall precursor, they said that they cannot exclude the possibly 
that VanS senses vancomycin via interactions with its D-Ala-D-Ala binding pocket, of which 
several could be available in these hexameric structures of vancomycin.      
 
It therefore appears that greater analysis is required to elucidate the oligomerisation state of 
vancomycin that is present in solution during NMR and fluorescence studies (as presented in 
this thesis), and its interaction with VanS proteins. Since the addition of cell wall penta-
peptide or tri-peptide analogues (which are soluble in aqueous media) are able to induce 
back-to-back, face-to-face and side-to-side dimeric vancomycin structures, this could 
provide a new route to study VanS-vancomycin interactions by NMR, without the difficulty 
of using detergent-solubilised Lipid II in titration experiments. Alternatively, VanS 
interactions with oligomeric vancomycin molecules, and Lipid II, could be assessed in a 
more native environment, by reconstituting the proteins into liposomes, which is discussed in 
more detail in the recommendations for future work (see section 6.6).  
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6 Summary and Conclusions 
 
6.1 Background and Objectives 
 
The work discussed in Chapters 3 – 5 covers three key areas: structural/mechanistic studies 
of VanS proteins, antibiotic binding to VanS, and the role of VanS oligomerisation in signal 
transduction. As a prerequisite to these studies, vanS genes from two species were cloned, 
recombinantly expressed and purified into appropriate membrane mimetics. Proteins were 
also characterised for their identity, homogeneity and fold, to ensure they would be suitable 
for structural and ligand binding studies.  This section details progress to address the 
questions highlighted in section 1.7 of the Introduction, using the findings from this research 
project and outlines the conclusions from these studies.   
 
6.2 Efforts towards Crystallisation or an NMR Structure of a VanS protein 
 
To improve upon previous crystallographic studies of C-His-tagged VanS proteins within the 
Warwick group (Williams, 2007), crystal trials were conducted using tag-cleaved VanS 
proteins, which would reduce the possibility of crystallising other histidine-rich impurity 
proteins expressed in E. coli (e.g. AcrB). vanS genes were selected from two species (E. 
faecium and S. coelicolor) which exhibited different resistance phenotypes to glycopeptide 
antibiotics. These genes were cloned into pProEx vectors and overexpressed as TEV-
cleavable, N-His-tagged VanS proteins. The proteins were able to be purified by IMAC and 
found to be in a well-folded, homogenous and active state. Attempts were then made to 
crystallise these VanS proteins, by removing the His-tag, and applying samples to 96-well 
crystal screens. Additionally, it had been found previously that crystallisation trials in DDM 
detergent only gave low resolution (8Å) crystals (Williams, 2007), which was proposed to 
result from the large steric size of its micelles (50-70 kDa). 
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To select for an appropriate detergent in place of DDM, a detergent screen was conducted, 
which found that highly soluble, and active VanS protein could be achieved in DPC 
detergent, which has a smaller micellar size (15-25 kDa) and thereby might improve growth 
by increasing protein-protein interactions in the crystal. However, despite these efforts, no 
crystals of the VanSA protein could be obtained in these studies in DPC or DDM detergents. 
This is a setback in improving the 8Å resolution of the VanSA diffraction pattern, but it is 
clear that crystallisation of VanSA or another VanS protein requires wider screening and 
increased collaboration with specialist membrane protein research groups. 
 
Efforts towards elucidation of the VanS structure by NMR spectroscopy required greater 
optimisation of construct design and expression protocols, since no protocols were available 
in the literature to overexpress and purify a VanS protein in labelled NMR media. It was 
decided to initially study the membrane-bound VanS sensor domain, by truncating the C-
terminal kinase domain. This had the added advantage that the binding affinity of potential 
glycopeptide ligands to the extracellular sensor loop could be interrogated, to determine 
whether a direct binding mechanism was involved, or if binding was indirect as proposed 
from biochemical assays for inducers of VanS activity.  
 
The isolated sensor domains of VanSA and VanSSC were obtained through unconventional 
‘Round-the-horn’ PCR techniques to insert an enzymatic cleavage site, for removal of the C-
terminal domain, and selective purification of the His-tagged, N-terminal sensor domain. 
These sensor domains were labelled in 
15
N M9 minimal media, using optimised expression 
protocols and allowed 
1
H-
15
N HSQC NMR investigations on the sensor domain structure 
(and antibiotic binding). This has resulted in the first known 
1
H-
15
N HSQC spectra of VanS 
proteins from enterococci and Streptomyces, and high resolution spectra were achieved by 
selecting appropriate detergents (e.g. lyso-lipids) and optimising buffer conditions. By using 
improved sensitivity 3D NMR experiments, it should be possible to assign residues in the 
sensor domain, and other domains, leading toward an NMR structure for the VanS protein.  
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6.3 Characterising the Mechanism of VanS autophosphorylation 
 
Autophosphorylation activity of his-tagged VanS proteins was assessed by a combination of 
ADP release and phosphate release assays, which had been developed by Quigley (2010) and 
enabled the continuous measurement of VanS ATPase function. These methods provided an 
alternative route to the use of radiolabelling to track phosphorylation and have been shown 
in these studies to be applicable to full-length detergent-purified VanS proteins. 
 
The ADP release assays allowed quantification of ATP turnover, showing that ADP is 
released from VanS after phosphorylation, as proposed by Marina et al., (2005), and before 
VanR binding occurs. In conjunction with the ADP release assay, an inorganic phosphate 
release assay demonstrated release of phosphate during autophosphorylation, showing the 
high lability of the phospho-histidine bond. In comparison to the activity observed for MBP-
VanSAΔ95 by Wright et al., (1993), and full-length VanSA by Quigley (2010), it appears that 
phosphorylation reactions in these studies require longer timescales to complete. This is may 
be due to the presence of excess detergent micelles which would hamper the ability of the 
VanS catalytic domain to phosphorylate its conserved His site.  
 
In addition to increased reaction times, the nmoles of ADP produced in assays was greater 
than the nmoles of VanS present, and the percentage of phosphorylation (subtracting for 
phosphate release) over 1 hour was greater than 100%, indicating formation of a secondary 
product or multiple-site phosphorylation. Quigley (2010) also calculated a value for 
phosphorylation of VanSA of  >100%, and explained this by demonstrating that VanSA also 
synthesises a secondary product, AP4. Attempts to identify any secondary reaction products 
by analysing products of a simplified reaction between ATP and VanS over time (without 
regeneration of ATP) using anion-exchange chromatography were not conclusive and AP4 
formation could not be observed. Anion exchange assays did, however, clearly show the 
conversion of ATP to ADP, which supports that VanS proteins purified in these studies were 
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functionally active kinases. Multiple-site phosphorylation was not assessed in the time length 
of these studies, but approaches to identify phosphorylation sites were discussed and could 
include site-directed mutagenesis (at the conserved His site) or tandem mass spectrometry 
techniques (see section 3.13.4).   
 
6.4 Assessing the Binding of Potential Antibiotic Ligands to VanS proteins 
 
Although the general consensus has been that E. faecium VanSA is unlikely to bind directly 
to glycopeptide antibiotics, as it appears to be induced by several structurally unrelated 
antibiotics in biochemical assays, no biophysical data has been collected to support this 
theory, and several assays do not concur on the identities of inducers. By using fluorescence 
spectroscopic techniques and solution state NMR experiments biophysical data has now been 
collected which supports a direct interaction between vancomycin and VanSA (as well as 
VanSSC). Fluorescence assays were conducted based on the observance of a direct interaction 
between S. coelicolor VanSSC and a fluorescent vancomycin photoaffinity probe (VPP) 
(Koteva et al., 2010), and it was surmised that this protein could be used as a positive control 
of vancomycin binding. Furthermore, based on the affinity of vancomycin for the D-Ala-D-
Ala N-terminus of cell wall precursors, in-house synthesised Lipid II was added to samples 
of a fluorescently tagged vancomycin analogue (BODIPY), as a control experiment, to show 
that the altered vancomycin molecule could still bind its target substrate.  
 
The addition of purified VanS proteins to BODIPY-vancomycin solutions (in the presence of 
detergent micelles), resulted in red shifts of 4-5 nm of the emission maxima (~ 510 nm to 
~515 nm), for both VanSSC and VanSA, similar to that observed for the Lipid II control. 
These shifts indicated a change in the environment of the BODIPY fluorophore, resulting 
from interaction of BODIPY-vancomycin with VanS, presumably at the exposed sensor 
domain of the protein.  
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Purified sensor domains of 
15
N-labelled VanSA and VanSSC protein samples were then 
analysed by 
1
H-
15
N HSQC NMR titration experiments, to test for a direct interaction of 
vancomycin to the exposed VanS sensor loop. These experiments supported the fluorescence 
data, showing a number of statistically significant Chemical Shift Perturbations upon 
addition of vancomycin. Peak shifts appeared to cluster to a particular region of the spectrum 
for a range of detergents, which could also indicate a binding site. However, the assignment 
of these peaks could not be achieved during these studies and the kinetics for the binding of 
vancomycin to VanS (KD) could not be determined from the NMR titration data collected (as 
only two ligand concentrations were tested).     
 
It should be noted however that the magnitude of the CSP values was relatively low, 
compared to systems involving fast exchange to a bound state or binding at a well-defined 
site. Indeed CSP values in the range obtained have been found by e.g. Morrison et al., 
(2003), to indicate ligand binding in multiple conformations. Based on the asymmetric 
conformations of vancomycin binding sites in crystal structures (see section 5.6.3), it is 
possible that these low CSP values reflect an interaction of vancomycin with VanS through 
multiple binding modes, although this would require much greater experimental study. 
 
6.5 Assessing the role of TM domain association in Signal transduction  
 
Conformational changes must occur within the transmembrane region to transduce signals to 
towards the kinase domain (Wang, 2012) and it was postulated that TM helix-helix 
interactions could provide this route for signal transduction. ToxCAT homo-oligomerisation 
assays developed in the Warwick group were conducted to study VanS TM-TM interactions 
as a function of CAT activity, and showed that although VanSA TM domains did not 
oligomerise, VanSSC TM domains demonstrated significant association, which is proposed to 
result from additional dimerisation motifs e.g. GxxxG close-packing motifs.  
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However, this does not appear to be a major feature in the mechanism of TCS signal 
transduction, and recent structures of isolated HK sensor domains have shown that ligand 
binding to the HK sensor loop effects structural changes in the TM region, triggering 
rotations or piston-like translations of the TM helices. These conformational changes alter 
the position of the TM helices in the membrane, and activate a kinase or phosphatase state, 
implying that rotations or displacements are likely to be the key modulators of TCS signal 
transduction across the membrane. However, one cannot exclude the possibility that signal 
transduction may also involve hetero-oligomerisation, which could be tested using a 
GALLEX in vivo reporter assay (as mentioned in section 5.1).  
 
As a further observation, the strengths of dimerization of VanS TM domains in vivo, 
correlate well with Native PAGE data collected for full-length VanS proteins in vitro. Native 
PAGE data shows that a higher percentage of VanSSC dimer appears to be stabilised in DPC 
micelles than the VanSA dimer. This fits well with the higher propensity of VanSSC helices to 
dimerise, as presented in the ToxCAT data.  
 
This PhD study has provided increased knowledge of the structure and function of VanS 
proteins from two different species, and their ligand binding properties. NMR-based titration 
data has now provided, for the first time, evidence for a direct binding between VanSA and 
vancomycin antibiotic, challenging consensus opinion in the literature. As a result of this 
PhD research, a number of avenues can be explored in future studies, and recommendations 
for a plan of future work is detailed in section 6.6.    
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6.6 Recommendations for Future Work 
 
Future work should continue in all of the avenues detailed above (structural/functional 
elucidation, antibiotic binding and signalling mechanisms). Substantial progress has been 
made towards obtaining structural data for the VanS proteins using solution state NMR, and 
this technique indicates for the first time, a direct interaction between vancomycin and the 
VanSA protein. It would therefore be pertinent to focus on firstly assigning the residues in the 
VanS sensor domain involved in binding.  
 
Towards this goal, 
15
N-labelled VanS proteins could be assigned without additional labelling 
by using e.g. 3D HSQC-TOCSY or HSQC-NOESY experiments (Marion et al., 1989a; 
1989b; Zuiderweg & Fesik, 1989). These assign proton spin systems to a specific residue 
and allow assignment of potentially overlapping peaks using a series of 2D 
1
H-
15
N slices, 
edited with respect to the frequency of the 
15
N heteronucleus, in a third dimension. Increased 
protein yields ( ≥ 1 mM) of VanSA and VanSSC would be required to conduct these 
experiments, since a resolvable HSQC spectrum must be collected in around one hour, and 
typically, experiments involve 32 or more individual HSQC slices. Protein yields of VanSA 
could be improved by optimising expression protocols, e.g. by further increasing cell density 
prior to induction (as suggested by Sivashanmugam et al., 2009; see section 4.7.2). For 
VanSSC, improvements are required in the level of soluble expression, which could be 
achieved through codon-optimisation of the gene, or using affinity tags that aid solubility 
such as MBP (e.g. in the pMAL system, see section 4.7.1).  
 
Perhaps a simpler strategy to assign residue types to specific peaks in the VanS HSQC 
spectra could even be a selective ‘unlabelling’ approach (Krishnarjuna et al., 2011). In this 
approach, a specific amino acid is ‘unlabelled’ by feeding the host bacteria 15N-labelled 
ammonium chloride as the sole source of nitrogen, along with the amino acid to be assigned, 
in unlabelled form. This leads to the selected amino acids in the protein being unlabelled and 
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as a result of which, cross-peaks from these residues disappear in the HSQC spectrum. This 
route could be highly beneficial to selectively ‘unlabel’ the tryptophan residues in the 
VanSSC sensor domain, to confirm whether the peak shifts observed at ~10 ppm (in Figure 
5.4.1.9F) result from interaction of vancomycin with the exposed Trp-41 residue in the 
VanSSC sensor loop.   
 
Alternatively, if the protein can be expressed with 
13
C  and 
15
N labels, triple-resonance NMR 
experiments such as HNCO, HN(CA)CO, HNCA, and HN(CO)CA (Grzesiek & Bax, 1992) 
could be conducted, which would provide greater sensitivity and complete sequential 
assignment. The experiments are named according to the nuclei involved in the experiment, 
and the order of nuclei in the name gives the sequence for the path of magnetisation. For 
instance the HNCO experiment provides the connectivities between the amide proton of a 
residue with the carbonyl carbon of the preceding residues. This experiment is often used in 
tandem with HN(CA)CO, in which the amide resonance of a residue is correlated with the 
carbonyl carbon of the same residue, as well as that of the preceding residues. In this way, 
triple-resonance experiments can provide assignment of the residue type (including side-
chain resonances) and their connectivity in the protein sequence (often referred to as 
‘walking’ along the backbone of the polypeptide). 
 
Assuming that assignment is feasible, the high quality of the HSQC spectra obtained here, 
opens the door to numerous structural studies of this protein. For example, further in-depth 
studies could be conducted on the mechanistic details of ligand binding, and its effect upon 
the structure and dynamics of the protein. This could then allow identification of those 
structural motifs which can bind to and activate the VanS kinase, leading to production of 
resistance genes.  
 
 
[298] 
 
In addition, a promising avenue for future work that does not depend on assignment, is the 
ability to use the NMR titration assay to screen vancomycin-based antibiotics and fragments 
thereof, e.g. the glycopeptide aglycone, dissacharride moieties, etc. to identify other ligands 
for this Two-Component System.  A titration curve of chemical shift vs. concentration of 
ligand could be fitted from this data, to obtain a value for the dissociation constant of each 
ligand (KD), provided enough ligand concentrations are tested.    
 
Furthermore, to support NMR-based (and fluorescence-based) titration data, other 
biophysical techniques could also be conducted. For example, SPR and ITC techniques are 
applicable to membrane proteins, and can provide thermodynamic and kinetic data for ligand 
binding (Patching, 2014; Rajarathnam & Rösgen, 2014). SPR ligand-binding assays are 
label-free and conventionally involve immobilisation of a receptor (reconstituted in lipid) 
onto a sensor chip surface whilst an analyte solution containing the interacting molecule 
flows over the sensor. Binding is detected by measuring small differences in the refractive 
index due to changes in thickness at the sensor surface (Whelan et al., 2002).  Although 
many experimental procedures exist for SPR measurements, one method to analyse VanS-
antibiotic binding could be to apply detergent-solubilised His-tagged VanS proteins to a 
functionalised nickel surface (Giess et al., 2004) (similar to that in IMAC, see Figure 6.6.1). 
The detergent solution could then be diluted and exchanged for lipids (to form a bilayer), to 
study binding to the VanS sensor on addition of an antibiotic-containing analyte solution.  
 
In the case of ITC experiments, the thermodynamics of binding between VanS proteins and 
antibiotic ligands could be studied in detergent micelles, provided that titrations are 
controlled to avoid protein-detergent interactions affecting the result. ITC techniques can be 
powerful tools e.g. Sikora & Turner, (2005), analysed the oligomerisation state of a 
transmembrane protein, EmrE, which like VanS, is believed to be functionally active as a 
dimer. However ITC data was able to show that the molar ratio of drug molecules that bound 
to ErmE was 1:1, and therefore oligomerisation was not a requirement for drug binding. 
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Figure 6.6.1: Conceptual representation of the protein-tethered lipid bilayer, reproduced 
from Giess et al., 2004. The interaction between the terminal His-tag of the membrane 
protein and a Copper-NTA group is magnified at the left side. 
 
 
In terms of characterising the functional activity of VanS, the new anti-pHis activity assay 
developed for histidine kinases by Kee et al., (2013) (see section 3.13.3) shows great 
promise. This assay could be easily incorporated into the current Western blotting screens, to 
test for purification of active VanS proteins, prior to structural or ligand binding techniques. 
Using the ADP/Pi release assays presented here, in conjunction with anti-pHis blotting 
assays (Kee et al., 2013; Wang et al., 2014), it may also be possible to determine the kinetic 
parameters for the binding of ATP to VanS such as the Michaelis-Menten constant (KM), the 
turnover number of substrate to product (KCAT) and the maximal velocity (VMax). 
Furthermore, phosphotransfer and phosphatase assays could be developed based on the 
ADP/Pi or anti-pHis system, to model the full kinetic profile of the VanRS system.  
 
  
[300] 
 
Finally, the mechanism of signal transduction could be further studied through the use of e.g. 
GALLEX in vivo reporter systems, which analyse the role of hetero-oligomerisation in signal 
transduction, and allow a second measure of homo-oligomerisation to ToxCAT. It would 
also be beneficial to couple the observed binding of VanS to vancomycin, with the activation 
of resistance genes in vivo, to assess whether the binding is productive. This could be 
accomplished by using the vanH gene reporter system, developed by Koteva et al., (2010), 
(as mentioned in section 1.4.2), who previously demonstrated that their vancomycin probe 
was a bioactive ligand of S. coelicolor VanS, as it was able to induce vanH gene production.    
 
The new insights gained from these studies into the structure and function of VanSA and 
VanSSC proteins, and the recommended plan of future work to support and improve upon this 
data, should lead to a detailed knowledge of the VanRS two-component system. Further 
information on the VanRS system could also lead to the rational design of novel inhibitors 
(like that of amidine vancomycin in section 1.6.2) which, in conjunction with glycopeptide 
antibiotics, could provide a more targeted therapy against antibiotic resistance mechanisms 
in these Two-Component Systems.  
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Appendix 
 
Table A1: A list of detergent classes tested in these studies and their properties (according to data in the literature). 
 
Detergent (abbreviation) Type Mean Aggregation 
number (‘a’) 
CMC 
(mM)* 
Mean Molecular 
Weight (Da)
Δ
 
Reagent 
Source 
Data Reference 
1,2-dihexanoyl-sn-glycero-3-
phosphocholine (C6-DHPC) 
Zwitterionic 19-20 15 453.5 Avanti Polar 
Lipids 
Hauser, (2000) 
1,2-diheptanoyl-sn- glycero-3-
phosphocholine  (C7-DHPC) 
Zwitterionic 25-30 1.4 481.6 Avanti Polar 
Lipids 
Hauser, (2000) 
n-dodecyl β-D-maltoside (DDM) Non-ionic 98 0.17-0.3 510.6 Anatrace Bhairi, (1997) 
n-decyl β-D-maltoside (DM) Non-ionic 69 1.8 482.6 Anatrace Oliver et al., (2013) 
n-dodecyl phosphocholine (DPC) Zwitterionic 56 1.1 351.3 Avanti Polar 
Lipids 
Wüthrich, (1986) 
1-myristoyl-2-hydroxy-sn-glycero-3-
phosphocholine (LMPC-14) 
Zwitterionic 108 0.07-
0.12 
467.6 Avanti Polar 
Lipids 
Oliver et al., (2013) 
1-palmitoyl-2-hydroxy-sn-glycero-3-
[phospho-1’-rac-glycerol] (LPPG) 
Anionic 160-170 0.018 506.5 Avanti Polar 
Lipids 
Oliver et al., (2013) 
1-myristoyl-2-hydroxy-sn-glycero-3-
[phospho-1’-rac-glycerol] (LMPG-14) 
Anionic 55 0.16 478.5 Avanti Polar 
Lipids 
Oliver et al., (2013) 
n-octyl β-D-glucoside (OG) Non-ionic 84 18-20 292.4 Anatrace Bhairi, (1997) 
Sodium dodecyl sulphate (SDS) Anionic 62 8-14 293.4 Anatrace Nishikido (1983) 
Triton X-100 (Triton) Non-ionic 100-155 0.2-0.25 625 Anatrace Bhairi, (1997) 
 
*All CMCs are reported for conditions of detergent in H2O from data collected at 298K.  
Δ
 Average molecular weights (Da) are given for detergents composed of mixtures of different chain length
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Figure A1: A plot of the volume-size distribution for a sample of VanSA protein purified in 
2 mM DPC detergent, collected at room temperature using a Malvern Nano Zetasizer.  
 
 
 
Figure A2: 12% SDS-PAGE gel showing purification of N-His6-VanSSC by affinity 
chromatography. Membranes were extracted and solubilised from 6L of expressed cells, in 
1% DPC and purified in a buffer containing 0.075% DPC. MR – Protein ladder (GE), Lane 1 
– FT, Lanes 2 – 4 20-40 mM Imidazole wash steps, Lane 5-7 – 300 mM Imidazole elution.  
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Figure A3: Gel filtration profiles of GE Healthcare standards applied to a Superose 12 
10/300GL column, under an isocratic gradient of 100% B. Buffer B: 20 mM HEPES pH 
7.8, 300 mM NaCl, 0.075% w/v DPC. Standards were: Aldolase (‘Aldo’, 158 kDa), Bovine 
Serum Albumin (‘BSA’, 66.9 kDa), Carbonic Anhydrase (‘CA’, 29 kDa), Ribonuclease A 
(‘Ribo’, 13.7 kDa) and Aprotinin (‘Apro’, 6.5 kDa). CA and BSA samples were added in the 
same sample, all other standards were run separately. 
 
 
 
Figure A4: Gel filtration profile of IMAC-purified tag-cleaved VanSA protein, applied to a 
Superose 12 10/300 GL column under an isocratic gradient of 100% B. Buffer B: 20 mM 
HEPES pH 7.8, 300 mM NaCl, 0.075% w/v DPC. The chromatogram shows a single peak 
and samples were concentrated and used in crystal trials at the SGC (Oxford).   
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Figure A5: 12% SDS-PAGE gel showing tag-cleaved (wild-type) VanSA protein after gel 
filtration and concentration to 200 μL. Lane 1 – 2 μg protein, Lane 2 – 4 μg protein, Lane 3 
– 8 μg, Lane 4 – 12 μg protein.   
 
 
Figure A6: A graph to show the relative percentage of each nucleotide product present 
over time during turnover of ATP by the VanSA kinase, plotted from peak integration of 
anion exchange data. Points were plotted using values in Table 3.11.4.1A and percentage 
integrals were calculated relative to the total reaction products at each timepoint. 
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Figure A7: Western blot showing relative expression levels of full-length VanSA proteins 
in 
15
N M9 minimal media. Cell cultures were concentrated (reduced in volume) by a factor 
of 1x, 2x or 4x, before induction with 0.2 mM IPTG. The effect of adding iron (+) into the 
minimal media (at 75 μM) was also assessed, against unsupplemented controls (-). MR – 
Magic Mark XP His-tagged ladder (Invitrogen). 
 
 
Figure A8: Western blot showing initial digestion products of VanSSC-3C upon 1:1 
incubation with 3C protease at room temperature for 4 hours. Key bands are labeled with 
arrows. MR  - MagicMark XP ladder.  Lane 1: 3C protease (~ 66 kDa), Lane 2: Digestion 
mixture containing VanSSC-3C and 3C protease.  
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Figure A9: Purified 3C protease applied to a precast 12% Novex Tris-glycine gel (left) and 
the blotted with anti-MBP (right). MR - Color Plus Prestained 7-175 kDa Protein (NEB). 
 
 
 
 
Figure A10: A 12% Tris-glycine gel showing purified N-terminal sensor domains of 
VanSA (lane 1) and VanSSC (lane 2) in DPC detergent, after two weeks of NMR analyses at 
310K. MR – ColorPlus Prestained Protein Ladder, Broad Range (10-230 kDa). 
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Figure A11: Western blots comparing detergent solubilisation of membrane pellets 
containing VanSA (top) or VanSSC (bottom) proteins. All detergents were added to 1% w/v 
(except OG (1.8%) as it has a higher CMC). S – Soluble supernatant fraction, P – insoluble 
pellet fraction. VanS band is indicated by a red arrow. MR – MagicMark ladder (Invitrogen).  
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Figure A12: Overlayed 2D 
1
H-
15N HSQC of 300 μM VanSA N-terminal domain solubilised 
in 50 mM LPPG, 50 mM Sodium acetate pH 4.6, during titration of detergent-solubilised 
vancomycin. [Vancomycin]:[protein] ratios of 0:1 (red), 1:1 (green),  4:1 (blue). Spectra 
were collected at 310 K and peaks of interest are highlighted by arrows.  
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Figure A13: Overlayed 2D 
1
H-
15N HSQC spectra of 200 μM VanSSC N-terminal domain 
solubilised in 50 mM DPC, 20 mM HEPES pH 6.8, during titration of detergent-
solubilised vancomycin. [Vancomycin]:[protein] ratios of 0:1 (red), 1:1 (green), 4:1 (blue). 
Spectra were collected at 310K and peaks of interest are highlighted by arrows. 
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Figure A14: Chemical shift changes for each peak in the 
1
H-
15
N HSQC spectrum of 
VanSA protein in DPC (from Fig. 5.4.1.3A) on addition of vancomycin, represented by a 
bar chart of peak number (ascending 
1
H
N
) against chemical shift change (Δδ). Changes 
for side-chain and backbone 
1
H
N
 protons were calculated using the equation:    
 √    [  
          
  ], against a threshold value (σ, red line). Peaks with significant CSPs 
are annotated by starring. (A) Chemical shift changes upon adding a 1:1 molar ratio of  
[vancomycin]:[protein] (B) Chemical shift changes upon adding a 4:1 molar ratio of  
[vancomycin]:[protein].  
0
0.005
0.01
0.015
0.02
0.025
0.03
1 7 13 19 25 31 37 43 49 55 61 67 73 79 85 91 97
C
h
e
m
ic
a
l 
S
h
if
t 
C
h
a
n
g
e
, 
Δ
δ
(p
p
m
)
Peak Number
*1
*5
*7
*8
*3
1:1 – 0:1 DPCVanSA
0
0.005
0.01
0.015
0.02
0.025
0.03
0.035
1 7 13 19 25 31 37 43 49 55 61 67 73 79 85 91 97
C
h
e
m
ic
a
l 
S
h
if
t 
C
h
a
n
g
e
, 
Δ
δ
(p
p
m
)
Peak Number
*1
*5
*7
*2
*4
*6
DPC4:1 – 0:1 VanSA
(a)
(b)
[338] 
 
 
 
Figure A15: Chemical shift changes for individual peaks in the 
1
H-
15
N HSQC spectrum of 
VanSSC protein in LPPG (from Fig. 5.4.1.4) on addition of vancomycin, represented by a 
bar chart of peak number (ascending 
1
H
N
) against chemical shift change (Δδ). Changes 
for side-chain and backbone 
1
H
N
 protons were calculated using the equation:    
 √    [  
          
  ], against a threshold value (σ, red line). Peaks with significant CSPs 
are annotated by starring. (A) Chemical shift changes upon adding a 1:1 molar ratio of  
[vancomycin]:[protein] (B) Chemical shift changes upon adding a 4:1 molar ratio of  
[vancomycin]:[protein].  
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Figure A16: Overlayed 2D 
1
H-
15N HSQC of 200 μM VanSSC N-terminal domain (red) or 
300 μM full-length protein (green), collected at 310K on a 700 MHz spectrometer. The 
proteins were both solubilised in 50 mM DPC, 75mM NaCl and 20 mM HEPES pH 6.8.  
 
